catalog_id,smiles,product_name,pubchem_id,chemical_name,molecular_formula,cas_numeber,molecular_weight_batch,target_class,primary_target,primary_action,brief_description,batch,rdkit_smiles,chemical_cluster_0.75,medoid_0.75
189,[O-][N+](=O)C1=C(C=C2NC(=O)C(=O)NC2=C1)[N+]([O-])=O,DNQX,3899541,"6,7-Dinitroquinoxaline-2,3-dione",C8H4N4O6,[2379-57-9],252.14,Ion Channels,AMPA Receptors,Antagonist,Selective non-NMDA iGluR antagonist,14,O=c1[nH]c2cc([N+](=O)[O-])c([N+](=O)[O-])cc2[nH]c1=O,87,1
190,[O-][N+](=O)C1=C(C=C2NC(=O)C(=O)NC2=C1)C#N,CNQX,3721046,"6-Cyano-7-nitroquinoxaline-2,3-dione",C9H4N4O4,[115066-14-3],232.16,Ion Channels,AMPA Receptors,Antagonist,Potent and selective non-NMDA iGluR antagonist,34,N#Cc1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+](=O)[O-],87,0
223,OC(=O)C1=CC(O)=C2C=CC=CC2=N1,Kynurenic acid,3845,4-Hydroxyquinoline-2-carboxylic acid,C10H7NO3,[492-27-3],207.19,Ion Channels,Non-selective Ionotropic Glutamate,Antagonist,Broad spectrum glutamatergic antagonist,58,O=C(O)c1cc(O)c2ccccc2n1,156,1
237,OC(=O)C1=CC(O)=C2C=CC(Cl)=CC2=N1,7-Chlorokynurenic acid,1884,7-Chloro-4-hydroxyquinoline-2-carboxylic acid,C10H6ClNO3,[18000-24-3],229.6251,Transporters,Glutamate Transporters,Inhibitor,Potent competitive inhibitor of L-glutamate uptake,6,O=C(O)c1cc(O)c2ccc(Cl)cc2n1,156,0
286,OC(=O)C1=NC2=CC(Cl)=CC(Cl)=C2C(O)=C1,"5,7-Dichlorokynurenic acid",1779,"5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid",C10H5Cl2NO3,[131123-76-7],276.08,Ion Channels,NMDA Receptors,Antagonist,Potent NMDA antagonist; acts at glycine site,6,O=C(O)c1cc(O)c2c(Cl)cc(Cl)cc2n1,156,0
357,CC(=O)NCCC1=CNC2=CC=CC=C12,N-Acetyltryptamine,70547,,C12H14N2O,[1016-47-3],202.26,Enzymes,Other Transferases,Substrate,Substrate for serotonin N-acetyl transferase,2,CC(=O)NCCc1c[nH]c2ccccc12,795,1
369,Cl.NCCCCCCNS(=O)(=O)C1=CC=CC2=C(Cl)C=CC=C12,W-7 hydrochloride,124887,N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride,C16H21ClN2O2S.HCl,[61714-27-0],377.33,Cell biology,Calcium Binding Protein,Antagonist,Calmodulin antagonist. Inhibits myosin light chain kinase,8,NCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,851,0
373,NS(=O)(=O)C1=CC=CC2=C3NC(=O)C(=O)NC3=CC(=C12)[N+]([O-])=O,NBQX,3272524,"2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide",C12H8N4O6S,[118876-58-7],340.78,Ion Channels,AMPA Receptors,Antagonist,Potent AMPA antagonist; more selective than CNQX (Cat. No. 0190),16,NS(=O)(=O)c1cccc2c1c([N+](=O)[O-])cc1[nH]c(=O)c(=O)[nH]c12,87,0
415,CCCCOC1=CC(CC2CNC(=O)N2)=CC=C1OC,Ro 20-1724,5087,4-(3-Butoxy-4-methoxyphenyl)methyl-2-imidazolidone,C15H22N2O3,[29925-17-5],278.35,Enzymes,Phosphodiesterases,Inhibitor,PDE4 inhibitor,4,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC,364,1
421,Cl.Cl.FC1=CC=C(C=C1)C(OCCN1CCN(CCCC2=CC=CC=C2)CC1)C1=CC=C(F)C=C1,GBR 12909 dihydrochloride,104920,1-[2-[Bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride,C28H32F2N2O.2HCl,[67469-78-7],523.49,Transporters,Dopamine Transporters,Inhibitor,Selective DA uptake inhibitor; also ? ligand,5,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1,289,1
431,Cl.ClC1=C2C=CC=C(C2=CC=C1)S(=O)(=O)N1CCCNCC1,ML 9 hydrochloride,108047,1-(5-Chloronaphthalenesulfonyl)homopiperazine hydrochloride,C15H17ClN2O2S.HCl,[105637-50-1],370.3,Enzymes,Myosin Light Chain Kinase,Inhibitor,Myosin light chain kinase inhibitor,5,O=S(=O)(c1cccc2c(Cl)cccc12)N1CCCNCC1,850,0
456,CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O,Chlormezanone,2717,"2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one-1,1-dioxide",C11H12ClNO3S,[80-77-3],273.73,Ion Channels,GABAA Receptors,Benzodiazepine,Positive allosteric modulator of benzodiazepine site,4,CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1,585,1
478,NP(N)(=O)NC(=O)C1=CC=C(F)C=C1,Flurofamide,51173,N-(Diaminophosphinyl)-4-fluorobenzamide,C7H9FN3O2P,[70788-28-2],217.14,Enzymes,Other Hydrolases,Inhibitor,Urease inhibitor,1,NP(N)(=O)NC(=O)c1ccc(F)cc1,507,1
523,OC(=O)C(O)=O.FC1=CC=C(C=C1)C(=O)C1CCN(CCCCC2=CC=CC=C2)CC1,4F 4PP oxalate,24745966,4-(4-Fluorobenzoyl)-1-(4-phenylbutyl)piperidine oxalate,C22H26FNO.C2H2O4,[144734-36-1],429.49,7-TM Receptors,5-HT2A Receptors,Antagonist,Selective 5-HT2A antagonist,3,O=C(c1ccc(F)cc1)C1CCN(CCCCc2ccccc2)CC1,282,1
541,Cl.O=S(=O)(N1CCCNCC1)C1=C2C=CN=CC2=CC=C1,Fasudil hydrochloride,163751,,C14H17N3O2S.HCl,[105628-07-7],327.83,Enzymes,Rho-kinases,Inhibitor,Inhibitor of cyclic nucleotide dependent- and Rho-kinases,3,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,850,1
542,Cl.Cl.CC1CNCCN1S(=O)(=O)C1=CC=CC2=CN=CC=C12,H-7 dihydrochloride,73332,(�)-1-(5-Isoquinolinesulphonyl)-2-methylpiperazine dihydrochloride,C14H17N3O2S.2HCl,[108930-17-2],373.3,Enzymes,Broad Spectrum Protein Kinase Inhibitors,Inhibitor,Protein kinase inhibitor,6,CC1CNCCN1S(=O)(=O)c1cccc2cnccc12,850,0
554,CNC(=O)C1=CC2=C(NC3=C2C=CC=C3)C=N1,FG 7142,4375,N-Methyl-?-carboline-3-carboxamide,C13H11N3O,[78538-74-6],225.25,Ion Channels,GABAA Receptors,Benzodiazepine,Benzodiazepine inverse agonist,12,CNC(=O)c1cc2c(cn1)[nH]c1ccccc12,792,1
589,Cl.O=C(OCCN1CCOCC1)C1(CCCCC1)C1=CC=CC=C1,PRE-084 hydrochloride,11314197,2-(4-Morpholinethyl) 1-phenylcyclohexanecarboxylate hydrochloride,C19H27NO3.HCl,[138847-85-5],353.89,Other Pharmacology,Sigma1 Receptors,Agonist,Highly selective ?1 agonist,2,O=C(OCCN1CCOCC1)C1(c2ccccc2)CCCCC1,320,1
593,OC(=O)C1=CC(=CC=C1NCCCC1=CC=CC=C1)[N+]([O-])=O,NPPB,4549,5-Nitro-2-(3-phenylpropylamino)benzoic acid,C16H16N2O4,[107254-86-4],300.31,Ion Channels,Ca2+-Activated Chloride Channels,Blocker,Inhibits calcium-sensitive chloride currents,4,O=C(O)c1cc([N+](=O)[O-])ccc1NCCCc1ccccc1,210,0
607,C#CCCCCCCCCCCCCCCCC(O)=O,17-ODYA,1449,17-Octadecynoic acid,C18H32O2,[34450-18-5],280.45,Enzymes,Hydroxylases,Inhibitor,LTB ?-hydroxylase inhibitor,4,C#CCCCCCCCCCCCCCCCC(=O)O,26,1
640,CN1C2CCC1CC(C2)OC(=O)C1=CC(Cl)=CC(Cl)=C1,MDL 72222,1683,"Tropanyl 3,5-dichlorobenzoate",C15H17Cl2NO2,[40796-97-2],314.21,Ion Channels,5-HT3 Receptors,Antagonist,5-HT3 antagonist,3,CN1C2CCC1CC(OC(=O)c1cc(Cl)cc(Cl)c1)C2,258,1
653,O[C@@H]1CCCC[C@H]1N(CC3)CCC3C2=CC=CC=C2.Cl,(+/-)-Vesamicol hydrochloride,659839,(�)-trans-2-(4-Phenylpiperidinyl)cyclohexanol hydrochloride,C17H25NO.HCl,[120447-62-3],295.85,Transporters,Acetylcholine Transporters,Inhibitor,Inhibits ACh transport,5,O[C@@H]1CCCC[C@H]1N1CCC(c2ccccc2)CC1,136,1
665,N=C(NCCC[C@H](N)C(OC)=O)N[N+]([O-])=O.Cl,L-NAME hydrochloride,135193,NG-Nitro-L-arginine methyl ester hydrochloride,C7H15N5O4.HCl,[51298-62-5],269.69,Enzymes,Non-selective NOS,Inhibitor,Non-selective NOS inhibitor,7,COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-],28,1
670,CCC(C)N(C)C(=O)C1=NC(C2=CC=CC=C2Cl)=C2C=CC=CC2=C1,PK 11195,1345,1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide,C21H21ClN2O,[85532-75-8],352.86,Other Pharmacology,Translocator Protein,Ligand,Antagonist at peripheral benzodiazepine receptors,11,CCC(C)N(C)C(=O)c1cc2ccccc2c(-c2ccccc2Cl)n1,629,1
671,CC(C)OC1=CC=C2C(OC3=C(C=C(C=C3)C(O)=O)C2=O)=C1,AH 6809,119461,6-Isopropoxy-9-xanthone-2-carboxylic acid,C17H14O5,[33458-93-4],298.3,7-TM Receptors,Prostanoid Receptors,Antagonist,EP1 and EP2 receptor antagonist,4,CC(C)Oc1ccc2c(=O)c3cc(C(=O)O)ccc3oc2c1,804,1
685,[H][C@]2(C3=CC=C(OC)C=C3)[C@@]([H])(OC(C)=O)C(N(CCN(C)C)C1=CC=CC=C1S2)=O.Cl,Diltiazem hydrochloride,62920,"(2S-cis)-3-(Acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one hydrochloride",C22H26N2O4S.HCl,[33286-22-5],450.98,Ion Channels,Cav1.x Channels,Blocker,CaV1.x blocker,4,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,413,1
691,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO,Dipyridamole,3108,"2,6-bis(Diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine",C24H40N8O4,[58-32-2],504.63,Transporters,Nucleoside Transporters,Inhibitor,Adenosine transport inhibitor,4,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,40,1
703,Cl.ClC1=NC(SC2CCNCC2)=CC=C1,Anpirtoline hydrochloride,6917943,6-Chloro-2-[piperidinyl-4-thio]pyridine hydrochloride,C10H13ClN2S.HCl,[99201-87-3],265.2,7-TM Receptors,5-HT1B Receptors,Agonist,Highly potent 5-HT1B agonist; also 5-HT3 antagonist,6,Clc1cccc(SC2CCNCC2)n1,854,1
706,Br.CCCN(CCC)C1CCC2=CC=C(O)C=C2C1,7-Hydroxy-DPAT hydrobromide,11957566,(�)-7-Hydroxy-2-dipropylaminotetralin hydrobromide,C16H25NO.HBr,[76135-30-3],328.28,7-TM Receptors,D3 Receptors,Agonist,Dopamine agonist (D3 ? D2 < > D4),3,CCCN(CCC)C1CCc2ccc(O)cc2C1,120,0
713,NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2,Cyclothiazide,2910,"6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiazidiazine-7-sulfonamide-1,1-dioxide",C14H16ClN3O4S2,[2259-96-3],389.87,Ion Channels,AMPA Receptors,Modulator,Positive allosteric modulator of AMPA receptors; inhibits AMPA desensitization,8,NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O,895,1
741,CN(C)CCCN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CNC2=CC=CC=C12,GF 109203X,2396,2-[1-(3-Dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl) maleimide,C25H24N4O2,[133052-90-1],416.99,Enzymes,Protein Kinase C,Inhibitor,Protein kinase C inhibitor,6,CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21,785,1
742,ClC1=C2C(N[C@@H]([C@](O)=O)C[C@@H]2NC(NC3=CC=CC=C3)=O)=CC(Cl)=C1,"L-689,560",6604749,"trans-2-Carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline",C17H15Cl2N3O3,[139051-78-8],380.23,Ion Channels,NMDA Receptors,Antagonist,Highly potent NMDA antagonist,5,O=C(Nc1ccccc1)N[C@H]1C[C@H](C(=O)O)Nc2cc(Cl)cc(Cl)c21,610,1
760,CC1(C)CCC(C)(C)C2=CC(=CC=C12)C(=O)NC1=CC=C(C=C1)C(O)=O,AM 580,2126,"4-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid",C22H25NO3,[102121-60-8],364.95,Nuclear Receptors,Retinoic Acid Receptors,Agonist,Retinoic acid analog; RAR? agonist,3,CC1(C)CCC(C)(C)c2cc(C(=O)Nc3ccc(C(=O)O)cc3)ccc21,456,1
764,[H][C@@](N1C[C@@H](C)N(CC=C)C[C@@H]1C)(C1=CC=C(C=C1)C(=O)N(CC)CC)C1=CC=CC(OC)=C1,SNC 80,123924,"(+)-4-[(?R)-?-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide",C28H39N3O2,[156727-74-1],449.64,7-TM Receptors,Delta Opioid Receptors,Agonist,Highly selective non-peptide ? agonist,21,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C,224,1
767,Cl.CNCCCCOC1=CC=CC=C1CC1=CC=CC=C1,Bifemelane hydrochloride,43962,4-(2-Benzylphenoxy)-N-methylbutylamine hydrochloride,C18H23NO.HCl,[62232-46-6],305.84,Enzymes,Monoamine Oxidase,Inhibitor,Non-selective MAO inhibitor,2,CNCCCCOc1ccccc1Cc1ccccc1,215,1
778,ClC1=C(Cl)C=C(CC(N([C@@]([H])([C@]3=CC=CC=C3)CN2CCCC2)C)=O)C=C1.Cl,"ICI 199,441 hydrochloride",3082717,"2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide hydrochloride",C21H24Cl2N2O.HCl,[115199-84-3],427.8,7-TM Receptors,Kappa Opioid Receptors,Agonist,Potent ? agonist,2,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H](CN1CCCC1)c1ccccc1,625,1
807,Cl.OC1=NOC2=C1CCNC2,THIP hydrochloride,5702253,"4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrochloride",C6H8N2O2.HCl,[85118-33-8],176.6,Ion Channels,GABAA Receptors,Agonist,GABAA agonist,20,Oc1noc2c1CCNC2,1,1
880,O=C1ON=C2C=NC3=C(C=CC=C3)N12,ODQ,1456,"1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one",C9H5N3O2,[41443-28-1],187.16,Cell biology,Other Nitric Oxide,Inhibitor,Selective inhibitor of NO-sensitive guanylyl cyclase,6,O=c1onc2cnc3ccccc3n12,765,1
894,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O,(RS)-(+/-)-Sulpiride,5355,(RS)-(�)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide,C15H23N3O4S,[15676-16-1],341.42,7-TM Receptors,Non-selective Dopamine,Antagonist,Standard selective D2-like antagonist,3,CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,335,1
895,NS(C1=CC(C(NC[C@]2([H])CCCN2CC)=O)=C(OC)C=C1)(=O)=O,(S)-(-)-Sulpiride,688272,(S)-(-)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide,C15H23N3O4S,[23672-07-3],341.42,7-TM Receptors,Non-selective Dopamine,Antagonist,Standard selective D2-like antagonist,5,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,335,0
905,COC1=CC=C(C=C1OC1CCCC1)C1CNC(=O)C1,Rolipram,5092,4-(3-(Cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one,C16H21NO3,[61413-54-5],275.35,Enzymes,Phosphodiesterases,Inhibitor,PDE4 inhibitor,19,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1,370,1
909,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1,Tropicamide,5593,N-Ethyl-3-hydroxy-2-phenyl-N-(pyridinylmethyl)propanamide,C17H20N2O2,[1508-75-4],284.36,7-TM Receptors,M4 Receptors,Antagonist,Selective M4 antagonist,3,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1,219,1
911,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,Glibenclamide,3488,5-Chloro-N-[2-[4-[[[(Cylcohexylamino)carbonyl]amino]sulphonyl]phenyl]ethyl]-2-methoxybenzamide,C23H28ClN3O5S,[10238-21-8],494,Ion Channels,Inward rectifier Potassium Channels,Blocker,Kir6 (KATP) channel blocker,4,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,335,0
921,[H][C@@](C1)2[C@](CC(N=C(C=CC=C4)C4=C3)=C3C2)([C@]5=CC=CC(O)=C5)CCN1C.Br.Br,SB 205607 dihydrobromide,56972161,"(R*,S*)-(�)-2-Methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide",C23H24N2O.2HBr,[1217628-73-3],542.31,7-TM Receptors,Delta Opioid Receptors,Agonist,"Selective, high affinity non-peptide ?1 agonist",5,CN1CC[C@]2(c3cccc(O)c3)Cc3nc4ccccc4cc3C[C@H]2C1,127,1
924,O=C(O)/C=C\C(O)=O.C[C@]1(N4)C3=C(C=CC=C3)C[C@@H]4C2=C1C=CC=C2,(+)-MK 801 maleate,6420042,"(5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate",C16H15N.C4H4O4,[77086-22-7],337.37,Ion Channels,NMDA Receptors,Antagonist,Non-competitive NMDA antagonist; acts at ion channel site,12,C[C@]12N[C@H](Cc3ccccc31)c1ccccc12,144,1
927,Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Fluoxetine hydrochloride,62857,N-Methyl-3-[(4-trifluoromethyl)phenoxy]-3-phenylpropylamine hydrochloride,C17H18F3NO.HCl,[56296-78-7],345.78,Transporters,5-HT Transporters,Inhibitor,5-HT reuptake inhibitor,5,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,181,0
937,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1,Pimozide,16362,"1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one",C28H29F2N3O,[2062-78-4],461.55,7-TM Receptors,Non-selective Dopamine,Antagonist,D2-like antagonist; also high affinity 5-HT7 antagonist,9,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,262,0
942,CS(=O)(=O)NC1=C(OC2CCCCC2)C=C(C=C1)[N+]([O-])=O,NS 398,4553,N-[2-Cyclohexyloxy-4-nitrophenyl]methanesulfonamide,C13H18N2O5S,[123653-11-2],314.36,Enzymes,Cyclooxygenase,Inhibitor,Cyclooxygenase-2 (COX-2) inhibitor,2,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1OC1CCCCC1,89,1
947,CCCOC1=C(C=CC=C1)C1=NC2=C(NN=N2)C(=O)N1,Zaprinast,5722,2-(2-Propyloxyphenyl)-8-azapurin-6-one,C13H13N5O2,[37762-06-4],271.28,7-TM Receptors,GPR35,Agonist,GPR35 agonist,10,CCCOc1ccccc1-c1nc2nn[nH]c2c(=O)[nH]1,667,1
950,[H]OC(=O)\C=C\C(=O)O[H].OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1.OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1,Xamoterol hemifumarate,6440459,1-(4-Hydroxyphenoxy)-3-[2-(4-morpholinocarboxamido)ethylamino]-2-propanol hemifumarate,C16H25N3O5.0.5C4H4O4,[73210-73-8],401.93,7-TM Receptors,Adrenergic Beta-1 Receptors,Agonist,Selective ?1 partial agonist,4,O=C(NCCNCC(O)COc1ccc(O)cc1)N1CCOCC1,433,0
955,O=C(O)/C=C\C(O)=O.C[C@@]14C3=C(C=CC=C3)C[C@H](N4)C2=C1C=CC=C2,(-)-MK 801 maleate,16219612,"(5R,10S)-(-)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cylcohepten-5,10-imine maleate",C16H15N.C4H4O4,[121917-57-5],337.37,Ion Channels,NMDA Receptors,Antagonist,NMDA antagonist; less active enantiomer of (+)-MK 801,2,C[C@@]12N[C@@H](Cc3ccccc31)c1ccccc12,144,0
956,Br.Br.CN(C)CCN(C)CCC1=CC=C(Cl)C(Cl)=C1,BD 1047 dihydrobromide,45073418,"N-[2-(3,4-Dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide",C13H20Cl2N2.2HBr,[138356-21-5],437.04,Other Pharmacology,Sigma1 Receptors,Antagonist,?1 selective antagonist,4,CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1,626,1
991,Cl.COC1=CC(OC)=CC(COC2=CC(N)=C(Cl)C=C2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)=C1,RS 39604 hydrochloride,19081934,"1-[4-Amino-5-chloro-2-(3,5-dimethoxyphenyl)methyloxy]-3-[1-[2-methylsulphonylamino]ethyl]piperidin-4-yl]propan-1-one hydrochloride",C26H36ClN3O6S.HCl,[167710-87-4],595.06,7-TM Receptors,5-HT4 Receptors,Antagonist,5-HT4 antagonist,3,COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1,338,1
993,[H]OC(=O)\C=C\C(=O)O[H].CC(C)(C)NCC(O)COC1=C2C=C(NC2=CC=C1)C#N.CC(C)(C)NCC(O)COC1=C2C=C(NC2=CC=C1)C#N,Cyanopindolol hemifumarate,45073413,4-[3-[tert-Butylamino]-2-hydroxypropoxy]-1H-indole-2-carbonitrile hemifumarate,C16H21N3O2.�C4H4O4,[69906-86-1],345.4,7-TM Receptors,5-HT1A Receptors,Antagonist,5-HT1A and 5-HT1B antagonist; also ?-adrenergic antagonist,4,CC(C)(C)NCC(O)COc1cccc2[nH]c(C#N)cc12,347,1
995,Cl.FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1,Spiperone hydrochloride,11957687,"8-[4-(4-Fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one hydrochloride",C23H26FN3O2.HCl,[2022-29-9],431.94,7-TM Receptors,5-HT2A Receptors,Antagonist,5-HT2A antagonist; also D2-like antagonist,10,O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1,281,0
999,CC/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)/C1=CC=C(OCCN(C)C)C=C1.O=C(O)CC(O)(C(O)=O)CC(O)=O,Tamoxifen citrate,2733525,"(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine citrate",C26H29NO.C6H8O7,[54965-24-1],563.65,Nuclear Receptors,Estrogen and Related Receptors,Modulator,Estrogen receptor partial agonist/antagonist,4,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,435,1
1000,[Cl-].CCN(C1=CC=CC=C1)C1=CC(NC)=[N+](C)C(C)=N1,ZD 7288,123983,"4-Ethylphenylamino-1,2-dimethyl-6-methylaminopyrimidinium chloride",C15H21ClN4,[133059-99-1],301.82,Ion Channels,HCN Channels,Blocker,Inhibits pacemaker (If) current,6,CCN(c1ccccc1)c1cc(NC)[n+](C)c(C)n1,233,1
1003,OC1(CCN(CC2=CNC3=CC=CC=C23)CC1)C1=CC=C(Cl)C=C1,"L-741,626",133633,3-[[4-(4-Chlorophenyl)-4-hydroxypiperidin-l-yl]methyl-1H-indole,C20H21ClN2O,[81226-60-0],340.85,7-TM Receptors,D2 Receptors,Antagonist,High affinity D2 antagonist,5,OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1,795,0
1027,O=C(NC4=CC=CC=C4)C3(C2C3)OC1=CC=CC=C1/C2=N/O,PHCCC,5866327,N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide,C17H14N2O3,[179068-02-1],294.31,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Antagonist,Potent group I mGlu antagonist,7,O=C(Nc1ccccc1)C12CC1/C(=N\O)c1ccccc1O2,638,1
1028,O=C(OCC)C3(C2C3)OC1=CC=CC=C1/C2=N/O,CPCCOEt,6278000,7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester,C13H13NO4,[179067-99-3],247.25,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Antagonist,Selective non-competitive mGlu1 antagonist,12,CCOC(=O)C12CC1/C(=N\O)c1ccccc1O2,638,0
1034,CCC(=O)NC1CC(C2=CC=CC=C2)C2=C(C1)C=CC=C2,4-P-PDOT,3976006,cis-4-Phenyl-2-propionamidotetralin,C19H21NO,[620170-78-7],283.88,7-TM Receptors,Melatonin (MT) Receptors,Antagonist,MT2 antagonist,6,CCC(=O)NC1Cc2ccccc2C(c2ccccc2)C1,132,1
1036,NC1=NC(NCCC2=CC=C(O)C=C2)=NC2=NC(=NN12)C1=CC=CO1,ZM 241385,176407,"4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol",C16H15N7O2,[139180-30-6],337.34,7-TM Receptors,Adenosine A2A Receptors,Antagonist,Potent and highly selective A2A antagonist,14,Nc1nc(NCCc2ccc(O)cc2)nc2nc(-c3ccco3)nn12,164,0
1041,CCN1C(=O)NC2=C1C=CC=C2,1-EBIO,82320,1-Ethyl-2-benzimidazolinone,C9H10N2O,[10045-45-1],162.19,Ion Channels,Ca2+-Activated Potassium Channels,Activator,Activator of epithelial KCa channels,7,CCn1c(=O)[nH]c2ccccc21,263,1
1047,OC1=CC=C2C(C[C@@H](CCCCCCCCCS(CCCC(F)(C(F)(F)F)F)=O)C3([H])[C@@]([H])2CC[C@@]4(C)[C@@](CC[C@@H]4O)3[H])=C1,"ICI 182,780",17756771,"7?,17?-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol",C32H47F5O3S,[129453-61-8],606.77,Nuclear Receptors,Estrogen and Related Receptors,Antagonist,Estrogen receptor antagonist,22,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)C3[C@@H]1CC[C@@H]2O,122,1
1050,Cl.COC1=CC(OC)=C(NS(=O)(=O)C2=CC=C(C=C2)C(F)(F)F)C=C1C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O,RS 102221 hydrochloride,18931299,"8-[5-(2,4-Dimethoxy-5-(4-trifluoromethylphenylsulphonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride",C27H31F3N4O7S.HCl,[187397-18-8],658.09,7-TM Receptors,5-HT2C Receptors,Antagonist,Selective 5-HT2C antagonist,14,COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(C(F)(F)F)cc1,110,1
1051,OC1=C(NS(=O)(C)=O)C=C(C(O)CNC(C)(C)CC2=CC=CC=C2)C=C1.Cl,Zinterol hydrochloride,37989,"N-[5-[2-[(1,1-Dimethyl-2-phenylethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulphonamide hydrochloride",C19H26N2O4S,[37000-20-7],414.95,7-TM Receptors,Adrenergic Beta-2 Receptors,Agonist,Selective ?2 agonist,4,CC(C)(Cc1ccccc1)NCC(O)c1ccc(O)c(NS(C)(=O)=O)c1,431,1
1061,Cl.[H][C@]12CCCN(CCC)[C@]1([H])CC1=CNN=C1C2,(-)-Quinpirole hydrochloride,55397,"(4aR-trans)-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H-pyrazolo[3,4-g]quinoline hydrochloride",C13H21N3.HCl,[85798-08-9],287.31,7-TM Receptors,Non-selective Dopamine,Agonist,Selective D2-like agonist,17,CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@H]21,37,1
1063,NC1=NC(NCCC4=CC=C(CCC(O)=O)C=C4)=NC2=C1N=CN2[C@@H]3O[C@H]([C@](NCC)=O)[C@@H](O)[C@H]3O.Cl,CGS 21680 hydrochloride,10256643,4-[2-[[6-Amino-9-(N-ethyl-?-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid hydrochloride,C23H29N7O6.HCl,[124431-80-7],549.5,7-TM Receptors,Adenosine A2A Receptors,Agonist,A2A agonist,16,CCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)nc(NCCc4ccc(CCC(=O)O)cc4)nc32)[C@H](O)[C@@H]1O,842,0
1080,Br.CCCN(CCC)[C@@H]1CCC2=CC=CC(O)=C2C1,(R)-(+)-8-Hydroxy-DPAT hydrobromide,11957570,(2R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide,C16H25NO.HBr,[78095-19-9],328.29,7-TM Receptors,5-HT1A Receptors,Agonist,Selective 5-HT1A agonist; enantiomer of 8-Hydroxy-DPAT hydrobromide (Cat. No. 0529),8,CCCN(CCC)[C@@H]1CCc2cccc(O)c2C1,120,1
1081,Cl[H].OC(=O)C1CCCN(CC\C=C(\C2=CC=CC=C2)C2=CC=CC=C2)C1,SKF 89976A hydrochloride,6917797,"1-(4,4-Diphenyl-3-butenyl)-3-piperidinecarboxylic acid hydrochloride",C22H25NO2.HCl,[85375-15-1],371.91,Transporters,GABA Transporters,Inhibitor,Potent GAT-1 inhibitor; brain penetrant,1,O=C(O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1,298,1
1088,OP(CC1CCCCC1)(C[C@@H](O)CN[C@@H](C)C2=CC(Cl)=C(Cl)C=C2)=O.Cl,CGP 54626 hydrochloride,197583,"[S-(R*,R*)]-[3-[[1-(3,4-Dichlorophenyl)ethyl]amino]-2-hydroxypropyl](cyclohexylmethyl) phosphinic acid",C18H28Cl2NO3P.HCl,[149184-21-4],444.76,7-TM Receptors,GABAB Receptors,Antagonist,Potent and selective GABAB antagonist,2,C[C@H](NC[C@H](O)CP(=O)(O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1,624,1
1097,O=C2[C@@]3(C)C([C@@]4(OC(C)=O)[C@H](OC4)C[C@@H]3O)[C@H](OC(C7=CC=CC=C7)=O)[C@@]1(O)[C@](C)(C)C([C@H]2OC(C)=O)=C(C)[C@@H](OC([C@H](O)[C@H]([C@]5=CC=CC=C5)NC(C6=CC=CC=C6)=O)=O)C1,Taxol,441276,"[2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-?-(Benzoylamino)-?-hydroxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester benzenepropanoic acid",C47H51NO14,[33069-62-4],862.93,Cell biology,Microtubules,Other,Promotes assembly and inhibits disassembly of microtubules,8,CC(=O)O[C@H]1C(=O)[C@@]2(C)C([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,14,1
1098,COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC,Tranilast,5282230,"2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid",C18H17NO5,[53902-12-8],327.34,Other Pharmacology,Miscellaneous Compounds,Other,Antiallergic; inhibits inflammatory mediator release from mast cells,1,COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC,534,1
1099,C=C[C@](C3)(C)O[C@]2(C)[C@@H](OC(C)=O)[C@@H](O)[C@@]1([H])C(C)(C)CC[C@H](O)[C@@](C)1[C@](O)2C3=O,Forskolin,47936,"[3R-(3?,4a?,5?,6?,6a?,10?,10a?,10b?)]-5-(Acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho[2,1-b]pyran-1-one",C22H34O7,[66575-29-9],410.51,Enzymes,Adenylyl Cyclase,Activator,Adenylyl cyclase activator,3,C=C[C@@]1(C)CC(=O)[C@@]2(O)[C@](C)(O1)[C@@H](OC(C)=O)[C@@H](O)[C@H]1C(C)(C)CC[C@H](O)[C@@]12C,15,1
1102,O=C1C=CC2=C(C(O)=CC=C2[C@@]([H])(O)[C@@](NC(C)C)(CC)[H])N1.Cl,Procaterol hydrochloride,43091,(�)-erythro-8-Hydroxy-5-[1-hydroxy-2-(isopropylamino)butyl]carbostyril hydrochloride,C16H22N2O3.HCl,[62929-91-3],398.88,7-TM Receptors,Adrenergic Beta-2 Receptors,Agonist,Potent ?2 agonist,3,CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,809,1
1110,OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O,Genistein,5280961,"5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one",C15H10O5,[446-72-0],270.24,Enzyme-Linked Receptors,EGFR,Inhibitor,EGFR kinase inhibitor. Also estrogen and PPAR? ligand,4,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,800,1
1114,ClC1=CC=C2NC(=O)CSC(C3=CC=CC=C3Cl)C2=C1,CGP 37157,2688,"7-Chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one",C15H11Cl2NOS,[75450-34-9],324.22,Transporters,Na+/Ca2+ Exchanger,Inhibitor,Antagonist of mitochondrial Na+/Ca2+ exchange,4,O=C1CSC(c2ccccc2Cl)c2cc(Cl)ccc2N1,767,1
1130,Cl.O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1,LY 294002 hydrochloride,11957589,2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride,C19H17NO3.HCl,[934389-88-5],352.82,Enzymes,PI 3-Kinase,Inhibitor,Prototypical PI 3-kinase inhibitor; also inhibits other kinases,4,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,308,1
1140,[Na+].[H][C@@]12COP([O-])(=O)O[C@@]1([H])[C@@H](O)[C@@H](O2)N1C(Br)=NC2=C1N=CN=C2N,"8-Bromo-cAMP, sodium salt",23702958,"8-Bromoadenosine-3',5'-cyclic monophosphate sodium salt",C10H10BrN5NaO6P,[76939-46-3],466.12,Cell biology,cAMP,Other,Cell-permeable cAMP analog,8,Nc1ncnc2c1nc(Br)n2[C@@H]1O[C@@H]2COP(=O)([O-])O[C@H]2[C@H]1O,839,1
1141,[Na+].[H][C@@]12COP([O-])(=O)O[C@@]1([H])[C@@H](OC(=O)CCC)[C@@H](O2)N1C=NC2=C1N=CN=C2NC(=O)CCC,"Dibutyryl-cAMP, sodium salt",23663967,"N6,O2'-Dibutyryl adenosine 3',5'-cyclic monophosphate sodium salt",C18H23N5NaO8P,[16980-89-5],500.38,Cell biology,cAMP,Other,Cell-permeable cAMP analog,14,CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2COP(=O)([O-])O[C@H]2[C@H]1OC(=O)CCC,839,0
1202,CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1,SB 203580,176155,4-[5-(4-Fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-1H-imidazol-4-yl]pyridine,C21H16FN3OS,[152121-47-6],377.44,Enzymes,p38,Inhibitor,Selective inhibitor of p38 MAPK,5,CS(=O)c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,57,1
1206,CC(=O)NNC(=O)N1CC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2,SC 19220,4336830,"8-Chloro-dibenzo(Z)[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-acetylhydrazide",C16H14ClN3O3,[19395-87-0],331.76,7-TM Receptors,Prostanoid Receptors,Antagonist,Selective EP1 receptor antagonist,3,CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc21,640,0
1212,Cl.CC1=CC=CC(=N1)C#CC1=CC=CC=C1,MPEP hydrochloride,9794588,2-Methyl-6-(phenylethynyl)pyridine hydrochloride,C14H11N.HCl,[219911-35-0],229.71,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Antagonist,Potent mGlu5 antagonist; also positive allosteric modulator of mGlu4 receptors,10,Cc1cccc(C#Cc2ccccc2)n1,722,1
1213,COC1=C(N)C(=CC=C1)C1=CC(=O)C2=CC=CC=C2O1,PD 98059,9794588,2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one,C16H13NO3,[167869-21-8],267.28,Enzymes,MEK,Inhibitor,MEK inhibitor,9,COc1cccc(-c2cc(=O)c3ccccc3o2)c1N,805,1
1217,ClC1=CC=C2N=C(NC(=O)CC3=CC=CC=C3)N3N=C(N=C3C2=C1)C1=CC=CO1,MRS 1220,393595,"N-[9-Chloro-2-(2-furanyl)[1,2,4]-triazolo[1,5-c]quinazolin-5-yl]benzene acetamide",C21H14ClN5O2,[183721-15-5],403.83,7-TM Receptors,Adenosine A3 Receptors,Antagonist,Highly potent and selective hA3 antagonist,4,O=C(Cc1ccccc1)Nc1nc2ccc(Cl)cc2c2nc(-c3ccco3)nn12,164,0
1223,[H][C@@](OCC1=CC=CC=C1)(C(O)=O)[C@@]([H])(C(O)=O)N.[H][C@](OCC2=CC=CC=C2)(C(O)=O)[C@]([H])(C(O)=O)N,DL-TBOA,90479771,DL-threo-?-Benzyloxyaspartic acid,C11H13NO5,[205309-81-5],243.73,Transporters,Glutamate Transporters,Inhibitor,Selective non-transportable inhibitor of EAATs,15,N[C@H](C(=O)O)[C@H](OCc1ccccc1)C(=O)O,209,1
1226,OC(C(OC)=C3)=C(OC)C=[C@@]3[C@@H]2C1=CC6=C(OCO6)C=C1[C@@H](O[C@]4([H])O[C@@](CO[C@@H](C)O7)([H])[C@]7([H])[C@H](O)[C@H]4O)[C@@H]5[C@@H]2[C@](OC5)=O,Etoposide,36462,"[5R-[5?,5a?,8a?,9?(R*)]]-9-[(4,6-?-Ethylidene-?-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6-(5aH)-one",C29H32O13,[33419-42-0],597.57,Enzymes,DNA Topoisomerase,Inhibitor,Topoisomerase II inhibitor,6,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,16,1
1244,CS(O)(=O)=O.NC(=N)SCCC1=CC=C(OCC2=CC=C(C=C2)[N+]([O-])=O)C=C1,KB-R7943 mesylate,9823846,2-[2-[4-(4-Nitrobenzyloxy)phenyl]ethyl]isothiourea mesylate,C16H17N3O3S.CH3SO3H,[182004-65-5],427.49,Transporters,Na+/Ca2+ Exchanger,Inhibitor,Na+/Ca2+ exchange inhibitor (reverse mode),3,N=C(N)SCCc1ccc(OCc2ccc([N+](=O)[O-])cc2)cc1,440,1
1248,Cl.C[C@H](NC[C@H](O)CP(O)(=O)CC1=CC=CC=C1)C1=CC=C(Cl)C(Cl)=C1,CGP 55845 hydrochloride,5311042,"(2S)-3-[[(1S)-1-(3,4-Dichlorophenyl)ethyl]amino-2-hydroxypropyl](phenylmethyl)phosphinic acid hydrochloride",C18H22Cl2NO3P.HCl,[149184-22-5],438.71,7-TM Receptors,GABAB Receptors,Antagonist,Potent and selective GABAB antagonist,9,C[C@H](NC[C@H](O)CP(=O)(O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1,624,0
1253,O=C(NC(C)(C)C)[C@@]([C@]3=CC=CC=C3)([H])CN(CC2)CCN2C1=C(OC)C=CC=C1.Cl.Cl,(S)-WAY 100135 dihydrochloride,6604839,(S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide dihydrochloride,C24H33N3O2.2HCl,[149007-54-5],477.48,7-TM Receptors,5-HT1A Receptors,Antagonist,Potent and selective 5-HT1A antagonist,6,COc1ccccc1N1CCN(C[C@H](C(=O)NC(C)(C)C)c2ccccc2)CC1,350,1
1262,Br.COC1=CC=C(C=C1)C1=NN(CCCC(O)=O)C(=N)C=C1,SR 95531 hydrobromide,107895,6-Imino-3-(4-methoxyphenyl)-1(6H)-pyridazinebutanoic acid hydrobromide,C15H17N3O3.HBr,[104104-50-9],368.23,Ion Channels,GABAA Receptors,Antagonist,Competitive and selective GABAA antagonist,14,COc1ccc(-c2ccc(=N)n(CCCC(=O)O)n2)cc1,412,1
1264,OC1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1,SB 202190,16759148,4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol,C20H14N3OF,[152121-30-7],335.85,Enzymes,p38,Inhibitor,"Potent, selective inhibitor of p38 MAPK",5,Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,57,0
1296,Cl.OC(=O)C1=CCCN(CCOC(C2=CC=C(C=C2)C(F)(F)F)C2=CC=C(C=C2)C(F)(F)F)C1,CI 966 hydrochloride,198692,"1-[2-[bis[4-(Trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride",C23H21F6NO3.HCl,[110283-66-4],509.87,Transporters,GABA Transporters,Inhibitor,Selective inhibitor of GAT-1,1,O=C(O)C1=CCCN(CCOC(c2ccc(C(F)(F)F)cc2)c2ccc(C(F)(F)F)cc2)C1,288,1
1305,CCOC(=O)C1=C(C)NC(=S)NC1C1=CC(O)=CC=C1,Monastrol,5353454,"1,2,3,4-Tetrahydro-4-(3-hydroxyphenyl)-6-methyl-2-thioxo-5-pyrimidinecarboxylic acid, ethyl ester",C14H16N2O3S,[254753-54-3],292.35,Enzymes,Kinesin,Inhibitor,Selective inhibitor of mitotic kinesin Eg5,4,CCOC(=O)C1=C(C)NC(=S)NC1c1cccc(O)c1,124,1
1312,CC1=C(C)C(NC2=CC(Cl)=NC(SCC(O)=O)=N2)=CC=C1,WY 14643,5694,"[[4-Chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid",C14H14ClN3O2S,[50892-23-4],323.8,Nuclear Receptors,PPARalpha Receptors,Agonist,Selective PPAR? agonist,5,Cc1cccc(Nc2cc(Cl)nc(SCC(=O)O)n2)c1C,490,1
1317,Cl.CCCOC1=CC=C2NC=C(C2=N1)C1=CCNCC1,CP 94253 hydrochloride,11652258,"5-Propoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrrolo[3,2-b]pyridine hydrochloride",C15H19N3O.HCl,[845861-39-4],298.3,7-TM Receptors,5-HT1B Receptors,Agonist,Potent and selective 5-HT1B agonist,4,CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1,564,1
1324,Cl.COC1(COC2=CC=CC=C2O1)C1=NCCN1,RX 821002 hydrochloride,11957683,"2-(2,3-Dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole hydrochloride",C12H14N2O3.HCl,[109544-45-8],270.72,7-TM Receptors,Adrenergic Alpha-2 Receptors,Antagonist,"Potent, selective ?2D antagonist",4,COC1(C2=NCCN2)COc2ccccc2O1,360,1
1327,O=C(N3[C@]([H])2CCC3)C4=C(C=CC(OC)=C4)N1C2=C(C(OCC)=O)N=C1,"L-655,708",5311203,"11,12,13,13a-Tetrahydro-7-methoxy-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylic acid, ethyl ester",C18H19N3O4,[130477-52-0],341.37,Ion Channels,GABAA Receptors,Benzodiazepine,Benzodiazepine inverse agonist; selective for ?5-containing GABAA receptors,6,CCOC(=O)c1ncn2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc1-2,342,1
1328,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1,Flumazenil,3373,"8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, ethyl ester",C15H14FN3O3,[78755-81-4],303.29,Ion Channels,GABAA Receptors,Benzodiazepine,Benzodiazepine antagonist,4,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,342,0
1332,OC[C@@H](CC)NC1=NC(N(C(C)C)C=N2)=C2C(NCC3=CC=CC=C3)=N1,Roscovitine,160355,(2R)-2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol,C19H26N6O,[186692-46-6],354.45,Enzymes,Cyclin-dependent Kinase,Inhibitor,Cdk inhibitor,2,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,825,0
1349,O=C1NC[C@@H](C2=CC(OC3CCCC3)=C(OC)C=C2)C1,(R)-(-)-Rolipram,448055,(4R)-4-[3-(Cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one,C16H21NO3,[85416-75-7],275.35,Enzymes,Phosphodiesterases,Inhibitor,PDE4 inhibitor. More active enantiomer of rolipram (Cat. No. 0905),15,COc1ccc([C@@H]2CNC(=O)C2)cc1OC1CCCC1,370,0
1372,O=C(NC3=CC(C)=NS3)NC1=CC(C=CN2C)=C2C=C1,SB 204741,3277600,N-(1-Methyl-1H-indolyl-5-yl)-N''-(3-methyl-5-isothiazolyl)urea,C14H14N4OS,[152239-46-8],286.35,7-TM Receptors,5-HT2B Receptors,Antagonist,"Potent, selective 5-HT2B antagonist",3,Cc1cc(NC(=O)Nc2ccc3c(ccn3C)c2)sn1,469,1
1393,O=C(C2=C(C)C(C4=CC=CC=C4)=NC3=CC=CC=C23)N[C@@H](CC)C1=CC=CC=C1,SB 222200,6604009,3-Methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide,C26H24N2O,[174635-69-9],380.48,7-TM Receptors,NK3 Receptor,Antagonist,"Potent, selective non-peptide NK3 antagonist. Brain penetrant",2,CC[C@H](NC(=O)c1c(C)c(-c2ccccc2)nc2ccccc12)c1ccccc1,241,1
1398,BrC1=CC=C2NC3=C(CC(=O)NC4=CC=CC=C34)C2=C1,Kenpaullone,3820,"9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one",C16H11BrN2O,[142273-20-9],331.68,Enzymes,Glycogen Synthase Kinase 3,Inhibitor,GSK-3? inhibitor; also inhibits cdks,2,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,789,1
1400,C\N=C1SN(C3=CC=CC=C3)C(C2=CC=CC=C2)=N/1.Br,SCH 202676 hydrobromide,9884675,"N-(2,3-Diphenyl-1,2,4-thiadiazol-5(2H)-ylidene)methanamine hydrobromide",C15H13N3S.HBr,[265980-25-4],348.26,Enzymes,Heterotrimeric G-protein GTPases,Inhibitor,Inhibitor of ligand binding to G-protein-coupled receptors,1,C/N=c1/nc(-c2ccccc2)n(-c2ccccc2)s1,243,1
1407,CC(C)(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C(Cl)C=C1,PP 2,4878,"3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",C15H16ClN5,[172889-27-9],301.78,Enzymes,Src Kinases,Inhibitor,"Potent, selective Src family kinase inhibitor",3,CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21,834,1
1408,CC1=CC(NC(=O)NC2N=C(C3=CC=CC=C3)C3=CC=CC=C3N(CC(=O)C3=C(C)C=CC=C3)C2=O)=CC=C1,YM 022,3452843,"(R)-N-[2,3-Dihydro-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)-urea",C32H28N4O3,[145084-28-2],516.6,7-TM Receptors,CCK2 Receptor,Antagonist,"Highly potent, selective non-peptide CCK2 antagonist",1,Cc1cccc(NC(=O)NC2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1,251,0
1412,O[C@H]1[C@H](N(C)S(=O)(CC)=O)C2=C(C=CC(C#N)=C2)OC(C)1C.O[C@@H]3[C@@H](N(C)S(=O)(CC)=O)C4=C(C=CC(C#N)=C4)OC(C)3C,Chromanol 293B,121846,"trans-N-[6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methyl-ethanesulfonamide",C15H20N2O4S,[163163-23-3],324.39,Ion Channels,Voltage-Gated Potassium Channels,Blocker,IKs blocker. Also blocks ICFTR,1,CCS(=O)(=O)N(C)[C@@H]1c2cc(C#N)ccc2OC(C)(C)[C@H]1O,74,1
1418,OC1=CC=C(C=C1)\C=C\C1=CC(O)=CC(O)=C1,Resveratrol,445154,"5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol",C14H12O3,[501-36-0],230.05,Enzymes,Cyclooxygenase,Inhibitor,Cyclooxygenase inhibitor,4,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,888,0
1422,CCN1C(=O)NC2=C1C=C(Cl)C(Cl)=C2,DCEBIO,656765,"5,6-Dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one",C9H8Cl2N2O,[60563-36-2],231.08,Ion Channels,CFTR,Activator,Activates Cl- conductance and hKCa3.1 channels,3,CCn1c(=O)[nH]c2cc(Cl)c(Cl)cc21,263,0
1426,CCCC1=C(N(N=C1C1=CC=C(O)C=C1)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,PPT,6095481,"4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol",C24H22N2O3,[263717-53-9],390.95,Nuclear Receptors,Estrogen and Related Receptors,Agonist,Subtype-selective ER? agonist,8,CCCc1c(-c2ccc(O)cc2)nn(-c2ccc(O)cc2)c1-c1ccc(O)cc1,647,1
1430,CS(=O)(=O)C1=CC=C(C=C1)C1=C(SC(Br)=C1)C1=CC=C(F)C=C1,DuP 697,3177,5-Bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-thiophene,C17H12BrFO2S2,[88149-94-4],411.3,Enzymes,Cyclooxygenase,Inhibitor,Cyclooxygenase-2 (COX-2) inhibitor,1,CS(=O)(=O)c1ccc(-c2cc(Br)sc2-c2ccc(F)cc2)cc1,63,1
1435,NC1=C2N=CN(C3CCCO3)C2=NC=N1,SQ 22536,5270,9-(Tetrahydro-2-furanyl)-9H-purin-6-amine,C9H11N5O,[17318-31-9],205.22,Enzymes,Adenylyl Cyclase,Inhibitor,Adenylyl cyclase inhibitor,2,Nc1ncnc2c1ncn2C1CCCO1,842,0
1436,C1(/N[C@@H]2[C@H]([C@]3=CC=CC=C3)CCC2)=N\CCCCCCCCCCC1.Cl,MDL 12330A hydrochloride,6917816,"(�)-N-[(1R*,2R*)-2-Phenylcyclopentyl]-azacyclotridec-1-en-2-amine hydrochloride",C23H36N2.HCl,[40297-09-4],381.51,Enzymes,Adenylyl Cyclase,Inhibitor,Adenylyl cyclase inhibitor; also cyclic nucleotide PDE inhibitor,2,c1ccc([C@@H]2CCC[C@@H]2N/C2=N/CCCCCCCCCCC2)cc1,135,1
1441,Cl.CN(C)C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)NC1=C(C)C(C)=NO1,BMS 182874 hydrochloride,56972163,"5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide hydrochloride",C17H19N3O3S.HCl,[1215703-04-0],381.88,7-TM Receptors,Endothelin ETA Receptors,Antagonist,"Highly selective, orally active non-peptide ETA antagonist",1,Cc1noc(NS(=O)(=O)c2cccc3c(N(C)C)cccc23)c1C,852,1
1448,[H]OC(=O)\C=C\C(=O)O[H].COC1=CC=C(C=C1)C[C@H](C)NC[C@@H](O)C1=CC(NC([H])=O)=C(O)C=C1.COC1=CC=C(C=C1)C[C@H](C)NC[C@@H](O)C1=CC(NC([H])=O)=C(O)C=C1,Formoterol hemifumarate,9832292,"(�)-(R,R)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl] formamide hemifumarate",C19H24N2O4.�C4H4O4,[43229-80-7],420.47,7-TM Receptors,Adrenergic Beta-2 Receptors,Agonist,Potent and selective ?2 agonist,2,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,430,1
1453,[H]OC(=O)\C=C\C(=O)O[H].CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Clemastine fumarate,5281069,(2R)-2-[2-[(1R)-1-(4-Chlorophenylethoxy]ethyl]-1-methyl-2-pyrrolidine fumarate,C21H26ClNO.C4H4O4,[14976-57-9],459.97,7-TM Receptors,Histamine H1 Receptors,Antagonist,H1 antagonist,3,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,301,1
1454,Cl.Cl.CC1=NN=C(C2=CC=C(N)C=C2)C2=C(C1)C=C1OCOC1=C2,GYKI 52466 dihydrochloride,10042240,"4-(8-Methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine dihydrochloride",C17H15N3O2.HCl,[2319722-40-0],375.25,Ion Channels,AMPA Receptors,Antagonist,Selective non-competitive AMPA antagonist,7,CC1=NN=C(c2ccc(N)cc2)c2cc3c(cc2C1)OCO3,753,1
1470,CC(O)=O.FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(=C1)C(=O)NCC1CCCCN1,Flecainide acetate,41022,"N-(2-Piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide acetate",C17H20F6N2O3.C2H4O2,[54143-56-5],474.4,Ion Channels,Voltage-gated Sodium Channels,Blocker,Cardiac Na+ channel blocker. Antiarrhythmic,2,O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F,336,1
1475,CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)OC2=C1C=C(C=C2)C#N,"(-)-[3R,4S]-Chromanol 293B",121846,"N-[(3R,4S)-6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methylethanesulfonamide",C15H20N2O4S,[163163-24-4],324.39,Ion Channels,Voltage-Gated Potassium Channels,Blocker,IKs blocker. Enantiomer of Chromanol 293B (Cat. No. 1412),2,CCS(=O)(=O)N(C)[C@H]1c2cc(C#N)ccc2OC(C)(C)[C@@H]1O,74,0
1479,[H][C@@]23CCC1=CC(CCC1=C2[C@@H]([C@]5=CC=C(N(C)C)C=C5)C[C@@]4(C)[C@]([H])3CC[C@@](C#CC)4O)=O,Mifepristone,55245,"(11?,17?)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one",C29H35NO2,[84371-65-3],429.6,Nuclear Receptors,Progesterone Receptor,Antagonist,Progesterone and glucocorticoid receptor antagonist,2,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,10,1
1483,[H]OC(=O)\C=C\C(=O)O[H].COC(=O)N1CCN(C(CN2CCCC2)C1)C(=O)CC1=CC=C(Cl)C(Cl)=C1,GR 89696 fumarate,6442840,"4-[(3,4-Dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-1-piperazinecarboxylic acid methyl ester fumarate",C19H25Cl2N3O3.C4H4O4,[126766-32-3],530.4,7-TM Receptors,Kappa Opioid Receptors,Agonist,Subtype-selective ? agonist,2,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C(CN2CCCC2)C1,625,0
1508,[O-][N+](=O)C1=CC(C(=O)NC2=CC=CC=C2)=C(Cl)C=C1,GW 9662,644213,2-Chloro-5-nitro-N-phenylbenzamide,C13H9N2O3Cl,[22978-25-2],276.68,Nuclear Receptors,PPARgamma Receptors,Antagonist,Selective covalent PPAR? antagonist,1,O=C(Nc1ccccc1)c1cc([N+](=O)[O-])ccc1Cl,93,0
1511,O[C@@H](CN[C@H]2CCCC3=C2C=CC=C3)COC1=C(CC)C=CC=C1.Cl,SR 59230A hydrochloride,24978529,"1-(2-Ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol hydrochloride",C21H27NO2.HCl,[1135278-41-9],361.91,7-TM Receptors,Adrenergic Beta-3 Receptors,Antagonist,Potent and selective ?3 antagonist,5,CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc21,142,1
1513,CC(C)(CO)CC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C,CGP 7930,5024764,"3,5-bis(1,1-Dimethylethyl)-4-hydroxy-?,?-dimethyl-benzenepropanol",C19H32O2,[57717-80-3],292.46,7-TM Receptors,GABAB Receptors,Modulator,Positive allosteric modulator of GABAB receptors,3,CC(C)(CO)Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,862,1
1530,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,Lovastatin,53232,"(2S)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl-2-methyl butanoate",C24H36O5,[75330-75-5],404.54,Enzymes,HMG-CoA Reductase,Inhibitor,Potent HMG-CoA reductase inhibitor,1,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,18,1
1545,O=C(OC)C1=C(C)NC(C)=C([N+]([O-])=O)[C@@H]1[C@]2=CC=CC=C2C(F)(F)F,(R)-(+)-Bay K 8644,6604881,"(4R)-1,4-Dihydro-2,6-dimethyl-5-nitro-4-[2-trifluoromethyl)phenyl]-3-pyridinecarboxylic acid methyl ester",C16H15F3N2O4,[98791-67-4],356.3,Ion Channels,Cav1.x Channels,Blocker,CaV1.x blocker; (R)-(+)-enantiomer of (�)-Bay K 8644; also TMEM176B inhibitor,3,COC(=O)C1=C(C)NC(C)=C([N+](=O)[O-])[C@@H]1c1ccccc1C(F)(F)F,128,1
1546,O=C(OC)C1=C(C)NC(C)=C([N+]([O-])=O)[C@H]1[C@]2=CC=CC=C2C(F)(F)F,(S)-(-)-Bay K 8644,6603728,"(4S)-1,4-Dihydro-2,6-dimethyl-5-nitro-4-[2-trifluoromethyl)phenyl]-3-pyridinecarboxylic acid methyl ester",C16H15F3N2O4,[98625-26-4],360.8,Ion Channels,Cav1.x Channels,Activator,CaV1.x activator; (S)-(-)-enantiomer of (�)-Bay K 8644,7,COC(=O)C1=C(C)NC(C)=C([N+](=O)[O-])[C@H]1c1ccccc1C(F)(F)F,128,0
1549,OC(=O)C1=CC=C2C=C(C=CC2=C1)C1=CC=C(O)C(=C1)C12CC3CC(CC(C3)C1)C2,CD 437,135411,"6-(4-Hydroxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid",C27H26O3,[125316-60-1],398.5,Nuclear Receptors,Retinoic Acid Receptors,Agonist,RAR?-selective agonist,4,O=C(O)c1ccc2cc(-c3ccc(O)c(C45CC6CC(CC(C6)C4)C5)c3)ccc2c1,458,0
1579,O[C@@H]1[C@@H](CO)O[C@@H](N(C=N3)C2=C3C(NC)=NC(C#CCCCC)=N2)[C@@H]1O,HEMADO,10981286,2-(1-Hexynyl)-N-methyladenosine,C17H23N5O4,[403842-38-6],374.91,7-TM Receptors,Adenosine A3 Receptors,Agonist,High affinity selective A3 agonist,1,CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,841,0
1580,ClC1=CC=CC(NC2=C3C(N(C(C)C)C=N3)=NC(N[C@H]([C@@H](C)C)CO)=N2)=C1,Purvalanol A,456214,(2R)-2-[[6-[(3-Chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol,C19H25ClN6O,[212844-53-6],388.9,Enzymes,Cyclin-dependent Kinase,Inhibitor,"Cdk inhibitor; potently inhibits cdk1, cdk2 and cdk5",3,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,825,1
1581,CC(C)[C@H](CO)NC1=NC(NC2=CC(Cl)=C(C=C2)C(O)=O)=C2N=CN(C(C)C)C2=N1,Purvalanol B,448991,(2R)-2-[[6-[(3-Chloro-4-carboxyphenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol,C20H25ClN6O3,[212844-54-7],441.92,Enzymes,Cyclin-dependent Kinase,Inhibitor,"Selective cdk inhibitor; potently inhibits cdk1, cdk2 and cdk5",6,CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(=O)O)c(Cl)c2)c2ncn(C(C)C)c2n1,825,0
1586,Br.CN1CCC2=CC(Br)=C(O)C=C2C(C1)C1=CC=CC=C1,SKF 83566 hydrobromide,23581817,"8-Bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol hydrobromide",C17H18BrNO.HBr,[108179-91-5],413.15,7-TM Receptors,D1 and D5 Receptors,Antagonist,Potent and selective D1-like antagonist; also inhibits adenylyl cyclase 2,10,CN1CCc2cc(Br)c(O)cc2C(c2ccccc2)C1,139,1
1588,ClC(C=C3)=C(Cl)C=[C@@]3[C@H]2C1=CC=CC=C1[C@H](NC)C2.Cl,Indatraline hydrochloride,10314472,"(1R,3S)-rel-3-(3,4-Dichlorophenyl)-2,3-dihydro-N-methyl-1H-inden-1-amine hydrochloride",C16H15Cl2N.HCl,[96850-13-4],328.67,Transporters,5-HT Transporters,Inhibitor,Potent 5-HT uptake inhibitor; also inhibits dopamine and noradrenalin uptake,8,CN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,622,1
1591,Cl.CCCN(CC1CC1)C1=C(Cl)C(NC2=C(Cl)C=C(Cl)C=C2Cl)=NC(C)=N1,NBI 27914 hydrochloride,45073446,"5-Chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride",C18H20Cl4N4.HCl,[1215766-76-9],470.66,7-TM Receptors,CRF1 Receptors,Antagonist,Selective non-peptide CRF1 antagonist,2,CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl,85,1
1592,Cl.Cl.CC(C)C1=CC=C(CN2C=CC3=C2C=CC2=NC(NC4CC4)=NC(N)=C32)C=C1,SCH 79797 dihydrochloride,45073452,"N3-Cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine dihydrochloride",C23H25N5.2HCl,[1216720-69-2],444.41,7-TM Receptors,Protease-Activated Receptors,Antagonist,"Potent, selective non-peptide PAR1 antagonist",5,CC(C)c1ccc(Cn2ccc3c4c(N)nc(NC5CC5)nc4ccc32)cc1,829,1
1594,OC(=O)\C=C/C(O)=O.C[C@@H](CN1CCC(CC2=CC=CC=C2)CC1)[C@@H](O)C1=CC=C(O)C=C1,Ro 25-6981 maleate,53250677,"(?R,?S)-?-(4-Hydroxyphenyl)-?-methyl-4-(phenylmethyl)-1-piperidinepropanol maleate",C22H29NO2.C4H4O4,[1312991-76-6],455.55,Ion Channels,NMDA Receptors,Antagonist,GluN2B-selective NMDA antagonist,7,C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1,293,1
1612,OC1=CC(S(N2[C@@H](CCN3CCC(C)CC3)CCC2)(=O)=O)=CC=C1.Cl,SB 269970 hydrochloride,11957684,(2R)-1-[(3-Hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine hydrochloride,C18H28N2O3S.HCl,[261901-57-9],388.95,7-TM Receptors,5-HT7 Receptors,Antagonist,Potent and selective 5-HT7 antagonist; brain penetrant,9,CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1,297,1
1614,NC(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=CC=N1)C1=CC2=C(OCO2)C=C1,SB 431542,4521392,"4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide",C22H16N4O3,[301836-41-9],420.42,Enzyme-Linked Receptors,TGF-beta Receptors,Inhibitor,"Potent, selective inhibitor of TGF-?RI, ALK4 and ALK7",14,NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCO4)c(-c3ccccn3)[nH]2)cc1,746,1
1615,COC1=CC=CC(NC(=O)\C=C\C2=CC=C(Cl)C=C2)=C1,SB 366791,667594,4'-Chloro-3-methoxycinnamanilide,C16H14ClNO2,[472981-92-3],287.75,Ion Channels,TRPV,Antagonist,"Potent, selective, competitive TRPV1 antagonist",1,COc1cccc(NC(=O)/C=C/c2ccc(Cl)cc2)c1,608,1
1635,[H][C@@]13[C@@](CN(C(CC4=C(OC)C=CC=C4)=N)C3)([H])C(CCC(C5=CC=CC=C5)1C2=CC=CC=C2)=O,RP 67580,107686,"(3aR,7aR)-Octahydro-2-[1-imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4H-isoindol",C29H30N2O2,[135911-02-3],443.07,7-TM Receptors,NK1 Receptor,Antagonist,Potent and selective NK1 antagonist,3,COc1ccccc1CC(=N)N1C[C@@H]2C(=O)CCC(c3ccccc3)(c3ccccc3)[C@@H]2C1,358,1
1636,[Br-].Br.C[N+](C)(C)CCCCCNCC12CC3CC(C1)CC(C2)C3,IEM 1460,6604954,"N,N,H,-Trimethyl-5-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]-1-pentanaminiumbromide hydrobromide",C19H37N2Br.HBr,[121034-89-7],499.37,Ion Channels,AMPA Receptors,Blocker,Open-channel blocker of AMPA currents; selective for non-GluA2-containing receptors,3,C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2,7,1
1637,O=C(N1[C@@H]([C@@](O)=O)C[C@H](C)CC1)[C@@H](NS(C2=CC=CC3=C2NCC(C)C3)(=O)=O)CCCNC(N)=N,Argatroban,6604954,"(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid",C23H36N6O5S,[74863-84-6],531.15,Enzymes,Other Proteases,Inhibitor,Potent thrombin inhibitor,1,CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,118,1
1646,OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C2=CC=CC=C12,Lonidamine,39562,"1-[(2,4-Dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid",C15H10Cl2N2O2,[50264-69-2],321.16,Enzymes,Hexokinases,Inhibitor,Mitochondrial hexokinase inhibitor,3,O=C(O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12,167,1
1661,Cl.CN1C=CC2=CC3=C(CCN3C(=O)NC3=CC=CN=C3)C=C12,SB 206553 hydrochloride,11957707,"3,5-Dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']dipyrrole-1(2H)-carboxamide hydrochloride",C17H16N4O.HCl,[1197334-04-5],333.3,7-TM Receptors,5-HT2C Receptors,Antagonist,Potent and selective 5-HT2B and 5-HT2C antagonist; orally active,4,Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1,468,1
1671,CCOC(=O)C1=C(C)NC2=CC=C3OC4N(CCC5=CC(OC)=CC=C45)CC3=C12,PD 102807,4995951,"3,6a,11,14-Tetrahydro-9-methoxy-2-methyl-(12H)-isoquino[1,2-b]pyrrolo[3,2-f][1,3]benzoxazine-1-carboxylic acid, ethyl ester",C23H24N2O4,[23062-91-1],392.45,7-TM Receptors,M4 Receptors,Antagonist,Selective M4 antagonist,5,CCOC(=O)c1c(C)[nH]c2ccc3c(c12)CN1CCc2cc(OC)ccc2C1O3,419,1
1674,CN1CCC2=C(CC3=CC=CC=C3CC1)NC1=CC=CC=C21,LE 300,4350931,"6,7,8,9,14,15-Hexahydro-7-methyl-5H-indolo[3,2-f][3]benzazecine",C20H22N2,[274694-98-3],303.92,7-TM Receptors,D1 and D5 Receptors,Antagonist,Potent and selective D1 antagonist,4,CN1CCc2ccccc2Cc2[nH]c3ccccc3c2CC1,141,1
1677,CC(C)(SC1=CC=C(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)C=C1)C(O)=O,GW 7647,3392731,2-[[4-[2-[[(Cyclohexylamino)carbonyl](4-cyclohexylbutyl)amino]ethyl]phenyl]thio]-2-methylpropanoic acid,C29H46N2O3S,[265129-71-3],502.75,Nuclear Receptors,PPARalpha Receptors,Agonist,"Highly selective, potent PPAR? agonist. Orally active",3,CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(=O)O,45,1
1691,O[C@@H]1[C@@H]([C@](NCC)=O)O[C@@H](N2C=NC3=C2N=CN=C3N)[C@@H]1O,NECA,448222,1-(6-Amino-9H-purin-9-yl)-1-deoxy-N-ethyl-?-D-ribofuranuronamide,C12H16N6O4,[35920-39-9],317.31,7-TM Receptors,Non-selective Adenosine,Agonist,High affinity adenosine agonist,4,CCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,842,1
1692,O=C1CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C2N1,Cilostazol,2754,"6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone",C20H27N5O2,[73963-72-1],369.47,Enzymes,Phosphodiesterases,Inhibitor,PDE3A inhibitor. Also adenosine uptake inhibitor,1,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,266,1
1694,CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C,Ibudilast,3671,"2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-1-propanone",C14H18N2O,[50847-11-5],230.31,Enzymes,Phosphodiesterases,Inhibitor,PDE inhibitor (non-selective),1,CC(C)C(=O)c1c(C(C)C)nn2ccccc12,257,1
1695,CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1,Cisapride,6917698,"(�)-4-Amino-5-chloro-N-[1-[(3R*,4S*)-3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenzamide",C23H29ClFN3O4,[81098-60-4],483.97,7-TM Receptors,5-HT4 Receptors,Agonist,5-HT4 agonist; stimulates intestinal ACh release,1,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,337,0
1700,O=C(C4=C3C=CC=C4)NC1=CC=CC=C1C3N(CC2)CCN2C(CC5(CCCC5)CC(N[C@@H](CCCNC(N)=N)C(NCCN6C(N(C7=CC=CC=C7)N(C8=CC=CC=C8)C6=O)=O)=O)=O)=O,BIIE 0246,2690,"N-[(1S)-4-[(Aminoiminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]amino]carbonyl]butyl]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-oxoethyl]-cyclopentaneacetamide",C49H57N11O6,[246146-55-4],900.56,7-TM Receptors,NPY Receptors,Antagonist,"Potent, selective non-peptide NPY Y2 receptor antagonist",5,N=C(N)NCCC[C@H](NC(=O)CC1(CC(=O)N2CCN(C3c4ccccc4NC(=O)c4ccccc43)CC2)CCCC1)C(=O)NCCn1c(=O)n(-c2ccccc2)n(-c2ccccc2)c1=O,117,1
1705,O[C@@H]1[C@@H](CO)O[C@@H](N(C=N4)C2=C4C(NC3CCCC3)=NC(Cl)=N2)[C@@H]1O,2-Chloro-N6-cyclopentyladenosine,123807,2-Chloro-N-cyclopentyladenosine,C15H20ClN5O4,[37739-05-2],374.31,7-TM Receptors,Adenosine A1 Receptors,Agonist,"Potent, selective A1 agonist",7,OC[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)nc(Cl)nc32)[C@H](O)[C@@H]1O,841,0
1706,CC(=O)NC1=CC=C(O)C=C1,Acetaminophen,1983,N-(4-Hydroxyphenyl)acetamide,C8H9NO2,[103-90-2],151.16,Enzymes,Cyclooxygenase,Inhibitor,Cyclooxygenase inhibitor; may be selective for COX-3,1,CC(=O)Nc1ccc(O)cc1,516,1
1742,Cl[H].COC1=CC=CC(CCC2=C(OCC[C@@H]3C[C@@H](O)CN3C)C=CC=C2)=C1,R-96544 hydrochloride,10668210,"(2R,4R)-5-[2-[2-[2-(3-Methoxyphenyl)ethyl]phenoxy]ethyl]-1-methyl-3-pyrrolidinol hydrochloride",C22H29NO3.HCl,[167144-80-1],391.94,7-TM Receptors,5-HT2A Receptors,Antagonist,"Potent, selective 5-HT2A antagonist",3,COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1,421,1
1743,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)\C=C\C#N,Bay 11-7085,5353432,"(2E)-3-[[4-(1,1-Dimethylethyl)phenyl]sulfonyl]-2-propenenitrile",C13H15NO2S,[196309-76-9],249.33,Cell biology,NF-kB/IkB,Inhibitor,Irreversible inhibitor of TNF-?-induced I?B? phosphorylation,2,CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1,865,1
1746,O=C(C3=C(OC)C=C(NC)C(Cl)=C3)N[C@@H]1CCN(CC2=CC=CC=C2)[C@@H]1C.O=C(C6=C(OC)C=C(NC)C(Cl)=C6)N[C@H]4CCN(CC5=CC=CC=C5)[C@H]4C,Nemonapride,76968489,cis-5-Chloro-2-methoxy-4-(methylamino)-N-[2-methyl-1-(phenylmethyl)-3-pyrrolidinyl]benzamide,C21H26ClN3O2,[75272-39-8],387.91,7-TM Receptors,Non-selective Dopamine,Antagonist,Highly potent D2-like antagonist; also 5-HT1A agonist,1,CNc1cc(OC)c(C(=O)N[C@@H]2CCN(Cc3ccccc3)[C@@H]2C)cc1Cl,337,0
1757,FC(C=C2)=CC=C2[C@@H](CCN(CC(O)=O)C)OC1=CC=C(C3=CC=CC=C3)C=C1.Cl,ALX 5407 hydrochloride,16078946,"N-[(3R)-3-([1,1'-Biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methylglycine hydrochloride",C24H24FNO3.HCl,[200006-08-2],429.92,Transporters,Glycine Transporters,Inhibitor,Selective non-transportable GlyT1 inhibitor,5,CN(CC[C@@H](Oc1ccc(-c2ccccc2)cc1)c1ccc(F)cc1)CC(=O)O,181,0
1777,OC(C=C3)=C(OC)C=C3C[C@@H](C(OC2)=O)[C@H]2CC1=CC(OC)=C(OC)C=C1,Arctigenin,64981,"(3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2(3H)-furanone",C21H24O6,[7770-78-7],372.42,Enzymes,MEK,Inhibitor,Potent MEK1 inhibitor. Also inhibits I?B? phosphorylation,3,COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc(OC)c(OC)c2)ccc1O,365,1
1779,O=C(C1=CCCN(CCO/N=C(C3=CC=CC=C3)/C2=CC=CC=C2)C1)O.Cl,NNC 711,123738,"1,2,5,6-Tetrahydro-1-[2-[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid hydrochloride",C21H22N2O3.HCl,[145645-62-1],391.38,Transporters,GABA Transporters,Inhibitor,Selective GAT-1 inhibitor,2,O=C(O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1,288,0
1780,COC(=O)CN1CN(C2=CC=CC=C2)C2(CCN(CC3=CC=C4C=CC=CC4=C3)CC2)C1=O,NNC 63-0532,3906780,"8-(1-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-3-acetic acid, methyl ester",C27H29N3O3,[250685-44-0],443.54,7-TM Receptors,NOP Receptors,Agonist,Potent non-peptide NOP agonist; brain penetrant,1,COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3ccc4ccccc4c3)CC2)C1=O,281,0
1795,Cl.COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CN2CCC1CC2,Zacopride hydrochloride,9928181,(�)-4-Amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxybenzamide hydrochloride,C15H20ClN3O2.HCl,[101303-98-4],364.28,Ion Channels,5-HT3 Receptors,Antagonist,Highly potent 5-HT3 antagonist; also 5-HT4 agonist,4,COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2,337,1
1803,COC(=O)C1=CSC(=N1)C(=O)C1=CNC2=CC=CC=C12,ITE,4668801,2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid methyl ester,C14H10N2O3S,[448906-42-1],286.3,Nuclear Receptors,Aryl Hydrocarbon Receptors,Agonist,Endogenous agonist for the transcription factor aryl hydrocarbon receptor,12,COC(=O)c1csc(C(=O)c2c[nH]c3ccccc23)n1,794,1
1808,Cl.Cl.CC1=CC=CC(CCN2CCC(CC2)C(=O)C2=CC=C(NS(C)(=O)=O)C=C2)=N1,E-4031 dihydrochloride,3087190,N-[4-[[1-[2-(6-Methyl-2-pyridinyl)ethyl]-4-piperidinyl]carbonyl]phenyl]methanesulfonamide dihydrochloride,C21H27N3O3S.2HCl,[113559-13-0],478.94,Ion Channels,Voltage-Gated Potassium Channels,Blocker,KV11.1 (hERG) channel blocker; inhibits rapid delayed rectifier K+ current (IKr),4,Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,282,0
1809,Cl.FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=S)NC3=CC=CC=C3C2=O)CC1,Altanserin hydrochloride,24978536,"3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,3-dihydro-2-thioxo-4(1H)-quinazolinone hydrochloride",C22H22FN3O2S.HCl,[1135280-78-2],456.96,7-TM Receptors,5-HT2A Receptors,Antagonist,5-HT2A receptor antagonist,1,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1,282,0
1810,ClC1=C(OC)C(C(NC[C@H]2N(CC)CCC2)=O)=C(O)C(Cl)=C1,Raclopride,3033769,"3,5-Dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide",C15H20Cl2N2O3,[84225-95-6],347.24,7-TM Receptors,Non-selective Dopamine,Antagonist,Potent and selective D2 and D3 antagonist,3,CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,335,0
1854,O=C(O)/C=C/C(O)=O.FC1=C(Cl)C=C(N(C[C@H](C)N)C=C2)C2=C1,Ro 60-0175 fumarate,6446435,(?S)-6-Chloro-5-fluoro-?-methyl-1H-indole-1-ethanamine fumarate,C11H12ClFN2.C4H4O4,[169675-09-6],342.75,7-TM Receptors,5-HT2C Receptors,Agonist,"Potent, selective 5-HT2C agonist",2,C[C@H](N)Cn1ccc2cc(F)c(Cl)cc21,830,1
1856,CCCC1=C(O)C(CC=O)=CC=C1OCCCOC1=CC=C(OCC(O)=O)C=C1,"L-165,041",4364841,[4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid,C22H26O7,[79558-09-1],402.44,Nuclear Receptors,PPARdelta Receptors,Agonist,Potent PPAR? agonist,3,CCCc1c(OCCCOc2ccc(OCC(=O)O)cc2)ccc(CC=O)c1O,426,1
1867,ClC1=C(NCCN2CCOCC2)C(=O)C2=NC=CC=C2C1=O,NSC 663284,379077,"6-Chloro-7-[[2-(4-morpholinyl)ethyl]amino]-5,8-quinolinedione",C15H16ClN3O3,[383907-43-5],321.76,Enzymes,Cdc25 Phosphatase,Inhibitor,"Potent, selective Cdc25 phosphatase inhibitor",1,O=C1C(Cl)=C(NCCN2CCOCC2)C(=O)c2ncccc21,319,1
1870,CC1=CC=C(C=C1)S(=O)(=O)NCC1=CC=CC=C1,BTS,95801,4-Methyl-N-(phenylmethyl)benzenesulfonamide,C14H15NO2S,[1576-37-0],261.34,Enzymes,Myosin,Inhibitor,Selective inhibitor of skeletal muscle myosin II ATPase activity,1,Cc1ccc(S(=O)(=O)NCc2ccccc2)cc1,106,1
1941,CC1=CC(C)=C(C(C)=C1)S(=O)(=O)NC1=CC=CC(=C1)C(F)(F)F,m-3M3FBS,761523,"2,4,6-Trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide",C16H16F3NO2S,[200933-14-8],343.36,Enzymes,Phospholipases,Activator,Phospholipase C activator,1,Cc1cc(C)c(S(=O)(=O)Nc2cccc(C(F)(F)F)c2)c(C)c1,78,0
1942,CC1=CC(C)=C(C(C)=C1)S(=O)(=O)NC1=C(C=CC=C1)C(F)(F)F,o-3M3FBS,770820,"2,4,6-Trimethyl-N-[2-(trifluoromethyl)phenyl]benzenesulfonamide",C16H16F3NO2S,[313981-55-4],343.36,Enzymes,Phospholipases,Activator,Inactive analog of m-3M3FBS (Cat. No. 1941),1,Cc1cc(C)c(S(=O)(=O)Nc2ccccc2C(F)(F)F)c(C)c1,78,1
1944,CCOC(=O)N1CC\C(CC1)=C1/C2=NC=CC=C2CCC2=C1C=CC(Cl)=C2,Loratidine,3957,"4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester",C22H23ClN2O2,[79794-75-5],382.88,7-TM Receptors,Histamine H1 Receptors,Antagonist,Peripheral H1 antagonist; antiallergic agent,1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,582,1
1955,O=C1N3C(SC=C3)=NC(C)=C1CCN4CC/C(CC4)=C(C5=CC=C(F)C=C5)/C2=CC=C(F)C=C2,Ritanserin,5074,"6-[2-[4-[Bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one",C27H25F2N3OS,[87051-43-2],477.57,7-TM Receptors,Non-selective 5-HT2,Antagonist,Potent 5-HT2 antagonist,9,Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1,283,1
1960,CC1=NC2=CC=C(NC(=O)NC3=CC=NC4=CC=CN=C34)C=C2O1,SB 334867,6604926,"N-(2-Methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea",C17H13N5O2,[792173-99-0],332.83,7-TM Receptors,OX1 Receptor,Antagonist,Selective non-peptide OX1 antagonist,11,Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1,382,1
1963,CN(C)C1=CC=C(NC(=O)NC2=CC(C)=NC3=C(F)C=C(F)C=C23)C=C1,SB 408124,4331799,"N-(6,8-Difluoro-2-methyl-4-quinolinyl)-N'-[4-(dimethylamino)phenyl]urea",C19H18F2N4O,[288150-92-5],356.37,7-TM Receptors,OX1 Receptor,Antagonist,Selective non-peptide OX1 antagonist,3,Cc1cc(NC(=O)Nc2ccc(N(C)C)cc2)c2cc(F)cc(F)c2n1,511,1
1965,[H][C@@]12C(C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(O3)=O)=C[C@H](C)C[C@@H]1OC(C(C)(C)CC)=O,Simvastatin,54454,"(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyly-2,2-dimethyl butanoate",C25H38O5,[79902-63-9],418.57,Enzymes,HMG-CoA Reductase,Inhibitor,HMG-CoA reductase inhibitor,3,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,18,0
1974,CC1=NN(C(C)=C1\C=N\N1CCN(CC2=CC=CC=C2)CC1)C1=CC=CC=C1,SANT-1,6878030,"N-[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methylene]-4-(phenylmethyl)-1-piperazinamine",C23H27N5,[304909-07-7],373.5,Cell biology,Hedgehog Signaling,Inhibitor,Inhibitor of hedgehog (Hh) signaling; antagonizes smoothened activity,1,Cc1nn(-c2ccccc2)c(C)c1/C=N/N1CCN(Cc2ccccc2)CC1,305,1
1980,O=C(CC1=C(C4=CC=C(C=CC=C5)C5=C4)NC2=C1C=CC3=C2C=CC=C3)N[C@@H]([C@](OC[C@@H](N)C)=O)CCCCN,"L-817,818",9937014,N2-[[2-(2-Naphthalenyl)-1H-benz[g]indol-3-yl]acetyl-D-lysine (2S)-2-aminopropyl ester,C33H36N4O3,[217480-27-8],559.19,7-TM Receptors,Somatostatin Receptors,Agonist,Potent and selective sst5 agonist,2,C[C@H](N)COC(=O)[C@@H](CCCCN)NC(=O)Cc1c(-c2ccc3ccccc3c2)[nH]c2c1ccc1ccccc12,775,1
1982,[H][C@]2(OCCNC2)[C@@H]([C@]3=CC=CC=C3)OC1=C(OCC)C=CC=C1.[H][C@@]5(OCCNC5)[C@H]([C@]6=CC=CC=C6)OC4=C(OCC)C=CC=C4.CS(=O)(O)=O.CS(=O)(O)=O,Reboxetine mesylate,76970698,(2R*)-2-[(R*)-(2-Ethoxyphenoxy)phenylmethyl]morpholine mesylate,C19H23NO3.CH3SO3H,[98769-84-7],409.5,Transporters,Adrenergic Transporters,Inhibitor,Potent and selective noradrenalin uptake inhibitor; orally active,6,CCOc1ccccc1O[C@H](c1ccccc1)[C@H]1CNCCO1,182,1
1985,O=C(NC)C3=CC(CCO2)=C(C=C3)[C@@H]2CCN1CCN(C4=CC=C(C(N)=O)C=C4)CC1,PNU 142633,9845148,"(1S)-1-[2-[4-[4-(Aminocarbonyl)phenyl]-1-piperazinyl]ethyl]-3,4-dihydro-N-methyl-1H-2-benzopyran-6-carboxamide",C24H30N4O3,[187665-65-2],431.54,7-TM Receptors,5-HT1D Receptors,Agonist,Highly selective 5-HT1D agonist,2,CNC(=O)c1ccc2c(c1)CCO[C@H]2CCN1CCN(c2ccc(C(N)=O)cc2)CC1,273,1
1991,OC(C=C4)=CC=C4N1C(C(C=C3)=CC=C3OCCN2CCCCC2)=C(C)C(C5=CC=C(O)C=C5)=N1.Cl.Cl,MPP dihydrochloride,45073474,"1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride",C29H31N3O3.2HCl,[911295-24-4],556.01,Nuclear Receptors,Estrogen and Related Receptors,Antagonist,Highly selective ER? antagonist,8,Cc1c(-c2ccc(O)cc2)nn(-c2ccc(O)cc2)c1-c1ccc(OCCN2CCCCC2)cc1,643,0
1992,NC1=CC=CC2=C1C[N+]([H])(C)CC2C3=CC=CC=C3.O=C(O)\C=C/C([O-])=O,Nomifensine,5358907,"1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine maleate",C16H18N2.C4H4O4,[32795-47-4],354.4,Transporters,Dopamine Transporters,Inhibitor,Potent noradrenalin and dopamine uptake inhibitor. Antidepressant,1,C[NH+]1Cc2c(N)cccc2C(c2ccccc2)C1,133,1
1999,Cl.Cl.O=C1N(C2=CC=CC=C2C1(CC1=CC=NC=C1)CC1=CC=NC=C1)C1=CC=CC=C1,Linopirdine dihydrochloride,14209557,"1,3-Dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-indol-2-one dihydrochloride",C26H21N3O.2HCl,[113168-57-3],468.89,Ion Channels,Voltage-Gated Potassium Channels,Blocker,KV7 (KCNQ) channel blocker,2,O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,715,1
2002,CS(O)(=O)=O.CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(CCCSC(N)=N)C2=CC=CC=C12,Ro 31-8220 mesylate,11628205,"3-[3-[2,5-Dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl carbamimidothioic acid ester mesylate",C25H23N5O2S.CH3SO3H,[138489-18-6],553.65,Enzymes,Broad Spectrum Protein Kinase Inhibitors,Inhibitor,Protein kinase inhibitor,2,Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21,785,0
2005,Cl.COC1=CC2=C(C=C1O)C(CCC1=CC=C(Cl)C=C1)N(C)CC2,Ro 04-5595 hydrochloride,46739,"1-[2-(4-Chlorophenyl)ethyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-7-isoquinolinol hydrochloride",C19H22ClNO2.HCl,[64047-73-0],368.3,Ion Channels,NMDA Receptors,Antagonist,GluN2B-selective NMDA antagonist,1,COc1cc2c(cc1O)C(CCc1ccc(Cl)cc1)N(C)CC2,375,1
2006,[H][C@@]4([C@](C)3[C@]5(C)[C@@](C([C@]6([H])CC5)=CC([C@@H]([C@](O)(C)C)O6)=O)(O)CC4)CC2=C3NC1=CC=CC=C12,Paxilline,105008,"(2R,4bS,6aS,12bS,12cR,14aS)-5,6,6a,7,12,12b,12c,13,14,14a-Decahydro-4b-hydroxy-2-(1-hydroxy-1-methylethyl)-12b,12c-dimethyl-2H-pyrano[2'',3'':5',6']benz[1',2':6,7]indeno[1,2-b]indol-3(4bH)-one",C27H33NO4.C2H3N,[57186-25-1],476.61,Enzymes,Ca2+-ATPase,Blocker,SERCA ATPase blocker. Also potent BKCa channel blocker,7,CC(C)(O)[C@H]1O[C@H]2CC[C@@]3(C)[C@@](O)(CC[C@H]4Cc5c([nH]c6ccccc56)[C@@]43C)C2=CC1=O,791,1
2009,O=C(NC2=C1NC(C3=CC=C(S(=O)(O)=O)C=C3)=N2)N(CCC)C1=O,PSB 1115,5311479,"4-(2,3,6,7-Tetrahydro-2,6-dioxo-1-propyl-1H-purin-8-yl)-benzenesulfonic acid",C14H14N4O5S,[152529-79-8],386.38,7-TM Receptors,Adenosine A2B Receptors,Antagonist,Selective human A2B antagonist; water-soluble,4,CCCn1c(=O)[nH]c2nc(-c3ccc(S(=O)(=O)O)cc3)[nH]c2c1=O,668,0
2010,CC[C@H](C3)N=C1N3C(N(C)C2=C1NC(C4=C(Cl)C(Cl)=CC(Cl)=C4)=N2)=O.Cl,PSB 10 hydrochloride,90488733,"8-Ethyl-1,4,7,8-tetrahydro-4-methyl-2-(2,3,5-trichlorophenyl)-5H-imidazo[2,1-i]purin-5-one monohydrochloride",C16H14Cl3N5O.HCl,[591771-91-4],435.14,7-TM Receptors,Adenosine A3 Receptors,Antagonist,"Potent, highly selective hA3 receptor antagonist/inverse agonist",1,CC[C@@H]1CN2C(=O)N(C)c3nc(-c4cc(Cl)cc(Cl)c4Cl)[nH]c3C2=N1,672,1
2018,CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1,Mirtazapine,4205,"1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine",C17H19N3,[85650-52-8],269.86,7-TM Receptors,Non-selective 5-HT2,Antagonist,"Potent 5-HT2 antagonist; also 5-HT3, H1 and ?2 antagonist; antidepressant",2,CN1CCN2c3ncccc3Cc3ccccc3C2C1,138,1
2019,CCCCN1C(=O)N(CCCO)C2=C(NC(=N2)C23CC4CC2CC(C3)C4)C1=O,PSB 36,11689583,"1-Butyl-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-3-(3-hydroxypropyl)-1H-purine-2,6-dione",C21H30N4O3,[524944-72-7],386.49,7-TM Receptors,Adenosine A1 Receptors,Antagonist,Potent and selective A1 antagonist,1,CCCCn1c(=O)c2[nH]c(C34CC5CC(CC3C5)C4)nc2n(CCCO)c1=O,670,1
2020,CC(C)(C)C1=CC(=CC(=C1)C(=O)\C=C\C1=CC=C(C=C1)C(O)=O)C(C)(C)C,Ch 55,6184667,"4-[(1E)-3-[3,5-bis(1,1-Dimethylethyl)phenyl]-3-oxo-1-propenyl]benzoic acid",C24H28O3,[110368-33-7],364.47,Nuclear Receptors,Retinoic Acid Receptors,Agonist,Potent RAR agonist,1,CC(C)(C)c1cc(C(=O)/C=C/c2ccc(C(=O)O)cc2)cc(C(C)(C)C)c1,460,1
2021,CN1C2=C(C=C3C(=C2)C(C)(C)CCC3(C)C)N=C(C2=CC=C(C=C2)C(O)=O)C2=C1C=CC=C2,LE 135,10410894,"4-(7,8,9,10-Tetrahydro-5,7,7,10,10-pentamethyl-5H-benzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid",C29H30N2O2,[155877-83-1],438.56,Nuclear Receptors,Retinoic Acid Receptors,Antagonist,Selective RAR? antagonist,2,CN1c2cc3c(cc2N=C(c2ccc(C(=O)O)cc2)c2ccccc21)C(C)(C)CCC3(C)C,455,1
2072,ClC1=CC(N)=CC(NC2=C3C(N(C(C)C)C=N3)=NC(N[C@H]([C@@H](C)C)CO)=N2)=C1,Aminopurvalanol A,6604931,(2R)-2-[[6-[(3-Amino-5-chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol,C19H26ClN7O,[220792-57-4],412.92,Enzymes,Cyclin-dependent Kinase,Inhibitor,"Selective cdk inhibitor; potently inhibits cdk1, cdk2 and cdk5",1,CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1,825,0
2079,O=C(C=CN(C[C@H](N)C(O)=O)C2=O)N2CC1=CC=CC=C1C(O)=O,UBP 302,6420161,"(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione",C15H15N3O6,[745055-91-8],342.31,Ion Channels,Kainate Receptors,Antagonist,Potent and selective kainate antagonist; active enantiomer of UBP 296 (Cat. No. 2078),5,N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(=O)O)c1=O)C(=O)O,679,1
2089,Cl.FC(F)(F)C1=CC=C(CCN2CCC3(CC2)OC(=O)NC2=CC=CC=C32)C=C1,RS 102895 hydrochloride,16759153,"1'-[2-[4-(Trifluoromethyl)phenyl]ethyl]-spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one hydrochloride",C21H21F3N2O2.HCl,[1173022-16-6],426.86,7-TM Receptors,Chemokine CC Receptors,Antagonist,CCR2b chemokine receptor antagonist,3,O=C1Nc2ccccc2C2(CCN(CCc3ccc(C(F)(F)F)cc3)CC2)O1,286,1
2095,C1(CC3C2)CC2(/N=C(N5CCOCC5)/NC4CCCCC4)CC(C3)C1.Cl,PNU 37883 hydrochloride,64392,"N-Cyclohexyl-N'-tricyclo[3.3.1.13,7]dec-1-yl-4-morpholinecarboximidamide hydrochloride",C21H35N3O.HCl,[57568-80-6],381.98,Ion Channels,Inward rectifier Potassium Channels,Blocker,Vascular Kir6 (KATP) channel blocker,1,C1CCC(N/C(=N/C23CC4CC(CC(C4)C2)C3)N2CCOCC2)CC1,47,1
2151,O[C@@H]1[C@@H](CO)O[C@@H](N2C3=C(C4=NC=N3)C(C(N)=NN4C)=C2)[C@@H]1O,API-2,65399,"1,5-Dihydro-5-methyl-1-?-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylen-3-amine",C13H16N6O4,[35943-35-2],333.82,Enzymes,Akt (Protein Kinase B),Inhibitor,Selective inhibitor of Akt/PKB signaling. Antitumor and antiviral,3,CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23,841,0
2160,Cl.Cl.OC(CN1C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2)CN1CCNCC1,Bax channel blocker,2729026,"3,6-Dibromo-?-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride",C19H21Br2N3O,[329349-20-4],558.14,Cell biology,Bcl-2 Family,Inhibitor,Allosteric inhibitor of Bax channel activation,1,OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc21,883,0
2161,Cl.Cl.Cl.CCN(CC)CCCC(C)NC1=NC(C)=CC(NC2=CC=C3N=C(C)C=C(N)C3=C2)=N1,NSC 23766,16759159,"N6-[2-[[4-(Diethylamino)-1-methylbutyl]amino]-6-methyl-4-pyrimidinyl]-2-methyl-4,6-quinolinediamine trihydrochloride",C24H35N7.3HCl,[1177865-17-6],576.01,Enzymes,Rho,Inhibitor,Selective inhibitor of Rac1-GEF interaction; antioncogenic,5,CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1,444,1
2175,O=C3[C@@H](CC(C)C)CN2CCC1=CC(OC)=C(OC)C=C1[C@@]([H])2C3,Tetrabenazine,11634155,"(3R,11bR)-rel-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one",C19H27NO3,[58-46-8],317.2,Transporters,Vesicular Monoamine Transporters,Inhibitor,Potent inhibitor of vesicular monoamine transport,4,COc1cc2c(cc1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,374,1
2176,CC1(C)C(=O)N=C2C1=C(O)C(=O)C1=CC=CC=C21,BVT 948,6604934,"4-Hydroxy-3,3-dimethyl-2H-benz[g]indole-2,5(3H)-dione",C14H11NO3,[39674-97-0],241.25,Enzymes,Protein Tyrosine Phosphatases,Inhibitor,Non-competitive protein tyrosine phosphatase inhibitor,3,CC1(C)C(=O)N=C2C1=C(O)C(=O)c1ccccc12,762,1
2183,CCCCCS(=O)(=O)CCCCCCCCCCN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1,ZK 164015,9806489,2-(4-Hydroxyphenyl)-3-methyl-1-[10-(pentylsulfonyl)decyl]-1H-indol-5-ol,C30H43NO4S,[177583-70-9],513.73,Nuclear Receptors,Estrogen and Related Receptors,Antagonist,Potent estrogen receptor antagonist,1,CCCCCS(=O)(=O)CCCCCCCCCCn1c(-c2ccc(O)cc2)c(C)c2cc(O)ccc21,646,1
2184,CCOC(=O)C1CSC(CC2=CC=C(OCC3=CC=C(C=C3)[N+]([O-])=O)C=C2)N1,SN-6,10222761,2-[[4-[(4-Nitrophenyl)methoxy]phenyl]methyl]-4-thiazolidinecarboxylic acid ethyl ester,C20H22N2O5S,[415697-08-4],402.16,Transporters,Na+/Ca2+ Exchanger,Inhibitor,Selective Na+/Ca2+ exchange inhibitor (reverse mode),2,CCOC(=O)C1CSC(Cc2ccc(OCc3ccc([N+](=O)[O-])cc3)cc2)N1,440,0
2185,N=C(N)SCC1=C(C=CC=C3)C3=C(C)C2=C1C=CC=C2.Cl,NSC 146109 hydrochloride,5458312,(10-Methyl-9-anthracenyl) methyl carbamimidothioic acid ester hydrochloride,C17H16N2S.HCl,[59474-01-0],321.35,Cell biology,p53,Activator,"Cell-permeable, genotype-selective antitumor agent; activates p53-dependent transcription",1,Cc1c2ccccc2c(CSC(=N)N)c2ccccc12,784,1
2194,CC1=C(CCN2CC\C(CC2)=C(/C2=CC=CC=C2)C2=CC=C(F)C=C2)C(=O)N2C=CSC2=N1,R 59-022,3012,"6-[2-[4-[(4-Fluorophenyl)phenylmethylene]-1-piperidinyl]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one",C27H26FN3OS,[93076-89-2],459.58,Enzymes,Diacylglycerol Kinase,Inhibitor,Diacylglycerol kinase inhibitor; increases PKC activity,1,Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccccc2)c2ccc(F)cc2)CC1,283,0
2195,OC(CN1CCC(CC2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,Eliprodil,60703,?-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol,C20H23ClFNO,[119431-25-3],347.86,Ion Channels,NMDA Receptors,Antagonist,Non-competitive and GluN2B-selective NMDA antagonist,1,OC(CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1,293,0
2197,O=S(C1=CC=C(NC(NCCCCCC)=O)C=C1)(NC2=CC=C(CCNC[C@H](O)COC3=CC=C(O)C=C3)C=C2)=O,"L-755,507",9829836,4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-benzenesulfonamide,C30H40N4O6S,[159182-43-1],593.74,7-TM Receptors,Adrenergic Beta-3 Receptors,Agonist,Very potent and selective ?3 partial agonist,3,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,433,1
2198,Cl.Cl.COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,Mibefradil dihydrochloride,60662,"(1S,2S)-2-[2-[[3-(1H-Benzimidazol-2yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetoacetate dihydrochloride",C29H38FN3O3.2HCl,[116666-63-8],582.07,Ion Channels,Cav3.x Channels,Blocker,CaV3.x blocker,4,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,163,1
2199,NC1=NC(NC[C@H]3CC[C@H](CNS(=O)(C4=CC=CC5=C4C=CC=C5)=O)CC3)=NC2=C1C=CC=C2.Cl,CGP 71683 hydrochloride,9849276,N-[[trans-4-[[(4-Amino-2-quinazolinyl)amino]methyl]cyclohexyl]methyl]-1-naphthalenesulfonamide hydrochloride,C26H29N5O2S.HCl,[192322-50-2],521.08,7-TM Receptors,NPY Receptors,Antagonist,Highly selective and potent non-peptide NPY Y5 receptor antagonist,3,Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12,171,1
2208,CCC1=C(OCCCCCC(C)(C)C2=NN=NN2)C=C(O)C(=C1)C(C)=O,LY 255283,122023,1-[5-Ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone,C19H28N4O3,[117690-79-6],364.96,7-TM Receptors,Leukotriene and Related Receptors,Antagonist,"Selective, competitive BLT2 receptor antagonist",1,CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1,20,1
2227,CCCCCCCCCCC(C)(C)C(=O)NC1=C(OC)C=C(OC)C=C1OC,CI 976,122327,"2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide",C23H39NO4,[114289-47-3],393.57,Enzymes,Acyl-CoA:Cholesterol Acyltransferase,Inhibitor,Selective ACAT inhibitor,1,CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC,22,1
2229,CC1=C(CSC2=CC(C)=C(OCC(O)=O)C=C2)SC(=N1)C1=CC(F)=C(C=C1)C(F)(F)F,GW 0742,9934458,[4-[[[2-[3-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]acetic acid,C21H17F4NO3S2,[317318-84-6],471.49,Nuclear Receptors,PPARdelta Receptors,Agonist,"Highly selective, potent PPAR? agonist",4,Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)c(F)c3)nc2C)ccc1OCC(=O)O,499,1
2237,CN(C)S(=O)(=O)C1=C(C)C=CC(=C1)[N+]([O-])=O,BRL 50481,2921148,"N,N,2-Trimethyl-5-nitro-benzenesulfonamide",C9H12N2O4S,[433695-36-4],244.26,Enzymes,Phosphodiesterases,Inhibitor,Selective PDE7 inhibitor,1,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)C,88,1
2261,C[C@@H](O)CNC(C)(C)CC(=O)N[C@@H]1CCC2=CC=CC=C2N(CC2=CC=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C1=O,"L-692,585",9872740,"3-[[(2R)-2-Hydroxypropyl]amino]-3-methyl-N-[(3R)-2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3-yl]-butanamide",C32H37N7O3,[145455-35-2],612.73,7-TM Receptors,Ghrelin Receptors,Agonist,"Potent, non-peptide ghrelin receptor agonist",4,C[C@@H](O)CNC(C)(C)CC(=O)N[C@@H]1CCc2ccccc2N(Cc2ccc(-c3ccccc3-c3nn[nH]n3)cc2)C1=O,664,0
2266,CCN(CC)C1=CC=C(C=C1)\C=N\NC(=O)C1=CC=C(O)C=C1,DY131,5497124,N-(4-(Diethylaminobenzylidenyl)-N'-(4-hydroxybenzoyl)-hydrazine,C18H21N3O2,[95167-41-2],311.38,Nuclear Receptors,Estrogen and Related Receptors,Agonist,Agonist selective for estrogen-related receptors ERR? and ERR?,1,CCN(CC)c1ccc(/C=N/NC(=O)c2ccc(O)cc2)cc1,890,1
2270,NC1=NC2=C(C=NN2CCC2=CC=CC=C2)C2=NC(=NN12)C1=CC=CO1,SCH 58261,176408,"2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine",C18H15N7O,[160098-96-4],345.36,7-TM Receptors,Adenosine A2A Receptors,Antagonist,"Potent, highly selective A2A antagonist",9,Nc1nc2c(cnn2CCc2ccccc2)c2nc(-c3ccco3)nn12,164,1
2275,BrC1=C2NN=NC2=C(Br)C(Br)=C1Br,TBB,1694,"4,5,6,7-Tetrabromobenzotriazole",C6HBr4N3,[17374-26-4],434.71,Enzymes,Casein Kinase 2,Inhibitor,Selective cell-permeable CK2 inhibitor,2,Brc1c(Br)c(Br)c2[nH]nnc2c1Br,4,1
2280,Cl.OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=CC=C(O)C=C2S1,Raloxifene hydrochloride,54900,[6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone hydrochloride,C28H27NO4S.HCl,[82640-04-8],510.04,Nuclear Receptors,Estrogen and Related Receptors,Modulator,Selective estrogen receptor modulator (SERM),2,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,643,0
2281,O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC3=C2N=C(Cl)N=C3NC4CCCC4)[C@@](C)1O,2'-MeCCPA,10475082,2-Chloro-N-cyclopentyl-2'-methyladenosine,C16H22ClN5O4,[205171-12-6],388.33,7-TM Receptors,Adenosine A1 Receptors,Agonist,Very selective and potent A1 receptor agonist,1,C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc21,841,0
2288,COC1=CC(C)=CC(OC)=C1[C@@H]1C=C(C)CC[C@H]1C(C)=C,O-1918,40469923,"1,3-Dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]benzene",C19H26O2,[536697-79-7],286.41,7-TM Receptors,Other Cannabinoids,Other,Silent antagonist for putative abnormal-CBD (Cat. No. 1297) receptor,1,C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(OC)cc(C)cc1OC,83,1
2292,CCN(CC)CCCCC1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,AQ-RA 741,129989,"11-[[4-[4-(Diethylamino)butyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one",C27H37N5O2,[123548-16-3],463.62,7-TM Receptors,M2 Receptors,Antagonist,High affinity and selective M2 antagonist,1,CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1,137,1
2299,Br.CN1CCC2=C(C=C(O)C(Cl)=C2)[C@@H]2[C@@H]1CCC1=CC=CC=C21,SCH 39166 hydrobromide,16759171,"(6aS-trans)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol hydrobromide",C19H20ClNO.HBr,[1227675-51-5],394.73,7-TM Receptors,D1 and D5 Receptors,Antagonist,High affinity D1-like antagonist,5,CN1CCc2cc(Cl)c(O)cc2[C@H]2c3ccccc3CC[C@@H]21,140,1
2301,[O-][N+](=O)C1=CC=C(Cl)C(=C1)C(=O)NC1=CC=NC=C1,T 0070907,2777391,2-Chloro-5-nitro-N-4-pyridinylbenzamide,C12H8N3O3Cl,[313516-66-4],277.67,Nuclear Receptors,PPARgamma Receptors,Antagonist,Highly potent and selective covalent PPAR? antagonist,1,O=C(Nc1ccncc1)c1cc([N+](=O)[O-])ccc1Cl,93,1
2303,O=C(C2=CC=C(Cl)C=C2)N[C@@H]1C3CCN(CC3)C1,PNU 282987,9795278,N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide,C14H17ClN2O,[711085-63-1],264.75,Ion Channels,Nicotinic (a7) Receptors,Agonist,Selective ?7 nAChR agonist,5,O=C(N[C@H]1CN2CCC1CC2)c1ccc(Cl)cc1,339,1
2309,COC1=CC=CC(OC)=C1C1=CC(=NN1C1=C(C=C(C=C1)C(=O)N(C)CCCN(C)C)C(C)C)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O,SR 142948,5311451,"2-[[[5-(2,6-Dimethoxyphenyl)-1-[4-[[[3-(dimethylamino)propyl]methylamino]carbonyl]-2-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]-tricyclo[3.3.1.13,7]decane-2-carboxylic acid",C39H51N5O6,[184162-64-9],753.42,7-TM Receptors,Neurotensin Receptors,Antagonist,Highly potent NTS receptor antagonist,3,COc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccc(C(=O)N(C)CCCN(C)C)cc1C(C)C,353,0
2310,O=S(C1=CC(OC)=C(OC)C=C1)(N2[C@@H]([C@@](N5CCC[C@H]5[C@@](N)=O)=O)[C@](C4=CC=CC=C4Cl)(O)C3=C2C=CC(Cl)=C3)=O,SR 49059,60943,"(2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide",C28H27Cl2N3O7S,[150375-75-0],629.51,7-TM Receptors,Vasopressin Receptors,Antagonist,"Selective, orally active vasopressin V1A receptor antagonist",2,COc1ccc(S(=O)(=O)N2c3ccc(Cl)cc3[C@](O)(c3ccccc3Cl)[C@@H]2C(=O)N2CCC[C@H]2C(N)=O)cc1OC,354,1
2311,CCCOC1=C(C=C(Br)C=C1)C1=C(NC(=C1)C1=CC=C(Cl)C=C1)C1=CC=NC=C1,"L-168,049",5311276,4-[3-(5-Bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]pyridine,C24H20BrClN2O,[191034-25-0],467.79,7-TM Receptors,Glucagon Receptor,Antagonist,"Potent, orally active human glucagon receptor antagonist",1,CCCOc1ccc(Br)cc1-c1cc(-c2ccc(Cl)cc2)[nH]c1-c1ccncc1,58,1
2316,CC(C)(C)C1=CC=C(C=C1)\C=C\C(=O)NC1=CC=C2OCCOC2=C1,AMG 9810,680502,"(2E)-N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-dimethylethyl)phenyl]-2-propenamide",C21H23NO3,[545395-94-6],337.42,Ion Channels,TRPV,Antagonist,"Potent and selective, competitive antagonist of TRPV1",2,CC(C)(C)c1ccc(/C=C/C(=O)Nc2ccc3c(c2)OCCO3)cc1,608,0
2318,[Na+].[H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@]12[H])C[C@@H](O)CC([O-])=O,Pravastatin sodium salt,16759173,"(?R,?R,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-?,?,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-1-naphthaleneheptanoic acid monosodium salt",C23H35NaO7,[81131-70-6],491.55,Enzymes,HMG-CoA Reductase,Inhibitor,HMG-CoA reductase inhibitor,3,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21,18,0
2324,CN1C(=S)NC(CC2=CNC3=CC=CC=C23)C1=O,Necrostatin-1,2828334,5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinone,C13H13N3OS,[4311-88-0],259.33,Enzymes,RIP Kinases,Inhibitor,RIP1 kinase inhibitor; inhibits necroptosis,2,CN1C(=O)C(Cc2c[nH]c3ccccc23)NC1=S,795,0
2332,CN(C(CC)(C3=CC=CC=C3)C/C=C/C2=CC=CC=C2)CC1CC1.Cl,(+)-Igmesine hydrochloride,6438339,(R)-(+)-N-Cyclopropylmethyl-?-ethyl-N-methyl-?-[(2E)-3-phenyl-2-propenyl)benzenemethanamine hydrochloride,C23H29CN.HCl,[130152-35-1],355.94,Other Pharmacology,Sigma1 Receptors,Ligand,Selective ?1 ligand; antidepressant,1,CCC(C/C=C/c1ccccc1)(c1ccccc1)N(C)CC1CC1,302,1
2333,O=[C@@]([C@@H]4CC[C@H](OC)CC4)C(C=C3)=CC1=C3N=C(OCCC2)C2=C1,JNJ 16259685,11313361,"(3,4-Dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-(cis-4-methoxycyclohexyl)-methanone",C20H23NO3,[409345-29-5],325.41,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Antagonist,"Highly potent, mGlu1-selective non-competitive antagonist",4,CO[C@H]1CC[C@@H](C(=O)c2ccc3nc4c(cc3c2)CCCO4)CC1,371,1
2337,Cl.COC1=C(OC)C=C2C(CCN3C(=O)N(C)C(\C=C23)=N\C2=C(C)C=C(C)C=C2C)=C1,Trequinsin hydrochloride,3060974,"2,3,6,7-Tetrahydro-9,10-dimethoxy-3-methyl-2-[(2,4,6-trimethylphenyl)imino]-4H-pyrimido[6,1-a]isoquinolin-4-one hydrochloride",C24H27N3O3.HCl,[78416-81-6],441.95,Enzymes,Phosphodiesterases,Inhibitor,Highly potent PDE3 inhibitor,1,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2,376,1
2339,CC1=NN=C2CN=C(C3=C(SC(CCC(=O)N4CCOCC4)=C3)N12)C1=CC=CC=C1Cl,WEB 2086,65889,"4-[3-[4[(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a]diazepin-2-yl]-1-oxopropyl]morpholine",C22H22N5O2SCl,[105219-56-5],455.96,7-TM Receptors,Platelet-activating Factor (PAF) Receptors,Antagonist,Potent PAF receptor antagonist,2,Cc1nnc2n1-c1sc(CCC(=O)N3CCOCC3)cc1C(c1ccccc1Cl)=NC2,631,1
2345,OP(O)(=O)CN1C(=O)C(=O)NC2=CC(=C(C=C12)N1CCOCC1)C(F)(F)F,ZK 200775,208953,"[[3,4-Dihydro-7-(4-morpholinyl)-2,3-dioxo-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]phosphonic acid",C14H15N3O6F3P,[161605-73-8],413.75,Ion Channels,AMPA Receptors,Antagonist,Competitive non-NMDA iGluR antagonist,1,O=c1[nH]c2cc(C(F)(F)F)c(N3CCOCC3)cc2n(CP(=O)(O)O)c1=O,313,1
2347,S=C(NC(NC(/C=C/C3=CC=CC=C3)=O)C(Cl)(Cl)Cl)NC1=C2C(C=CC=N2)=CC=C1,Salubrinal,5717801,"3-Phenyl-N-[2,2,2-trichloro-1-[[(8-quinolinylamino)thioxomethyl]amino]ethyl]-2-propenamide",C21H17N4OSCl3,[405060-95-9],488.82,Enzymes,Protein Ser/Thr Phosphatases,Inhibitor,Selective inhibitor of eIF2? dephosphorylation,1,O=C(/C=C/c1ccccc1)NC(NC(=S)Nc1cccc2cccnc12)C(Cl)(Cl)Cl,606,1
2348,[Na+].[O-]C(=O)C1=C(\C=C\C(=O)NC2=CC=CC=C2)C2=C(N1)C=C(Cl)C=C2Cl,Gavestinel,16759177,"4,6-Dichloro-3-[(1E)-3-oxo-3-(phenylamino)-1-propenyl]-1H-indole-2-carboxylic acid sodium salt",C18H11Cl2N2O3Na,[153436-38-5],428.71,Ion Channels,NMDA Receptors,Antagonist,Potent and selective NMDA antagonist; acts at the glycine site,1,O=C(/C=C/c1c(C(=O)[O-])[nH]c2cc(Cl)cc(Cl)c12)Nc1ccccc1,610,0
2349,O=C1CC2=C(CCN4[C@]32C(CC4)=CC[C@H](OC)C3)CO1.Br,Dihydro-beta-erythroidine hydrobromide,11957537,"(2S,13bS)-2-Methoxy-2,3,5,6,8,9,10,13-octahydro-1H,12H-benzo[i]pyrano[3,4-g]indolizin-12-one hydrobromide",C16H21NO3.HBr,[29734-68-7],356.26,Ion Channels,Nicotinic Receptors (Other Subtypes),Antagonist,"?4?2, muscle type and Torpedo nAChR antagonist",11,CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1,12,1
2373,OC(C1=CC=C(C=C1)N(CC(F)(F)F)S(=O)(=O)C1=CC=CC=C1)(C(F)(F)F)C(F)(F)F,T 0901317,447912,"N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]benzenesulfonamide",C17H12F9NO3S,[293754-55-9],481.33,Nuclear Receptors,LXR-like Receptors,Agonist,Potent liver X receptor (LXR) agonist; also CAR inverse agonist,2,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,520,1
2382,Cl.CC1=C(C2=CC(Cl)=CC=C2N1)C1=CCNCC1,EMD 386088 hydrochloride,56972198,"5-Chloro-2-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole hydrochloride",C14H15N2Cl.HCl,[1171123-46-8],283.2,7-TM Receptors,5-HT6 Receptors,Agonist,Potent 5-HT6 agonist,1,Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1,564,0
2385,Cl.Cl.C(CNC(C1=CC=CC=C1)C1=CC=CC=C1)NC(C1=CC=CC=C1)C1=CC=CC=C1,AMN 082 dihydrochloride,11698390,"N,N'-Bis(diphenylmethyl)-1,2-ethanediamine dihydrochloride",C28H28N2.2HCl,[97075-46-2],465.45,7-TM Receptors,Glutamate (Metabotropic) Group III Receptors,Agonist,Selective mGlu7 agonist,2,c1ccc(C(NCCNC(c2ccccc2)c2ccccc2)c2ccccc2)cc1,179,1
2386,CN1CC(=O)N=C1NC(=O)NC1=CC(Cl)=CC=C1,Fenobam,162834,"N-(3-Chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)urea",C11H11N4O2Cl,[57653-26-6],266.69,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Modulator,Potent and selective mGlu5 negative allosteric modulator (NAM),1,CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1,597,0
2392,CC(C)C1=C2C(C)=NN(C)C2=NC(NNC(=O)NC2=CC(Cl)=NC(Cl)=C2)=C1,JTE 013,10223146,"1-[1,3-Dimethyl-4-(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(3,5-dichloro-4-pyridinyl)-semicarbazide",C17H19N7OCl2,[383150-41-2],412.79,7-TM Receptors,Sphingosine-1-phosphate Receptors,Antagonist,S1P2 receptor antagonist,6,Cc1nn(C)c2nc(NNC(=O)Nc3cc(Cl)nc(Cl)c3)cc(C(C)C)c12,592,1
2394,O=C(NC3=C([N+]([O-])=O)C=CC=C3)N1[C@H]([C@@](N[C@H]([C@@](N(C)CC4=CC=CC=C4)=O)CC2=CC=C(C=CC=C5)C5=C2)=O)CCC1,SDZ NKT 343,9851211,1-[[(2-Nitrophenyl)amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide,C33H33N5O5,[180046-99-5],584.15,7-TM Receptors,NK1 Receptor,Antagonist,Highly selective human NK1 antagonist,1,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+](=O)[O-],201,1
2395,ClC(C(Cl)=C3)=CC=[C@@]3[C@H]2C1=CC=CC=C1[C@@H](NC)CC2.Cl,Sertraline hydrochloride,63009,"(1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride",C17H17Cl2N.HCl,[79559-97-0],342.69,Transporters,5-HT Transporters,Inhibitor,5-HT reuptake inhibitor,3,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,622,0
2408,NC1=CC=C(C=C1)C1=NC2=CC=C(C=C2N1)C1=NC2=CC=C(N)C=C2N1,Ro 90-7501,824226,"2'-(4-Aminophenyl)-[2,5'-bi-1H-benzimidazol]-5-amine",C20H16N6,[293762-45-5],353.9,Cell biology,Amyloid Beta Peptides,Inhibitor,Inhibitor of A?42 fibril formation,4,Nc1ccc(-c2nc3ccc(-c4nc5ccc(N)cc5[nH]4)cc3[nH]2)cc1,61,1
2412,OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.NC(=N)NCCC[C@@H](NC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)NCC1=CC=C(CNC(N)=O)C=C1,BIBO 3304 trifluoroacetate,5311022,N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-?-phenyl-benzeneacetamide ditrifluoroacetate,C29H35N7O3.2CF3CO2H,[2310085-85-7],757.69,7-TM Receptors,NPY Receptors,Antagonist,Highly selective NPY Y1 receptor antagonist,2,N=C(N)NCCC[C@@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(CNC(N)=O)cc1,116,1
2416,Cl.Cl.CN1CCC(CC1)NC1=NC=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=N1,BIBX 1382 dihydrochloride,46861540,"N8-(3-Chloro-4-fluorophenyl)-N2-(1-methyl-4-piperidinyl)-pyrimido[5,4-d]pyrimidine-2,8-diamine dihydrochloride",C18H19ClFN7.2HCl,[1216920-18-1],496.8,Enzyme-Linked Receptors,EGFR,Inhibitor,Highly selective EGFR-kinase inhibitor,1,CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,390,0
2440,ClC1=C(Cl)C=C(CN(CCCNC(=S)NCCCC2=CNC=N2)C2=CC=C(Br)C=N2)C=C1,NNC 26-9100,9893924,"1-[3-[N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino]propyl]-3-[3-(1H-imidazol-4-yl)propyl]thiourea",C22H25N6Cl2SBr,[199522-35-5],560.85,7-TM Receptors,Somatostatin Receptors,Agonist,Selective sst4 agonist,3,S=C(NCCCc1c[nH]cn1)NCCCN(Cc1ccc(Cl)c(Cl)c1)c1ccc(Br)cn1,878,1
2442,FC1=CC=C(NC2=CC3=C(C=C2NC2=CC=C(F)C=C2)C(=O)NC3=O)C=C1,CGP 53353,6711154,"5,6-bis[(4-Fluorophenyl)amino]-1H-isoindole-1,3(2H)-dione",C20H13F2N3O2,[145915-60-2],365.34,Enzymes,Protein Kinase C,Inhibitor,Selective inhibitor of PKC?II,1,O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21,503,1
2451,Cl[H].CN(C)[C@@H]1CCC2=C(C1)C1=CC(NC(=O)C3=CC=C(F)C=C3)=CC=C1N2,LY 344864 hydrochloride,56972176,"N-[(3R)-3-(Dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluorobenzamide hydrochloride",C21H22N3OF.HCl,[1217756-94-9],392.38,7-TM Receptors,5-HT1F Receptors,Agonist,Potent and selective 5-HT1F agonist,1,CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1,508,1
2456,Cl.CC1=CC=C(CC2(O)CCN(CCOC3=CC=C(O)C=C3)CC2)C=C1,Co 101244 hydrochloride,6918426,1-[2-(4-Hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]-4-piperidinol hydrochloride,C21H27NO3.HCl,[193356-17-1],382.41,Ion Channels,NMDA Receptors,Antagonist,GluN2B-selective NMDA antagonist,1,Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1,643,0
2457,O=C1NC(=O)C2=C1C1=C(NC3=CC=CC=C13)C1=C2C2=C(N1)C=CC=C2,Arcyriaflavin A,5327723,"12,13-Dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione",C20H11N3O2.C2H5OH,[118458-54-1],371.39,Enzymes,Cyclin-dependent Kinase,Inhibitor,Potent cdk4 inhibitor; also potently inhibits CaM kinase II; antiviral,1,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21,787,1
2458,COC1=CC2=C(NC3=CC=C(NC(=O)C4=CC=CC=C4)C=C3)N=CN=C2C=C1OCCCN1CCOCC1,ZM 447439,9914412,N-[4-[[6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamide,C29H31N5O4,[331771-20-1],540.61,Enzymes,Aurora Kinases,Inhibitor,Inhibits Aurora kinase B,4,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1,391,1
2463,COC1=CC=C(CCCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)C=C1,SCH 442416,10668061,"2-(2-Furanyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine",C20H19N7O2,[316173-57-6],389.42,7-TM Receptors,Adenosine A2A Receptors,Antagonist,"Very selective, high affinity A2A antagonist",5,COc1ccc(CCCn2ncc3c2nc(N)n2nc(-c4ccco4)nc32)cc1,164,0
2465,O[C@@H]1[C@@H](CO)O[C@@H](N(C=N4)C2=C4C(NC3CCCCC3)=NC=N2)[C@@H]1OC,SDZ WAG 994,164305,N-Cyclohexyl-2'-O-methyladenosine,C17H25N5O4,[130714-47-5],372.42,7-TM Receptors,Adenosine A1 Receptors,Agonist,"Potent, selective A1 agonist",1,CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc21,841,0
2471,OC(=O)\C=C/C(O)=O.CC1=C(C)C2=C(C=C1)C(=O)C1=CC=CC=C1N2CCCN,ER 27319 maleate,56972172,"10-(3-Aminopropyl)-3,4-dimethyl-9(10H)-acridinone maleate",C18H20N2O.C4H4O4,[1204480-26-1],396.17,Enzymes,Syk Kinase,Inhibitor,Selective Syk kinase inhibitor,1,Cc1ccc2c(=O)c3ccccc3n(CCCN)c2c1C,782,1
2474,Cl.OC(=O)CC1=CC=CC(OCCCN(CC(C2=CC=CC=C2)C2=CC=CC=C2)CC2=C(Cl)C(=CC=C2)C(F)(F)F)=C1,GW 3965 hydrochloride,16078973,"3-[3-[[[2-Chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]benzeneacetic acid hydrochloride",C33H31NO3ClF3.HCl,[405911-17-3],636.53,Nuclear Receptors,LXR-like Receptors,Agonist,Orally active liver X receptor (LXR) agonist,2,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,425,1
2475,Cl.CC1=C(O)C=C(NC2=C3C=CC(OCC4=CC=CC=C4)=CC3=NC=N2)C(F)=C1,ZM 323881 hydrochloride,22624897,5-((7-Benzyloxyquinazolin-4-yl)amino)-4-fluoro-2-methylphenol hydrochloride,C22H18FN3O2.HCl,[193000-39-4],411.86,Enzyme-Linked Receptors,VEGFR,Inhibitor,"Potent, selective inhibitor of VEGFR-2",1,Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O,205,1
2478,Cl.Cl.NCCC1=NC=CC=C1,2-Pyridylethylamine dihydrochloride,201148,2-Pyridineethanamine dihydrochloride,C7H10N2.2HCl,[3343-39-3],195.09,7-TM Receptors,Histamine H1 Receptors,Agonist,H1 agonist,2,NCCc1ccccn1,877,1
2479,CCCCCOC1=C2NC(=O)C(=CC2=CC=C1OC)C(=O)NCC1=CC2=C(OCO2)C=C1,JTE 907,9867770,"N-(1,3-Benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide",C24H26N2O6,[282089-49-0],438.48,7-TM Receptors,CB2 Receptors,Inverse Agonist,Selective CB2 receptor inverse agonist,1,CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4c(c3)OCO4)c(=O)[nH]c12,749,1
2481,Cl.CCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)C=C(C)N=C3C=C2)C=C1,JTC 801,5311339,N-(4-Amino-2-methyl-6-quinolinyl)-2-[(4-ethylphenoxy)methyl]benzamide hydrochloride,C26H25N3O2.HCl,[244218-51-7],470.48,7-TM Receptors,NOP Receptors,Antagonist,Selective NOP antagonist,4,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1,444,0
2489,C=C([C@@H]([C@](O)=O)[C@H](CCCCCCCC)O1)C1=O.C=C([C@H](C(O)=O)[C@@H](CCCCCCCC)O2)C2=O,C 75,90488767,"(2R*,3S*)-Tetrahydro-4-methylene-2-octyl-5-oxo-3-furancarboxylic acid",C14H22O4,[191282-48-1],254.32,Enzymes,Fatty Acid Synthase,Inhibitor,Potent fatty acid synthase inhibitor; proapoptotic,3,C=C1C(=O)O[C@@H](CCCCCCCC)[C@@H]1C(=O)O,24,1
2498,COC1=CC(OC)=C(Cl)C=C1NC(=O)NC1=NOC(C)=C1,PNU 120596,311434,"N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea",C13H14ClN3O4,[501925-31-1],311.72,Ion Channels,Nicotinic (a7) Receptors,Modulator,Positive allosteric modulator of ?7 nAChRs; active in vivo,3,COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl,385,1
2506,COC1=CC(C(C)C)=C2C(=O)N(COC3=CC(=O)N4C=CC=C(OCCN5CCCCC5)C4=N3)S(=O)(=O)C2=C1,SSR 69071,9872438,"2-[[6-Methoxy-4-(1-methylethyl)-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl]methoxy]-9-[2-(1-piperidinyl)ethoxy]-4H-pyrido[1,2-a]pyrimidin-4-one",C27H32N4O7S,[344930-95-6],565.64,Enzymes,Elastase,Inhibitor,"Potent, orally active human leukocyte elastase inhibitor",2,COc1cc(C(C)C)c2c(c1)S(=O)(=O)N(COc1cc(=O)n3cccc(OCCN4CCCCC4)c3n1)C2=O,645,1
2507,[H]OC(=O)\C=C\C(=O)O[H].C\C(C)=C\CCN1CCC(CC1)NC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1,J 104129 fumarate,56972189,(?R)-?-Cyclopentyl-?-hydroxy-N-[1-(4-methyl-3-pentenyl)-4-piperidinyl]benzeneacetamide fumarate,C24H36N2O2.C4H4O4,[257603-40-0],500.63,7-TM Receptors,M3 Receptors,Antagonist,Potent and selective M3 antagonist,2,CC(C)=CCCN1CCC(NC(=O)[C@](O)(c2ccccc2)C2CCCC2)CC1,299,1
2513,NC1=NC(=O)C2=C(N1)N(COCCO)C=N2,Acyclovir,2022,"2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one",C8H11N5O3,[59277-89-3],234.22,Enzymes,RNA/DNA Polymerase,Inhibitor,Inhibits viral DNA polymerase; antiherpetic agent,2,Nc1nc(=O)c2ncn(COCCO)c2[nH]1,827,1
2514,CCCCC1=NN(C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)S(=O)(=O)NC(=O)C1=C(C)C=CS1)C1=C(C=CC=C1)C(F)(F)F,"L-161,982",9961192,"N-[[4'-[[3-Butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]-3-methyl-2-thiophenecarboxamide",C32H29F3N4O4S2,[147776-06-5],654.72,7-TM Receptors,Prostanoid Receptors,Antagonist,Selective EP4 receptor antagonist,2,CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(-c2ccccc2S(=O)(=O)NC(=O)c2sccc2C)cc1,665,1
2520,BrC1=CC=C(C2=CC=C(S(N[C@@H]([C@H](C)C)C(O)=O)(=O)=O)C=C2)C=C1,PD 166793,9887870,"N-[(4'-Bromo[1,1'-biphenyl]-4-yl)sulfonyl]-L-valine",C17H18BrNO4S,[199850-67-4],412.3,Enzymes,Matrix Metalloprotease,Inhibitor,Broad spectrum MMP inhibitor,1,CC(C)[C@H](NS(=O)(=O)c1ccc(-c2ccc(Br)cc2)cc1)C(=O)O,68,1
2530,O=C(C2=CC=C3C(C=CC4=C3C=CC=C4)=C2)N1[C@@H]([C@](O)=O)[C@@H]([C@](O)=O)NCC1.O=C(C6=CC=C7C(C=CC8=C7C=CC=C8)=C6)N5[C@H](C(O)=O)[C@H](C(O)=O)NCC5,PPDA,90488770,"(2S*,3R*)-1-(Phenanthren-2-carbonyl)piperazine-2,3-dicarboxylic acid",C21H18N2O5,[684283-16-7],387.39,Ion Channels,NMDA Receptors,Antagonist,GluN2C/GluN2D-selective NMDA antagonist,2,O=C(O)[C@H]1NCCN(C(=O)c2ccc3c(ccc4ccccc43)c2)[C@H]1C(=O)O,778,1
2532,OC([C@@H](N)[C@H](OCC1=CC=CC(NC(C2=CC=C(C(F)(F)F)C=C2)=O)=C1)C(O)=O)=O,TFB-TBOA,52941382,(3S)-3-[[3-[[4-(Trifluoromethyl)benzoyl]amino]phenyl]methoxy]-L-aspartic acid,C19H17F3N2O6,[480439-73-4],430.85,Transporters,Glutamate Transporters,Inhibitor,High affinity EAAT1 and EAAT2 blocker,4,N[C@H](C(=O)O)[C@H](OCc1cccc(NC(=O)c2ccc(C(F)(F)F)cc2)c1)C(=O)O,209,0
2539,Cl.O=C(N1CCC(CC1)N1CCCC1)C1=CC=C(NC2=NC=CC(=N2)C2=CC3=CC=CC=C3S2)C=C1,IKK 16,56972179,N-(4-Pyrrolidin-1-yl-piperidin-1-yl)-[4-(4-benzo[b]thiophen-2-yl-pyrimidin-2-ylamino)phenyl]carboxamide hydrochloride,C28H29N5OS.HCl,[1186195-62-9],524.59,Enzymes,IkB Kinase,Inhibitor,Selective inhibitor of IKK,2,O=C(c1ccc(Nc2nccc(-c3cc4ccccc4s3)n2)cc1)N1CCC(N2CCCC2)CC1,276,1
2542,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=CC=C(F)C=C4F)C(F)=C3)=CC=NC2=C1,Ki 8751,11317348,"N-(2,4-Difluorophenyl)-N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-fluorophenyl]urea",C24H18F3N3O4,[228559-41-9],469.41,Enzyme-Linked Receptors,VEGFR,Inhibitor,"Potent, selective VEGFR-2 inhibitor",2,COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC,384,1
2550,O=C1C=C(C)C(/C(C)=N/C2=C(N)C=CC=C2)=C(O)N1O,SUN-B 8155,16079007,"5-[1-[(2-Aminophenyl)imino]ethyl]-1,6-dihydroxy-4-methyl-2(1H)-pyridone",C14H15N3O3,[345893-91-6],273.29,7-TM Receptors,Calcitonin and Related Receptors,Agonist,Non-peptide calcitonin agonist,2,C/C(=N\c1ccccc1N)c1c(C)cc(=O)n(O)c1O,810,1
2554,OC(C(C1(C[C@@H]2C3)C[C@H](C2)C[C@H]3C1)=C4)=CC5=C4C=C(C6=CC=C(C(O)=O)C=C6)C=C5,CD 1530,24868309,"4-(6-Hydroxy-7-tricyclo[3.3.1.13,7]dec-1-yl-2-naphthalenyl)benzoic acid",C27H26O3,[107430-66-0],402.99,Nuclear Receptors,Retinoic Acid Receptors,Agonist,Potent and selective RAR? agonist,2,O=C(O)c1ccc(-c2ccc3cc(O)c(C45C[C@H]6C[C@@H](C4)C[C@@H](C5)C6)cc3c2)cc1,458,1
2558,Cl.CCN(CC)CCCCN1C2=CC=CC=C2OC2=C1C=C(Cl)C=C2,10-DEBC hydrochloride,16760284,"10-[4'-(N,N-Diethylamino)butyl]-2-chlorophenoxazine hydrochloride",C20H25N2OCl.HCl,[925681-41-0],381.34,Enzymes,Akt (Protein Kinase B),Inhibitor,Selective Akt/PKB inhibitor,1,CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21,641,1
2559,NC(=O)NC1=C(C=C(S1)C1=CC=C(F)C=C1)C(N)=O,TPCA-1,9903786,2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide,C12H10FN3O2S,[507475-17-4],279.29,Enzymes,IkB Kinase,Inhibitor,"Potent, selective inhibitor of IKK?",5,NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O,531,1
2560,O=C1NC(=O)C2=C1C1=C3N(C4CCC(O4)N4C5=C(C=CC=C5)C2=C34)C2=CC=CC=C12,SB 218078,3387354,"9,10,11,12-Tetrahydro- 9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1,3(2H)-dione",C24H15N3O3,[135897-06-2],393.39,Enzymes,Checkpoint Kinases,Inhibitor,Chk1 inhibitor,1,O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1,788,1
2563,O=C(C3CCCCC3)N(CC2=CC=C(C4=CC=C(N(C)C)C=C4)C=C2)C1=CC(/C=C/C(OC)=O)=CC=C1,Fexaramine,5326713,"3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoic acid methyl ester",C32H36N2O3,[574013-66-4],496.64,Nuclear Receptors,LXR-like Receptors,Agonist,"Potent, selective farnesoid X receptor (FXR) agonist",2,COC(=O)/C=C/c1cccc(N(Cc2ccc(-c3ccc(N(C)C)cc3)cc2)C(=O)C2CCCCC2)c1,223,1
2571,OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,Amlodipine besylate,60496,"2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester benzenesulfonate",C20H25ClN2O5.C6H6O3S,[111470-99-6],567.05,Ion Channels,Cav1.x Channels,Blocker,CaV1.x blocker,1,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,128,0
2580,O=C1N(C(N)=O)C2=CC=C(Cl)C=C2/C1=C(O)\C3=CC=CS3,Tenidap,54683953,"(Z)-5-Chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide",C14H9N2O3SCl,[120210-48-2],320.75,Enzymes,Cyclooxygenase,Inhibitor,"NSAID, cyclooxygenase (COX-1) inhibitor. Also opener of KIR2.3",1,NC(=O)N1C(=O)/C(=C(\O)c2cccs2)c2cc(Cl)ccc21,595,1
2592,Br.COC1=C2C(CN)CC2=C(OC)C(Br)=C1,TCB-2,71433791,"(4-Bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide",C11H14BrNO2.HBr,[912342-28-0],353.05,7-TM Receptors,5-HT2A Receptors,Agonist,High affinity and potent 5-HT2A agonist,4,COc1cc(Br)c(OC)c2c1C(CN)C2,363,1
2598,CCN1C4=C(C=CC=C4)N([C@@H]2CCN(CC3CCCCCCC3)C[C@H]2CO)C1=O.CCN5C8=C(C=CC=C8)N([C@H]6CCN(CC7CCCCCCC7)C[C@@H]6CO)C5=O,(+/-)-J 113397,90488772,"(�)-1-[(3R*,4R*)-1-(Cyclooctylmethyl)-3-(hydroxymethyl)-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one",C24H37N3O2,[217461-40-0],404.07,7-TM Receptors,NOP Receptors,Antagonist,Potent and selective NOP antagonist,5,CCn1c(=O)n([C@@H]2CCN(CC3CCCCCCC3)C[C@H]2CO)c2ccccc21,261,1
2599,CCCN(C2)CCC[C@@]2([H])C1=CC=CC(S(=O)(C)=O)=C1.Cl,OSU 6162 hydrochloride,9836644,(3S)-3-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride,C15H23NO2S.HCl,[156907-84-5],322.37,7-TM Receptors,Dopaminergic-Related,Other,Dopamine stabilizer,2,CCCN1CCC[C@@H](c2cccc(S(C)(=O)=O)c2)C1,296,1
2606,O=C(O)C(O)=O.CCCN1CC(C2=CC(C3=CC=C(C)C=C3)=NO2)=CCC1,PD 144418 oxalate,9817231,"1,2,3,6-Tetrahydro-5-[3-(4-methylphenyl)-5-isoxazolyl]-1-propylpyridine oxalate",C18H22N2O.C2H2O4,[1794760-28-3],376.92,Other Pharmacology,Sigma1 Receptors,Ligand,"High affinity, selective ?1 ligand",1,CCCN1CCC=C(c2cc(-c3ccc(C)cc3)no2)C1,649,1
2607,C[C@](NC(OC5C3CC(CC5C6)CC6C3)=O)(C(NC[C@@H]([C@]4=CC=CC=C4)NC(CCC(O)=O)=O)=O)CC2=CNC1=CC=CC=C12,CI 988,108187,"4-[[(1R)-2-[[(2R)-3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[[(tricyclo[3.3.1.13,7]dec-2-yloxy)carbonyl]amino]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid",C35H42N4O6,[130332-27-3],623.74,7-TM Receptors,CCK2 Receptor,Antagonist,Potent and selective CCK2 antagonist,1,C[C@](Cc1c[nH]c2ccccc12)(NC(=O)OC1C2CC3CC(C2)CC1C3)C(=O)NC[C@H](NC(=O)CCC(=O)O)c1ccccc1,796,1
2609,CC1=NC2=C(S1)C(=O)C=C(NC1=CC=C(C)C=C1)C2=O,Ryuvidine,481747,"2-Methyl-5-[(4-methylphenyl)amino]-4,7-benzothiazoledione",C15H12N2O2S,[265312-55-8],284.33,Enzymes,Other Lysine Methyltransferases,Inhibitor,SETD8 inhibitor; also CDK4 inhibitor,2,Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1,651,1
2615,CNC1=NC=C2N=CN=C(NC3=CC=CC(Br)=C3)C2=C1,PD 158780,4707,"N4-(3-Bromophenyl)-N6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine",C14H12BrN5,[171179-06-9],330.18,Enzyme-Linked Receptors,EGFR,Inhibitor,Potent ErbB receptor family inhibitor,1,CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,389,1
2624,O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N)=NC2=O)C1,Decitabine,451668,"4-Amino-1-(2-deoxy-?-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one",C8H12N4O4,[2353-33-5],228.21,Enzymes,DNA Methyltransferases,Inhibitor,DNA methyltransferase inhibitor,3,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,841,0
2632,Cl.O=C(NCCCCN1CCOCC1)C1=CC2=CC=CC=C2O1,CL 82198 hydrochloride,16760373,N-[4-(4-Morpholinyl)butyl]-2-benzofurancarboxamide hydrochloride,C17H23N2O3.HCl,[1188890-36-9],338.83,Enzymes,Matrix Metalloprotease,Inhibitor,Selective inhibitor of MMP-13,2,O=C(NCCCCN1CCOCC1)c1cc2ccccc2o1,314,1
2633,CC1=CC(C(=O)NO)=C(N(CC2=CC=CC=C2)S(=O)(=O)C2=CC=C(OCCNC(=O)C3=CC4=CC=CC=C4O3)C=C2)C(C)=C1,WAY 170523,9830392,"N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide",C33H31N3O7S,[307002-73-9],613.68,Enzymes,Matrix Metalloprotease,Inhibitor,Potent and selective inhibitor of MMP-13,2,Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(C(=O)NO)c1,315,1
2634,CC(C)(C)OC([C@H]([C@]2=CC=CC=C2)NC([C@H](C)NC(CC1=CC(F)=CC(F)=C1)=O)=O)=O,DAPT,5311272,"(2S)-N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine 1,1-dimethylethyl ester",C23H26F2N2O4,[208255-80-5],432.46,Cell biology,Neural Stem Cells,Other,?-secretase inhibitor; induces neuronal differentiation,8,C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1,183,1
2635,Cl.ClC1=C(Cl)C(=CC=C1)N1CCN(CCCCNC(=O)C2=CC=C3C(CC4=CC=CC=C34)=C2)CC1,NGB 2904,19366304,"N-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyl]-9H-fluorene-2-carboxamide",C28H29Cl2N3O.HCl,[189061-11-8],530.92,7-TM Receptors,D3 Receptors,Antagonist,Potent and selective D3 antagonist,1,O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2,275,1
2641,CC(C=CC=C2)=C2N1CCN(S(CC34CCC(C(C)4C)C[C@@H]3NC([C@@H](N)CCS(C)(=O)=O)=O)(=O)=O)CC1.Cl,"L-368,899 hydrochloride",90488775,"(2S)-2-Amino-N-[(1S,2S,4R)-7,7-dimethyl-1-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]bicyclo[2.2.1]hept-2-yl]-4-(methylsulfonyl)butanamide",C26H42N4O5S2.HCl,[160312-62-9],604.74,7-TM Receptors,Oxytocin Receptors,Antagonist,"Potent, non-peptide oxytocin receptor antagonist",3,Cc1ccccc1N1CCN(S(=O)(=O)CC23CCC(C[C@@H]2NC(=O)[C@@H](N)CCS(C)(=O)=O)C3(C)C)CC1,663,1
2649,OC(=O)CCC1=CC=C(NCC2=CC=CC(OC3=CC=CC=C3)=C2)C=C1,GW 9508,11595431,4-[[(3-Phenoxyphenyl)methyl]amino]benzenepropanoic acid,C22H21NO3,[885101-89-3],347.41,7-TM Receptors,Free Fatty Acid Receptors,Agonist,Potent and selective FFA1 (GPR40) agonist,1,O=C(O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,451,0
2652,FC1=C(F)C=C(OC2=CC=C(NC(C[C@H](N)C(O)=O)=O)C=C2)C(Br)=C1,WAY 213613,11531745,"N-[4-(2-Bromo-4,5-difluorophenoxy)phenyl]-L-asparagine",C16H13BrF2N2O4,[868359-05-1],415.19,Transporters,Glutamate Transporters,Inhibitor,"Potent, non-substrate EAAT2 inhibitor",1,N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(=O)O,447,1
2662,OC1=CC=C(C=C1)C1=C2N=C(C=C(N2N=C1C1=CC=CC=C1)C(F)(F)F)C(F)(F)F,PHTPP,11201035,"4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol",C20H11F6N3O,[805239-56-9],423.31,Nuclear Receptors,Estrogen and Related Receptors,Antagonist,Selective ER? antagonist,2,Oc1ccc(-c2c(-c3ccccc3)nn3c(C(F)(F)F)cc(C(F)(F)F)nc23)cc1,685,1
2664,CC2=C(C(C[C@]3([H])[C@@]([H])2C[C@@H]([C@@](N(C(NCC)=O)CCCN(C)C)=O)CN3CC=C)=CN1)/C/1=C,Cabergoline,90488776,N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)ergoline-8-carboxamide,C26H37N5O2,[81409-90-7],451.6,7-TM Receptors,Non-selective Dopamine,Agonist,D2-like agonist (D2>D3>D4),2,C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C(C)=c3c(c[nH]c3=C)C[C@H]21,119,1
2665,OC1=CC=C(Cl)C=C1CN1N=C(OC1=O)C1=CC=C(C=C1)C(F)(F)F,BMS 191011,10474339,"3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one",C16H10ClF3N2O3,[202821-81-6],370.71,Ion Channels,Ca2+-Activated Potassium Channels,Activator,Potent BKCa (KCa1.1) channel opener,2,O=c1oc(-c2ccc(C(F)(F)F)cc2)nn1Cc1cc(Cl)ccc1O,552,1
2682,[Na+].[O-]C(=O)CCCC1=CC=CC=C1,Sodium 4-Phenylbutyrate,5258,"4-Phenylbutyric acid, sodium salt",C10H11NaO2,[1716-12-7],190.68,Enzymes,Non-selective HDACs,Inhibitor,Histone deacetylase inhibitor,5,O=C([O-])CCCc1ccccc1,210,1
2684,OC1=CC=C(N=C(C(N3C4)=CC([C@](CC)(O)C(OC5)=O)=C5C3=O)C4=C2CC)C2=C1,SN 38,104842,"(4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione",C22H20N2O5,[86639-52-3],410.42,Enzymes,DNA Topoisomerase,Inhibitor,DNA topoisomerase I inhibitor; antitumor,2,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,690,1
2685,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,Carvedilol,2585,1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol,C24H26N2O4,[72956-09-3],406.47,7-TM Receptors,Non-selective Adrenergic Beta Receptors,Antagonist,Potent and non-selective ? antagonist; also potent ?1 antagonist,1,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,348,1
2688,CCC2=C4C(C(N3C4)=CC([C@](CC)(O)C(OC5)=O)=C5C3=O)=NC1=CC=C(OC(N6CCC(N7CCCCC7)CC6)=O)C=C12.Cl,CPT 11,74990,"(4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylic acid ester hydrochloride",C33H38N4O6.HCl,[100286-90-6],677.19,Enzymes,DNA Topoisomerase,Inhibitor,DNA topoisomerase I inhibitor; antitumor,2,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,690,0
2694,OC1=CC2=C(NC3=C2C2=C(C(=O)NC2=O)C(=C3)C2=CC=CC=C2)C=C1,PD 407824,4369491,"9-Hydroxy-4-phenyl-pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione",C20H12N2O3,[622864-54-4],332.82,Enzymes,Checkpoint Kinases,Inhibitor,Potent and selective inhibitor of Chk1 and Wee1,1,O=C1NC(=O)c2c1c(-c1ccccc1)cc1[nH]c3ccc(O)cc3c21,787,0
2705,ClC1=CC(C(N4C=CN=C4)C2=CC=C(N=CN3)C3=C2)=CC=C1.Cl.Cl,Liarozole dihydrochloride,121513844,5-[(3-Chlorophenyl)-1H-imidazol-1-ylmethyl]-1H-benzimidazole dihydrochloride,C17H13ClN4.2HCl,0,399.71,Nuclear Receptors,Retinoic Acid Receptors,Other,Blocks retinoic acid metabolism,3,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1,620,1
2706,CN1N=NC2=C(N=CN2C1=O)C(N)=O,Temozolomide,5394,"3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide",C6H6N6O2,[85622-93-1],197.75,Cell biology,Apoptosis Inducers,Other,DNA-methylating antitumor agent,2,Cn1nnc2c(C(N)=O)ncn2c1=O,678,1
2718,N1C=C(C(=N1)C1=CC=CC=N1)C1=CC=NC2=CC=CC=C12,LY 364947,447966,4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]-quinoline,C17H12N4,[396129-53-6],272.31,Enzyme-Linked Receptors,TGF-beta Receptors,Inhibitor,Selective inhibitor of TGF-?RI,1,c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1,741,0
2724,O=C(NC3=C(Br)C=CC=C3)NC1=CC=C(C#N)C2=C1NN=N2,SB 265610,9841667,N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea,C14H9BrN6O,[211096-49-0],375.18,7-TM Receptors,Chemokine CXC Receptors,Antagonist,Potent CXCR2 antagonist,6,N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2[nH]nnc12,548,1
2725,OC1=CC(=CC=C1NC(=O)NC1=CC=CC=C1Br)[N+]([O-])=O,SB 225002,3854666,N-(2-Bromophenyl)-N'-(2-hydroxy-4-nitrophenyl)urea,C13H10BrN3O4,[182498-32-4],352.14,7-TM Receptors,Chemokine CXC Receptors,Antagonist,Potent and selective CXCR2 antagonist,2,O=C(Nc1ccc([N+](=O)[O-])cc1O)Nc1ccccc1Br,548,0
2726,O=S(C1=CC(C)=CC=C1)(N(C)[C@H](C)CCN2CCC(C)CC2)=O.Cl,SB 258719 hydrochloride,56972181,3-Methyl-N-[(1R)-1-methyl-3-(4-methyl-1-piperidinyl)propyl]-N-methylbenzenesulfonamide hydrochloride,C18H30N2O2S.HCl,[1217674-10-6],374.97,7-TM Receptors,5-HT7 Receptors,Antagonist,Selective 5-HT7 antagonist,1,Cc1cccc(S(=O)(=O)N(C)[C@H](C)CCN2CCC(C)CC2)c1,297,0
2727,O=C(/N=C(N)/N)C(C=N3)=C(C4CC4)N3C1=C2C(N=CC=C2)=CC=C1.Cl.Cl,Zoniporide dihydrochloride,22267855,[1-(Quinolin-5-yl)-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine dihydrochloride,C17H16N6O.2HCl,[241799-10-0],393.27,Transporters,Na+/H+ Exchanger,Inhibitor,Selective NHE1 inhibitor,2,NC(N)=NC(=O)c1cnn(-c2cccc3ncccc23)c1C1CC1,734,1
2731,NC1=C2C(NC3=CC=C(F)C=C3)=NNC2=NC=N1,CGP 57380,11644425,"N3-(4-Fluorophenyl)-1H-pyrazolo-[3,4-d]pyrimidine-3,4-diamine",C11H9FN6,[522629-08-9],244.23,Enzymes,Mnk,Inhibitor,Selective inhibitor of Mnk1,3,Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12,503,0
2747,Cl.COC1=C(C=CC=C1)C1(O)CCN(CCCN2C3=C(C=CC=C3)C3=C2C=CC=C3)CC1,NNC 05-2090 hydrochloride,18782760,1-[3-(9H-Carbazol-9-yl)propyl]-4-(2-methoxyphenyl)-4-piperidinol hydrochloride,C27H30N2O2.HCl,[184845-18-9],451.01,Transporters,GABA Transporters,Inhibitor,GABA uptake inhibitor; moderately BGT-1 selective,1,COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc32)CC1,780,1
2748,COC1=CC=C(C2CC(=NCCS2)C2=C(O)C=C(C)OC2=O)C(OC)=C1,KF 38789,5373277,"3-[7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-1,4-thiazepin-5-yl]-4-hydroxy-6-methyl-2H-pyran-2-one",C19H21NO5S,[257292-29-8],375.44,Cell biology,Cell Adhesion Molecules,Other,Selective inhibitor of P-selectin-mediated cell adhesion,2,COc1ccc(C2CC(c3c(O)cc(C)oc3=O)=NCCS2)c(OC)c1,417,1
2749,C[C@H](C2=CN=CN2)C1=C(C)C(C)=CC=C1.Cl,Dexmedetomidine hydrochloride,6918081,"4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole hydrochloride",C13H16N2.HCl,[145108-58-3],241.24,7-TM Receptors,Adrenergic Alpha-2 Receptors,Agonist,"Potent, highly selective ?2 agonist. Active isomer of medetomidine (Cat. No. 5160)",1,Cc1cccc([C@H](C)c2cnc[nH]2)c1C,758,1
2757,ClC1=CC=C(OC(C=CC(Cl)=C3)=C3C2C(N[C@H]4CC[N@@+](C/C5=C/CCCCCC5)(CC)CC4)=O)C2=C1.ClC6=CC=C(OC(C=CC(Cl)=C8)=C8C7C(N[C@@H]9CC[N@+](C/C%10=C/CCCCCC%10)(CC)CC9)=O)C7=C6.[I-].[I-],UCB 35625,6918496,"1,4-trans-1-(1-Cycloocten-1-ylmethyl)-4-[[(2,7-dichloro-9H-xanthen-9-yl)carbonyl]amino]-1-ethylpiperidinium iodide",C30H37Cl2IN2O2,0,655.44,7-TM Receptors,Chemokine CC Receptors,Antagonist,Potent CCR1 and CCR3 antagonist,3,CC[N@+]1(C/C2=C/CCCCCC2)CC[C@H](NC(=O)C2c3cc(Cl)ccc3Oc3ccc(Cl)cc32)CC1,642,1
2758,CCN1CCC(OC(N)=N2)=C2CC1.Cl.Cl,B-HT 933 dihydrochloride,169743,"6-Ethyl-5,6,7,8-tetrahydro-4H-oxazolo[4,5-d]azepin-2-amine dihydrochloride",C9H15N3O.2HCl,[36067-72-8],267.67,7-TM Receptors,Adrenergic Alpha-2 Receptors,Agonist,Selective ?2 agonist,4,CCN1CCc2nc(N)oc2CC1,821,1
2760,O[C@H](COC2=CC=CC(CNC(C)=O)=C2)CNCCC1=CC=C(NS(=O)(C3=CC=CC=C3)=O)C=C1,"L-748,337",10028830,N-[[3-[(2S)-2-Hydroxy-3-[[2-[4-[(phenylsulfonyl)amino]phenyl]ethyl]amino]propoxy]phenyl]methyl]-acetamide,C26H31N3O5S,[244192-94-7],497.61,7-TM Receptors,Adrenergic Beta-3 Receptors,Antagonist,Selective ?3 antagonist,4,CC(=O)NCc1cccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3ccccc3)cc2)c1,433,0
2767,O=C1[C@H](NC(NC4=CC=CC(C)=C4)=O)N=C(C3=CC=CC=C3)C2=C(C=CC=C2)N1C,"L-365,260",5311201,"N-[(3R)-2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)urea",C24H22N4O2,[118101-09-0],407.47,7-TM Receptors,CCK2 Receptor,Antagonist,Selective CCK2 antagonist,2,Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(C)C2=O)c1,251,1
2768,O=C(NC3=C(OC)C=CC(Cl)=C3)NC2=CC(C)=NC1=CC=CC=C12,PQ 401,9549305,N-(5-Chloro-2-methoxyphenyl)-N'-(2-methyl-4-quinolinyl)urea,C18H16ClN3O2,[196868-63-0],346.29,Enzyme-Linked Receptors,Insulin and insulin-like Receptors,Inhibitor,IGF1R inhibitor,1,COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12,385,0
2773,O=C3N2C1=C(N3)C=CC=C1C[C@@H](NC)C2.O=C(/C=C\C(O)=O)O,Sumanirole maleate,9818478,"(R)-5,6-Dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (2Z)-2-butenedioate",C11H13N3O.C4H4O4,[179386-44-8],319.31,7-TM Receptors,D2 Receptors,Agonist,Selective D2 agonist,1,CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1,264,1
2778,CC1=C(C)N(C3=C(C)C=C(C)C=C3C)C2=C1C(N(CC)CCCC)=NC(C)=N2.Cl,Antalarmin hydrochloride,16078945,"N-Butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride",C24H34N4.HCl,[220953-69-5],415.01,7-TM Receptors,CRF1 Receptors,Antagonist,CRF1 antagonist,2,CCCCN(CC)c1nc(C)nc2c1c(C)c(C)n2-c1c(C)cc(C)cc1C,84,1
2779,CC1=CN(C3=C(C)C=C(C)C=C3C)C2=C1C(N(CC)CCCC)=NC(C)=N2.Cl,CP 154526,11475094,"N-Butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride",C23H32N4.HCl,[257639-98-8],400.99,7-TM Receptors,CRF1 Receptors,Antagonist,"Selective, non-peptide CRF1 antagonist",3,CCCCN(CC)c1nc(C)nc2c1c(C)cn2-c1c(C)cc(C)cc1C,84,0
2783,O=C(CNC2(CO)CCCC2)N1[C@@H](C#N)CC[C@H]1C#N.Cl,DPPI 1c hydrochloride,11381415,"1-[[[(1-Hydroxymethyl)cyclopentyl]amino]acetyl]-2,5-cis-pyrrolidinedicarbonitrile hydrochloride",C14H20N4O2.HCl,[866396-70-5],312.8,Enzymes,Dipeptidyl Peptidase IV (DPP-IV),Inhibitor,Dipeptidyl peptidase IV (DPP-IV) inhibitor,4,N#C[C@@H]1CC[C@H](C#N)N1C(=O)CNC1(CO)CCCC1,6,1
2791,O=C(NNC(CCSCC4=CC=CO4)=O)N3CC1=CC=CC=C1OC2=CC=C(Cl)C=C23,SC 51322,9933831,"8-Chloro-2-[3-[(2-furanylmethyl)thio]-1-oxopropyl]-dibenz(Z)[b,f][1,4]oxazepine-10(11H)-carboxylic acid hydrazide",C22H20ClN3O4S,[146032-79-3],457.93,7-TM Receptors,Prostanoid Receptors,Antagonist,Potent EP1 receptor antagonist,1,O=C(CCSCc1ccco1)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc21,640,0
2794,NC1=NC=NC2=C1C=NN2C3=CC=CC=C3,PP 3,4879,"1-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",C11H9N5,[5334-30-5],211.22,Enzymes,Src Kinases,Inhibitor,Negative control for PP 2 (Cat. No. 1407),2,Nc1ncnc2c1cnn2-c1ccccc1,836,1
2815,[Na+].CCCC(CCC)C([O-])=O,"Valproic acid, sodium salt",16760703,Sodium 2-propylpentanoate,C8H15NaO2,[1069-66-5],169.79,Enzymes,Non-selective HDACs,Inhibitor,Histone deacetylase inhibitor,1,CCCC(CCC)C(=O)[O-],27,1
2827,O=C(C3=CC=CC4=C3C=CC=C4)NC2=C(C#N)C1=C(S2)CCCC1,TCS JNK 5a,766949,"N-(3-Cyano-4,5,6,7-tetrahydrobenzo[b]thienyl-2-yl)-1-naphthalenecarboxamide",C20H16N2OS,[312917-14-9],332.42,Enzymes,JNK/c-jun,Inhibitor,Selective inhibitor of JNK2 and JNK3,1,N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2,773,1
2830,ClC(C(Cl)=C3)=CC=C3CCC(C=C2)=CC=C2NC1=C(C(O)=O)C=CC=C1,PD 118057,9864959,"2-[[4-[2-(3,4-Dichlorophenyl)ethyl]phenyl]amino]benzoic acid",C21H17Cl2NO2,[313674-97-4],386.27,Ion Channels,Voltage-Gated Potassium Channels,Activator,Selective KV11.1 (hERG) channel activator,1,O=C(O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1,626,0
2831,ClC1=CC=CC(C(C(C)NC(C)(C)C)=O)=C1.Cl,Bupropion hydrochloride,62884,"1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride",C13H18ClNO.HCl,[31677-93-7],276.2,Transporters,Dopamine Transporters,Inhibitor,Non-selective inhibitor of dopamine and noradrenalin transporters,2,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,602,1
2838,OC1=CC=CC([C@@H](O)CNC)=C1.Cl,(R)-(-)-Phenylephrine hydrochloride,441279,(R)-(-)-1-(3-Hydroxyphenyl)-2-methylaminoethanol hydrochloride,C9H13NO2.HCl,[61-76-7],203.67,7-TM Receptors,Adrenergic Alpha-1 Receptors,Agonist,?1 agonist,1,CNC[C@H](O)c1cccc(O)c1,432,1
2839,O=C1N([C@@H](CC)C(N)=O)CCC1,Levetiracetam,5284583,(2S)-(2-Oxopyrrolidin-1-yl)butyramide,C8H14N2O2,[102767-28-2],170.21,Cell biology,"Translocation, Exocytosis & Endocytosis",Other,Antiepileptic; binds SV2A,1,CC[C@@H](C(N)=O)N1CCCC1=O,44,1
2840,O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(C(N)=O)=C2N)[C@@H]1O,AICAR,17513,N1-(?-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide,C9H14N4O5,[2627-69-2],258.23,Enzymes,AMPK,Activator,AMPK activator,7,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N,841,0
2845,O=C1C2=C(N=CN2)N(CC(C)C)C(N1C)=O,IBMX,3758,"3,7-Dihydro-1-methyl-3-(2-methylpropyl)-1H-purine-2,6-dione",C10H14N4O2,[28822-58-4],222.24,Enzymes,Phosphodiesterases,Inhibitor,PDE inhibitor (non-selective),8,CC(C)Cn1c(=O)n(C)c(=O)c2[nH]cnc21,677,1
2849,O=C(CSC5=CC=CC=C5)NC(C=C4)=CC=C4N1C(C2=CC(OCO3)=C3C=C2)=NC(OC)=N1,SecinH3,1029232,"N-[4-[5-(1,3-Benzodioxol-5-yl)-3-methoxy-1H-1,2,4-triazol-1-yl]phenyl]-2-(phenylthio)acetamide",C24H20N4O4S,[853625-60-2],460.5,Enzymes,Arf,Inhibitor,Sec7-specific GEF inhibitor; selective for cytohesin family,3,COc1nc(-c2ccc3c(c2)OCO3)n(-c2ccc(NC(=O)CSc3ccccc3)cc2)n1,747,1
2850,C12=CC=CC=C1C3=C(C(C=CC=C4)=C4SC3)N2,PD 146176,297589,"6,11-Dihydro[1]benzothiopyrano[4,3-b]indole",C15H11NS,[4079-26-9],237.32,Enzymes,Lipoxygenase,Inhibitor,Selective 15-lipoxygenase inhibitor,1,c1ccc2c(c1)SCc1c-2[nH]c2ccccc12,790,1
2864,NC(NC(N(C)C)=N)=N.Cl,Metformin hydrochloride,14219,"N,N-Dimethylimidodicarbonimidic diamide hydrochloride",C4H11N5.HCl,[1115-70-4],165.62,Enzymes,AMPK,Activator,Activator of LKB1/AMPK; antidiabetic agent,2,CN(C)C(=N)NC(=N)N,872,1
2867,OC(=O)\C=C/C(O)=O.NC1=C(NC(OCC)=O)C=CC(NCC2=CC=C(F)C=C2)=N1,Flupirtine maleate,53276,N-[2-Amino-6-[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbamic acid ethyl ester maleate,C15H17FN4O2.C4H4O4,[75507-68-5],420.4,Ion Channels,Voltage-Gated Potassium Channels,Activator,KV7 channel activator; also GABAA modulator and indirect NMDA antagonist,3,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N,498,1
2870,FC1=CC=[C@@]([C@H](N(C3=CC(F)=CC=C3F)S(C2=CC=C(Cl)C=C2)(=O)=O)C)C(CCCC(O)=O)=C1,BMS 299897,11249248,"2-[(1R)-1-[[(4-Chlorophenyl)sulfonyl](2,5-difluorophenyl)amino]ethyl-5-fluorobenzenebutanoic acid",C24H21ClF3NO4S,[290315-45-6],511.94,Enzymes,Gamma-Secretase,Inhibitor,Potent ?-secretase inhibitor,2,C[C@H](c1ccc(F)cc1CCCC(=O)O)N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1,572,1
2893,COC(C=CC=C3)=C3CN[C@H]1C(CC4)CCN4[C@H]1[C@H](C5=CC=CC=C5)C2=CC=CC=C2,CP 96345,104943,"(2S,3S)-N-(2-Methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine",C28H32N2O,[132746-60-2],412.57,7-TM Receptors,NK1 Receptor,Antagonist,Potent and selective NK1 antagonist,1,COc1ccccc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1,357,0
2896,O=C1C2=C(N=CN2CC(NC3=CC=C(C(C)C)C=C3)=O)N(C)C(N1C)=O,HC 030031,1150897,"2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide",C18H21N5O3,[349085-38-7],355.39,Ion Channels,TRPA1,Blocker,Selective TRPA1 blocker,4,CC(C)c1ccc(NC(=O)Cn2cnc3c2c(=O)n(C)c(=O)n3C)cc1,676,1
2901,O=C(N3C(C=C(Cl)C(C)=C4)=C4CC3)NC(C=C2)=CN=C2OC1=CC=CN=C1C.Cl.Cl,SB 242084,16219981,"6-Chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-carboxyamide dihydrochloride",C21H19ClN4O2.2HCl,[1215566-78-1],476.79,7-TM Receptors,5-HT2C Receptors,Antagonist,Selective 5-HT2C antagonist; brain penetrant,3,Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2,468,0
2902,O=C(N)C4=CC=C(C=C4)C1=NC(C2=CC(OCCO5)=C5C=C2)=C(C3=NC=CC=C3)N1,D 4476,6419753,"4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide",C23H18N4O3,[301836-43-1],411.92,Enzymes,Casein Kinase 1,Inhibitor,Selective CK1 inhibitor. Also inhibits TGF-?RI,2,NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1,746,0
2907,O=C2NC1=CC=C(OC)C=C1/C2=C/C3=CNC=N3,SU 9516,5289419,"(Z)-1,3-Dihydro-3-(1H-imidazol-4-ylmethylene)-5-methoxy-2H-indol-2-one",C13H11N3O2,[377090-84-1],245.75,Enzymes,Cyclin-dependent Kinase,Inhibitor,Cdk inhibitor; potently inhibits cdk1 and cdk2,2,COc1ccc2c(c1)/C(=C/c1c[nH]cn1)C(=O)N2,770,1
2910,O=S(C2=CC=CC1=CN=CC=C12)(NCCNC/C=C/C3=CC=C(Br)C=C3)=O.Cl.Cl,H 89 dihydrochloride,5702541,N-[2-[[3-(4-Bromophenyl)-2-propenyl]amino]ethyl]-5-isoquinolinesulfonamide dihydrochloride,C20H20BrN3O2S.2HCl,[130964-39-5],532.79,Enzymes,Protein Kinase A,Inhibitor,Protein kinase A inhibitor,6,O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12,851,0
2913,ClC1=CC=CC(Cl)=C1/C(OC3CCCCCC3)=C/N2N=CN=C2,Ro 64-5229,10428048,"(Z)-1-[2-Cycloheptyloxy-2-(2,6-dichlorophenyl)ethenyl]-1H-1,2,4-triazole",C17H19Cl2N3O,[246852-46-0],352.26,7-TM Receptors,Glutamate (Metabotropic) Group II Receptors,Antagonist,"Selective, non-competitive mGlu2 antagonist",1,Clc1cccc(Cl)c1/C(=C/n1cncn1)OC1CCCCCC1,868,1
2917,OC2(CCCCC2)C(CN(C)C)C1=CC=C(OC)C=C1.Cl,Venlafaxine hydrochloride,62923,1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride,C17H27NO2.HCl,[99300-78-4],313.86,Transporters,5-HT Transporters,Inhibitor,5-HT and NA reuptake inhibitor (SNRI),1,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,411,1
2921,CC1=NC(C#CC2=CN=CC=C2)=CS1.Cl,MTEP hydrochloride,45073467,"3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine hydrochloride",C11H8N2S.HCl,[1186195-60-7],241.22,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Antagonist,Potent and selective mGlu5 antagonist,4,Cc1nc(C#Cc2cccnc2)cs1,721,1
2924,OC[C@H]1O[C@@H](N2C=NC3=C2N=CN=C3SCC4=CC=C([N+]([O-])=O)C=C4)[C@H](O)[C@@H]1O,NBMPR,65407,6-S-[(4-Nitrophenyl)methyl]-6-thioinosine,C17H17N5O6S,[38048-32-7],419.41,Transporters,Nucleoside Transporters,Inhibitor,Equilibrative nucleoside transporter 1 (ENT1) inhibitor,3,O=[N+]([O-])c1ccc(CSc2ncnc3c2ncn3[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)cc1,841,0
2930,OC1=CC(C(N=C4N5CCOCC5)=NC3=C4OC2=NC=CC=C23)=CC=C1.Cl,PI 103 hydrochloride,16739368,"3-[4-(4-Morpholinylpyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol hydrochloride",C19H16N4O3.HCl,[371935-79-4],407.34,Enzymes,PI 3-Kinase,Inhibitor,"Inhibitor of PI 3-kinase, mTOR and DNA-PK",3,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,309,1
2937,CCC2(C3=CN=CN3)CC1=CC=CC=C1C2.Cl,Atipamezole hydrochloride,13649426,"5-(2-Ethyl-2,3-dihydro-1H-indene-2-yl)-1H-imidazole hydrochloride",C14H16N2.HCl,[104075-48-1],248.75,7-TM Receptors,Adrenergic Alpha-2 Receptors,Antagonist,Selective ?2 antagonist,1,CCC1(c2cnc[nH]2)Cc2ccccc2C1,759,1
2952,O=C(NC2=C(N)C=CC=C2)C1=CC=C(NC(C)=O)C=C1,CI 994,2746,4-(Acetylamino)-N-(2-aminophenyl)benzamide,C15H15N3O2,[112522-64-2],269.3,Enzymes,Class I HDACs,Inhibitor,Class I histone deacetylase inhibitor; orally active,1,CC(=O)Nc1ccc(C(=O)Nc2ccccc2N)cc1,478,1
2957,CCC2=C(C(NCCC3=CC=C(N4CCCCC4)C=C3)=O)NC1=CC=C(Cl)C=C12,Org 27569,44828492,5-Chloro-3-ethyl-N-[2-[4-(1-piperidinyl)phenyl]ethyl-1H-indole-2-carboxamide,C24H28ClNO3,[868273-06-7],409.95,7-TM Receptors,CB1 Receptors,Modulator,Potent allosteric modulator of CB1 receptors,1,CCc1c(C(=O)NCCc2ccc(N3CCCCC3)cc2)[nH]c2ccc(Cl)cc12,566,1
2960,ClC1=C(Cl)C(C2C(C(OC)=O)=C(C)NC(C)=C2C(OCC)=O)=CC=C1,Felodipine,3333,"4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester",C18H19Cl2NO4,[72509-76-3],384.25,Ion Channels,Cav1.x Channels,Blocker,CaV1.x blocker,1,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,128,0
2964,NC2=NC(N3CCN(C(C4COC(C=CC=C5)=C5O4)=O)CC3)=NC1=CC(OC)=C(OC)C=C12.CS(=O)(O)=O,Doxazosin mesylate,62978,"4-Amino-2-[4-(1,4-benzodioxan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazoline methanesulfonate",C23H25N5O5.CH3SO3H,[77883-43-3],547.58,7-TM Receptors,Adrenergic Alpha-1 Receptors,Antagonist,?1 antagonist,1,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,395,1
2966,O=C(O)/C=C\C(O)=O.CN(CC#C)CC2=CC1=CC=CC=C1OC3=C2C=CC=C3,CGP 3466B maleate,9821821,"N-(Dibenz[b,f]oxepin-10-ylmethyl)-N-Methyl-N-(2-propynyl)amine maleate",C19H17NO.C4H4O4,[200189-97-5],391.42,Enzymes,Other Dehydrogenases,Inhibitor,GAPDH inhibitor; neuroprotective,1,C#CCN(C)CC1=Cc2ccccc2Oc2ccccc21,639,1
2972,ClC1=C(C2=NN=NN2CC3=CN=CC=C3)C=CC=C1Cl.Cl,A 438079 hydrochloride,11688742,"3-[[5-(2,3-Dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine hydrochloride",C13H9Cl2N5.HCl,[899431-18-6],342.61,Ion Channels,P2X Receptors,Antagonist,Competitive P2X7 antagonist,5,Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl,848,1
2976,ClC(C=C2)=CC=C2C1=CC=C(C(NC3=CC(OC)=CC(OC)=C3)=O)O1,A 803467,16038374,"5-(4-Chlorophenyl)-N-(3,5-dimethoxyphenyl)-2-furancarboxamide",C19H16ClNO4,[944261-79-4],357.79,Ion Channels,Voltage-gated Sodium Channels,Blocker,Selective NaV1.8 channel blocker,3,COc1cc(NC(=O)c2ccc(-c3ccc(Cl)cc3)o2)cc(OC)c1,600,1
2977,O=C(N)C(S3)=C(OCC4=CC=CC=C4C(F)(F)F)C=C3N2C1=CC(OC)=C(OC)C=C1N=C2,GW 843682X,9826308,"5-(5,6-Dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)phenyl]methoxy]-2-thiophenecarboxamide",C22H18F3N3O4S,[660868-91-7],481.96,Enzymes,Polo-like Kinase,Inhibitor,Selective inhibitor of PLK1 and PLK3,2,COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC,538,1
2979,OC1=C(C2=CC(C3=CC=CC=C3)=C(C#N)C(N2)=O)C=C(Br)C=C1,TCS PIM-1 1,1235170,3-Cyano-4-phenyl-6-(3-bromo-6-hydroxy)phenyl-2(1H)-pyridone,C18H11BrN2O2,[491871-58-0],367.2,Enzymes,Pim Kinase,Inhibitor,"Selective, ATP-competitive Pim-1 kinase inhibitor",2,N#Cc1c(-c2ccccc2)cc(-c2cc(Br)ccc2O)[nH]c1=O,254,1
2981,C/C(C2=CC1=CC=CC=C1C=C2)=C\C(NC3=C(C(O)=O)C=CC=C3)=O,BIBR 1532,9927531,2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoic acid,C21H17NO3,[321674-73-1],331.36,Enzymes,Telomerase,Inhibitor,Selective telomerase inhibitor,3,C/C(=C\C(=O)Nc1ccccc1C(=O)O)c1ccc2ccccc2c1,534,0
2993,FC1=C(C=CC=C2)C2=C(C3=CC(C(C)C)=NC(N)=N3)C=C1.Cl,RS 127445 hydrochloride,9905058,4-(4-Fluoro-1-naphthalenyl)-6-(1-methylethyl)-2-pyrimidinamine hydrochloride,C17H16FN3.HCl,[199864-86-3],326.8,7-TM Receptors,5-HT2B Receptors,Antagonist,High affinity and selective 5-HT2B antagonist,4,CC(C)c1cc(-c2ccc(F)c3ccccc23)nc(N)n1,817,1
2995,O=C(NC2=CC(C(F)(F)F)=CC=C2Cl)NC1=C(O)C=CC(Cl)=C1,NS 1738,310378,N-(5-Chloro-2-hydroxyphenyl)-N'-[2-chloro-5-(trifluoromethyl)phenyl]urea,C14H9Cl2F3N2O2,[501684-93-1],365.13,Ion Channels,Nicotinic (a7) Receptors,Modulator,Positive allosteric modulator of ?7 nAChRs; active in vivo,1,O=C(Nc1cc(Cl)ccc1O)Nc1cc(C(F)(F)F)ccc1Cl,551,1
3000,FC(C=C3)=C(Cl)C=C3NC2=NC=NC1=CC(OC)=C(OCCCN4CCOCC4)C=C12,Iressa,123631,N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,C22H24ClFN4O3,[184475-35-2],446.9,Enzyme-Linked Receptors,EGFR,Inhibitor,"Orally active, selective EGFR inhibitor",3,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,391,0
3023,COC(C=C3)=CC=C3/C=C/C2=NC1=CC=CC=C1C(NCCCN(C)C)=N2.Cl.Cl,CP 31398 dihydrochloride,56972205,"N'-[2-[2-(4-Methoxyphenyl)ethenyl]-4-quinazolinyl]-N,N-dimethyl-1,3-propanediamine dihydrochloride",C22H26N4O.HCl,[1217195-61-3],453.41,Cell biology,p53,Other,p53-stabilizing agent,1,COc1ccc(/C=C/c2nc(NCCCN(C)C)c3ccccc3n2)cc1,414,1
3026,O=C2C1=CC=CC(NC(C4=CC=C(OCCCCC5=CC=CC=C5)C=C4)=O)=C1OC(C3=NN=NN3)=C2,ONO 1078,4887,N-[4-Oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4(4-phenylbutoxy)benzamide,C27H23N5O4,[103177-37-3],490.51,7-TM Receptors,Leukotriene and Related Receptors,Antagonist,Selective CysLT1 antagonist; also TREK2 activator,1,O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1,212,1
3036,O=C(NC(CCC(O)=O)C(N(CCCOC)CCCCC)=O)C1=CC=C(Cl)C(Cl)=C1,Loxiglumide,60182,"4-[(3,4-Dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxopentanoic acid",C21H30Cl2N2O5,[107097-80-3],461.38,7-TM Receptors,CCK1 Receptor,Antagonist, CCK1 antagonist; active in vivo,1,CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,623,1
3037,O=C2NC1=CC=CC=C1/C2=C/C3=C(C)C=C(C)N3,SU 5416,5329098,"3-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one",C15H14N2O,[204005-46-9],238.28,Enzyme-Linked Receptors,VEGFR,Inhibitor,"VEGFR inhibitor. Also inhibits KIT, RET, MET and FLT3",6,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1,769,0
3041,ClC1=CC(COC2=NC(N3CCNCC3)=CN=C2)=CC=C1.Cl,CP 809101 hydrochloride,56972220,2-[(3-Chlorophenyl)methoxy]-6-(1-piperazinyl)pyrazine hydrochloride,C15H17N4OCl.HCl,[1215721-40-6],341.24,7-TM Receptors,5-HT2C Receptors,Agonist,Potent and selective 5-HT2C agonist,2,Clc1cccc(COc2cncc(N3CCNCC3)n2)c1,612,1
3044,O=C(NC(C)(C)C)NC2=NC1=NC(NCCCCN(CC)CC)=NC=C1C=C2C3=CC(OC)=CC(OC)=C3,PD 173074,1401,"N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea",C28H41N7O3,[219580-11-7],528.17,Enzyme-Linked Receptors,FGFR,Inhibitor,FGFR1 and -3 inhibitor,5,CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1,824,1
3050,C[C@@H](NCCOC2=CC=CC=C2OCC)CC1=CC=C(OC)C(S(=O)(N)=O)=C1.Cl,Tamsulosin hydrochloride,5362376,5-[(2R)-2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-benzenesulfonamide hydrochloride,C20H28N2O5S.HCl,[106463-17-6],449.47,7-TM Receptors,Adrenergic Alpha-1 Receptors,Antagonist,Selective ?1A antagonist,1,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,346,1
3062,OC1=C(NC(NC2=C(O)C=CC(C(F)(F)F)=C2)=O)C=C(C(F)(F)F)C=C1,NS 1643,10177784,"N,N'-Bis[2-hydroxy-5-(trifluoromethyl)phenyl]urea",C15H10F6N2O3,[448895-37-2],398.26,Ion Channels,Voltage-Gated Potassium Channels,Activator,KV11.1 (hERG) channel activator; antiarrhythmic,1,O=C(Nc1cc(C(F)(F)F)ccc1O)Nc1cc(C(F)(F)F)ccc1O,551,0
3063,NC1=NC=NC2=C1C(C3=C4C(C=CC=C4)=CC=C3)=NN2C(C)(C)C,1-Naphthyl PP1,4877,"1-(1,1-Dimethylethyl)-3-(1-naphthalenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",C19H19N5,[221243-82-9],317.39,Enzymes,Src Kinases,Inhibitor,Src family kinase inhibitor; also inhibits c-Abl,2,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21,834,0
3066,O=C(C2=CC=C(C3=CSC(N4CCN(C)CC4)=N3)C=C2)NC1(CCCCC1)C(NCC#N)=O,L 006235,9912381,N-[1-[[(Cyanomethyl)amino]carbonyl]cyclohexyl]-4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzamide,C24H30N6O2S,[294623-49-7],466.6,Enzymes,Cathepsin,Inhibitor,Potent cathepsin K inhibitor,3,CN1CCN(c2nc(-c3ccc(C(=O)NC4(C(=O)NCC#N)CCCCC4)cc3)cs2)CC1,274,1
3077,CC1=CC=C(NC3=C2CCNC3CC4=CC=C(OC)C(OC)=C4)C2=C1.Cl,LY 272015 hydrochloride,9929423,"1-[(3,4-Dimethoxyphenyl)methy]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-b]indole hydrochloride",C21H24N2O2.HCl,[172895-15-7],372.89,7-TM Receptors,5-HT2B Receptors,Antagonist,High affinity 5-HT2B antagonist; orally active,1,COc1ccc(CC2NCCc3c2[nH]c2ccc(C)cc32)cc1OC,362,1
3078,CC(C1=CC=CC=C1N2CCN3CCC(C(C4=CC=C(F)C=C4)=O)CC3)(C)C2=O.Cl,LY 310762 hydrochloride,11957576,"1-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-one hydrochloride",C24H27FN2O2.HCl,[192927-92-7],430.94,7-TM Receptors,5-HT1D Receptors,Antagonist,Selective 5-HT1D antagonist,1,CC1(C)C(=O)N(CCN2CCC(C(=O)c3ccc(F)cc3)CC2)c2ccccc21,282,0
3081,CS(=O)(O)=O.NC(C1=CC=C2C(C=CC(OC(C3=CC=C(NC(N)=N)C=C3)=O)=C2)=C1)=N.CS(=O)(O)=O,Nafamostat mesylate,54953,4-[(Aminoiminomethyl)amino]benzoic acid 6-(aminoiminomethyl)-2-naphthalenyl ester dimethanesulfonate,C19H17N5O2.2CH4O3S,[82956-11-4],539.59,Enzymes,Other Proteases,Inhibitor,"Serine protease inhibitor, inhibits tryptase",3,N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1,446,1
3083,CCC1=C(C(OC)=O)N=CC3=C1C2=CC(OC)=C(OC)C=C2N3.Cl,DMCM hydrochloride,45261899,"4-Ethyl-6,7-dimethoxy-9H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester hydrochloride",C17H18N2O4.HCl,[1215833-62-7],350.8,Ion Channels,GABAA Receptors,Benzodiazepine,Benzodiazepine inverse agonist,3,CCc1c(C(=O)OC)ncc2[nH]c3cc(OC)c(OC)cc3c12,366,1
3092,O=C(C2=NC=C(OC=C3)C3=C2)N[C@@H]1C4CCN(CC4)C1.Cl,PHA 543613 hydrochloride,56972222,"N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-furo[2,3-c]pyridine-5-carboxamide hydrochloride",C15H17N3O2.HCl,[1586767-92-1],312.28,Ion Channels,Nicotinic (a7) Receptors,Agonist,Potent and selective ?7 nAChR agonist,3,O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1,339,0
3093,C(C=N2)(C4=CC=C(OCCN5CCCCC5)C=C4)=CN1C2=C(C3=CC=NC=C3)C=N1.Cl.Cl,Dorsomorphin dihydrochloride,49761481,"6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)-pyrazolo[1,5-a]pyrimidine dihydrochloride",C24H25N5O.2HCl,[1219168-18-9],499.43,Enzymes,AMPK,Inhibitor,Potent AMPK inhibitor; also BMP type I receptor inhibitor,5,c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1,743,0
3094,CN(CC3)C[C@@H](O)[C@H]3[C@]1=C(OC(C4=CC=CC=C4Cl)=CC2=O)C2=C(O)C=C1O.Cl,Flavopiridol hydrochloride,9910986,"2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one hydrochloride",C21H20ClNO5.HCl,[131740-09-5],442.8,Enzymes,Cyclin-dependent Kinase,Inhibitor,Cdk inhibitor; potently inhibits cdk2 and cdk9,1,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,630,1
3100,CC[C@@H]3N(CC5CC5)C1=C2C(C(C4=CC=C(Cl)C=C4Cl)=NN2C3)=NC(C)=C1.Cl,NBI 35965 hydrochloride,71433630,"(7S)-6-(Cyclopropylmethyl)-2-(2,4-dichlorophenyl)-7-ethyl-7,8-dihydro-4-methyl-6H-1,3,6,8a-tetraazaacenaphthylene hydrochloride",C21H22Cl2N4.HCl,[1782228-59-4],451.3,7-TM Receptors,CRF1 Receptors,Antagonist,Potent and selective CRF1 antagonist,3,CC[C@H]1Cn2nc(-c3ccc(Cl)cc3Cl)c3nc(C)cc(c32)N1CC1CC1,581,1
3108,CCCCNC1=CC(C(O)=O)=CC(S(=O)(N)=O)=C1OC2=CC=CC=C2,Bumetanide,2471,3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid,C17H20N2O5S,[28395-03-1],364.42,Transporters,Na+/K+/Cl- Symporter,Inhibitor,Na+/2Cl-/K+ (NKCC) symporter inhibitor,3,CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,453,1
3109,ClC1=CC(NCC2=CC=CO2)=C(C(O)=O)C=C1S(=O)(N)=O,Furosemide,3440,5-(Aminosulfonyl)-4-chloro-2-([2-furanylmethyl]amino)benzoic acid,C12H11ClN2O5S,[54-31-9],330.74,Transporters,Na+/K+/Cl- Symporter,Inhibitor,Na+/2Cl-/K+ (NKCC) symporter inhibitor; also GABAA antagonist,1,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,545,1
3113,CCNC2=NC1=CC=C(Cl)C=C1C(C3=CC=CC=C3)(C)O2.Cl,Etifoxine hydrochloride,171544,"6-Chloro-2-N-ethyl-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-amine hydrochloride",C17H17ClN2O.HCl,[56776-32-0],346.25,Other Pharmacology,Translocator Protein,Ligand,Ligand of the translocator protein (TSPO); also GABAA receptor potentiator,1,CCNC1=Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1,637,1
3114,CC1=C2C(CCC(COC3=CC=C(CC4C(NC(S4)=O)=O)C=C3)(C)O2)=C(C)C(O)=C1C,Troglitazone,5591,"5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione",C24H27NO5S,[97322-87-7],441.54,Nuclear Receptors,PPARgamma Receptors,Agonist,Selective PPAR? agonist; antidiabetic agent,5,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,439,0
3118,COC1=CC=CC=C1OCC(CN2CCN(CC(NC3=C(C)C=CC=C3C)=O)CC2)O.Cl.Cl,Ranolazine dihydrochloride,71279,"N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide dihydrochloride",C24H33N3O4.2HCl,[95635-56-6],509.47,Enzymes,Other Dehydrogenases,Activator,"Antianginal, activates pyruvate dehydrogenase",2,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,348,0
3129,O=C(N[C@@H]2CCCC[C@@H]2NC(CNC(C3=C(NC(NC(C)C)=O)C=CC(C(F)(F)F)=C3)=O)=O)C1=CC=C(SC)C=C1,BMS CCR2 22,24801690,2-[(Isopropylaminocarbonyl)amino]-N-[2-[[cis-2-[[4-(methylthio)benzoyl]amino]cyclohexyl]amino]-2-oxoethyl]-5-(trifluoromethyl)benzamide,C28H34F3N5O4S,[445479-97-0],593.66,7-TM Receptors,Chemokine CC Receptors,Antagonist,"High affinity, potent CCR2 antagonist",3,CSc1ccc(C(=O)N[C@@H]2CCCC[C@@H]2NC(=O)CNC(=O)c2cc(C(F)(F)F)ccc2NC(=O)NC(C)C)cc1,324,1
3133,CCCN(CCC)CCC1=CC=C(OC)C(OCCC2=CC=CC=C2)=C1.Cl,NE 100 hydrochloride,9952420,"4-Methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine hydrochloride",C23H33NO2.HCl,[149409-57-4],391.97,Other Pharmacology,Sigma1 Receptors,Antagonist,Selective ?1 antagonist,3,CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,364,0
3134,O=C(C3=CC=C(OCCO4)C4=C3)N[C@@H]1C2CCN(CC2)C1.O=C(/C=C/C(O)=O)O,PHA 568487,56972212,"N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-2,3-dihydro-1,4-benzodioxin-6-carboxamide fumarate",C16H20N2O3.C4H4O4,[527680-57-5],422.43,Ion Channels,Nicotinic (a7) Receptors,Agonist,Selective ?7 nAChR agonist,2,O=C(N[C@H]1CN2CCC1CC2)c1ccc2c(c1)OCCO2,339,0
3136,O[C@@H]1[C@@H](CO)O[C@@H](N3C2=NC(Cl)=NC(N)=C2N=C3)[C@@H]1O,2-Chloroadenosine,8974,6-Amino-2-chloropurine riboside,C10H12ClN5O4,[146-77-0],301.69,7-TM Receptors,Non-selective Adenosine,Agonist,Adenosine receptor agonist,1,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,841,1
3140,O=C1NCCC2=C1C=C(C3=CC=NC=C3)N2.Cl,PHA 767491 hydrochloride,11715766,"1,5,6,7-Tetrahydro-2-(4-pyridinyl)-4H-pyrrolo[3,2-c]pyridin-4-one hydrochloride",C12H11N3O.HCl,[942425-68-5],285.73,Enzymes,MK2,Inhibitor,MK2 inhibitor; also cdk inhibitor; potently inhibits cdk9,2,O=C1NCCc2[nH]c(-c3ccncc3)cc21,59,1
3188,O=C(CCC4CCCC4)N(CCN(C)C)CC(C=C2)=CC=C2C1=CC=C(CNCCC3=CC=CC=C3)C=C1.Cl.Cl,SB 699551,11983346,"N-[2-(Dimethylamino)ethyl]-N-[[4'-[[(2-phenylethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclopentanepropanamide dihydrochloride",C34H45N3O.2HCl,[864741-95-7],629.7,7-TM Receptors,5-HT5 Receptors,Antagonist,Selective 5-ht5a antagonist,2,CN(C)CCN(Cc1ccc(-c2ccc(CNCCc3ccccc3)cc2)cc1)C(=O)CCC1CCCC1,222,1
3189,Cl.ClC1=CC(Cl)=CC(NS(C2=CC(N3CCNCC3)=C(OC)C=C2)(=O)=O)=C1OC,SB 399885 hydrochloride,6918649,"N-(3,5-Dichloro-2-methoxyphenyl)-4-methoxy-3-(1-piperazinyl)benzenesulfonamide hydrochloride",C18H21Cl2N3O4S.HCl,[402713-81-9],487.31,7-TM Receptors,5-HT6 Receptors,Antagonist,Potent and selective 5-HT6 antagonist,3,COc1ccc(S(=O)(=O)Nc2cc(Cl)cc(Cl)c2OC)cc1N1CCNCC1,112,1
3190,OC(C=C1)=CC=C1/C=C2/C(NC(S2)=N)=O,Mirin,1206243,"Z-5-(4-Hydroxybenzylidene)-2-imino-1,3-thiazolidin-4-one",C10H8N2O2S,[1198097-97-0],233.76,Enzymes,ATM & ATR Kinase,Inhibitor,MRN-ATM pathway inhibitor,2,N=C1NC(=O)/C(=C/c2ccc(O)cc2)S1,888,0
3191,CN(C1=CC=CC=C1CN2CCCN(CC4=C(N(C)C)C=CC=C4)C2C3=CC=NC=C3)C,GANT 61,421610,"2,2'-[[Dihydro-2-(4-pyridinyl)-1,3(2H,4H)-pyrimidinediyl]bis(methylene)]bis[N,N-dimethylbenzenamine",C27H35N5,[500579-04-4],429.61,Cell biology,Hedgehog Signaling,Inhibitor,GLI antagonist; inhibits Hedgehog (Hh) signaling,2,CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1,361,1
3197,[H][C@]12C(C)(C)CCC[C@@](C)1[C@@H](C=O)C(C=O)=CC2,Polygodial,72503,"(1R,4aS,8aS)-1,4,4a,5,6,7,8,8a-Octahydro-5,5,8a-trimethyl-1,2-naphthalenedicarboxaldehyde",C15H22O2,[6754-20-7],234.33,Ion Channels,TRPA1,Activator,TRPA1 channel activator; analgesic and antifungal,2,CC1(C)CCC[C@@]2(C)[C@H]1CC=C(C=O)[C@@H]2C=O,32,1
3198,O=C(NC2=C1NC(C3=CC=C(S(N4CCN(C5=CC=C(Cl)C=C5)CC4)(=O)=O)C=C3)=N2)N(CCC)C1=O,PSB 603,44185871,8-[4-[4-(4-Chlorophenzyl)piperazide-1-sulfonyl)phenyl]]-1-propylxanthine,C24H25ClN6O4S,[1092351-10-4],533.51,7-TM Receptors,Adenosine A2B Receptors,Antagonist,Highly selective A2B antagonist,2,CCCn1c(=O)[nH]c2nc(-c3ccc(S(=O)(=O)N4CCN(c5ccc(Cl)cc5)CC4)cc3)[nH]c2c1=O,668,0
3199,O=C(NC2=C1NC(C3=CC=C(S(N4CCN(CC5=CC=C(Cl)C=C5)CC4)(=O)=O)C=C3)=N2)N(CCC)C1=O,PSB 0788,44186581,8-[4-[4-(4-Chlorobenzyl)piperazide-1-sulfonyl)phenyl]]-1-propylxanthine,C25H27ClN6O4S,[1027513-54-7],543.04,7-TM Receptors,Adenosine A2B Receptors,Antagonist,Selective A2B antagonist,1,CCCn1c(=O)[nH]c2nc(-c3ccc(S(=O)(=O)N4CCN(Cc5ccc(Cl)cc5)CC4)cc3)[nH]c2c1=O,668,1
3200,O=C1N(CCC)C(C(NC(C3=CC=C(OCC(NCCN)=O)C=C3)=N2)=C2N1CCC)=O.Cl.Cl,XAC,121513846,"N-(2-Aminoethyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide dihydrochloride",C21H28N6O4.2HCl,[1962928-23-9],501.41,7-TM Receptors,Non-selective Adenosine,Antagonist,Adenosine receptor antagonist,3,CCCn1c(=O)c2[nH]c(-c3ccc(OCC(=O)NCCN)cc3)nc2n(CCC)c1=O,668,0
3211,CC1=NC(C4=C(NC(C(C)(C)C)=N4)C2=CC=C(N=CC=N3)C3=C2)=CC=C1,SB 525334,9967941,"6-[2-(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline",C21H21N5,[356559-20-1],352.43,Enzyme-Linked Receptors,TGF-beta Receptors,Inhibitor,Selective inhibitor of TGF-?RI,4,Cc1cccc(-c2nc(C(C)(C)C)[nH]c2-c2ccc3nccnc3c2)n1,746,0
3212,CC1=CC(NC(CC)CC)=C(C)C(OC2=C(C)C=C(C)C=C2C)=N1.Cl,CP 376395 hydrochloride,24806455,"N-(1-Ethylpropyl)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-4-pyridinamine hydrochloride",C21H30N2.HCl,[1013933-37-3],362.94,7-TM Receptors,CRF1 Receptors,Antagonist,Potent and selective CRF1 antagonist; binds at an allosteric site,1,CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C,86,1
3219,O=P(CC)(CCCN)O.Cl,CGP 36216 hydrochloride,90488815,(3-Aminopropyl)ethylphosphinic acid hydrochloride,C5H14NO2P.HCl,[1781834-71-6],187.6,7-TM Receptors,GABAB Receptors,Antagonist,GABAB antagonist; displays activity at presynaptic receptors,1,CCP(=O)(O)CCCN,876,1
3235,O=C(C4=CC(C#N)=CC=C4)NC1=CC(C3=CC=CC=C3)=NN1C2=CC=CC=C2,CDPPB,11245456,"3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide",C23H16N4O,[781652-57-1],364.4,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Modulator,Positive allosteric modulator of mGlu5 receptors,5,N#Cc1cccc(C(=O)Nc2cc(-c3ccccc3)nn2-c2ccccc2)c1,248,1
3239,O=C(N3)CCC1=C3C=CC(NC2=NC(NCC4=CC=CC(S(=O)(C)=O)=C4)=C(C(F)(F)F)C=N2)=C1,PF 573228,11612883,"3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone",C22H20F3N5O3S,[869288-64-2],495.99,Enzymes,Focal Adhesion Kinase,Inhibitor,Potent and selective FAK inhibitor,3,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1,408,1
3240,OC1(C2=CC=CC=C2)CC3N(C(C5=CC=CC=C5C)C4=C(C)C=CC=C4)C(CC3)C1,SCH 221510,9887077,3-Endo-8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol,C28H31NO,[322473-89-2],397.55,7-TM Receptors,NOP Receptors,Agonist,Potent and selective NOP agonist,2,Cc1ccccc1C(c1ccccc1C)N1C2CCC1CC(O)(c1ccccc1)C2,757,1
3241,O=C(N[C@H]4CCC(OC(C)(C)C)=O)[C@]3([H])CC1=C([C@H](CC(C)C)N3C4=O)NC2=C1C=CC(OC)=C2,Ko 143,10322450,"(3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester",C26H35N3O5,[461054-93-3],474.07,Transporters,Multidrug Transporters,Inhibitor,Potent and selective BCRP inhibitor,4,COc1ccc2c3c([nH]c2c1)[C@H](CC(C)C)N1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)[C@@H]1C3,420,1
3250,FC(C=CC(F)=C3)=C3C1=NN=C2N1N=C(OCC4=NC=NN4C)C(C(C)(C)C)=C2,"L-838,417",9908880,"3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine",C19H19F2N7O,[286456-42-6],403.9,Ion Channels,GABAA Receptors,Agonist,GABAA partial agonist; displays subtype selectivity,5,Cn1ncnc1COc1nn2c(-c3cc(F)ccc3F)nnc2cc1C(C)(C)C,859,1
3253,O=C1C2=C([C@@](C[C@H]5[C@]4(O5)[C@](O6)3[C@@H]6[C@H]7[C@](C(C)C)(O7)[C@H]4O)([H])[C@]3(C)CC2)CO1,Triptolide,107985,"(3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-3b,4,4a,6,6a,7a,7b,8b,9,10-Decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one",C20H24O6,[38748-32-2],360.4,Enzymes,RNA/DNA Polymerase,Other,"Inhibits RNAPII-mediated transcription; antitumor, anti-inflammatory and immunosuppressive",3,CC(C)[C@]12O[C@H]1[C@@H]1O[C@@]13[C@@]1(C)CCC4=C(COC4=O)[C@@H]1C[C@@H]1O[C@@]13[C@@H]2O,13,1
3254,O=S(NC1=NC(C2=CC=CC([N+]([O-])=O)=C2)=CS1)(C3=CC=C(OC)C(OC)=C3)=O,Ro 61-8048,5282337,"3,4-Dimethoxy-N-[4-(3-nitrophenyl)-2-thiazolyl]benzenesulfonamide",C17H15N3O6S2,[199666-03-0],421.45,Enzymes,Kynurenine 3-monooxygenase,Inhibitor,Potent kynurenine 3-monooxygenase (KMO) inhibitor,5,COc1ccc(S(=O)(=O)Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1OC,113,1
3255,Cl.CN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C1,PJ 34 hydrochloride,16760621,"N-(5,6-Dihydro-6-oxo-2-phenanthridinyl)-2-acetamide hydrochloride",C17H17N3O2.HCl,[344458-15-7],358.82,Enzymes,Poly(ADP-ribose) Polymerase,Inhibitor,Potent PARP inhibitor,4,CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1,793,1
3256,O=C(O)C(O)C(O)C(O)=O.OC(CNC(C)C)COC1=CC=C(CCOC)C=C1.OC(CNC(C)C)COC2=CC=C(CCOC)C=C2,Metoprolol tartrate,6420057,1-[4-(2-Methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol hemitartrate,C15H25NO3.�C4H6O6,[56392-17-7],342.4,7-TM Receptors,Adrenergic Beta-1 Receptors,Antagonist,Selective ?1 antagonist,1,COCCc1ccc(OCC(O)CNC(C)C)cc1,434,1
3259,OC[C@@H]1[C@@H](O)C(F)(F)[C@H](N2C(N=C(N)C=C2)=O)O1.Cl,Gemcitabine hydrochloride,69101485,"(+)-2'-Deoxy-2',2'-difluorocytidine hydrochloride",C9H11F2N3O4.HCl,[122111-03-9],299.66,Cell biology,"DNA, RNA and Protein Synthesis",Inhibitor,DNA synthesis inhibitor,3,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,845,1
3263,CC(C)(C)C1=NC(C2=CC(OCO4)=C4C=C2)=C(C3=NC(C)=CC=C3)N1,SB 505124,9858940,"2-[4-(1,3-Benzodioxol-5-yl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-6-methyl-pyridine",C20H21N3O2,[694433-59-5],335.4,Enzyme-Linked Receptors,TGF-beta Receptors,Inhibitor,"Selective inhibitor of TGF-?RI, ALK4 and ALK7",2,Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1,746,0
3264,O=C(NC5CCOCC5)C(C=C4)=CC=C4C1=CC(C2=CNN=C2C3=CC=CC=N3)=CC=N1,GW 788388,10202642,4-[4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide,C25H23N5O2,[452342-67-5],429.98,Enzyme-Linked Receptors,TGF-beta Receptors,Inhibitor,Potent and selective inhibitor of TGF-?RI,1,O=C(NC1CCOCC1)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1,742,1
3269,FC(C=CC(Cl)=C3)=C3C2=NC1=NC=CN=C1C(NC4=CC=NC=C4)=N2,SD 208,10316032,2-(5-Chloro-2-fluorophenyl)-4-[(4-pyridyl)amino]pteridine,C17H10ClFN6,[627536-09-8],357.25,Enzyme-Linked Receptors,TGF-beta Receptors,Inhibitor,Potent ATP-competitive TGF-?RI inhibitor,4,Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1,563,1
3270,O=C(CC1CC(C2=CC=CC=C2)=NO1)O,GIT 27,10798271,"4,5-Dihydro-3-phenyl-5-isoxazoleacetic acid",C11H11NO3,[6501-72-0],205.21,Cell biology,Cytokines,Other,Immunomodulator; reduces production of pro-inflammatory cytokines,1,O=C(O)CC1CC(c2ccccc2)=NO1,227,1
3282,FC1=C2C(C[C@@H](N(C4CCC4)C3CCC3)CO2)=C(C(N)=O)C=C1.Cl,NAD 299 hydrochloride,90488823,"(3R)-3-(Dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrochloride",C18H23FN2O2.HCl,[184674-99-5],359.35,7-TM Receptors,5-HT1A Receptors,Antagonist,"Selective, high affinity 5-HT1A antagonist",3,NC(=O)c1ccc(F)c2c1C[C@@H](N(C1CCC1)C1CCC1)CO2,530,1
3291,NC1=NC(NS(C(C=C3)=CC=C3C2=CC=C(C#N)C=C2)(=O)=O)=CC=C1,PF 915275,23725123,"N-(6-Amino-2-pyridinyl)-4'-cyano-[1,1'-biphenyl]-4-sulfonamide",C18H14N4O2S,[857290-04-1],350.39,Enzymes,11b-Hydroxysteroid Dehydrogenase,Inhibitor,Potent and selective 11?-hydroxysteroid dehydrogenase inhibitor,2,N#Cc1ccc(-c2ccc(S(=O)(=O)Nc3cccc(N)n3)cc2)cc1,67,1
3292,O=C(C2=CN=CC=C2)C(C)(C)C1=CC=CN=C1,Metyrapone,4174,"2-Methyl-1,2-di-3-pyridinyl-1-propanone",C14H14N2O,[54-36-4],226.27,Enzymes,Hydroxylases,Inhibitor,11-? hydroxylase inhibitor,4,CC(C)(C(=O)c1cccnc1)c1cccnc1,476,0
3295,O=C(C(C=CC=C4)=C4C3=O)N3[C@H](C(O)=O)CC2=CNC1=CC=CC=C12,RG 108,702558,N-Phthalyl-L-tryptophan,C19H14N2O4,[48208-26-0],334.33,Enzymes,DNA Methyltransferases,Inhibitor,Non-nucleoside DNA methyltransferase inhibitor,2,O=C(O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O,795,0
3296,ClC1=CC=C(/C=C(C)/C(C)=N/O)C=C1,AP 18,9584673,4-(4-Chlorophenyl)-3-methyl-3-buten-2-one oxime,C11H12ClNO,[55224-94-7],209.67,Ion Channels,TRPA1,Blocker,Reversible TRPA1 channel blocker,2,CC(=C\c1ccc(Cl)cc1)/C(C)=N/O,884,1
3297,O=C(N(C)C)NC1(C4=CC=CC=C4)CCN(CCC[C@]3(CN(C(C5=CC=CC=C5)=O)CCC3)[C@]2=CC=C(Cl)C(Cl)=C2)CC1.Cl,SSR 146977 hydrochloride,90488827,"N1-[1-3-[(3R)-1-Benzoyl-3-(3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-piperidinyl]-N,N-dimethylurea hydrochloride",C35H42Cl2N4O2.HCl,[264618-38-4],694.14,7-TM Receptors,NK3 Receptor,Antagonist,Potent and selective NK3 antagonist,1,CN(C)C(=O)NC1(c2ccccc2)CCN(CCC[C@]2(c3ccc(Cl)c(Cl)c3)CCCN(C(=O)c3ccccc3)C2)CC1,627,1
3301,O=C(N(CC)CC)C(C=C4)=CC=C4NC1=NC(NC=N2)=C2C(OCC3CCCCC3)=N1,NU 6140,10202471,"4-[[6-(Cyclohexylmethoxy)-1H-purin-2-yl]amino]-N,N-diethylbenzamide",C23H30N6O2,[444723-13-1],427.02,Enzymes,Cyclin-dependent Kinase,Inhibitor,Cdk2 inhibitor; also potent inhibitor of aurora kinase A and B,1,CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,225,1
3302,CC1(C)C2=C(C=C(C3=C(O)C=CC(/C=C/C(O)=O)=C3)C(C)=C2)C(C)(C)CC1,CD 3254,44566110,"3-[4-Hydroxy-3-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)phenyl]-2-propenoic acid",C24H28O3,[196961-43-0],377.99,Nuclear Receptors,Retinoid X Receptor,Agonist,Potent and selective RXR? agonist,2,Cc1cc2c(cc1-c1cc(/C=C/C(=O)O)ccc1O)C(C)(C)CCC2(C)C,454,1
3304,O=C2NC1=CC(C4=CC=CC=C4)=CC=C1/C2=C/C3=C(C)C(CCC(O)=O)=C(C)N3,SU 16f,5329150,"5-[1,2-Dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid",C24H22N2O3,[251356-45-3],386.44,Enzyme-Linked Receptors,PDGFR,Inhibitor,Potent and selective PDGFR? inhibitor,1,Cc1[nH]c(/C=C2\C(=O)Nc3cc(-c4ccccc4)ccc32)c(C)c1CCC(=O)O,769,1
3308,CC(N(O)C(N)=O)C2=CC1=CC=CC=C1S2,Zileuton,60490,N-(1-Benzo[b]thien-2-ylethyl)-N-hydroxyurea,C11H12N2O2S,[111406-87-2],236.29,Enzymes,Lipoxygenase,Inhibitor,5-LOX inhibitor; orally bioavailable,1,CC(c1cc2ccccc2s1)N(O)C(N)=O,533,1
3313,CC(C)(C)C1=C2C(C(O)(C(F)(F)F)C(O2)=O)=CC(C(C)(C)C)=C1,rac BHFF,4332683,"5,7-Bis(1,1-dimethylethyl)-3-hydroxy-3(trifluoromethyl)-2(3H)-benzofuranone",C17H21F3O3,[123557-91-5],330.34,7-TM Receptors,GABAB Receptors,Modulator,Potent and selective postitive allosteric modulator of  GABAB receptors,1,CC(C)(C)c1cc(C(C)(C)C)c2c(c1)C(O)(C(F)(F)F)C(=O)O2,863,1
3314,O=C1NN=C(SC3=NC=C([N+]([O-])=O)S3)N1C2=CC=C4C(OCCO4)=C2,BI 78D3,2747117,"4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-3H-1,2,4-triazol-3-one",C13H9N5O5S2,[883065-90-5],379.37,Enzymes,JNK/c-jun,Inhibitor,"Selective, competitive JNK inhibitor",1,O=c1[nH]nc(Sc2ncc([N+](=O)[O-])s2)n1-c1ccc2c(c1)OCCO2,754,1
3316,NC1=NC=CC(C2=C(C4=CC=C(F)C=C4)N=CN2C3CCCCC3)=N1.Cl.Cl,PF 670462,51049607,4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-2-pyrimidinamine dihydrochloride,C19H20FN5.2HCl,[950912-80-8],410.32,Enzymes,Casein Kinase 1,Inhibitor,Potent and selective CK1? and CK1? inhibitor,1,Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCCCC2)n1,64,1
3319,ClC1=CC=CC(CNCCC2=CC=C(NC(C3=CC=CS3)=N)C=C2)=C1.Cl.Cl,ARL 17477 dihydrochloride,9824646,N-[4-[2-[[(3-Chlorophenyl)methyl]amino]ethyl]phenyl]-2-thiophenecarboxamide dihydrochloride,C20H20ClN3S.2HCl,[866914-87-6],442.83,Enzymes,nNOS,Inhibitor,Selective nNOS inhibitor,1,N=C(Nc1ccc(CCNCc2cccc(Cl)c2)cc1)c1cccs1,614,1
3323,O=C(NC4=C(C=CC(NCCNCCO)=N5)C5=CC=C4)CC1(C3)CC2CC(CC3C2)C1.Cl.Cl,AZ 10606120 dihydrochloride,56972227,"N-[2-[[2-[(2-Hydroxyethyl)amino]ethyl]amino]-5-quinolinyl]-2-tricyclo[3.3.1.13,7]dec-1-ylacetamide dihydrochloride",C25H34N4O2.2HCl,[607378-18-7],540.52,Ion Channels,P2X Receptors,Antagonist,Potent P2X7 receptor antagonist,2,O=C(CC12CC3CC(CC(C3)C1)C2)Nc1cccc2nc(NCCNCCO)ccc12,160,1
3324,OC[C@H](CC6=CC=CC=C6)NC1=C2C(N(CC3=CC=C(C7=CC=CC=C7)C=C3)C=N2)=NC(OC4=CC=C(CCC5)C5=C4)=N1,QS 11,42623900,"(2S)-2-[2-(Indan-5-yloxy)-9-(1,1'-biphenyl-4-yl)methyl)-9H-purin-6-ylamino]-3-phenyl-propan-1-ol",C36H33N5O2,[944328-88-5],572.18,Enzymes,Arf,Inhibitor,ARFGAP1 inhibitor; modulates Wnt/?-catenin signaling,3,OC[C@H](Cc1ccccc1)Nc1nc(Oc2ccc3c(c2)CCC3)nc2c1ncn2Cc1ccc(-c2ccccc2)cc1,826,1
3326,CN(CCC2=C(C3=CC=CC=C3)NC1=CC=C(OC)C=C12)C,BGC 20-761,6918515,"5-Methoxy-N,N-dimethyl-2-phenyl-1H-indole-3-ethanamine",C19H22N2O,[17375-63-2],312.41,7-TM Receptors,5-HT6 Receptors,Antagonist,High affinity 5-HT6 antagonist,1,COc1ccc2[nH]c(-c3ccccc3)c(CCN(C)C)c2c1,415,1
3327,OC1=CC2=C(OC3=C2CCCNC3=O)C=C1,CID 755673,755673,"2,3,4,5-Tetrahydro-7-hydroxy-1H-benzofuro[2,3-c]azepin-1-one",C12H11NO3,[521937-07-5],217.22,Enzymes,Protein Kinase D,Inhibitor,Selective protein kinase D inhibitor,3,O=C1NCCCc2c1oc1ccc(O)cc21,806,1
3333,CCCCN1C(C6=CC=CC=C6)=NC(C7=CC=CC=C7)=C1CN(CC3=CC(OCO5)=C5C=C3)CC2=CC=C(OCO4)C4=C2,NDT 9513727,10210160,"N,N-Bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-Imidazole-5-methanamine",C36H35N3O4,[439571-48-9],573.68,Cell biology,Complement,Modulator,"Potent, selective human C5a receptor negative allosteric modulator (NAM)",2,CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc2c(c1)OCO2)Cc1ccc2c(c1)OCO2,748,1
3342,O=C(NS(C4=C(OC)C=CC(Br)=C4)(=O)=O)/C=C/C1=CC=CC=C1CC3=CC2=CC=CC=C2C=C3,"L-798,106",15551229,N-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide,C27H22BrNO4S,[244101-02-8],536.44,7-TM Receptors,Prostanoid Receptors,Antagonist,Potent and highly selective EP3 antagonist,4,COc1ccc(Br)cc1S(=O)(=O)NC(=O)/C=C/c1ccccc1Cc1ccc2ccccc2c1,541,1
3347,CC1=CC=C(NC(C(C)C)=O)C=C1C(CC4)CCN4CC(C=C3)=CC=C3OC2=CC(F)=C(F)C=C2.Cl,SNAP 94847 hydrochloride,56972235,"N-[3-[1-[[4-(3,4-Difluorophenoxy)phenyl]methyl]-4-piperidinyl]-4-methylphenyl]-2-methylpropanamide hydrochloride",C29H32F2N2O2.HCl,[1781934-47-1],533.05,7-TM Receptors,Melanin-concentrating Hormone Receptors,Antagonist,Potent and selective MCH1 antagonist,2,Cc1ccc(NC(=O)C(C)C)cc1C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1,449,1
3351,CC(C)N(CCCCOCC(NS(C)(=O)=O)=O)C1=NC(C3=CC=CC=C3)=C(C2=CC=CC=C2)N=C1,Selexipag,9913767,"2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)acetamide",C26H32N4O4S,[475086-01-2],496.62,7-TM Receptors,Prostanoid Receptors,Agonist,Selective prostacyclin IP1 receptor agonist,2,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,240,1
3352,NC1=C(/C=N/OCCN2CCOCC2)C(NC3=CC(Cl)=C(OCC4=CC=CC=C4)C=C3)=NC=N1.Cl,JNJ 28871063 hydrochloride,17747413,5E-4-Amino-6-(4-benzyloxy-3-chlorophenylamino)pyrimidine-5-carboxaldehyde N-(2-morpholin-4-ylethyl) oxime hydrochloride,C24H27ClN6O3.HCl,[944342-90-9],523.92,Enzyme-Linked Receptors,EGFR,Inhibitor,Potent ErbB receptor family inhibitor,2,Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1/C=N/OCCN1CCOCC1,392,1
3354,O=C(C2=CC=C(CN(CC)CC)C=C2)N(CCC3=CC=CC=C3OC)[C@@H]1CCNC1.Cl.Cl,PF 429242 dihydrochloride,90488837,4-[(Diethylamino)methyl]-N-[2-(2-methoxyphenyl)ethyl]-N-(3R)-3-pyrrolidinylbenzamide dihydrochloride,C25H35N3O2.2HCl,[2248666-66-0],500.51,Cell biology,SREBP,Inhibitor,Competitive inhibitor of SREBP site 1 protease,3,CCN(CC)Cc1ccc(C(=O)N(CCc2ccccc2OC)[C@@H]2CCNC2)cc1,216,1
3361,O=C(NC3=NC=C(C(F)(F)F)C=C3)N(CC2)CCN2C1=C(C(F)(F)F)C=CC=N1,JNJ 17203212,11339118,4-[3-(Trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamide,C17H15F6N5O,[821768-06-3],419.32,Ion Channels,TRPV,Antagonist,"Reversible, competitive and potent TRPV1 antagonist",1,O=C(Nc1ccc(C(F)(F)F)cn1)N1CCN(c2ncccc2C(F)(F)F)CC1,470,1
3364,CN(CCC3)CCN3C2=NC1=CC(OC)=C(OC)C=C1C(NC4CCN(CC5=CC=CC=C5)CC4)=N2.Cl.Cl.Cl,BIX 01294,46945860,"2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6,7-dimethoxy-N-[1-(phenylmethyl)-4-piperidinyl]-4-quinazolinamine trihydrochloride",C28H38N6O2.3HCl,[1392399-03-9],631.54,Enzymes,G9a/GLP,Inhibitor,GLP and G9a inhibitor,2,COc1cc2nc(N3CCCN(C)CC3)nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC,393,0
3366,BrC1=C2C(N=C(C3=CC=C(O)C=C3)O2)=CC(O)=C1,WAY 200070,9861330,"7-Bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol",C13H8BrNO3,[440122-66-7],306.11,Nuclear Receptors,Estrogen and Related Receptors,Agonist,Selective ER? agonist,1,Oc1ccc(-c2nc3cc(O)cc(Br)c3o2)cc1,892,1
3367,OC1=[C@]([C@]2=C(O)C(C(C=O)=C(O)C(O)=C3C(C)C)=C3C=C2C)C(C)=CC4=C1C(C=O)=C(O)C(O)=C4C(C)C,AT 101,3503,"(-)-1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-[2,2'-binaphthalene]-8,8'-dicarboxaldehyde",C30H30O8,[90141-22-3],518.56,Cell biology,Bcl-2 Family,Other,Downregulates Bcl-2 and Mcl-1; pro-apoptotic,4,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,808,1
3368,CC2=C(S(NC3=CC=C(OC)C(N4CCNCC4)=C3)(=O)=O)SC1=CC=C(Cl)C=C12.Cl,SB 271046 hydrochloride,6918455,5-Chloro-N-[4-methoxy-3-(1-piperazinyl)phenyl]-3-methyl-benzo[b]thiophen-2-sulfonamide hydrochloride,C20H22ClN3O3S2.HCl,[209481-24-3],506.47,7-TM Receptors,5-HT6 Receptors,Antagonist,Selective 5-HT6 antagonist; orally active,2,COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1,112,0
3370,O=C1[C@@H]([C@](N/N=C(C)/C3=CC=CC(Br)=C3)=O)[C@H]([C@]2=CC=CC=C2)CN1,AC 264613,25108278,"(�)-(3R*,4S*)-2-Oxo-4-phenyl-3-pyrollidinecarboxylic acid 2-[1-(3-bromophenyl)ethylidene]hydrazide",C19H18BrN3O2,[1051487-82-1],400.27,7-TM Receptors,Protease-Activated Receptors,Agonist,PAR2 receptor agonist,1,C/C(=N\NC(=O)[C@@H]1C(=O)NC[C@H]1c1ccccc1)c1cccc(Br)c1,131,1
3371,C[C@@](C)(C)[C@H](NCC3=CC=NC=C3)C(N(C2)CCC1=C2C=C(OC)C(OC)=C1)=O.Cl,TCS OX2 29,53302033,"(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanone hydrochloride",C23H31N3O3.HCl,[1610882-30-8],488.02,7-TM Receptors,OX2 Receptor,Antagonist,Potent and selective OX2 antagonist,2,COc1cc2c(cc1OC)CN(C(=O)[C@@H](NCc1ccncc1)C(C)(C)C)CC2,372,1
3378,ClC1=C(N(C(C)C)CC)N=C(N)C(C(NC(N)=N)=O)=N1,EIPA,1795,3-Amino-N-(aminoiminomethyl)-6-chloro-5-[ethyl(1-methylethyl)amino]-2-pyrazinecarboxamide,C11H18ClN7O,[1154-25-2],304.26,Ion Channels,TRPP,Blocker,Inhibits TRPP3-mediated currents; also inhibits the Na+/H+ exchanger (NHE),2,CCN(c1nc(N)c(C(=O)NC(=N)N)nc1Cl)C(C)C,871,0
3379,NC1=C(Cl)N=C(C(NC(NC2=CC=CC=C2)=N)=O)C(N)=N1.CS(=O)(O)=O,Phenamil,9604979,"3,5-Diamino-6-chloro-N-[imino(phenylamino)methyl]pyrazinecarboxamide methanesulfonate salt",C12H12ClN7O.CH3SO3H,[1161-94-0],415.34,Ion Channels,TRPP,Blocker,Inhibits TRPP3-mediated currents; also inhibits epithelial Na+ channels,1,N=C(NC(=O)c1nc(Cl)c(N)nc1N)Nc1ccccc1,871,0
3380,NC1=C(Cl)N=C(C(NC(NCC2=CC=CC=C2)=N)=O)C(N)=N1.Cl,Benzamil,5702295,"N-(Benzylamidino)-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride",C13H14ClN7O.HCl,[161804-20-2],369.72,Transporters,Na+/Ca2+ Exchanger,Inhibitor,"NCX inhibitor, Deg/ENaC channel blocker; amiloride (Cat. No. 0890) derivative",3,N=C(NCc1ccccc1)NC(=O)c1nc(Cl)c(N)nc1N,871,1
3383,CC1=C2C(SC(C(NCC3=CC=C(OC)C=C3)=O)=C2N)=NC(C)=C1,VU 152100,864492,"3-Amino-N-(4-methoxybenzyl)-4,6-dimethylthieno[2,3-b]pyridine carboxamide",C18H19N3O2S,[409351-28-6],341.43,7-TM Receptors,M4 Receptors,Modulator,Positive allosteric modulator of M4 receptors,2,COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1,466,1
3388,CC(C)(C#N)C1=CC(CN2C=NC=N2)=CC(C(C)(C)C#N)=C1,Anastrozole,2187,"?1,?1,?3,?3-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile",C17H19N5,[120511-73-1],293.37,Enzymes,Cytochrome P450,Inhibitor,Potent aromatase (CYP19) inhibitor,1,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,866,1
3389,O=C(C(O)(C)CS(C2=CC=C(F)C=C2)(=O)=O)NC1=CC(C(F)(F)F)=C(C#N)C=C1,Bicalutamide,2375,N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide,C18H14F4N2O4S,[90357-06-5],430.37,Nuclear Receptors,Androgen Receptor,Antagonist,Non-steroidal androgen receptor antagonist,1,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,514,1
3410,CC1(C)C2=C(C=CC(C(O)C(NC3=CC=C(C(O)=O)C=C3F)=O)=C2)C(C)(C)CC1,BMS 961,2418,"3-Fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-2-naphthalenyl)acetyl]amino]-benzoic acid",C23H26FNO4,[185629-22-5],399.46,Nuclear Receptors,Retinoic Acid Receptors,Agonist,Selective RAR? agonist,1,CC1(C)CCC(C)(C)c2cc(C(O)C(=O)Nc3ccc(C(=O)O)cc3F)ccc21,456,0
3411,CC1(C)C2=C(C=CC(C4(OCCO4)C3=CC=C(C(O)=O)C=C3)=C2)C(C)(C)CC1,SR 11237,127019,"4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl]-benzoic acid",C24H28O4,[146670-40-8],380.48,Nuclear Receptors,Retinoid X Receptor,Agonist,Pan RXR agonist,3,CC1(C)CCC(C)(C)c2cc(C3(c4ccc(C(=O)O)cc4)OCCO3)ccc21,456,0
3417,COC(C=CC=C3)=C3CN[C@@H]1[C@H]([C@]2=CC=CC=C2)NCCC1.Cl.Cl,CP 99994 dihydrochloride,68466923,"(2S,3S)-N-[(2-Methoxyphenyl)methyl]-2-phenyl-3-piperidinamine dihydrochloride",C19H24N2O.2HCl,[145148-39-6],373.83,7-TM Receptors,NK1 Receptor,Antagonist,High affinity NK1 antagonist,1,COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1,357,1
3433,O=S(NC1=C(OC)C=C(NC3=CC=CC=C3)C=C1)(C2=C(C(OC)=O)SC=C2)=O,GSK 0660,46233311,3-[[[2-Methoxy-4-(phenylamino)phenyl]amino]sulfonyl]-2-thiophenecarboxylic acid methyl ester,C19H18N2O5S2,[1014691-61-2],418.49,Nuclear Receptors,PPARdelta Receptors,Antagonist,Selective PPAR? antagonist,1,COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC,187,1
3489,FC(C=C5)=CC=C5CN2C1=CC=CC=C1N=C2NC3CCN(CCC4=CC=C(OC)C=C4)CC3,Astemizole,2247,1-[(4-Fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine,C28H31FN4O,[68844-77-9],458.57,7-TM Receptors,Histamine H1 Receptors,Antagonist,"Orally active, potent H1 antagonist; also KV11.1 (hERG) channel blocker",4,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,284,0
3495,O[C@@H]1[C@@H](CO)O[C@@H](N3C2=NC(F)=NC(N)=C2N=C3)[C@H]1O,Fludarabine,657237,9-?-D-Arabinofuranosyl-2-fluoro-9H-purin-6-amine,C10H12FN5O4,[21679-14-1],285.23,Cell biology,"DNA, RNA and Protein Synthesis",Inhibitor,Purine analog; inhibits DNA synthesis,1,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,841,0
3496,FC1=CC=C(CN2C[C@@H](C)N(C(COC3=CC=C(Cl)C=C3NC(N)=O)=O)CC2)C=C1,BX 471,512282,(2R)-1-[[2-[(Aminocarbonyl)amino]-4-chlorophenoxy]acetyl]-4-[(4-fluorophenyl)methyl]-2-methylpiperazine,C21H24ClFN4O3,[217645-70-0],457.41,7-TM Receptors,Chemokine CC Receptors,Antagonist,"Potent, selective CCR1 antagonist",3,C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O,280,1
3505,O=C1C(C)(C)C2=C(C=CC(C(NC3=CC=C(C(O)=O)C=C3)=O)=C2)C(C)1C,BMS 753,9884820,"4-[[(2,3-Dihydro-1,1,3,3-tetramethyl-2-oxo-1H-inden-5-yl)carbonyl]amino]benzoic acid",C21H21NO4,[215307-86-1],351.4,Nuclear Receptors,Retinoic Acid Receptors,Agonist,RAR?-selective agonist,1,CC1(C)C(=O)C(C)(C)c2cc(C(=O)Nc3ccc(C(=O)O)cc3)ccc21,456,0
3506,O=C(N2CCC[C@H]2C#N)CNCCNC1=NC=C(C#N)C=C1.Cl.Cl,NVP DPP 728 dihydrochloride,9799555,6-[[2-[[2-(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethyl]amino]ethyl]amino-3-pyridinecarbononitrile dihydrochloride,C15H18N6O.2HCl,[207556-62-5],375.77,Enzymes,Dipeptidyl Peptidase IV (DPP-IV),Inhibitor,"Potent, orally active dipeptidyl peptidase IV (DPP-IV) inhibitor",1,N#Cc1ccc(NCCNCC(=O)N2CCC[C@H]2C#N)nc1,71,1
3507,O=C(C3=CC=C(C(O)=O)C=C3)NC(C=C2)=CC1=C2C(C)(C)CCC(C)1C,AM 80,108143,"4-[[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]benzoic acid",C22H25NO3,[94497-51-5],387.47,Nuclear Receptors,Retinoic Acid Receptors,Agonist,RAR? agonist; anticancer agent,2,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21,456,0
3523,OC1=C(/C=N/O)C=CC(C2=CC=C(O)C(F)=C2)=C1Cl,FERb 033,74429219,"2-Chloro-3'-fluoro-3,4'-dihydroxy-[1,1-biphenyl]-4-carboxaldehyde oxime",C13H9ClFNO3,[1111084-78-6],290.68,Nuclear Receptors,Estrogen and Related Receptors,Agonist,Potent and selective ER? agonist,1,O/N=C/c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O,558,1
3528,O=C(C(N(C)C)=O)C2=CN(C)C1=CC(Cl)=C(C(N3[C@H](C)CN(CC4=CC=C(F)C=C4)[C@@H](C)C3)=O)C=C12.Cl,SCIO 469 hydrochloride,16035045,"6-Chloro-5-[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-?-oxo-1H-Indole-3-acetamide hydrochloride",C27H30ClFN4O3.HCl,0,562.97,Enzymes,p38,Inhibitor,Selective p38 MAPK inhibitor,1,C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1,280,0
3530,C1(CCCN2CCC(OC(C4=CC=CC=C4)C3=CC=CC=C3)CC2)=NN=NN1,HQL 79,6540277,4-(Diphenylmethoxy)-1-(3-2H-tetrazol-5-yl)propyl]-piperidine,C22H27N5O,[162641-16-9],377.48,Enzymes,Other Synthases/Synthetases,Inhibitor,Human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor,1,c1ccc(C(OC2CCN(CCCc3nnn[nH]3)CC2)c2ccccc2)cc1,289,0
3531,C2(C=CC=C3)=C3/C(C(C=CC=C4)=C4C=C2)=C1CCN(CCCCC5=NNN=N5)CC/1,AT 56,11741525,"4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-piperidine",C25H27N5,[162640-98-4],406.53,Enzymes,Other Synthases/Synthetases,Inhibitor,L-PGDS inhibitor,2,C1=Cc2ccccc2C(=C2CCN(CCCCc3nn[nH]n3)CC2)c2ccccc21,292,1
3534,O=C(N/N=C/C2=CC=C(C)O2)C1=C(OC3=CC=CC=C3)C=CC=C1,PNU 74654,9836739,2-Phenoxybenzoic acid-[(5-methyl-2-furanyl)methylene]hydrazide,C19H16N2O3,[113906-27-7],320.34,Cell biology,Beta-catenin,Other,?-catenin binder; inhibits Wnt signaling,1,Cc1ccc(/C=N/NC(=O)c2ccccc2Oc2ccccc2)o1,536,1
3535,[Na+].CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=C1C(=O)NCC([O-])=O,Sivelestat sodium salt,23664980,"N-{2-[({4-[(2,2-Dimethylpropanoyl)oxy]phenyl}sulfonyl)amino]benzoyl}glycine sodium salt",C20H21N2NaO7S,[150374-95-1],528.5,Enzymes,Elastase,Inhibitor,Selective leukocyte elastase inhibitor,3,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)[O-])cc1,102,1
3542,O=C(N[C@@H](CC3=CC=CC=C3)[C@H](C(N(OC)C)=O)O)C2=CC1=CC(Cl)=CC=C1N2,CP 316819,10273347,"5-Chloro-N-[(1S,2R)-2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide",C21H22ClN3O4,[186392-43-8],415.87,Enzymes,Phosphorylases,Inhibitor,Selective glycogen phosphorylase inhibitor,1,CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1,567,1
3545,NCCC1=CNC=N1.Cl.Cl,Histamine dihydrochloride,5818,2-(4-Imidazolyl)ethylamine dihydrochloride,C5H9N3.2HCl,[56-92-8],184.07,7-TM Receptors,Histamine H1 Receptors,Agonist,Endogenous histamine receptor agonist,1,NCCc1c[nH]cn1,877,0
3550,O=C(C)NCCC2=CNC1=CC=C(OC)C=C12,Melatonin,896,N-Acetyl-5-methoxytryptamine,C13H16N2O2,[73-31-4],232.28,7-TM Receptors,Melatonin (MT) Receptors,Agonist,Endogenous hormone; agonist at MT1 and MT2,1,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,795,0
3562,O=S(NC[C@H](CC4)CC[C@@H]4NC1=NC(C2=CC=CC=C2SCC3)=C3S1)(C)=O,LU AA33810,22254068,"N-[[trans-4-[(4,5-Dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]methanesulfonamide",C19H25N3O2S3,[304008-29-5],432.63,7-TM Receptors,NPY Receptors,Antagonist,Potent NPY Y5 receptor antagonist,2,CS(=O)(=O)NC[C@H]1CC[C@H](Nc2nc3c(s2)CCSc2ccccc2-3)CC1,633,1
3567,O=C3N(C4=C(C)C=CC=C4C)C1=NC7=C(C=CC=C7)N1C2=NC(NC5=CC=C(N6CCN(C)CC6)C=C5)=NC=C23,TC-S 7003,11785878,"6-(2,6-Dimethylphenyl)-2-[[4-(4-methyl-1-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-one",C31H30N8O,[847950-09-8],539.63,Enzymes,Src Kinases,Inhibitor,Potent Lck inhibitor,1,Cc1cccc(C)c1-n1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n2c3ccccc3nc12,403,1
3569,CCCCCCOC1=NSN=C1C2=CCCN(C)C2.OC(C(O)=O)=O,Xanomeline oxalate,18920248,"3-[4-(Hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methylpyridine oxalate",C14H23N3OS.C2H2O4,[141064-23-5],371.46,7-TM Receptors,M1 Receptors,Agonist,Functionally selective M1 agonist,4,CCCCCCOc1nsnc1C1=CCCN(C)C1,38,1
3570,O=C1CC[C@@]2(C)C(CC[C@]3([H])[C@@]([H])2CC[C@@]/4(C)[C@]([H])3CC(C4=C/C)=O)=C1,Z-Guggulsterone,6450278,"(Z)-Pregna-4,17(20)-diene-3,16-dione",C21H28O2,[39025-23-5],314.25,Nuclear Receptors,Other Nuclear Receptors,Other,Broad spectrum steroid receptor ligand. More active isomer of guggulsterone (Cat. No. 2013),1,C/C=C1\C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,8,0
3572,O=C(C(C(C5CCCC5)=C4)=CC=C4C2=CNC1=NC=C(C3=CC=CC=C3)C=C12)O,GSK 650394,25022668,"2-Cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-benzoic acid",C25H22N2O2,[890842-28-1],386.95,Enzymes,Other Kinases,Inhibitor,Serum- and glucocorticoid-regulated kinase (SGK) inhibitor,3,O=C(O)c1ccc(-c2c[nH]c3ncc(-c4ccccc4)cc23)cc1C1CCCC1,229,1
3573,CC1=CC=CC2=C1CC[C@H](CN3CCC(C4=C(Cl)C=CC=C4Cl)CC3)C[C@@H]2O.Cl,SB 612111 hydrochloride,21061234,"7-[[4-(2,6-Dichlorophenyl)-1-piperidinyl]methyl]-6,7,8,9-tetrahydro-1-methyl-5H-benzocyclohepten-5-ol hydrochloride",C24H29Cl2NO.HCl,[371980-94-8],459.36,7-TM Receptors,NOP Receptors,Antagonist,Selective NOP antagonist,3,Cc1cccc2c1CC[C@H](CN1CCC(c3c(Cl)cccc3Cl)CC1)C[C@@H]2O,294,1
3575,O=C(N[C@@H](C)CN3CCC(N5C4=C(NC5=O)C=C(Cl)C=C4)CC3)C(C=C2)=CC1=C2C=CC=C1.Cl,VU 0155069,56972237,"N-[(1S)-2-[4-(5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl-2-naphthalenecarboxamide",C26H27ClN4O2.HCl,[1781834-89-6],526.45,Enzymes,Phospholipases,Inhibitor,Potent and selective PLD1 inhibitor,1,C[C@@H](CN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)NC(=O)c1ccc2ccccc2c1,262,0
3576,O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1N(C=N3)C2=C3C(NC4C5CCC(C5)C4)=NC=N2,(+/-)-5'-Chloro-5'-deoxy-ENBA,42636897,N-Bicyclo[2.2.1]hept-2-yl-5'-chloro-5'-deoxyadenosine,C17H22ClN5O3,[103626-26-2],384.34,7-TM Receptors,Adenosine A1 Receptors,Agonist,Highly selective A1 agonist,5,O[C@@H]1[C@@H](CCl)O[C@@H](n2cnc3c(NC4CC5CCC4C5)ncnc32)[C@@H]1O,841,0
3579,BrC1=CC(C(C3=C4C2=C(O3)C=CC=C2)=NCC(N4)=O)=CC=C1,5-BDBD,9841560,"5-(3-Bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one",C17H11BrN2O2,[768404-03-1],355.19,Ion Channels,P2X Receptors,Antagonist,Potent and selective P2X4 antagonist,2,O=C1CN=C(c2cccc(Br)c2)c2oc3ccccc3c2N1,766,1
3581,COC1=C(OC)C=C(N=C(N4CCC(N5CCCCC5)CC4)N=C2NC3CCCCCC3)C2=C1.Cl.Cl,C 021 dihydrochloride,56972238,"2-[1,4'-Bipiperidin]-1'-yl-N-cycloheptyl-6,7-dimethoxy-4-quinazolinamine dihydrochloride",C27H41N5O2.2HCl,[1784252-84-1],558.59,7-TM Receptors,Chemokine CC Receptors,Antagonist,Potent CCR4 antagonist,1,COc1cc2nc(N3CCC(N4CCCCC4)CC3)nc(NC3CCCCCC3)c2cc1OC,393,0
3586,O=S(CC1=CC=C(NC=C2CCN(C)C)C2=C1)(NC)=O.O=C(CCC(O)=O)O,Sumatriptan succinate,59772,3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide succinate,C14H21N3O2S.C4H6O4,[103628-48-4],413.49,7-TM Receptors,5-HT1D Receptors,Agonist,"5-HT1A, 5-HT1B and 5-HT1D agonist",1,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,797,1
3587,O=[C@]([C@@H]3CCC[C@H]3[C@@](O)=O)C(C=C2)=CC=C2C1=CC=C(NC(NC4=CC=CC=C4)=O)C=C1,A 922500,24768261,"(1R,2R)-2-[[4'-[[Phenylamino)carbonyl]amino] [1,1'-biphenyl]-4-yl]carbonyl]cyclopentanecarboxylic acid",C25H24N2O4,[959122-11-3],428.48,Enzymes,Diacylglycerol O-Acyltransferase,Inhibitor,Potent DGAT-1 inhibitor,2,O=C(Nc1ccccc1)Nc1ccc(-c2ccc(C(=O)[C@@H]3CCC[C@H]3C(=O)O)cc2)cc1,250,1
3595,O=C([C@H]([C@]2=CC=CC=C2)NC([C@@H]([C@@H](C(NO)=O)O)CC(C)C)=O)OC1CCCC1,CHR 2797,15547703,?-[[(2R)-2-[(1S)-1-Hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-benzeneacetic acid cyclopently ester,C21H30N2O6,[238750-77-1],406.48,Enzymes,Aminopeptidases,Inhibitor,Aminopeptidase inhibitor,4,CC(C)C[C@@H](C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1)[C@H](O)C(=O)NO,185,1
3600,O=C(N2)N(C3CCN(CCNC(C4=CC5=C(C=CC(F)=C5)N4)=O)CC3)C1=C2C=CC=C1.Cl,FIPI,90488864,"N-[2-[4-(2,3-Dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethy]-5-fluoro-1H-indole-2-carboxamide hydrochloride",C23H24FN5O2.HCl,[1781834-93-2],484.95,Enzymes,Phospholipases,Inhibitor,Phospholipase D inhibitor,3,O=C(NCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1cc2cc(F)ccc2[nH]1,262,1
3601,OCCNC3CCC(C3=CC=C4)=C4C1=NOC(C2=CC(OCC)=C(OCC)C=C2)=N1.Cl,CYM 5442 hydrochloride,90488865,"2-(4-(5-(3,4-Diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino) ethanol hydrochloride",C23H27N3O4.HCl,[1783987-80-3],454.95,7-TM Receptors,Sphingosine-1-phosphate Receptors,Agonist,Selective S1P1 receptor agonist,3,CCOc1ccc(-c2nc(-c3cccc4c3CCC4NCCO)no2)cc1OCC,716,1
3605,CC(C)N2C1=NC(N[C@H](CC)CO)=NC(NCC3=CC=C(C4=NC=CC=C4)C=C3)=C1N=C2.Cl.Cl.Cl,(R)-CR8,90488866,(2R)-2-[[9-(Methylethyl)-6-[[[4-(2-pyridinyl)phenyl]methyl]amino]-9H-purin-2-yl]amino]-1-butanol trihydrochloride,C24H29N7O.3HCl,[1786438-30-9],563.44,Enzymes,Cyclin-dependent Kinase,Inhibitor,Cdk inhibitor; potently inhibits cdk1 and cdk2; also inhibits CK1,1,CC[C@H](CO)Nc1nc(NCc2ccc(-c3ccccn3)cc2)c2ncn(C(C)C)c2n1,825,0
3607,NC2=NN=C(S2)SC1=NC=C([N+]([O-])=O)S1,SU 3327,11837140,"5-[(5-Nitro-2-thiazolyl)thio]-1,3,4thiadiazol-2-amine",C5H3N5O2S3,[40045-50-9],261.3,Enzymes,JNK/c-jun,Inhibitor,Selective JNK inhibitor,1,Nc1nnc(Sc2ncc([N+](=O)[O-])s2)s1,754,0
3620,CC(O2)(C)O[C@H]1[C@@H]2[C@H](OC(C)(C)O3)[C@@]3(COS(N)(=O)=O)OC1,Topiramate,5284627,"2,3:4,5-Bis-O-(1-methylethylidene)-?-D-fructopyranose sulfamate",C12H21NO8S,[97240-79-4],339.36,Ion Channels,Kainate Receptors,Antagonist,GluK1 antagonist; inhibits carbonic anhydrase (CA) II and IV; also positive allosteric modulator of GABAA receptors,1,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,893,1
3621,CC1=CN(C[C@@H](C(O)=O)N)C(N(CC2=C(C(O)=O)SC=C2)C1=O)=O,UBP 310,6420160,"(S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxy-thiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione",C14H15N3O6S,[902464-46-4],357.85,Ion Channels,Kainate Receptors,Antagonist,GluK1-selective kainate antagonist,4,Cc1cn(C[C@H](N)C(=O)O)c(=O)n(Cc2ccsc2C(=O)O)c1=O,679,0
3624,O[C@@H]1[C@@H](CO)O[C@@H](N3C2=NC=NC(N)=C2N=C3)[C@@H]1O,Adenosine,60961,9-?-D-Ribofuranosyl-9H-purin-6-amine,C10H13N5O4,[58-61-7],267.24,7-TM Receptors,Non-selective Adenosine,Agonist,Endogenous adenosine receptor agonist,1,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,841,0
3626,CC(NC[C@@H](O)COC3=C(C#N)C(Cl)=CC=C3)(C)CC2=CC1=CC=CC=C1C=C2.Cl,NPS 2143 hydrochloride,9868131,"2-Chloro-6-[(2R)-3-[[1,1-dimethyl-2-(2-naphthalenyl)ethyl]amino-2-hydroxypropoxy]benzonitrile hydrochloride",C24H25ClN2O2.HCl,[324523-20-8],445.38,7-TM Receptors,Calcium-Sensing Receptor,Antagonist,Selective calcium-sensing receptor (CaSR) antagonist; orally active calcilytic agent,2,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N,347,0
3634,O=C(C1=CC(OC(F)(F)F)=CC=C1N2CC3=CC=C(OC)C=C3)C2=O,VU 0238429,42633508,1-(4-Methoxybenzyl)-5-trifluoromethoxyisatin,C17H12F3NO4,[1160247-92-6],351.28,7-TM Receptors,M5 Receptors,Modulator,Selective positive allosteric modulator of M5 receptors,1,COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc32)cc1,704,1
3642,COC(C(OC)=C3)=CC1=C3N=CN=C1NC2=CC=C(OC4=CC=CC=C4)C=C2,Src I1,1474853,"6,7-Dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine",C22H19N3O3,[179248-59-0],373.4,Enzymes,Src Kinases,Inhibitor,Dual site Src kinase inhibitor,1,COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC,391,0
3649,Cl.Cl.COC1=C(CN[C@H]2CCCN[C@H]2C2=CC=CC=C2)C=C(OC(F)(F)F)C=C1,CP 122721 hydrochloride,90664465,"(2S,3S)-N-[[2-Methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-3-piperidinamine dihydrochloride",C20H23F3N2O2.2HCl,[145877-52-7],453.33,7-TM Receptors,NK1 Receptor,Antagonist,High affinity NK1 antagonist,1,COc1ccc(OC(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1,357,0
3650,O=C(C2=CC=CC3=C2C=CC=C3)N[C@H](C(OC)=O)CC1=CC=C([N+]([O-])=O)C=C1,SB 328437,10474776,N-(1-Naphthalenylcarbonyl)-4-nitro-L-phenylalanine methyl ester,C21H18N2O5,[247580-43-4],378.38,7-TM Receptors,Chemokine CC Receptors,Antagonist,Potent and selective CCR3 antagonist,1,COC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)c1cccc2ccccc12,773,0
3657,S=C(NC(NC(/C=C/C2=CC=CC=C2)=O)C(Cl)(Cl)Cl)NC1=CC=C(Cl)C=C1,Sal 003,5717737,"3--Phenyl-N-(2,2,2-trichloro-1-((((4-chlorophenyl)amino)carbonothioyl)amino)ethyl)acrylamide",C18H15Cl4N3OS,[1164470-53-4],472.22,Enzymes,Protein Ser/Thr Phosphatases,Inhibitor,Cell-permeable inhibitor of eIF2? dephosphorylation,1,O=C(/C=C/c1ccccc1)NC(NC(=S)Nc1ccc(Cl)cc1)C(Cl)(Cl)Cl,606,0
3661,O=[C@@]([C@H]2CCCN2CC3=CC=CC=C3)NCCCN1CCC4(OCC5=C4C=CC=C5)CC1.Cl.Cl,BAN ORL 24,56840444,"(2R)-1-(Phenylmethyl)-N-[3-(spiro[isobenzofuran-1(3H),4'-piperidin]-1-yl)propyl-2-pyrrolidinecarboxamide",C27H35N3O2.2HCl,[1401463-54-4],515.52,7-TM Receptors,NOP Receptors,Antagonist,Potent and selective NOP antagonist,3,O=C(NCCCN1CCC2(CC1)OCc1ccccc12)[C@H]1CCCN1Cc1ccccc1,287,1
3663,CC(C)(C)OC(CN(CC2=CC=C(Cl)C=C2)CC1=CC=C([N+]([O-])=O)S1)=O,GSK 4112,50905018,"1,1-Dimethylethyl-N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl])glycinate",C18H21ClN2O4S,[1216744-19-2],396.89,Nuclear Receptors,Rev-Erb Receptors,Agonist,Selective Rev-Erb? agonist,1,CC(C)(C)OC(=O)CN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,574,1
3667,O=C(C3COC(C=CC=C4)=C4O3)NC1=CC=C(C2=CNN=C2)C=C1OCCN(C)C.Cl.Cl,SR 3677 dihydrochloride,90255168,"N-[2-[2-(Dimethylamino)ethoxy]-4-(1H-pyrazol-4-yl)phenyl-2,3-dihydro-1,4-benzodioxin-2-carboxamide dihydrochloride",C22H24N4O4.2HCl,[1781628-88-3],490.38,Enzymes,Rho-kinases,Inhibitor,"Potent, selective Rho-kinase (ROCK) inhibitor",2,CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1,387,1
3670,NC3=NC2=C(S3)C=CC1=CC=CC=C12,SKA 31,94880,"Naphtho[1,2-d]thiazol-2-ylamine",C11H8N2S,[40172-65-4],200.26,Ion Channels,Ca2+-Activated Potassium Channels,Activator,Activator of KCa3.1 and KCa2 channels,1,Nc1nc2c(ccc3ccccc32)s1,777,1
3679,O=C(C4=CC=C(Cl)C=C4)NC2=C(C3=CC=CS3)N=C1C=CC=CN12,DS2,979718,"4-Chloro-N-[2-(2-thienyl)imidazo[1,2-a]pyridin-3-yl]benzamide",C18H12ClN3OS,[374084-31-8],358.33,Ion Channels,GABAA Receptors,Modulator,Positive allosteric modulator of GABAA receptors; displays subunit selectivity,2,O=C(Nc1c(-c2cccs2)nc2ccccn12)c1ccc(Cl)cc1,151,1
3683,ClC(C(Cl)=C4)=CC=C4CO/N=C/C1=C(C3=CC=C(Cl)C=C3)N=C2N1C=CS2,CITCO,9600409,"6-(4-Chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime",C19H12Cl3N3OS,[338404-52-7],436.74,Nuclear Receptors,Constitutive Androstane Receptor,Agonist,Selective CAR agonist,2,Clc1ccc(-c2nc3sccn3c2/C=N/OCc2ccc(Cl)c(Cl)c2)cc1,635,1
3685,[H][C@@]23CCC1=CC(CC[C@@](C)1[C@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3CC[C@@H]4[C@@](CO)=O)=O,Corticosterone,5753,"(11?)-11,21-Dihydroxypregn-4-ene-3,20-dione",C21H30O4,[50-22-6],346.46,Nuclear Receptors,Glucocorticoid Receptor,Agonist,Endogenous glucocorticoid,2,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO,8,0
3694,[Na+].OC1=CC(=NC2=CC=CC=C12)C([O-])=O,Kynurenic acid sodium salt,52974250,4-Hydroxyquinoline-2-carboxylic acid sodium salt,C10H6NNaO3,[2439-02-3],233.67,Ion Channels,Non-selective Ionotropic Glutamate,Antagonist,Sodium salt of kynurenic acid (Cat. No. 0223),2,O=C([O-])c1cc(O)c2ccccc2n1,156,0
3695,[Na+].NC(C([O-])=O)C1=CC(O)=CC=C1Cl,CHPG Sodium salt,52974246,(RS)-2-Chloro-5-hydroxyphenylglycine sodium salt,C8H7ClNNaO3,[1303993-73-8],237.1,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Agonist,Selective mGlu5 agonist; sodium salt of CHPG (Cat. No. 1049),3,NC(C(=O)[O-])c1cc(O)ccc1Cl,593,1
3701,CC(C)(C)C(NC(CC3=CC(OC)=C(OC)C=C3)=O)N/C(NC2=CC=CC1=NC=CC=C12)=N/C#N,A 740003,11351968,"N-[1-[[(Cyanoamino)(5-quinolinylamino)methylene]amino]-2,2-dimethylpropyl]-3,4-dimethoxybenzeneacetamide",C26H30N6O3,[861393-28-4],474.55,Ion Channels,P2X Receptors,Antagonist,Potent and selective P2X7 antagonist,3,COc1ccc(CC(=O)NC(N/C(=N/C#N)Nc2cccc3ncccc23)C(C)(C)C)cc1OC,733,1
3706,NC1=NNC2=C1C=C(C3=C(C=CC=C5)N5N=C3C4=CC=CC=C4)N=N2,FR 180204,11493598,"5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine",C18H13N7,[865362-74-9],331.84,Enzymes,ERK,Inhibitor,Selective ERK inhibitor,3,Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12,256,1
3710,OCC1(COC)C(C2CCN1CC2)=O,PRIMA-1MET,52918385,2-(Hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one,C10H17NO3,[5291-32-7],199.25,Cell biology,p53,Other,Restores mutant p53 activity,6,COCC1(CO)C(=O)C2CCN1CC2,42,1
3718,ClC(C=C2)=CC=C2COC1=C(C(N[C@@H](C)C3=CC=CC=C3)=O)SC=C1,AS 1949490,44473434,3-[(4-Chlorophenyl)methoxy]-N-[(1S)-1-phenylethyl]thiophene-2-carboxamide,C20H18ClNO2S,[1203680-76-5],371.88,Enzymes,Inositol Phosphatases,Inhibitor,SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2) inhibitor,1,C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1,604,1
3721,O=C(NC5(C(O)=O)C4CC(CC5C6)CC6C4)C2=NN(C(C3=C(OC)C=CC=C3OC)=C2)C1=C(C=CC(Cl)=C7)C7=NC=C1,SR 48692,119192,"2-[[[1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]-tricyclo[3.3.1.13,7]decane-2-carboxylic acid",C32H31ClN4O5,[146362-70-1],588.87,7-TM Receptors,Neurotensin Receptors,Antagonist,Selective non-peptide NTS1 antagonist,1,COc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12,353,1
3722,O=C(NCCCN5CCOCC5)C2=C1N=C(C4=CC=CC=C4)C=C(C3=CC=CC=C3)N1N=C2,Reversan,2298706,"N-[3-(4-Morpholinyl)propyl]-5,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamide",C26H27N5O2,[313397-13-6],441.52,Transporters,Multidrug Transporters,Inhibitor,Selective MRP1 and P-gp inhibitor,1,O=C(NCCCN1CCOCC1)c1cnn2c(-c3ccccc3)cc(-c3ccccc3)nc12,314,0
3724,ClC1=CC=CC(Cl)=C1C3=CC2=CN=C(NCCCCN(CC)CC)N=C2N=C3NC(NC(C)(C)C)=O,PD 161570,5328135,"N-[6-(2,6-Dichlorophenyl)-2-[[4-(diethylamino)butyl]amino]pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea",C26H35Cl2N7O,[192705-80-9],532.51,Enzyme-Linked Receptors,FGFR,Inhibitor,Selective FGFR inhibitor,1,CCN(CC)CCCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(NC(=O)NC(C)(C)C)nc2n1,824,0
3726,O=C1CC(C2=CC=C(C(F)(F)F)C=C2)C(C(NC3=C(F)C=C(NN=C4)C4=C3)=O)=C(C)N1,GSK 429286,11373846,"4-[4-(Trifluoromethyl)phenyl]-N-(6-Fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide",C21H16F4N4O2,[864082-47-3],436.87,Enzymes,Rho-kinases,Inhibitor,Selective Rho-kinase (ROCK) inhibitor,3,CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1,502,1
3739,O=C(CCC(O)=O)OC(CN(C)C)COC1=CC=CC=C1CCC2=CC(OC)=CC=C2.Cl,Sarpogrelate hydrochloride,444005,Succinic acid mono-(1-dimethylaminomethyl-2-(2-[2-(3-methoxyphenyl)ethyl]phenoxy)ethyl) ester hydrochloride,C24H31NO6.HCl,[135159-51-2],465.97,7-TM Receptors,5-HT2A Receptors,Antagonist,Selective 5-HT2A antagonist,1,COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,421,0
3742,CC1=NC(C2=NNC=C2C4=NC3=CC=CN=C3C=C4)=CC=C1,RepSox,449054,"2-(3-(6-Methylpyridine-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine",C17H13N5,[446859-33-2],287.32,Enzyme-Linked Receptors,TGF-beta Receptors,Inhibitor,Potent and selective inhibitor of TGF-?RI,4,Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1,741,0
3743,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1.Cl,BF 2649 hydrochloride,11551689,1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidine hydrochloride,C17H26ClNO.HCl,[903576-44-3],332.31,7-TM Receptors,Histamine H3 Receptors,Inverse Agonist,Potent and selective H3 inverse agonist,2,Clc1ccc(CCCOCCCN2CCCCC2)cc1,290,1
3745,ClC1=CC=C(S(N2CCN(CC3=CC=CC=C3)CC2)(=O)=O)C([N+]([O-])=O)=C1,RN 1747,5068295,1-(4-Chloro-2-nitrophenyl)sulfonyl-4-benzylpiperazine,C17H18ClN3O4S,[1024448-59-6],395.87,Ion Channels,TRPV,Agonist,Selective TRPV4 agonist,2,O=[N+]([O-])c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1,305,0
3746,CC(C)NCCN(C(C)C)S(C1=C(Cl)C=C(Cl)C=C1)(=O)=O,RN 1734,3601086,"2,4-Dichloro-N-isopropyl-N-(2-isopropylaminoethyl)benzenesulfonamide",C14H22Cl2N2O2S,[946387-07-1],353.31,Ion Channels,TRPV,Antagonist,Selective TRPV4 antagonist,2,CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl,570,1
3748,OC1=C(CSCC2)C2=NC(C3=CC=C(C(F)(F)F)C=C3)=N1,XAV 939,2726824,"3,5,7,8-Tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one",C14H11F3N2OS,[284028-89-3],312.31,Enzymes,Tankyrase,Inhibitor,Potent tankyrase inhibitor,5,Oc1nc(-c2ccc(C(F)(F)F)cc2)nc2c1CSCC2,554,1
3753,NC1=NC(N4C[C@H](N)CC4)=C2C(C(C=CC=C3)=C3CCC2)=N1.Cl.Cl,A 943931 dihydrochloride,56972240,"4-((3R)-3-amino-pyrrolidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2-ylamine",C17H21N5.2HCl,[1227675-50-4],386.33,7-TM Receptors,Histamine H4 Receptors,Antagonist,Potent and selective H4 antagonist,1,Nc1nc2c(c(N3CC[C@@H](N)C3)n1)CCCc1ccccc1-2,816,1
3754,OC(C(O)C(O)=O)C(O)=O.C1(C=C([C@H]4CNC[C@@H]3C4)C3=C2)=C2N=CC=N1,Varenicline tartrate,5310966,"7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine tartrate",C13H13N3.C4H6O6,[375815-87-5],361.37,Ion Channels,Nicotinic (a4b2) Receptors,Agonist,Selective ?4?2 nAChR partial agonist; orally active,3,c1cnc2cc3c(cc2n1)[C@H]1CNC[C@@H]3C1,858,1
3756,O=C(C4CCC(F)(F)CC4)N[C@@H](CCN2C3CCC2CC(N5C(C)=NN=C5C(C)C)C3)C1=CC=CC=C1,Maraviroc,483407,"4,4-Difluoro-N-{(1S)-3-[3-(3-isopropyl- 5-methyl-4H-1,2,4-triazol-4-yl)- 8-azabicyclo[3.2.1]oct-8-yl]-1- phenylpropyl}cyclohexanecarboxamide",C29H41F2N5O,[376348-65-1],513.67,7-TM Receptors,Chemokine CC Receptors,Antagonist,Selective CCR5 antagonist,1,Cc1nnc(C(C)C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,176,1
3757,CN(CCC2=CC=C(NS(=O)(C)=O)C=C2)CCOC1=CC=C(NS(=O)(C)=O)C=C1,Dofetilide,71329,1-(4-Methanesulphonamidophenoxy)-2-[N-(4-methanesulphonamidophenethyl)-N-methylamino]ethane,C19H27N3O5S2,[115256-11-6],441.56,Ion Channels,Voltage-Gated Potassium Channels,Blocker,KV11.1 (hERG) channel blocker; inhibits rapid delayed rectifier K+ current (IKr),1,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,436,1
3758,ClC3=CC2=C(C=C3)OC1=CC=CC=C1CN2C(NNC(CCC4=CC=NC=C4)=O)=O.Cl,SC 51089,132748,"8-Chlorodibenz(Z)[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[1-oxo-3-(4-pyridinyl)propyl]hydrazide hydrochloride",C22H19ClN4O3.HCl,[146033-02-5],477.35,7-TM Receptors,Prostanoid Receptors,Antagonist,Selective EP1 receptor antagonist,1,O=C(CCc1ccncc1)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc21,640,1
3761,OC1=C([C@@H]([C@]2=CC=CC=C2)CCN(C(C)C)C(C)C)C=C(C)C=C1.OC([C@H](O)[C@@H](O)C(O)=O)=O,Tolterodine L-tartrate,443878,"2-[(1R)-3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol (2R,3R)-2,3-dihydroxybutanedioate",C22H31NO.C4H6O6,[124937-52-6 ],475.57,7-TM Receptors,Non-selective Muscarinics,Antagonist,"Potent, non-selective muscarinic receptor antagonist",1,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,180,1
3768,O=C(NCCN(CC)CC)C1=C(C)NC(/C=C2\C(NC3=C2C=C(F)C=C3)=O)=C1C.OC(C[C@H](O)C(O)=O)=O,Sunitinib malate,6456015,"N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioate salt",C22H27FN4O2.C4H6O5,[341031-54-7],532.56,Enzyme-Linked Receptors,VEGFR,Inhibitor,"Potent VEGFR, PDGFR? and KIT inhibitor",1,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,769,0
3771,[H][C@@]1(O[C@@H]([C@H](C)[C@@H](O[C@@]3([H])[C@H](O)[C@@H](N(C)C)C[C@@H](C)O3)[C@](C)(O)C[C@@H](C)C2)[C@@H](C)C(O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)N2C)=O)O[C@@H](C)[C@H](O)[C@](C)(OC)C1,Azithromycin,447043,"13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-?-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one",C38H72N2O12,[83905-01-5],785.01,Cell biology,"DNA, RNA and Protein Synthesis",Other,Antibiotic; inhibits 50S ribosomal subunit formation and elongation at transpeptidation,1,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,17,1
3784,O=C(O)C(O)(CC(O)=O)CC(O)=O.CN1CCN(S(C2=CC=C(OCC)C(C(NC4=C3N(C)N=C4CCC)=NC3=O)=C2)(=O)=O)CC1,Sildenafil citrate,62853,"1-[[3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate",C22H30N6O4S.C6H8O7,[171599-83-0],671.2,Enzymes,Phosphodiesterases,Inhibitor,Potent PDE5 inhibitor; orally active,1,CCCc1nn(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)[nH]c12,669,1
3785,CN(C1=NC(NC4=CC=C(OCCN(CC)CC)C=C4)=NC=C1C=C2C3=C(Cl)C=CC=C3Cl)C2=O.Cl.Cl,PD 166285 dihydrochloride,9916391,"6-(2,6-Dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one dihydrochloride",C26H27Cl2N5O2.2HCl,[212391-63-4],612.37,Enzymes,Src Kinases,Inhibitor,"Potent Src inhibitor; also inhibits FGFR1, PDGFR? and Wee1",1,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,404,0
3786,CC(C=C3)=CC=C3C1=CC(C(F)(F)F)=NN1C2=CC=C(S(=O)(N)=O)C=C2,Celecoxib,2662,4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide,C17H14F3N3O2S,[169590-42-5],381.37,Enzymes,Cyclooxygenase,Inhibitor,Selective cyclooxygenase-2 (COX-2) inhibitor,1,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,682,1
3793,O=C(NC3=C(C(O)=O)C=CC=C3)N1CCC(C2=C(C(F)(F)F)C=CC=C2)CC1,A 1120,25138295,2-(4-(2-(Trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoic acid,C20H19F3N2O3,[1152782-19-8],392.37,Other Pharmacology,Miscellaneous Compounds,Other,High affinity retinol-binding protein 4 (RBP4) ligand,1,O=C(O)c1ccccc1NC(=O)N1CCC(c2ccccc2C(F)(F)F)CC1,534,0
3798,[K+].CCCCC1=NC(Cl)=C(CO)N1CC2=CC=C(C3=CC=CC=C3C(N=N4)=NN4)C=C2,Losartan potassium,11476710,"2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol potassium salt",C22H22ClKN6O,[124750-99-8],479.02,7-TM Receptors,Angiotensin AT1 Receptors,Antagonist,"Selective, non-peptide AT1 antagonist",3,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,664,0
3800,COCCOCOC(C(C3(CC5C4)CC(C5)CC4C3)=C2)=CC1=C2C=C(C6=CC=C(C(O)=O)C=C6)C=C1,CD 2665,216241,"4-[6-[(2-Methoxyethoxy)methoxy]-7-tricyclo[3.3.1.13,7]dec-1-yl-2-naphthalenyl)benzoic acid",C31H34O5,[170355-78-9],486.6,Nuclear Receptors,Retinoic Acid Receptors,Antagonist,Selective RAR?/? antagonist,3,COCCOCOc1cc2ccc(-c3ccc(C(=O)O)cc3)cc2cc1C12CC3CC(CC(C3)C1)C2,458,0
3803,NC1=NC=NC2=C1N=C(NCC5=CC=C(Cl)C(Cl)=C5)N2[C@@H]3O[C@H](COCC4=CC=C(C#N)C=C4)[C@@H](O)[C@H]3O,VER 155008,25195348,"5'-O-[(4-Cyanophenyl)methyl]-8-[[(3,4-dichlorophenyl)methyl]amino]-adenosine",C25H23Cl2N7O4,[1134156-31-2],560.9,Cell biology,Hsp70,Inhibitor,Hsp70 inhibitor,2,N#Cc1ccc(COC[C@H]2O[C@@H](n3c(NCc4ccc(Cl)c(Cl)c4)nc4c(N)ncnc43)[C@H](O)[C@@H]2O)cc1,844,1
3815,ClC(C=CC=C2)=C2CCCN[C@H](C)C1=CC=CC(OC)=C1.Cl,R 568 hydrochloride,158796,2-Chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-benzenepropanamine hydrochloride,C18H22ClNO.HCl,[177172-49-5],340.29,7-TM Receptors,Calcium-Sensing Receptor,Modulator,Positive allosteric modulator of human calcium-sensing receptor (CaSR),1,COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1,423,1
3817,CC(C)(C)C2=C1C=NN=C(C4=NOC(C)=C4)N1N=C2OCC3=NC=NN3C,MRK 016,6918583,"3-(1,1-Dimethylethyl)-7-(5-methyl-3-isoxazolyl)-2-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-pyrazolo[1,5-d][1,2,4]triazine",C17H20N8O2,[342652-67-9],368.39,Ion Channels,GABAA Receptors,Inverse Agonist,?5-selective GABAA inverse agonist,3,Cc1cc(-c2nncc3c(C(C)(C)C)c(OCc4ncnn4C)nn23)no1,859,0
3822,CC1(C)C2=C(C=C(C5(SCCS5)C3=CC(C=CC(C(O)=O)=C4)=C4C=C3)C=C2)C(C)(C)CC1,MM 11253,10389639,"6-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,3-dithiolan-2-yl]-2-naphthalenecarboxylic acid",C28H30O2S2,[345952-44-5],462.67,Nuclear Receptors,Retinoic Acid Receptors,Antagonist,RAR?-selective antagonist,2,CC1(C)CCC(C)(C)c2cc(C3(c4ccc5cc(C(=O)O)ccc5c4)SCCS3)ccc21,456,0
3823,CC(C)C1=C2C(C(C3=CC=CC=C3)=CC(C4=CC=C(C5=CC=C(C(O)=O)C=C5)N4)=N2)=CC=C1,ER 50891,10094345,4-[5-[8-(1-Methylethyl)-4-phenyl-2-quinolinyl]-1H-pyrrolo-2-benzoic acid,C29H24N2O2,[187400-85-7],437.01,Nuclear Receptors,Retinoic Acid Receptors,Antagonist,Selective RAR? antagonist,1,CC(C)c1cccc2c(-c3ccccc3)cc(-c3ccc(-c4ccc(C(=O)O)cc4)[nH]3)nc12,253,1
3824,CC(CCC(C)4C)(C)C1=C4C=C(C=CC(C3=CC(C(O)=O)=CS3)=C2)C2=C1,CD 2314,15293210,"5-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-3-thiophenecarboxylic acid",C23H24O2S,[170355-37-0],364.5,Nuclear Receptors,Retinoic Acid Receptors,Agonist,Selective RAR? agonist,3,CC1(C)CCC(C)(C)c2cc3cc(-c4cc(C(=O)O)cs4)ccc3cc21,456,0
3835,FC(F)(F)C(O)=O.OC1=CC=CC(OC2=C3C(NC(C4=CC=CC(N)=C4)=C3)=NC=N2)=C1.FC(F)(F)C(O)=O,TWS 119,90488884,"3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenol ditrifluoroacetate",C18H14N4O2.2CF3CO2H,[1507095-58-0],546.38,Enzymes,Glycogen Synthase Kinase 3,Inhibitor,GSK-3? inhibitor; induces neuronal differentiation in ESCs,2,Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1,812,1
3836,O=C(OC6=CC=C([N+]([O-])=O)C=C6)N(CC5)CCC5C(C2=CC=C(OCO3)C3=C2)(O)C1=CC(OCO4)=C4C=C1,JZL 184,25021165,"4-[Bis(1,3-benzodioxol-5-yl)hydroxymethyl]-1-piperidinecarboxylic acid 4-nitrophenyl ester",C27H24N2O9,[1101854-58-3],520.49,Enzymes,MAGL,Inhibitor,Potent MAGL inhibitor,4,O=C(Oc1ccc([N+](=O)[O-])cc1)N1CCC(C(O)(c2ccc3c(c2)OCO3)c2ccc3c(c2)OCO3)CC1,750,0
3837,CC1=NOC(=C1)C(=CNC1=CC=C(Cl)C=C1)C(=O)NC1=CC=C(Cl)C=C1,CCMI,67042344,[N-(4-Chlorophenyl)]-?-[(4-chlorophenyl)-aminomethylene]-3-methyl-5-isoxazoleacetamide,C19H15Cl2N3O2,[917837-54-8],388.25,Ion Channels,Nicotinic (a7) Receptors,Modulator,Positive allosteric modulator of ?7 nAChRs,1,Cc1cc(C(=CNc2ccc(Cl)cc2)C(=O)Nc2ccc(Cl)cc2)on1,598,1
3842,O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N2C(N=C(N)N=C2)=O,5-Azacytidine,9444,"4-Amino-1-?-D-ribofuranosyl-1,3,5-triazin-2(1H)-one",C8H12N4O5,[320-67-2],244.2,Enzymes,DNA Methyltransferases,Inhibitor,DNA methyltransferase inhibitor,2,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,841,0
3843,CC(C=C4)=CC=C4C1=CN(C2=C(S3)CCCC2)C3=N1.Br,Cyclic Pifithrin-alpha hydrobromide,11515812,"5,6,7,8-Tetrahydro-2-(4-methylphenyl)-imidazo[2,1-b]benzothiazole hydrobromide",C16H16N2S.HBr,[511296-88-1],349.29,Cell biology,p53,Inhibitor,p53 inhibitor,2,Cc1ccc(-c2cn3c4c(sc3n2)CCCC4)cc1,650,1
3852,N[C@H]1[C@H]([C@]2=CC=CC=C2)C1.Cl,Tranylcypromine hydrochloride,2723716,(�)-trans-2-Phenylcyclopropylamine hydrochloride,C9H11N.HCl,[1986-47-6],169.65,Enzymes,Histone Demethylases,Inhibitor,Irreversible inhibitor of LSD1; also inhibits MAO,3,N[C@@H]1C[C@H]1c1ccccc1,134,1
3863,O=C2C1=CC(F)=C(N4C[C@@]([C@H]5N)([H])[C@@]5([H])C4)N=C1N(C3=C(F)C=C(F)C=C3)C=C2C(O)=O.CS(=O)(O)=O,Trovafloxacin mesylate,62960,"7-[(1?,5?,6?)-6-Amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid mesylate",C20H15F3N4O3.CH3SO3H,[147059-75-4],512.46,Cell biology,"DNA, RNA and Protein Synthesis",Inhibitor,Antibiotic; inhibits bacterial DNA synthesis,1,N[C@H]1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12,524,1
3865,NC(N2C1=CC=CC=C1C(O)CC3=C2C=CC=C3)=O,Licarbazepine,114709,"10,11-Dihydro-10-hydroxy-5H-dibenz(Z)[b,f]azepin-5-carboxamide",C15H14N2O2,[29331-92-8],254.28,Ion Channels,Voltage-gated Sodium Channels,Blocker,Active metabolite of oxcarbazepine (Cat. No. 3864),1,NC(=O)N1c2ccccc2CC(O)c2ccccc21,145,1
3866,CN2CCC1=CC=CC(Cl)=C1CC2.Cl,SKF 86466 hydrochloride,10220250,"6-Chloro-N-methyl-2,3,4,5-tetrahydro-1-H-3-benzazepine hydrochloride",C11H14ClN.HCl,[86129-54-6],232.15,7-TM Receptors,Adrenergic Alpha-2 Receptors,Antagonist,Potent and selective ?2 antagonist,1,CN1CCc2cccc(Cl)c2CC1,141,0
3869,O=S(C)C(C=C3)=CC=C3C2=COC1=CC=C(C4=NN=C(C)O4)C=C12,TCS 2002,24855958,"2-Methyl-5-[3-[4-(methylsulfinyl)phenyl]-5-benzofuranyl]-1,3,4-oxadiazole",C18H14N2O3S,[1005201-24-0],338.38,Enzymes,Glycogen Synthase Kinase 3,Inhibitor,Potent GSK-3? inhibitor,1,Cc1nnc(-c2ccc3occ(-c4ccc(S(C)=O)cc4)c3c2)o1,802,1
3872,O=C1C=C(CN4CCOCC4)OC=C1OCCCCCSC3=CC=NC2=CC(C(F)(F)F)=CC=C23.Cl.Cl,EHT 1864,9938202,5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-(morpholinomethyl)-4H-pyran-4-one dihydrochloride,C25H27F3N2O4S.2HCl,[754240-09-0],599.49,Enzymes,Rho,Inhibitor,Potent Rac family inhibitor,2,O=c1cc(CN2CCOCC2)occ1OCCCCCSc1ccnc2cc(C(F)(F)F)ccc12,696,1
3875,ClC1=CC=CN=C1N2CCN(C(NC3=CC=C(C(C)(C)C)C=C3)=O)CC2,BCTC,9929425,"4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide",C20H25ClN4O,[393514-24-4],372.89,Ion Channels,TRPV,Antagonist,TRPV1 antagonist,1,CC(C)(C)c1ccc(NC(=O)N2CCN(c3ncccc3Cl)CC2)cc1,470,0
3877,O=C(NO)C3=CC1=C(C=C3)NC(C(CCCC2=CC=CC=C2)=N1)=O,TCS 2210,44607172,"1,2-Dihydro-N-hydroxy-2-oxo-3-(3-phenylpropyl)-6-quinoxalinecarboxamide",C18H17N3O3,[1201916-31-5],323.35,Cell biology,Neural Stem Cells,Other,Inducer of neuronal differentiation in MSCs,1,O=C(NO)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1,210,0
3887,ClC(C(Cl)=CC=C4)=C4N(CC3)CCN3C/C=C/CNC(C1=CC=C(C2=NC=CC=C2)C=C1)=O.Cl.Cl,PG 01037 dihydrochloride,90488894,"N-[(2E)-4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]-2-buten-1-yl]-4-(2-pyridyl)-benzamide dihydrochloride",C26H26Cl2N4O.2HCl,[675599-62-9],576.86,7-TM Receptors,D3 Receptors,Antagonist,Selective D3 antagonist,2,O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1,275,0
3891,O=[N+](C(C=C2)=CC=C2CN1CCOCCOCCN(CC3=CC=C([N+]([O-])=O)C=C3)CCOCC1)[O-].Cl.Cl,VU 590 dihydrochloride,71433535,"7,13-Bis[(4-nitrophenyl)methyl]-1,4,10-trioxa-7,13-diazacyclopentadecane dihydrochloride",C24H32N4O7.2HCl,[1783987-83-6],597.49,Ion Channels,Inward rectifier Potassium Channels,Blocker,Inhibitor of Kir1.1 (ROMK) and Kir7.1,1,O=[N+]([O-])c1ccc(CN2CCOCCOCCN(Cc3ccc([N+](=O)[O-])cc3)CCOCC2)cc1,306,1
3895,ClC1=C2C(C(C(N2)=O)=NO)=CC=C1Cl,NS 309,11637204,"6,7-Dichloro-1H-indole-2,3-dione 3-oxime",C8H4Cl2N2O2,[18711-16-5],231.04,Ion Channels,Ca2+-Activated Potassium Channels,Activator,Positive modulator of KCa2 and KCa3.1 channels,2,O=C1Nc2c(ccc(Cl)c2Cl)C1=NO,768,1
3896,CCCN(CCC3=CC=CS3)[C@H]2CCC1=C(O)C=CC=C1C2.Cl,Rotigotine hydrochloride,59226,"(6S)-5,6,7,8-Tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol hydrochloride",C19H25NOS.HCl,[125572-93-2],351.93,7-TM Receptors,D2 Receptors,Agonist,D2 and D3 agonist,3,CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1,120,0
3898,S=C(N2CCC(C(C4=CC=CC=C4)(O)C3=CC=CC=C3)CC2)NC1=CC=C(OCC)C=C1,SF 11,2936384,N-(4-Ethoxyphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinecarbothioamide,C27H30N2O2S,[443292-81-7],446.6,7-TM Receptors,NPY Receptors,Antagonist,NPY Y2 receptor antagonist,1,CCOc1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,300,1
3900,O=C(N2CCOC[C@H]2[C@@](N3CCC(CC(O)=O)CC3)=O)CC1=CC=C(NC(NC4=C(C)C=CC=C4)=O)C=C1,TCS 2314,11226207,1-[[(3S)-4-[2-[4-[[[(2-Methylphenyl)amino]carbonyl]amino]phenyl]acety]l-3-morpholinyl]carbonyl]-4-piperidinediacetic acid,C28H34N4O6,[317353-73-4],540.61,Enzyme-Linked Receptors,Integrins,Inhibitor,?4?1 (VLA-4) antagonist,1,Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(=O)O)CC2)cc1,202,1
3904,O=S(C2=CN(CCN(C)C)C1=NC=CC=C12)(C3=CC=CC(F)=C3)=O.Cl.Cl,WAY 208466 dihydrochloride,22028182,"3-[(-3-Fluorophenyl)sulfonyl]-N,N-dimethyl-1H-pyrrolo[2,3-b]pyridine-1-ethanamine dihydrochloride",C17H18FN3O2S.2HCl,[1207064-61-6],429.34,7-TM Receptors,5-HT6 Receptors,Agonist,Selective 5-HT6 agonist,4,CN(C)CCn1cc(S(=O)(=O)c2cccc(F)c2)c2cccnc21,727,1
3911,O=S2(C1=CC=CC=C1N(CCC3)[C@@]3([H])N2)=O,S 18986,637863,"(3aS)-2,3,3a,4-Tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine-5,5-dioxide",C10H12N2O2S,[175340-20-2],224.28,Ion Channels,AMPA Receptors,Modulator,Positive allosteric modulator of AMPA receptors,1,O=S1(=O)N[C@H]2CCCN2c2ccccc21,35,1
3912,CC1(C)C2=C(C=C(N(C)C(C=CC([N+]([O-])=O)=C5)=C5N=C3C4=CC=C(C(O)=O)C=C4)C3=C2)C(C)(C)CC1,HX 531,11755040,"4-(7,8,9,10-Tetrahydro-5,7,7,10.10-pentamethyl-2-nitro-5H-benzo[b]naphtho[2,3-e][1,4]-diazepin-12-yl)-benzoic acid",C29H29N3O4,[188844-34-0],483.56,Nuclear Receptors,Retinoid X Receptor,Antagonist,Potent RXR antagonist,3,CN1c2ccc([N+](=O)[O-])cc2N=C(c2ccc(C(=O)O)cc2)c2cc3c(cc21)C(C)(C)CCC3(C)C,455,0
3914,NC1=C2C(N([C@H]5CC[C@H](N6CCN(C)CC6)CC5)C=C2C3=CC=C(OC4=CC=CC=C4)C=C3)=NC=N1.Cl.Cl.Cl,A 419259 trihydrochloride,76848881,"7-[trans-4-(4-Methyl-1-piperazinyl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-Pyrrolo[2,3-d]pyrimidin-4-amine trihydrochloride",C29H34N6O.3HCl,[1435934-25-0],646.06,Enzymes,Src Kinases,Inhibitor,Inhibitor of Src family kinases,2,CN1CCN([C@H]2CC[C@H](n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1,832,0
3915,O=C2N=CN1N=C(SC4=CC=C(F)C=C4F)C=CC1=C2C3=C(Cl)C=CC=C3Cl,VX 745,3038525,"5-(2,6-Dichlorophenyl)-2-[2,4-difluorophenyl)thio]-6H-pyrimido[1,6-b]pyridazin-6-one",C19H9Cl2F2N3OS,[209410-46-8],436.26,Enzymes,p38,Inhibitor,Potent and selective p38? inhibitor,1,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,522,1
3916,NC(N(C3=C(F)C=CC=C3F)C1=CC=C(C(N)=O)C(C2=C(F)C=C(F)C=C2)=N1)=O,VX 702,10341154,"6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide",C19H12F4N4O2,[745833-23-2],422.34,Enzymes,p38,Inhibitor,Orally active p38? and p38? inhibitor,1,NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F,529,1
3919,ClC(C=C3)=CC=C3C1=CC(C(F)(F)F)=NN1C2=CC=C(S(=O)(N)=O)C=C2,SC 236,9865808,4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide,C16H11ClF3N3O2S,[170569-86-5],401.79,Enzymes,Cyclooxygenase,Inhibitor,Selective cyclooxygenase-2 (COX-2) inhibitor,1,NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(Cl)cc2)cc1,682,0
3920,O=C1N(C)C(NC[C@@H](N)CC5=CC=CC=C5)=NC(C4=CC=NC=C4)=C1C3=CC2=C(C=C3)C=CC=C2,AMG 548,11167112,2-[[(2S)-2-Amino-3-phenylpropyl]amino]-3-methyl-5-(2-naphthalenyl)-6-(4-pyridinyl)-4(3H)-pyrimidinone,C29H27N5O,[864249-60-5],470.57,Enzymes,p38,Inhibitor,Potent and selective p38? inhibitor,1,Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O,173,1
3924,O=C2N(C3CCN(C(C4=CC=C(OCCCNC(C)=O)C=C4)=O)CC3)C1=CC=CC=C1CC2,OPC 21268,114904,"N-[3-[4-[[4-(3,4-Dihydro-2-oxo-1(2H)quinolinyl)-1-piperidinyl]carbonyl]phenoxy]propyl]-acetamide",C26H31N3O4,[131631-89-5],449.54,7-TM Receptors,Vasopressin Receptors,Antagonist,Orally active vasopressin V1 antagonist,1,CC(=O)NCCCOc1ccc(C(=O)N2CCC(N3C(=O)CCc4ccccc43)CC2)cc1,277,1
3937,CCN2C1=NC=NC(N)=C1N=C2OCC,ANR 94,11805896,8-Ethoxy-9-ethyl-9H-purin-6-amine,C9H13N5O,[634924-89-3],207.23,7-TM Receptors,Adenosine A2A Receptors,Antagonist,Adenosine A2A antagonist,1,CCOc1nc2c(N)ncnc2n1CC,837,1
3938,O=C1C2=C(N=CN2CC(NC3=CC=C(C(C)CC)C=C3)=O)N(C)C(N1C)=O,TCS 5861528,2873523,"2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-[4-(1-methylpropyl)phenyl]acetamide",C19H23N5O3,[332117-28-9],369.42,Ion Channels,TRPA1,Blocker,TRPA1 blocker,1,CCC(C)c1ccc(NC(=O)Cn2cnc3c2c(=O)n(C)c(=O)n3C)cc1,676,0
3939,O=C(C3=C(C)N=NS3)NC1=CC=C(N2N=C(C(F)(F)F)C=C2C(F)(F)F)C=C1,YM 58483,2455,"N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide",C15H9F6N5OS,[223499-30-7],421.32,Ion Channels,Other Calcium Channels,Inhibitor,Inhibitor of SOCE in non-excitable cells,2,Cc1nnsc1C(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2C(F)(F)F)cc1,683,1
3948,OC(C3=CC=CC=C3)(C4=CC=CC=C4)C1CCN(CCCC(O)C2=CC=C(C(C)(C)C)C=C2)CC1,Terfenadine,5405,"?-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol",C32H41NO2,[50679-08-8],476.17,7-TM Receptors,Histamine H1 Receptors,Antagonist,H1 antagonist. Also KV11.1 (hERG) and Kir6 (KATP) channel blocker,1,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,300,0
3959,O=C2C1=CC(OC4=CC=C(F)C=C4)=CC=C1N=C(C)N2C[C@@H]3CN(C(C)C)CCC3.Cl,YIL 781,74889155,6-(4-Fluorophenoxy)-2-methyl-3-[[(3S)-1-(1-methylethyl)-3-piperidinyl]methyl]-4(3H)-quinazolinone,C24H28FN3O2.HCl,[1640226-17-0],459.47,7-TM Receptors,Ghrelin Receptors,Antagonist,Ghrelin receptor (GHS-R1a) antagonist,3,Cc1nc2ccc(Oc3ccc(F)cc3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,450,1
3960,O=C(C3=CC=CC=C3)NC2=NC(C=C1)=C(S2)C=C1NC(C45CC(C6)CC(CC6C5)C4)=O,NVP 231,4096211,"N-[2-(Benzoylamino)-6-benzothiazolyl]tricyclo[3.3.1.13,7]decane-1-carboxamide",C25H25N3O2S,[362003-83-6],440.56,Enzymes,Other Kinases,Inhibitor,"Potent, selective and reversible CerK inhibitor",1,O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1,158,1
3961,O=C(C2=CC=C(Cl)C=C2)NCCS(C1=CC=C(C(F)(F)F)C=N1)(=O)=O,GSK 3787,2800647,4-Chloro-N-[2-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]ethyl]benzamide,C15H12ClF3N2O3S,[188591-46-0],392.78,Nuclear Receptors,PPARdelta Receptors,Antagonist,Potent and selective PPAR? antagonist,3,O=C(NCCS(=O)(=O)c1ccc(C(F)(F)F)cn1)c1ccc(Cl)cc1,318,1
3963,ClC1=CC=C(OC)C=C1NC3=NC=NC2=CC(OCC4CCN(C)CC4)=C(OC)C=C23,AZM 475271,5330175,N-(2-Chloro-5-methoxyphenyl)-6-methoxy,C23H27ClN4O3,[476159-98-5],442.94,Enzymes,Src Kinases,Inhibitor,Src tyrosine kinase inhibitor,1,COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1,391,0
3966,O=C(NCC2=CC=C(OC)C=C2)NC1=NC=C([N+]([O-])=O)S1,AR-A 014418,448014,N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea,C12H12N4O4S,[487021-52-3],308.31,Enzymes,Glycogen Synthase Kinase 3,Inhibitor,Selective GSK-3 inhibitor,1,COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1,466,0
3968,CS(C(C=C3)=CC=C3NC1=NC(C2=CN=C(C)N2C(C)C)=CC=N1)(=O)=O,AZD 5438,16747683,4-[2-Methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine,C18H21N5O2S,[602306-29-6],371.46,Enzymes,Cyclin-dependent Kinase,Inhibitor,"Cdk inhibitor; potently inhibits cdk1, 2, 5 and 9",1,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,406,1
3984,ClC1=CC=[C@@]([C@@H]3[C@@H](N(C(N5CC(NCC5)=O)=O)C(C4=CC=C(OC)C=C4OC(C)C)=N3)[C@]2=CC=C(Cl)C=C2)C=C1,Nutlin-3,16755649,"(�)-4-[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one",C30H30Cl2N4O4,[548472-68-0],585.99,Enzymes,Ubiquitin E3 Ligases,Inhibitor,MDM2 antagonist; inhibits MDM2-p53 interaction,2,COc1ccc(C2=N[C@H](c3ccc(Cl)cc3)[C@H](c3ccc(Cl)cc3)N2C(=O)N2CCNC(=O)C2)c(OC(C)C)c1,583,1
3986,O=C(OCC)COC1=CC=C(CC[C@H](NC[C@H](O)C3=CC(Cl)=CC=C3)C2)C2=C1.Cl,SR 58611A hydrochloride,121888,"[[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]ox]yacetic acid ethyl ester hydrochloride",C22H26ClNO4.HCl,[121524-09-2],440.36,7-TM Receptors,Adrenergic Beta-3 Receptors,Agonist,?3 agonist; displays anxiolytic and antidepressant effects,1,CCOC(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1cccc(Cl)c1)CC2,617,1
3988,O=C3/C(C2=CC(NS(CC)(=O)=O)=CC=C2N3)=C(C4=CC=CC=C4)\NC1=CC=C(CN5CCCCC5)C=C1.Cl,Hesperadin hydrochloride,76968689,"N-[2,3-Dihydro-2-oxo-3-[(3Z)-phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-ethanesulfonamide hydrochloride",C29H32N4O3S.HCl,0,575.64,Enzymes,Aurora Kinases,Inhibitor,Potent Aurora kinase B inhibitor,1,CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2,247,1
3994,CN(C1=CN=C(NC4=CC=C(OC5CCN(C)CC5)C=C4OC)N=C1N2C3CCCC3)C2=O,AZ 3146,56973724,"9-Cyclopentyl-2-[[2-methoxy-4-[(1-methylpiperidin-4-yl)oxy]-phenyl]amino]-7-methyl-7,9-dihydro-8H-purin-8-one",C24H32N6O3,[1124329-14-1],452.55,Enzymes,Monopolar Spindle 1 Kinase,Inhibitor,Potent and selective Mps1 kinase inhibitor,1,COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2c(n1)n(C1CCCC1)c(=O)n2C,401,1
4000,ClC(C=C3)=CC=C3[S@]([C@@]1([C@]2=C(F)C=CC(F)=C2)CC[C@@H](NS(=O)(C(F)(F)F)=O)CC1)(=O)=O,MRK 560,11577204,"N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide",C19H17ClF5NO4S2,[677772-84-8],517.92,Enzymes,Gamma-Secretase,Inhibitor,?-secretase inhibitor; attenuates amyloid plaque deposition,1,O=S(=O)(N[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F,573,1
4005,O=C(C3=C(Cl)C=CC=C3Cl)NCC1=CC(OCO2)=C2C=C1,Alda 1,831629,"N-(1,3-Benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide",C15H11Cl2NO3,[349438-38-6],324.16,Enzymes,Aldehyde Dehydrogenase,Activator,ALDH2 activator; cardioprotective,1,O=C(NCc1ccc2c(c1)OCO2)c1c(Cl)cccc1Cl,749,0
4009,CCN(C(C4=NON=C4N)=N3)C1=C3C=NC(OC2=CC(NC(C5=CC=C(OCCN6CCOCC6)C=C5)=O)=CC=C2)=C1,GSK 269962,16095342,"N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]benzamide",C29H30N8O5,[850664-21-0],570.6,Enzymes,Rho-kinases,Inhibitor,Potent and selective ROCK inhibitor,1,CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21,819,1
4012,O=C(N2C[C@@](CC[N+]3(CC5)CCC(C4=CC=CC=C4)5CC3)([C@]6=CC=C(Cl)C(Cl)=C6)CCC2)CC1=CC(OC(C)C)=CC=C1.[Cl-],SR 140333,108166,"1-[2-[(3S)-3-(3,4-Dichlorophenyl)-1-[2-[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-1-azoniabicyclo[2.2.2]octane chloride",C37H45Cl3N2O2,[153050-21-6],674.14,7-TM Receptors,NK1 Receptor,Antagonist,Potent NK1 antagonist,1,CC(C)Oc1cccc(CC(=O)N2CCC[C@](CC[N+]34CCC(c5ccccc5)(CC3)CC4)(c3ccc(Cl)c(Cl)c3)C2)c1,627,0
4013,FC(C=C3)=CC=[C@@]3[C@@H]1N(CC4=C(CN(C)C)NN=N4)CCO[C@@H]1O[C@H](C)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2.Cl,L 760735,9809076,"5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl-N,N-dimethyl-1H-1,2,3-triazole-4-methanamine hydrochloride",C26H28F7N5O2.HCl,[188923-01-5],620.99,7-TM Receptors,NK1 Receptor,Antagonist,High affinity NK1 antagonist,1,C[C@@H](O[C@H]1OCCN(Cc2nn[nH]c2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,693,1
4021,ClC1=CC=C(NC(C(N3CCN(C)CC3)=O)=C2)C2=C1,JNJ 7777120,4908365,1-[(5-Chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine,C14H16ClN3O,[459168-41-3],277.75,7-TM Receptors,Histamine H4 Receptors,Antagonist,Selective H4 antagonist,2,CN1CCN(C(=O)c2cc3cc(Cl)ccc3[nH]2)CC1,567,0
4032,CCC(C=NC=N2)=C2N1CCN(CC4=NC3=CC(C(F)(F)F)=CC=C3N4)CC1,PF 4708671,51371303,2-[[4-(5-Ethylpyrimidin-4-yl)piperazin-1-yl]methyl]-5-(trifluoromethyl)-1H-benzo[d]imidazole,C19H21F3N6,[1255517-76-0],390.41,Enzymes,RSK,Inhibitor,S6K1 inhibitor,3,CCc1cncnc1N1CCN(Cc2nc3cc(C(F)(F)F)ccc3[nH]2)CC1,697,1
4046,CC1=C(OCCOCCCC)N=C(C2=CC=C(C(O)=O)C(F)=C2)S1,AC 261066,11530459,4-[4-(2-Butoxyethoxy-)-5-methyl-2-thiazolyl]-2-fluorobenzoic acid,C17H20FNO4S,[870773-76-5],353.41,Nuclear Receptors,Retinoic Acid Receptors,Agonist,RAR?2 agonist,1,CCCCOCCOc1nc(-c2ccc(C(=O)O)c(F)c2)sc1C,500,1
4048,CC1=C(C)C(C(C(C5CCCC5)C4)=O)=C4C=C1OCC2=CC(C3=CC=C(C(O)=O)C=C3)=CC=C2,BINA,9868580,"3'-[[(2-Cyclopentyl-2,3-dihydro-6,7-dimethyl-1-oxo-1H-inden-5-yl)oxy]methyl]-[1,1'-biphenyl]-4-carboxylic acid",C30H30O4,[866823-73-6],454.56,7-TM Receptors,Glutamate (Metabotropic) Group II Receptors,Modulator,Selective positive allosteric modulator of mGlu2 receptors,2,Cc1c(OCc2cccc(-c3ccc(C(=O)O)cc3)c2)cc2c(c1C)C(=O)C(C1CCCC1)C2,207,1
4053,O=C(N2CCC(C(CCC)=O)(C4=CC=CC=C4)CC2)[C@H](NC([C@@H](N)CC3=CN=CN3C)=O)CC1=CC=C(OC)C=C1.Cl.Cl,BMS 470539 dihydrochloride,60210130,1-[1-(3-Methyl-L-histidyl-O-methyl-D-tyrosyl)-4-phenyl-4-piperidinyl]-1-butanone dihydrochloride,C32H41N5O4.2HCl,[2341796-82-3],637.12,7-TM Receptors,Melanocortin Receptors,Agonist,"Potent, selective MC1 receptor agonist",1,CCCC(=O)C1(c2ccccc2)CCN(C(=O)[C@@H](Cc2ccc(OC)cc2)NC(=O)[C@@H](N)Cc2cncn2C)CC1,193,1
4056,O[C@@H]1C4=C(C)[C@@H](OC([C@H](O)[C@H]([C@]5=CC=CC=C5)NC(OC(C)(C)C)=O)=O)C[C@@](C(C)4C)(O)[C@@H](OC(C6=CC=CC=C6)=O)[C@@]([C@@]3(OC(C)=O)[C@H](OC3)C[C@@H]2O)([H])[C@]2(C)C1=O,Docetaxel,148124,"[2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-?-[[(1,1-Dimethylethoxy)carbonyl]amino]-?-hydroxy-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester benzenepropanoic acid",C43H53NO14,[114977-28-5],861.93,Cell biology,Microtubules,Other,Microtubule stabilizer,2,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,14,0
4057,Cl.Cl.OCCN1CCN(CCC=C2C3=CC(=CC=C3SC3=C2C=CC=C3)C(F)(F)F)CC1,Flupenthixol dihydrochloride,17011,4-[3-[2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl]-1-piperazineethanol dihydrochloride,C23H25F3N2OS.2HCl,[2413-38-9],507.44,7-TM Receptors,Non-selective Dopamine,Antagonist,Dopamine antagonist,2,OCCN1CCN(CCC=C2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,270,1
4067,O=C2NC1=C(Cl)C=CC(Cl)=C1C(CC(C3=CC=C(OC)C=C3)=O)2O,YK 4-279,44632017,"4,7-Dichloro-1,3-dihydro-3-hydroxy-3-[2-(4-methoxyphenyl)-2-oxoethyl]-2H-indol-2-one",C17H13Cl2NO4,[1037184-44-3],366.2,Cell biology,"DNA, RNA and Protein Synthesis",Inhibitor,Inhibitor of RNA helicase A (RHA),1,COc1ccc(C(=O)CC2(O)C(=O)Nc3c(Cl)ccc(Cl)c32)cc1,410,1
4076,BrC(C=C3)=CC1=C3N(CC(O)CNC4=CC=CC=C4)C2=C1C=C(Br)C=C2,P7C3,2836187,"3,6-Dibromo-?-[(phenylamino)methyl]-9H-carbazole-9-ethanol",C21H18Br2N2O,[301353-96-8],474.19,Enzymes,NAMPT,Activator,NAMPT activator; also proneurogenic and neuroprotective,1,OC(CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc21,883,0
4081,CC1=CC=C(NC3=C2CCNC3CC4=CC=C(OC)C(OC)=C4Cl)C2=C1.Cl,LY 266097 hydrochloride,9953184,"1-[(2-Chloro-3,4-dimethoxyphenyl)methyl]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-b]indole hydrochloride",C21H23ClN2O2.HCl,[172895-39-5],407.33,7-TM Receptors,5-HT2B Receptors,Antagonist,Selective 5-HT2B antagonist,1,COc1ccc(CC2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC,362,0
4083,O=C(NC3=O)C2=C3C1=CC(OC)=C(OC)C=C1C(CC)=N2,3F8,23829003,"5-Ethyl-7,8-dimethoxy-1H-pyrrolo[3,4-c]isoquinoline-1,3(2H)-dione",C15H14N2O4,[159109-11-2],290.78,Enzymes,Glycogen Synthase Kinase 3,Inhibitor,Potent and selective GSK-3? inhibitor,1,CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O,367,1
4085,C=C3[C@H]5[C@]24C1=C(O5)C(O)=CC=C1C[C@@H](N(CC6CC6)CC4)[C@@](O)2CC3.Cl,Nalmefene hydrochloride,5388881,"(5?)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol hydrochloride",C21H25NO3.HCl,[58895-64-0],407.41,7-TM Receptors,Miscellaneous/Non-selective Opioids,Antagonist,Opioid receptor antagonist,2,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,121,1
4089,O[C@@H]1[C@H](NC([C@@H](N)CC4=CC=C(OC)C=C4)=O)[C@@H](CO)O[C@H]1N3C2=NC=NC(N(C)C)=C2N=C3.Cl.Cl,Puromycin dihydrochloride,443311,"3'-[?-Amino-p-methoxyhydrocinnamamido]-3'-deoxy-N,N-dimethyladenosine dihydrochloride",C22H29N7O5.2HCl,[58-58-2],580.46,Cell biology,"DNA, RNA and Protein Synthesis",Inhibitor,Protein synthesis inhibitor,10,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@@H](n3cnc4c(N(C)C)ncnc43)[C@@H]2O)cc1,843,1
4092,CC(OC1=C(C(O)=O)C=CC=C1)=O,Aspirin,2244,2-Acetoxybenzoic acid,C9H8O4,[50-78-2],180.16,Enzymes,Cyclooxygenase,Inhibitor,Cyclooxygenase inhibitor; NSAID,1,CC(=O)Oc1ccccc1C(=O)O,535,1
4093,O=C1CC[C@@]2(C)C(CC[C@]3([H])[C@@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3CC[C@@](O)4[C@@](CO)=O)=C1,Hydrocortisone,5754,"11?,17?,21-Trihydroxypregn-4-ene-3,20-dione",C21H30O5,[50-23-7],362.46,Nuclear Receptors,Glucocorticoid Receptor,Other,Adrenal glucocorticoid; immunosuppressant,3,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,8,1
4102,O=C(OC2)C1=C2C(C)=C(OC)C(C/C=C(C)/CCC(OCCN3CCOCC3)=O)=C1O,Mycophenolate mofetil,5281078,"6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester",C23H31NO7,[128794-94-5],433.49,Enzymes,Other Dehydrogenases,Inhibitor,Inosine monophosphate dehydrogenase inhibitor,2,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,320,0
4105,O=C(C3=CC(Cl)=CC=C3)N2C(COC4=CC=C(OC)C=C4)C1=CC(OC)=C(OC)C=C1CC2,CIQ,4231127,"(3-Chlorophenyl) [3,4-dihydro-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-2(1H)-isoquinolinyl]methanone",C26H26ClNO5,[486427-17-2],467.94,Ion Channels,NMDA Receptors,Modulator,Potentiator of NMDA receptors containing GluN2C/GluN2D,3,COc1ccc(OCC2c3cc(OC)c(OC)cc3CCN2C(=O)c2cccc(Cl)c2)cc1,375,0
4107,O=S(C1=CC=C(C(O)=O)C=C1)(N(CCC)CCC)=O,Probenecid,4911,4-(Dipropylsulfamoyl)benzoic acid,C13H19NO4S,[57-66-9],285.36,Transporters,Multidrug Transporters,Inhibitor,MRP inhibitor,1,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,461,1
4117,CC(C)COCC(N3CCCC3)CN(C2=CC=CC=C2)CC1=CC=CC=C1.Cl,Bepridil hydrochloride,50088,N-Benzyl-N-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)aniline hydrochloride,C24H34N2O.HCl,[68099-86-5],421.02,Ion Channels,Non-selective Cav Channels,Blocker,Non-selective Ca2+ channel blocker; also NCX inhibitor,3,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,192,1
4118,NC1=NON=C1C3=NC2=CN=CC(C(N4CC[C@H](N)C4)=O)=C2N3CC.Cl.Cl,SB 772077B dihydrochloride,69157798,"(3S)-1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinamine dihydrochloride",C15H18N8O2.2HCl,[607373-46-6],424.29,Enzymes,Rho-kinases,Inhibitor,Potent Rho-kinase inhibitor; vasodilator,1,CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21,818,0
4124,O=C(S3)NC(C3CC(C=C2)=CC=C2OCCC1=NC=C(CC)C=C1)=O.Cl,Pioglitazone hydrochloride,60560,"5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochloride",C19H20N2O3S.HCl,[112529-15-4],392.9,Nuclear Receptors,PPARgamma Receptors,Agonist,Selective PPAR? agonist; antidiabetic agent,1,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,439,1
4126,CC(C)OC(C=C3)=CC=C3C(C=N2)=CN1C2=C(C4=CC=NC5=C4C=CC=C5)C=N1,DMH-1,50997747,"4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline",C24H20N4O,[1206711-16-1],380.44,Enzyme-Linked Receptors,BMP and Other Activin Receptors,Inhibitor,Selective ALK2 inhibitor,3,CC(C)Oc1ccc(-c2cnc3c(-c4ccnc5ccccc45)cnn3c2)cc1,743,1
4128,O=C(NC3=O)C(C4=CNC5=C4C=CC=C5)=C3C1=CN(CCC6CCCN6C)C2=CC=CC=C12,Bisindolylmaleimide II,2397,"3-(1H-Indol-3-yl)-4-[1-[2-(1-methyl-2-pyrrolidinyl)ethyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione",C27H26N4O2,[137592-45-1],447.53,Enzymes,Protein Kinase C,Inhibitor,Potent PKC inhibitor; also potent nAChR antagonist,1,CN1CCCC1CCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21,785,0
4132,O=C2C3=C(C=CC=C3)N(C)C1=NC(NC4=C(OCC)C=C(N5CCC(O)CC5)C=C4)=NC=C1N2C,XMD 8-92,46843772,"2-[[2-Ethoxy-4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one",C26H30N6O3,[1234480-50-2],479.05,Enzymes,ERK,Inhibitor,ERK5/BMK1 inhibitor; also BRD4 inhibitor,2,CCOc1cc(N2CCC(O)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C,398,0
4134,O=C(C4=NC(C=CC=C5)=C5N=C4)NC1(CC3C2)CC(C3)CC2C1,NPS 2390,7067728,"N-tricyclo[3.3.1.13,7]dec-1-yl-2-quinoxalinecarboxamide",C19H21N3O,[226878-01-9],307.39,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Antagonist,Group I mGlu antagonist,1,O=C(NC12CC3CC(CC(C3)C1)C2)c1cnc2ccccc2n1,159,1
4141,O=C(C3=CSC=C3)C1=C(C)N=C(NC2=CC=C(F)C=C2)S1,LY 2087101,11964458,[2-[(4-Fluorophenyl)amino]-4-methyl-5-thiazolyl]-3-thienylmethanone,C15H11FN2OS2,[913186-74-0],318.39,Ion Channels,Nicotinic (a7) Receptors,Modulator,"Allosteric potentiator of ?7, ?4?2 and ?4?4 nAChRs",2,Cc1nc(Nc2ccc(F)cc2)sc1C(=O)c1ccsc1,504,1
4143,C[C@H]1N(C3=NC(NC)=NC(C4=CC(NN=C5N)=C5C=C4)=C3)C[C@@H]([C@](NC2CCCCC2)=O)CC1,GSK 2334470,46215815,"(3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide",C25H34N8O,[1227911-45-6],480.61,Enzymes,Phosphoinositide-dependent Kinase 1,Inhibitor,"Highly potent, selective PDPK1 (PDK1) inhibitor",1,CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1,49,1
4144,NC1=NON=C1C(N3CC)=NC2=C3C(CO[C@@H]4CNCCC4)=CN=C2C#CC(C)(C)O,GSK 690693,90488916,"4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol",C21H27N7O3,[937174-76-0],438.99,Enzymes,Akt (Protein Kinase B),Inhibitor,Akt kinase inhibitor. Antitumor,1,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(CO[C@H]3CCCNC3)c21,818,0
4145,N[C@@H](CC(N4CC3=NN=C(C(F)(F)F)N3CC4)=O)CC2=NNC1=C(F)C(F)=CC=C12.OP(O)(O)=O,PK 44 phosphate,90488917,"(3R)-3-Amino-4-(6,7-difluoro-1H-indazol-3-yl)-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-butanone phosphate",C17H16F5N7O.H3PO4,[1017682-66-4],545.36,Enzymes,Dipeptidyl Peptidase IV (DPP-IV),Inhibitor,Potent and selective dipeptidyl peptidase IV (DPP-IV) inhibitor,1,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1n[nH]c2c(F)c(F)ccc12,692,1
4165,O=S(C1=CN=C(OCC)C(C3=NC(C2=NN(CCOC)C(CC)=C2N3)=O)=C1)(N4CCN(CC)CC4)=O.O=S(C5=CC=CC=C5)(O)=O,Gisadenafil besylate,23449797,"5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate",C23H33N7O5S.C6H6O3S,[334827-98-4],677.79,Enzymes,Phosphodiesterases,Inhibitor,Potent PDE5 inhibitor; orally bioavailable,1,CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc(=O)c2nn(CCOC)c(CC)c2[nH]1,669,0
4166,BrC1=CC(Br)=CC(C2=NN=NN2)=C1NC(NC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)=O,NS 5806,11642685,"N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[2,4-dibromo-6-(2H-tetrazol-5-yl)phenyl]urea",C16H8Br2F6N6O,[426834-69-7],574.07,Ion Channels,Voltage-Gated Potassium Channels,Activator,KV4.3 channel activator,1,O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)Nc1c(Br)cc(Br)cc1-c1nnn[nH]1,550,0
4167,O=C1C2=C(NC(C34CC(CC4C5)CC5C3)=N2)N(CCC)C(N1CCC)=O,KW 3902,64627,"8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione",C20H28N4O2,[136199-02-5],356.46,7-TM Receptors,Adenosine A1 Receptors,Antagonist,Selective A1 antagonist,1,CCCn1c(=O)c2nc(C34CC5CC(CC3C5)C4)[nH]c2n(CCC)c1=O,670,0
4171,O=C(NCCN3CCC(C(NCN4C5=CC(F)=CC=C5)=O)4CC3)C2=CC1=CC=CC=C1C=C2.Cl,VU 0364739 hydrochloride,46939225,"N-[2-[1-(3-Fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]ethyl]-2-naphthalenecarboxamide",C26H27FN4O2.HCl,[1244640-48-9],482.98,Enzymes,Phospholipases,Inhibitor,Potent and selective PLD2 inhibitor,2,O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc2ccccc2c1,281,1
4173,FC(C=C3)=CC=C3CCN(CC2)CCC2[C@@H](O)C1=C(OC)C(OC)=CC=C1,MDL 100907,5311271,"(R)-(+)-?-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperinemethanol",C22H28FNO3,[139290-65-6],373.46,7-TM Receptors,5-HT2A Receptors,Antagonist,Potent and selective 5-HT2A antagonist,3,COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,284,1
4174,NC(S2)=NC1=C2C[C@@H](NCCC)CC1.Cl.Cl,Pramipexole dihydrochloride,119569,"(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride",C10H17N3S.2HCl,[104632-25-9],284.25,7-TM Receptors,D3 Receptors,Agonist,Selective D3 agonist,1,CCCN[C@H]1CCc2nc(N)sc2C1,822,1
4179,C1(CN3CCCNCCNCCCNCC3)=CC=C(CNCC2=NC=CC=C2)C=C1.Br.Br.Br.Br.Br.Br,AMD 3465 hexahydrobromide,9897616,"N-[[4-(1,4,8,11-Tetraazacyclotetradec-1-ylmethyl)phenyl]methyl]-2-pyridinemethanamine hexahydrobromide",C24H38N6.6HBr,[185991-07-5],896.07,7-TM Receptors,Chemokine CXC Receptors,Antagonist,Potent and selective CXCR4 antagonist,2,c1ccc(CNCc2ccc(CN3CCCNCCNCCCNCC3)cc2)nc1,736,1
4181,O=C2/C(SC(NCC3=CC=CS3)=N2)=C/C1=CC=C(N=CC=C4)C4=C1,Ro 3306,11631681,5-(6-Quinolinylmethylene)-2-[(2-thienylmethyl)amino]-4(5H)-thiazolone,C18H13N3OS2,[872573-93-8],369.47,Enzymes,Cyclin-dependent Kinase,Inhibitor,Cdk1 inhibitor,2,O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1,726,1
4185,O=S(C1=CC=C(N2CCN(CC[C@H]3C(C=CC=C4)=C4CCO3)CC2)C=C1)(N)=O,Sonepiprazole,133079,"4-[4-[2-[(1S)-3,4-Dihydro-1H-2-benzopyran-1-yl)ethyl]-1-piperazinyl]-benzenesulfonamide",C21H27N3O3S,[170858-33-0],410.53,7-TM Receptors,D4 Receptors,Antagonist,Selective D4 antagonist,1,NS(=O)(=O)c1ccc(N2CCN(CC[C@@H]3OCCc4ccccc43)CC2)cc1,273,0
4186,O=C(/C(C#N)=C/C2=CN(C3=CC=CC=C3)C1=CC=CC=C12)O,UK 5099,6438504,2-Cyano-3-(1-phenyl-1H-indol-3-yl)-2-propenoic acid,C18H12N2O2,[56396-35-1],288.3,Transporters,Monocarboxylate Transporters,Inhibitor,MCT inhibitor; also inhibits of pyruvate transport,1,N#C/C(=C\c1cn(-c2ccccc2)c2ccccc12)C(=O)O,786,1
4188,ONC(C[C@H](C2=NC(C(N)=O)=NO2)CCCC1CCCCC1)=O,UK 383367,9818682,"3-(Aminocarbonyl)-?-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide",C15H24N4O4,[348622-88-8],324.38,Enzymes,Matrix Metalloprotease,Inhibitor,Potent and selective BMP-1 (PCP) inhibitor,1,NC(=O)c1noc([C@H](CCCC2CCCCC2)CC(=O)NO)n1,46,1
4189,N#CC(C3=CC=CC=C3)(C4=CC=CC=C4)CCCN1CCN(/N=C/C2=CN=CC=C2)CC1,SC 26196,9845201,"?,?-Diphenyl-4-[(3-pyridinylmethylene)amino]-1-piperazinepentanenitrile",C27H29N5,[218136-59-5],432.56,Enzymes,Other Oxygenases/Oxidases,Inhibitor,Selective fatty acid desaturase 2 inhibitor,1,N#CC(CCCN1CCN(/N=C/c2cccnc2)CC1)(c1ccccc1)c1ccccc1,291,1
4190,O=C(CC3=CC=C(C(C)C)C=C3)N(C2)CCC[C@H]2[C@@]1=CC(OC(C)(C)C(O)=O)=CC=C1,CP 775146,10410059,2-Methyl-2-[3-[(3S)-1-[2-[4-(1-methylethyl)phenyl]acetyl]-3-piperidinyl]phenoxy]-propanoic acid,C26H33NO4,[702680-17-9],432.55,Nuclear Receptors,PPARalpha Receptors,Agonist,"Selective, high affinity PPAR? agonist",1,CC(C)c1ccc(CC(=O)N2CCC[C@@H](c3cccc(OC(C)(C)C(=O)O)c3)C2)cc1,295,1
4196,FC1=CC=C(CN3C(/C(SC3=O)=C/C2=CC=C(OCC4=CC(B(O)O)=CC=C4)C=C2)=O)C=C1,HA 130,46911532,"B-[3-[[4-[[3-[(4-Fluorophenyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenoxy]methyl]phenyl]-boronic acid",C24H19BFNO5S,[1229652-21-4],463.29,Enzymes,Autotaxin,Inhibitor,Potent and selective autotaxin inhibitor,1,O=C1S/C(=C\c2ccc(OCc3cccc(B(O)O)c3)cc2)C(=O)N1Cc1ccc(F)cc1,443,1
4198,NCCCCCNC1(C2=CC=CC=C2)CCCCC1.Br.Br,IEM 1925 dihydrobromide,44561101,"N-(1-Phenylcyclohexyl)-1,5-pentanediamine dihydrobromide",C17H28N2.2HBr,[258282-23-4],431.25,Ion Channels,AMPA Receptors,Antagonist,Voltage- and use-dependent open-channel AMPA blocker,1,NCCCCCNC1(c2ccccc2)CCCCC1,636,1
4206,CC1=C(C3=CC=C(S(=O)(N)=O)C=C3)C(C2=CC=CC=C2)=NO1,Valdecoxib,119607,4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide,C16H14N2O3S,[181695-72-7],314.36,Enzymes,Cyclooxygenase,Inhibitor,Selective and potent COX-2 inhibitor,1,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,244,1
4216,CC(C)[C@@H]([C@@](O)=O)N(C(CCCC)=O)CC(C=C3)=CC=C3C1=CC=CC=C1C2=NN=NN2,Valsartan,60846,"(S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid",C24H29N5O3,[137862-53-4],449.03,7-TM Receptors,Angiotensin AT1 Receptors,Antagonist,"High affinity, selective AT1 antagonist",1,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,664,0
4220,O=C1N(CCC)C(C(NC(C3=CC=C(OCC(O)=O)C=C3)=N2)=C2N1CCC)=O,XCC,126079,"2-[4-(2,3,6,7-Tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetic acid",C19H22N4O5,[96865-83-7],386.4,7-TM Receptors,Non-selective Adenosine,Antagonist,Adenosine receptor antagonist,1,CCCn1c(=O)c2[nH]c(-c3ccc(OCC(=O)O)cc3)nc2n(CCC)c1=O,668,0
4222,CN(C)CCCN2C1=CC=CC=C1C(/C=C(C(NCCCCCCCC)=O)\C#N)=C2,Dynole 34-2,44157463,2-Cyano-3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-N-octyl-2-propenamide,C25H36N4O,[1128165-88-7],408.58,Enzymes,Dynamin,Inhibitor,Dynamin I inhibitor,1,CCCCCCCCNC(=O)/C(C#N)=C/c1cn(CCCN(C)C)c2ccccc12,786,0
4228,O=C(C)N1CCN(C(/C=C/C2=CC([N+]([O-])=O)=C(SC3=CC=CC=C3C(C)C)C=C2)=O)CC1,A 286982,9846729,(2E)-1-(4-Acetyl-1-piperazinyl)-3-[4-[[2-(1-methylethyl)phenyl]thio]-3-nitrophenyl]-2-propen-1-one,C24H27N3O4S,[280749-17-9],458.05,Enzyme-Linked Receptors,Integrins,Inhibitor,Potent inhibitor of the LFA-1/ICAM-1 interaction,1,CC(=O)N1CCN(C(=O)/C=C/c2ccc(Sc3ccccc3C(C)C)c([N+](=O)[O-])c2)CC1,756,1
4236,CCNC(CC4)(C(N)=O)CCN4C1=NC=NC2=C1N=C(C5=C(Cl)C=CC=C5)N2C3=CC=C(Cl)C=C3.Cl,CP 945598 hydrochloride,16223963,1-[8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4-carboxamide hydrochloride,C25H25Cl2N7O.HCl,[686347-12-6],546.88,7-TM Receptors,CB1 Receptors,Antagonist,CB1 antagonist,1,CCNC1(C(N)=O)CCN(c2ncnc3c2nc(-c2ccccc2Cl)n3-c2ccc(Cl)cc2)CC1,656,1
4248,O=C(C=C3)N(C5=CC=CC(C(F)(F)F)=C5)C2=C3C=NC1=CC=C(C4=CC=C(N)N=C4)C=C12,Torin 2,51358113,"9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H)-one",C24H15F3N4O,[1223001-51-1],441.41,Enzymes,mTOR,Inhibitor,Potent and selective mTOR inhibitor,3,Nc1ccc(-c2ccc3ncc4ccc(=O)n(-c5cccc(C(F)(F)F)c5)c4c3c2)cn1,687,1
4249,ClC1=C(OCCCC)C=CC(C2=CN=CC(C(NCC3=CC=CN=C3N4CCOCC4)=O)=C2)=C1,A 887826,46919335,5-(4-Butoxy-3-chlorophenyl)-N-[[2-(4-morpholinyl)-3-pyridinyl]methyl-3-pyridine carboxamide,C26H29ClN4O3,[1266212-81-0],480.99,Ion Channels,Voltage-gated Sodium Channels,Blocker,Potent voltage-dependent NaV1.8 channel blocker,1,CCCCOc1ccc(-c2cncc(C(=O)NCc3cccnc3N3CCOCC3)c2)cc1Cl,316,1
4255,O=C(NNC(NC2=CC=CC3=C2C=CC=C3)=O)C1=CC(OC)=CC(OC)=C1,TC-O 9311,3376937,"3,5-Dimethoxybenzoic acid 2-[(1-naphthalenylamino)carbonyl]hydrazide",C20H19N3O4,[444932-31-4],378.89,7-TM Receptors,Orphan 7-TM Receptors,Agonist,Potent and selective GPR139 agonist,1,COc1cc(OC)cc(C(=O)NNC(=O)Nc2cccc3ccccc23)c1,481,1
4256,CC3=C(SC=C3)/C(C2=C(C)C=CS2)=C\CCN1C[C@H](C(O)=O)CCC1.Cl,Tiagabine hydrochloride,91274,"(3R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid hydrochloride",C20H25NO2S2.HCl,[145821-59-6],424.02,Transporters,GABA Transporters,Inhibitor,Selective GAT-1 inhibitor; anticonvulsant,1,Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C,298,0
4257,OC1=CC2=C(NC(C3=NN(C(C)C)C4=C3C(N)=NC=N4)=C2)C=C1,PP 242,25243800,"2-[4-Amino-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-1H-indol-5-ol",C16H16N6O,[1092351-67-1],317.35,Enzymes,mTOR,Inhibitor,Dual mTORC1/mTORC2 inhibitor,3,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,833,1
4266,COC(C=C4)=CC=C4C1CC(C3=CC=CC=C3)=NN1C2=CC=C(S(=O)(N)=O)C=C2,ML 141,2950007,"4-[4,5-Dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl]benzenesulfonamide",C22H21N3O3S,[71203-35-5],407.49,Enzymes,Rho,Inhibitor,Selective Cdc42 Rho family inhibitor,2,COc1ccc(C2CC(c3ccccc3)=NN2c2ccc(S(N)(=O)=O)cc2)cc1,244,0
4268,CC(C)OC1=CC=C(CC2=CC=C(NC3=NCCN3)C=C2)C=C1.Cl,Ro 1138452 hydrochloride,91826074,"4,5-Dihydro-N-[4-[[4-(1-methylethoxy)phenyl]methyl]phenyl]-1H-imidazol-2-amine hydrochloride",C19H23N3O.HCl,,345.87,7-TM Receptors,Prostanoid Receptors,Antagonist,Selective prostacyclin IP receptor antagonist,1,CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1,745,1
4273,O=C2C3=C(C=CC=C3)N(C)C1=NC(NC4=C(OC)C=C(C(N5CCC(N6CCN(C)CC6)CC5)=O)C=C4)=NC=C1N2C,LRRK2-IN-1,46843906,"5,11-Dihydro-2-[[2-methoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one",C31H38N8O3,[1234480-84-2],579.1,Enzymes,LRRK2,Inhibitor,Potent and selective LRRK2 inhibitor,1,COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C,398,0
4277,O=C([C@H](N)C4CCCCC4)NC1=CC3=C(C(C=NNC3=O)=C(C5=CN(C)N=C5)N2)C2=C1,PF 477736,16750408,"(R)-?-Amino-N-[5,6-dihydro-2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1H-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]-cyclohexaneacetamide",C22H25N7O2,[952021-60-2],419.48,Enzymes,Checkpoint Kinases,Inhibitor,Selective Chk1 inhibitor,1,Cn1cc(-c2[nH]c3cc(NC(=O)[C@H](N)C4CCCCC4)cc4c3c2C=NNC4=O)cn1,55,1
4278,O=C2NC1=CC=C(NC3=NC=C(C(F)(F)F)C(NCC4=CC=CC=C4N(C)S(=O)(C)=O)=N3)C=C1C2,PF 431396,11598628,"N-Methyl-N-[2-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide",C22H21F3N6O3S,[717906-29-1],515.51,Enzymes,Focal Adhesion Kinase,Inhibitor,Dual FAK/PYK2 inhibitor,2,CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O,408,0
4281,NC1=C(C(COC4=CC(Cl)=CC=C4)=NN2C3CCOCC3)C2=NC=N1.Cl,PF 4800567 hydrochloride,71751553,"3-[(3-Chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride",C17H18ClN5O2.HCl,[1391052-28-0],396.27,Enzymes,Casein Kinase 1,Inhibitor,Selective casein kinase 1? inhibitor,2,Nc1ncnc2c1c(COc1cccc(Cl)c1)nn2C1CCOCC1,832,0
4288,OC(C=C2)=CC=C2C1=NOC(CC(OC)=O)C1,ISO 1,6098948,"4,5-Dihydro-3-(4-hydroxyphenyl)-5-isoxazoleacetic acid methyl ester",C12H13NO4,[478336-92-4],235.24,Cell biology,Cytokines,Inhibitor,Macrophage migration inhibitory factor (MIF) inhibitor,2,COC(=O)CC1CC(c2ccc(O)cc2)=NO1,227,0
4289,CC(C)OC1=C(C#N)C=C(C2=NC(C3=C(CCC4NCCC(O)=O)C4=CC=C3)=NO2)C=C1.Cl,RP 001 hydrochloride,90488927,"N-[4-[5-[3-Cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl]-?-alanine hydrochloride",C24H24N4O4.HCl,[1781880-34-9],468.93,7-TM Receptors,Sphingosine-1-phosphate Receptors,Agonist,Potent S1P1 agonist,1,CC(C)Oc1ccc(-c2nc(-c3cccc4c3CCC4NCCC(=O)O)no2)cc1C#N,716,0
4293,FC1=CC(F)=CC=C1N2C(/C=N/NC(NC(C)(C)C)=S)=C(C(OC)=O)C=N2,CID 2745687,9581011,"1-(2,4-Difluorophenyl)-5-[[2-[[(1,1-dimethylehyl)amino]thioxomethyl]hydrazinylidene]methyl]-1H-pyrazole-4-carboxylic acid methyl ester",C17H19F2N5O2S,[264233-05-8],395.43,7-TM Receptors,GPR35,Antagonist,GPR35 antagonist,1,COC(=O)c1cnn(-c2ccc(F)cc2F)c1/C=N/NC(=S)NC(C)(C)C,525,1
4297,C=CCNC2=NC=NC1=CC=C(Br)C=C12,SMER 28,1560402,6-Bromo-N-2-propenyl-4-quinazolinamine,C11H10BrN3,[307538-42-7],264.12,Cell biology,Autophagy,Activator,Positive regulator of autophagy,1,C=CCNc1ncnc2ccc(Br)cc12,388,1
4299,CC(N(C4=CN=CC=C4)C(C)=C3)=C3/C=C(SC2=O)/C(N2C1=CC=CC=C1)=O,iCRT 14,5967294,"5-[[2,5-Dimethyl-1-(3-pyridinyl)-1H-pyrrol-3-yl]methylene]-3-phenyl-2,4-thiazolidinedion",C21H17N3O2S,[677331-12-3],375.44,Cell biology,Beta-catenin,Other,Inhibits ?-catenin-responsive transcription (CRT),1,Cc1cc(/C=C2\SC(=O)N(c3ccccc3)C2=O)c(C)n1-c1cccnc1,714,1
4305,ClC1=NC=C(NC(C2=CC(F)=C(F)C=C2)=O)C=N1,ICA 069673,10149311,"N-(2-Chloro-5-pyrimidinyl)-3,4-difluorobenzamide",C11H6ClF2N3O,[582323-16-8],269.63,Ion Channels,Voltage-Gated Potassium Channels,Activator,KV7.2/KV7.3 channel opener,2,O=C(Nc1cnc(Cl)nc1)c1ccc(F)c(F)c1,518,1
4306,O=C(NCC(N[C@@H]2CCN([C@H]3CC[C@](C4=CC=C(OC)N=C4)(O)CC3)C2)=O)C1=CC(C(F)(F)F)=CC=C1.CS(=O)(O)=O.CS(=O)(O)=O,INCB 3284 dimesylate,11679268,N-[2-[[(3R)-1-[trans-4-Hydroxy-4-(6-methoxy-3-pyridinyl)cyclohexyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)-benzamide dimethanesulfonate,C26H31F3N4O4.2CH4O3S,[887401-93-6],712.76,7-TM Receptors,Chemokine CC Receptors,Antagonist,Selective CCR2 antagonist,2,COc1ccc([C@]2(O)CC[C@H](N3CC[C@@H](NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,325,1
4307,OCC4=CC=C(O4)C2=NN(CC3=CC=CC=C3)C1=CC=CC=C12,YC 1,5712,3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole,C19H16N2O2,[170632-47-0],304.34,Enzymes,Guanylyl Cyclase,Activator,Soluble guanylyl cyclase (sGC) activator; induces G1 cell cycle arrest,1,OCc1ccc(-c2nn(Cc3ccccc3)c3ccccc23)o1,167,0
4308,C#CCN[C@@H]2CCC1=CC=CC=C12.CS(=O)(O)=O,Rasagiline mesylate,3052775,"(1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine methanesulfonate",C12H13N.CH3SO3H,[161735-79-1],267.34,Enzymes,Monoamine Oxidase,Inhibitor,Selective and irreversible MAO-B inhibitor,1,C#CCN[C@@H]1CCc2ccccc21,142,0
4311,O=C(OC(C)(C)C)N1CCC(COC(NC2=CC=CC=C2OC)=O)CC1,GW 542573X,24885053,"4-[[[[(2-Methoxyphenyl)amino]carbonyl]oxy]methyl]-piperidinecarboxylic acid-1,1-dimethylethyl ester",C19H28N2O5,[660846-41-3],364.44,Ion Channels,Ca2+-Activated Potassium Channels,Activator,Selective activator of KCa2.1 channels,1,COc1ccccc1NC(=O)OCC1CCN(C(=O)OC(C)(C)C)CC1,351,1
4317,O=C(N[C@@H]2[C@H](C3=CC=CC=C3)OC(C)(C)OC2)NC1=C(Br)C=C(Br)C=C1,JNJ 10397049,9869934,"N-(2,4-Dibromophenyl)-N'-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]-urea",C19H20Br2N2O3,[708275-58-5],484.18,7-TM Receptors,OX2 Receptor,Antagonist,Selective OX2 receptor antagonist,1,CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@H](c2ccccc2)O1,130,1
4319,O=C(NC3=CC=C(S(=O)(C(F)(F)F)=O)C=C3)C(CC2)=CCN2C1=C(C(F)(F)F)C=CC=N1,A 784168,11420211,"3,6-Dihydro-3'-(trifluoromethyl)-N-[4-[(trifluoromethyl)sulfonyl]phenyl]-[1(2H),2'-bipyridine]-4-carboxamide",C19H15F6N3O3S,[824982-41-4],479.4,Ion Channels,TRPV,Antagonist,Potent and selective TRPV1 antagonist,2,O=C(Nc1ccc(S(=O)(=O)C(F)(F)F)cc1)C1=CCN(c2ncccc2C(F)(F)F)CC1,470,0
4323,FC1=CC=CC(C#CC2=CC=C(C(NC3CCC3)=O)C=N2)=C1.Cl,VU 0360172 hydrochloride,53384852,N-Cyclobutyl-6-[2-(3-fluorophenyl)ethynyl]-3-pyridinecarboxamide hydrochloride,C18H15FN2O.HCl,[1309976-62-2],330.78,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Modulator,Positive allosteric modulator of mGlu5 receptors,3,O=C(NC1CCC1)c1ccc(C#Cc2cccc(F)c2)nc1,723,1
4326,CCN1C3=C(C=CC=C3)C2=C1C=CC(CNC)=C2.Cl,PhiKan 083,16255105,9-Ethyl-N-methyl-9H-carbazole-3-methanamine hydrochloride,C16H18N2. HCl,[880813-36-5],274.79,Cell biology,p53,Other,p53 stabilizing agent,1,CCn1c2ccccc2c2cc(CNC)ccc21,779,1
4334,NC1=C3C(N([C@@H]4O[C@H](CO)[C@@H](O)[C@@H]4O)C=N3)=NC(SCCC2=CC=C(S(=O)(O)=O)C=C2)=N1.N,PSB 0777 ammonium salt,90488932,4-[2-[(6-Amino-9-b-D-ribofuranosyl-9H-purin-2-yl)thio]ethyl]benzenesulfonic acid ammonium salt,C18H20N5O7S2.NH4,[2122196-16-9],527.57,7-TM Receptors,Adenosine A2A Receptors,Agonist,Potent adenosine A2A agonist,2,Nc1nc(SCCc2ccc(S(=O)(=O)O)cc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,841,0
4336,O=C(C)/C=C1SC2=CC=C(OC)C=C2N\1CC,TG 003,647991,(1Z)-1-(3-Ethyl-5-methoxy-2(3H)-benzothiazolylidene)-2-propanone,C13H15NO2S,[719277-26-6],249.33,Enzymes,Cdc2-like kinases,Inhibitor,Potent inhibitor of Clk-family kinases; also inhibits DYRK1A/B,2,CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21,19,1
4343,CC(C)N(CC5)CCC5NC1=C2C(C=C(OCCCN4CCCC4)C(OC)=C2)=NC(C3CCCCC3)=N1,UNC 0638,46224516,2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine,C30H47N5O2,[1255580-76-7],509.73,Enzymes,G9a/GLP,Inhibitor,Selective G9a and GLP inhibitor,2,COc1cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2cc1OCCCN1CCCC1,393,0
4344,ClC1=CC(S(NC2=C(C)C=C([N+]([O-])=O)C=C2)(=O)=O)=C(Cl)C=C1,FH 535,3463933,"2,5-Dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide",C13H10Cl2N2O4S,[108409-83-2],361.2,Cell biology,Beta-catenin,Other,Inhibitor of Wnt/?-catenin signaling,1,Cc1cc([N+](=O)[O-])ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl,89,0
4346,FC(C=C2)=CC=[C@@]2[C@@H]1CCCN1S(C3=CC=C(C)C=C3)(=O)=O,Ro 67-7476,32681978,(2S)-2-(4-Fluorophenyl)-1-[(4-methylphenyl)sulfonyl]-pyrrolidine,C17H18FNO2S,[298690-60-5],319.39,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Modulator,Positive allosteric modulator of mGlu1 receptors,1,Cc1ccc(S(=O)(=O)N2CCC[C@H]2c2ccc(F)cc2)cc1,108,1
4349,CC4=CC2=C(S4)NC1=CC=CC=C1N=C2N3CCN(C)CC3,Olanzapine,4585,"2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine",C17H20N4S,[132539-06-1],312.43,7-TM Receptors,5-HT2A Receptors,Antagonist, 5-HT2A antagonist; also D2 antagonist; atypical antipsychotic,2,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,269,1
4350,O=C(NC)C1=C(SC2=CC=C(C(/C=C/C4=CC=CC=N4)=NN3)C3=C2)C=CC=C1,Axitinib,6450551,N-Methyl-[[3[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide,C22H18N4OS,[319460-85-0],386.47,Enzyme-Linked Receptors,VEGFR,Inhibitor,"Potent VEGFR-1, -2 and -3 inhibitor",1,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,537,1
4351,[H][C@@]12CC[C@@](C[C@H](OC(C4=CC=C(F)C=C4)C3=CC=C(F)C=C3)C2)([H])N1CCCC.Cl,JHW 007 hydrochloride,71771746,(3-endo)-3-[Bis(4-fluorophenyl)methoxy]-8-butyl-8-azabicyclo[3.2.1]octane hydrochloride,C24H29F2NO.HCl,[202645-74-7],421.95,Transporters,Dopamine Transporters,Inhibitor,High affinity dopamine uptake inhibitor,1,CCCCN1[C@H]2CC[C@@H]1C[C@H](OC(c1ccc(F)cc1)c1ccc(F)cc1)C2,260,1
4354,NC2=NC1=CC=CC=C1N2S(=O)(C3=CC=C(C)C=C3)=O,ML 130,1088438,1-[(4-Methylphenyl)sulfonyl]-1H-benzimidazol-2-amine,C14H13N3O2S,[799264-47-4],287.34,Cell biology,NF-kB/IkB,Inhibitor,Inhibits NOD1-induced NF-?B activation,1,Cc1ccc(S(=O)(=O)n2c(N)nc3ccccc32)cc1,107,1
4355,O=C(N(CC)C6=C5C=CC=C6)N5[C@H]1CCCN(C2=NC(C3=CC(C=CC=C4)=C4O3)=CC=N2)C1,TC-F 2,25198728,"1-[(3S)-1-[4-(2-Benzofuranyl)-2-pyrimidinyl]-3-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one",C26H25N5O2,[1304778-15-1],439.51,Enzymes,Fatty Acid Amide Hydrolase (FAAH),Inhibitor,"Potent, reversible and selective FAAH inhibitor",1,CCn1c(=O)n([C@H]2CCCN(c3nccc(-c4cc5ccccc5o4)n3)C2)c2ccccc21,261,0
4361,ClC1=CC(Cl)=C(OC)C=C1NC3=C(C#N)C=NC2=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23,Bosutinib,5328940,"4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile",C26H29Cl2N5O3,[380843-75-4],539.46,Enzymes,Src Kinases,Inhibitor,Dual Src-Abl inhibitor; antiproliferative,1,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,391,0
4374,[H][C@]12CC[C@](CC(NC(N3C(C=CC=C4)=C4N(C(C)C)C3=O)=O)C2)([H])N1C.Cl,BIMU 8,5311028,"2,3-Dihydro-N-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-3-(1-methylethyl)-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride",C19H26N4O2.HCl,[134296-40-5],387.91,7-TM Receptors,5-HT4 Receptors,Agonist,Potent 5-HT4 agonist,4,CC(C)n1c(=O)n(C(=O)NC2C[C@@H]3CC[C@H](C2)N3C)c2ccccc21,259,1
4375,O=C4C2=NC1=NON=C1N=C2C3=CC=CC=C34,SMER 3,568763,"9H-Indeno[1,2-e][1,2,5]oxadiazolo[3,4-b]pyrazin-9-one",C11H4N4O2,[67200-34-4],224.18,Enzymes,Ubiquitin E3 Ligases,Inhibitor,Selective inhibitor of E3 ubiquitin ligase,1,O=C1c2ccccc2-c2nc3nonc3nc21,760,1
4382,N#CC(C=C2)=CC=C2C(N3N=CN=C3)C1=CC=C(C#N)C=C1,Letrozole,3902,"4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile",C17H11N5,[112809-51-5],289.8,Enzymes,Cytochrome P450,Inhibitor,"Potent, reversible non-steroidal aromatase inhibitor",1,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,69,1
4387,O=C(C4=CC=C(Cl)C=C4)N[C@@H](CCCC3)[C@H]3N[C@H](C)C1=C2C(C=CC=C2)=CC=C1.Cl,Calhex 231 hydrochloride,11849513,"4-Chloro-N-[(1S,2S)-2-[[(1R)-1-(1-naphthalenyl)ethyl]amino]cyclohexyl]-benzamide hydrochloride",C25H27ClN2O.HCl,0,443.41,7-TM Receptors,Calcium-Sensing Receptor,Modulator,Negative allosteric modulator of calcium-sensing receptor (CaSR),1,C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12,772,0
4388,O=C1CC(C3=CC=NC(C#N)=C3)=NC2=C(C=C(Br)C=C2)N1,MNI 137,25210562,"4-(8-Bromo-2,3-dihydro-2-oxo-1H-1,5-benzodiazepin-4-yl)-2-pyridinecarbonitrile",C15H9BrN4O,[946619-21-2],341.16,7-TM Receptors,Glutamate (Metabotropic) Group II Receptors,Modulator,Selective negative allosteric modulator of group II mGlu receptors,1,N#Cc1cc(C2=Nc3ccc(Br)cc3NC(=O)C2)ccn1,882,1
4395,O=C(NCCN2CCOCC2)C1=CC=C(Cl)C=C1,Moclobemide,4235,4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide,C13H17ClN2O2,[71320-77-9],268.74,Enzymes,Monoamine Oxidase,Inhibitor,Reversible MAO-A inhibitor,1,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,318,0
4400,FC(C=C2F)=CC=C2C1=NOC(CC(N3CCOCC3)=O)C1,(+/-)-CPSI 1306,59723793,"2-[3-(3-(2,4-Difluorophenyl)-4,5-dihydro-5-isoxazolyl]-1-(4-morpholinyl)ethanone",C15H16F2N2O3,[1309793-47-2],310.3,Cell biology,Cytokines,Other,Reported macrophage migration inhibitory factor (MIF) inhibitor,1,O=C(CC1CC(c2ccc(F)cc2F)=NO1)N1CCOCC1,227,0
4407,CC1=CC(C)=NN1C2=NC(C3=CC=CC(N4CCC(OC)CC4)=N3)=CC(NC(C)=O)=N2,TC-G 1004,25074316,"N-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-[6-(4-methoxy-1-piperidinyl)-2-pyridinyl]-4-pyrimidinyl]acetamide",C22H27N7O2,[1061747-72-5],430.51,7-TM Receptors,Adenosine A2A Receptors,Antagonist,Potent and selective A2A antagonist,1,COC1CCN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)CC1,488,1
4414,FC1=C(C(C)(O)C)C=CN2C1=NC=C2C3=CC=C(F)C(C4=CC=C(F)C=C4C#N)=C3,TP 003,10001434,"2',4-Difluoro-5'-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-a]-pyridin-3-yl]-[1,1'-biphenyl]-2-carbonitrile",C23H16F3N3O,[628690-75-5],407.39,Ion Channels,GABAA Receptors,Benzodiazepine,GABAA partial agonist; acts at benzodiazepine site,1,CC(C)(O)c1ccn2c(-c3ccc(F)c(-c4ccc(F)cc4C#N)c3)cnc2c1F,860,1
4416,CC1=CC(C)=NC(C#CC2=CC=CC(F)=C2)=C1N.Cl,ADX 10059 hydrochloride,18454771,"2-[(3-Fluorophenyl)ethynyl]-4,6-dimethyl-3-pyridinamine hydrochloride",C15H13FN2.HCl,[757949-98-7],276.74,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Modulator,Negative allosteric modulator of mGlu5 receptors,1,Cc1cc(C)c(N)c(C#Cc2cccc(F)c2)n1,723,0
4417,C12=CC=CC=C1N=C(NCC4=CC=CC=C4)N=C2NCC3=CC=CC=C3,DBeQ,676352,"N2,N4-Bis(phenylmethyl)-2,4-quinazolinediamine",C22H20N4,[177355-84-9],340.42,Enzymes,p97 ATPase,Inhibitor,Selective and reversible p97 ATPase inhibitor,1,c1ccc(CNc2nc(NCc3ccccc3)c3ccccc3n2)cc1,170,1
4423,ClC(C=C1Cl)=CC=C1C2=NC(NCCNC3=CC=C(C#N)C=N3)=NC=C2C4=NC=C(C)N4,CHIR 99021,9956119,"6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile",C22H18Cl2N8,[252917-06-9],465.34,Enzymes,Glycogen Synthase Kinase 3,Inhibitor,Highly selective GSK-3 inhibitor,12,Cc1cnc(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)[nH]1,71,0
4430,FC(C=CC=C3)=C3CN2N=C(C4=NC=C(C5CC5)C(N)=N4)C1=CC=CN=C12,BAY 41-2272,9798973,"5-Cyclopropyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-pyrimidinamine",C20H17FN6,[256376-24-6],369.4,Enzymes,Guanylyl Cyclase,Activator,Soluble guanylyl cyclase (sGC) activator,1,Nc1nc(-c2nn(Cc3ccccc3F)c3ncccc23)ncc1C1CC1,728,1
4431,O=C(NC3=NC(C(F)(F)F)=CC=C3)NC2=CC=NC1=CC(OC)=CC=C12,A 1070722,49830684,1-(7-Methoxyquinolin-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea,C17H13F3N4O2,[1384424-80-9],362.31,Enzymes,Glycogen Synthase Kinase 3,Inhibitor,"Highly potent, selective GSK-3 inhibitor",1,COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1,383,1
4432,CC(C=C3)=CC=C3C1=CSC2=C1C(SCCC(O)=O)=NC=N2,TTP 22,1536915,"3-[[5-(4-Methylphenyl)thieno[2,3-d]pyrimidin-4-yl]thio]propanoic acid",C16H14N2O2S2,[329907-28-0],330.42,Enzymes,Casein Kinase 2,Inhibitor,"High affinity, selective CK2 inhibitor",1,Cc1ccc(-c2csc3ncnc(SCCC(=O)O)c23)cc1,232,1
4434,BrC(C=C3)=CC1=C3N(CC(O)CN(C)C)C2=C1C=C(Br)C=C2,Wiskostatin,2775510,"3,6-Dibromo-?-[(dimethylamino)methyl]-9H-cabazole-9-ethanol",C17H18Br2N2O,[253449-04-6],426.15,Cell biology,Actin,Inhibitor,N-WASP inhibitor; inhibits Arp2/3 activation,1,CN(C)CC(O)Cn1c2ccc(Br)cc2c2cc(Br)ccc21,883,1
4435,CC(C(NC(C)=O)=CC=C4)=C4NC1=NC=NC(N2CCC(OCC3=CC=C(OC(F)(F)F)C=C3)CC2)=N1,TC-N 1752,53361524,"N-[2-Methyl-3-[[4-[4-[[4-(trifluoromethoxy)phenyl]methoxy]-1-piperidinyl]-1,3,5-triazin-2-yl]amino]phenyl]acetamide",C25H27F3N6O3,[1211866-85-1],516.52,Ion Channels,Voltage-gated Sodium Channels,Blocker,NaV channel blocker,1,CC(=O)Nc1cccc(Nc2ncnc(N3CCC(OCc4ccc(OC(F)(F)F)cc4)CC3)n2)c1C,487,1
4439,O=C(NC2CC2)C1=NOC(C3=CC=CS3)=C1,ISX 9,19582717,N-Cyclopropyl-5-(2-thienyl)-3-isoxazolecarboxamide,C11H10N2O2S,[832115-62-5],234.27,Cell biology,Neural Stem Cells,Other,Neurogenic agent; induces neuronal differentiation of SVZ progenitors and also induces cardiomyogenic differentiation,2,O=C(NC1CC1)c1cc(-c2cccs2)on1,150,1
4440,O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,Rivastigmine tartrate,6918078,"N-Ethyl-N-methylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (2R,3R)-2,3-dihydroxybutanedioate",C14H22N2O2.C4H6O6,[129101-54-8],400.42,Enzymes,Cholinesterases,Inhibitor,Dual AChE and BChE inhibitor,1,CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,226,1
4444,CCCC1=CC(C2=NC(C3=CC=C(C)C=C3)=CS2)=CC=N1.Br,Fatostatin A,2850562,4-[4-(4-Methylphenyl)-2-thiazolyl]-2-propylpyridine hydrobromide,C18H18N2S.HBr,[298197-04-3],375.33,Cell biology,SREBP,Inhibitor,Cell permeable inhibitor of SREBP activation,2,CCCc1cc(-c2nc(-c3ccc(C)cc3)cs2)ccn1,648,1
4445,O=C2NC1=CC=C(NS(C3=CC=CC=C3OC)(=O)=O)C=C1CN2C,PFI 1,71271629,"2-Methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide",C16H17N3O4S,[1403764-72-6],351.89,Cell biology,Bromodomains,Inhibitor,BET bromodomain inhibitor,1,COc1ccccc1S(=O)(=O)Nc1ccc2c(c1)CN(C)C(=O)N2,111,1
4447,CN(CC(O)=O)CC[C@@H](OC2=CC=C(C(F)(F)F)C=C2)C1=CC=CC=C1,Org 24598,5311285,N-Methyl-N-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-glycine,C19H20F3NO3,[372198-97-5],367.36,Transporters,Glycine Transporters,Inhibitor,Potent and selective inhibitor of the glial glycine transporter GlyT1b; active in vivo,1,CN(CC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1)CC(=O)O,181,1
4453,OCCN1N=C(C3=CC=NC=C3)C(C2=CC=C(/C(CC4)=N/O)C4=C2)=C1,GDC 0879,11717001,"(E)-2,3-Dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-1H-inden-1-one oxime",C19H18N4O2,[905281-76-7],338.87,Enzymes,Raf Kinase,Inhibitor,Potent B-Raf inhibitor,1,OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1,557,1
4457,CC(C(C2=CC=C(Cl)C(Cl)=C2)(C)O1)=C(C#N)/C1=C(C#N)\C#N,YE 120,12138435,"2-[3-Cyano-5-(3,4-dichlorophenyl)-4,5-dimethyl-2(5H)-furanylidene]propanedinitrile",C16H9Cl2N3O,[383124-82-1],330.17,7-TM Receptors,GPR35,Agonist,GPR35 agonist,1,CC1=C(C#N)C(=C(C#N)C#N)OC1(C)c1ccc(Cl)c(Cl)c1,628,1
4459,C[C@H](NC2=CC(C(C4=CC=C(OCO5)C5=C4)=NO3)=C3C=N2)C1=CC=CC=C1,TC-S 7005,24971422,"3-(1,3-Benzodioxol-5-yl)-N-[(1S)-1-phenylethyl]-isoxazolo[5,4-c]pyridin-5-amine",C21H17N3O3,[1082739-92-1],359.38,Enzymes,Polo-like Kinase,Inhibitor,Potent and selective PLK2 inhibitor,3,C[C@H](Nc1cc2c(-c3ccc4c(c3)OCO4)noc2cn1)c1ccccc1,747,0
4462,BrC1=CC(C2=NN=NN2)=C(NC(NC3=CC(C(F)(F)F)=CC=C3)=O)C=C1,NS 3623,9954236,N-[4-Bromo-2-(1H-tetrazol-5-yl-phenyl]-N'-[3-(trifluoromethyl)phenyl]-urea,C15H10BrF3N6O,[343630-41-1],427.18,Ion Channels,Voltage-Gated Potassium Channels,Activator,KV11.1 (hERG)  and KV4.3 channel activator; antiarrhythmic,1,O=C(Nc1cccc(C(F)(F)F)c1)Nc1ccc(Br)cc1-c1nnn[nH]1,550,0
4463,CCOC(=O)C1CC2=CC=CC=C2CN1C(=O)C1=CC=C(SC)S1,SR 8278,53393127,"1,2,3,4-Tetrahydro-2-[[5-(methylthio)-2-thienyl]carbonyl]-3-isoquinolinecarboxylic acid ethyl ester",C18H19NO3S2,[1254944-66-5],361.48,Nuclear Receptors,Rev-Erb Receptors,Antagonist,Rev-Erb? antagonist,2,CCOC(=O)C1Cc2ccccc2CN1C(=O)c1ccc(SC)s1,149,1
4464,OC2=CC=C(C(O)=O)C1=CC=CN=C12,IOX 1,459617,8-Hydroxy-5-quinolinecarboxylic acid,C10H7NO3,[5852-78-8],189.17,Enzymes,Histone Demethylases,Inhibitor,Histone demethylase inhibitor; cell permeable,1,O=C(O)c1ccc(O)c2ncccc12,731,1
4465,O=C(N[C@H](CO)C3=CC(Cl)=CC=C3)C1=CC(C2=NC(NC4=CC=C(F)C=C4Cl)=NC=C2C)=CN1,TCS ERK 11e,11634725,4-[2-[(2-Chloro-4-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide,C24H20Cl2FN5O2,[896720-20-0],504.85,Enzymes,ERK,Inhibitor,Potent and selective ERK2 inhibitor,2,Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,619,1
4470,O=C(N3CCN(CCC4=CC=C(F)C=C4)CC3)C1=C2C(C(C#N)=CN2)=CC=C1.Cl,EMD 281014 hydrochloride,9887933,7-[[4-[2-(4-Fluorophenyl)ethyl]-1-piperazinyl]carbonyl]-1H-indole-3-carbonitrile hydrochloride,C22H21FN4O.HCl,[443144-27-2],412.89,7-TM Receptors,5-HT2A Receptors,Antagonist,Selective 5-HT2A antagonist,1,N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12,284,0
4472,NC1=NC(SCC(N)=O)=C(C#N)C(C2=CC=C(OCC3CC3)C=C2)=C1C#N,BAY 60-6583,11717831,"2-[[6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-pyridinyl]thio]-acetamide",C19H17N5O2S,[910487-58-0],383.94,7-TM Receptors,Adenosine A2B Receptors,Agonist,Potent A2B agonist; cardioprotective,4,N#Cc1c(N)nc(SCC(N)=O)c(C#N)c1-c1ccc(OCC2CC2)cc1,73,1
4473,C[C@@H](C3=CC=CC=C3)NC(NC2=CC=CC1=NC=CC=C12)=NC#N,A 804598,53325874,"N-Cyano-N""-[(1S)-1-phenylethyl]-N'-5-quinolinyl-guanidine",C19H17N5,[1125758-85-1],315.37,Ion Channels,P2X Receptors,Antagonist,Potent and selective P2X7 antagonist,2,C[C@H](NC(=NC#N)Nc1cccc2ncccc12)c1ccccc1,733,0
4478,O=C(CO3)N(CC4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)CC1=C3N=CC=C1C2=C(F)C=CC=C2,GPBAR-A,11656002,"4-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-6-(2-fluorophenyl)-4,5-dihydro-pyrido[3,2-f]-1,4-oxazepin-3(2H)-one",C23H15F7N2O2,[877052-79-4],484.37,7-TM Receptors,GPBA Receptors,Agonist,GPBA receptor (TGR5) agonist,1,O=C1COc2nccc(-c3ccccc3F)c2CN1Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1,694,1
4479,CC(C1=CC=C(O)C(C=O)=C1O2)=CC2=O,4mu8C,12934390,7-Hydroxy-4-methyl-2-oxo-2H-1-benzopyran-8-carboxaldehyde,C11H8O4,[14003-96-4],206.43,Enzymes,IRE1,Inhibitor,Inhibits IRE1? endoribonuclease activity,1,Cc1cc(=O)oc2c(C=O)c(O)ccc12,807,1
4481,O=C(NC(C)C3=NC=CS3)NC(C(OC)=C2)=CC=C2OC1=C4C(C=C(OC)C(OC)=C4)=NC=C1,Ki 20227,9869779,"N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea",C24H24N4O5S,[623142-96-1],480.54,Enzyme-Linked Receptors,Other RTKs,Inhibitor,c-Fms inhibitor; suppresses osteolysis and osteoclast accumulation,5,COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1,384,0
4484,O=C(NC2=CN=CC=C2)C1=CC=C(CNS(C3=CC=C(C(C)(C)C)C=C3)(=O)=O)C=C1,STF 31,984333,"4-[[[[4-(1,1-Dimethylethyl)phenyl]sulfonyl]amino]methyl]-N-3-pyridinylbenzamide",C23H25N3O3S,[724741-75-7],423.53,Enzymes,NAMPT,Inhibitor,NAMPT inhibitor; also GLUT1 inhibitor,2,CC(C)(C)c1ccc(S(=O)(=O)NCc2ccc(C(=O)Nc3cccnc3)cc2)cc1,477,1
4485,CC(C1=CC([N+]([O-])=O)=C(SC2=CC=C(F)C=C2F)S1)=O,P 22077,46931953,"1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]-ethanone",C12H7F2NO3S2,[1247819-59-5],315.32,Enzymes,Deubiquitinating Enzymes,Inhibitor,USP7 inhibitor,1,CC(=O)c1cc([N+](=O)[O-])c(Sc2ccc(F)cc2F)s1,523,1
4487,CCOC(C=C3)=CC=C3N2C(C1=CC=CN=C1N=C2C(N(CC4=CC=CN=C4)C(CC5=CC=C(OC(F)(F)F)C=C5)=O)C)=O,(+/-)-AMG 487,10282265,"N-1-[(3-4(-Ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(3-pyridinylmethyl)-4-(trifluoromethoxy)benzeneacetamide",C32H28F3N5O4,[947536-03-0],608.09,7-TM Receptors,Chemokine CXC Receptors,Antagonist,CXCR3 antagonist; inhibits cell migration and metastasis,2,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,700,1
4489,CN1C2=C(C=CC=C2)C3=C(C=CC=C3)[C@H](NC([C@@H](NC(CC4=CC(F)=CC(F)=C4)=O)C)=O)C1=O,DBZ,11454028,"N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide",C26H23F2N3O3,[209984-56-5],463.48,Enzymes,Gamma-Secretase,Inhibitor,?-secretase inhibitor; inhibits Notch pathway,3,C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@@H]1C(=O)N(C)c2ccccc2-c2ccccc21,183,0
4491,O=C2C(C4=NN(C(CCC(O)=O)=O)C(C5=CC=C(Br)C=C5)C4)=C(C3=CC=CC=C3)C1=CC(C)=CC=C1N2,DQP 1105,2723792,"5-(4-Bromophenyl)-3-(1,2-dihydro-6-methyl-2-oxo-4-phenyl-3-quinolinyl)-4,5-dihydro-?-oxo-1H-pyrazole-1-butanoic acid",C29H24BrN3O4,[380560-89-4],571.93,Ion Channels,NMDA Receptors,Antagonist,GluN2C/GluN2D-selective NMDA antagonist,1,Cc1ccc2[nH]c(=O)c(C3=NN(C(=O)CCC(=O)O)C(c4ccc(Br)cc4)C3)c(-c3ccccc3)c2c1,252,1
4494,OC(C=C2)=CC=C2C[C@@H](C#N)C1=CC=C(O)C=C1,(R)-DPN,6604873,"(R)-2,3-bis(4-Hydroxyphenyl)-propionitrile",C15H13NO2,[524047-78-7],239.27,Nuclear Receptors,Estrogen and Related Receptors,Agonist,Enantiomer of DPN (Cat. No. 1494),1,N#C[C@H](Cc1ccc(O)cc1)c1ccc(O)cc1,891,1
4499,O=C(OC(C)(C)C)C[C@@H]1N=C(C4=CC=C(Cl)C=C4)C3=C(SC(C)=C3C)N2C1=NN=C2C,(+)-JQ1,46907787,"(6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester",C23H25ClN4O2S,[1268524-70-4],456.99,Cell biology,Bromodomains,Inhibitor,Potent and selective BET bromodomain inhibitor; cell permeable,11,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,578,1
4507,CC(C)(C)CCN1C[C@@]2([H])[C@@]([C@@H]2CNC(C3=CC(Cl)=CC(Cl)=C3)=O)([H])C1.Cl,ML 218 hydrochloride,2723792,"3,5-Dichloro-N-[[(1?,5?,6-exo,6?)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-benzamide hydrochloride",C19H26Cl2N2O.HCl,[2319922-08-0],405.79,Ion Channels,Cav3.x Channels,Blocker,CaV3.x blocker,1,CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1,340,1
4510,O=C(NCC4=CC=C(F)C=C4)N1CC2N(C(OC(C5=CC=CC=C5)2C3=CC=CC=C3)=O)CC1,SHA 68,11374217,"N-[(4-Fluorophenyl)methyl]tetrahydro-3-oxo-1,1-diphenyl-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxamide",C26H24FN3O3,[847553-89-3],449.99,7-TM Receptors,Neuropeptide S Receptors,Antagonist,Selective Neuropeptide S receptor antagonist,1,O=C(NCc1ccc(F)cc1)N1CCN2C(=O)OC(c3ccccc3)(c3ccccc3)C2C1,285,1
4513,O=C(NC2=CC=C(C3=CC=CC=C3)C=C2)C1=CC=CC=C1C(O)=O,Kartogenin,2826191,"2-[((1,1'-Biphenyl)-4-ylamino)carbonyl]benzoic acid",C20H15NO3,[4727-31-5],321.84,Cell biology,Mesenchymal Stem Cells,Other,Potently induces chondrogenesis in MSCs,1,O=C(O)c1ccccc1C(=O)Nc1ccc(-c2ccccc2)cc1,249,1
4514,O=C(NCC2(C3=CC=C(OC)C=C3)CCOCC2)C1=CC=C(NC(C4=CC=CO4)=O)C=C1,JW 55,2946601,N-[4-[[[[Tetrahydro-4-(4-methoxyphenyl)-2H-pyran-4-yl]methyl]amino]carbonyl]phenyl]-2-furancarboxamide,C25H26N2O5,[664993-53-7],438.98,Enzymes,Tankyrase,Inhibitor,Tankyrase inhibitor,1,COc1ccc(C2(CNC(=O)c3ccc(NC(=O)c4ccco4)cc3)CCOCC2)cc1,467,1
4517,BrC1=CC=C(OCC(N23)=NOC3=O)C2=C1,NS 2028,4551,"8-Bromo-1H,4H-[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-1-one",C9H5BrN2O3,[204326-43-2],269.05,Enzymes,Guanylyl Cyclase,Inhibitor,Potent soluble guanylyl cyclase (sGC) inhibitor,2,O=c1onc2n1-c1cc(Br)ccc1OC2,881,1
4518,O=C(NC3=CC(OCC)=CC=C3)C1=CC(C(F)(F)F)=C(N2CCCC2)C=C1,EPPTB,25175634,N-(3-Ethoxyphenyl)-4-(1-pyrrolidinyl)-3-(trifluoromethyl)benzamide,C20H21F3N2O2,[1110781-88-8],378.39,7-TM Receptors,Trace Amine 1 Receptor,Antagonist,Trace amine 1 (TA1)  receptor antagonist/inverse agonist,1,CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(C(F)(F)F)c2)c1,483,0
4519,O=C(NC3=C(C)C=C(C)C=C3C)C1CC2CCC1C2,ML 213,3111211,"N-(2,4,6-Trimethylphenyl)-bicyclo[2.2.1]heptane-2-carboxamide",C17H23NO,[489402-47-3],257.37,Ion Channels,Voltage-Gated Potassium Channels,Activator,KV7.2 and KV7.4 channel opener,1,Cc1cc(C)c(NC(=O)C2CC3CCC2C3)c(C)c1,82,1
4525,O=C(NC3=C(Cl)C=NC=C3Cl)C1=CC(OC2CCCC2)=C(OC)C=C1,Piclamilast,154575,"3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide",C18H18Cl2N2O3,[144035-83-6],381.25,Enzymes,Phosphodiesterases,Inhibitor,Potent and selective PDE4 inhibitor,1,COc1ccc(C(=O)Nc2c(Cl)cncc2Cl)cc1OC1CCCC1,369,1
4536,NC1=C3C(N(CC(C)(O)C)C(COCC)=N3)=C2C(C=CC=C2)=N1,Resiquimod,159603,"1-[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol",C17H22N4O2,[144875-48-9],314.38,Enzyme-Linked Receptors,Toll-like Receptors,Agonist,Toll-like receptor 7 (TLR7) agonist,3,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,154,1
4540,FC1=CC=C(NC(NC2=CC=C(S(=O)(N)=O)C=C2)=O)C=C1,U 104,310360,4-[[[(4-Fluorophenyl)amino]carbonyl]amino]-benzesulfonamide,C13H12FN3O3S,[178606-66-1],309.32,Enzymes,Carbonic anhydrases,Inhibitor,Potent carbonic anhydrase (CA) IX and XII inhibitor,1,NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,510,1
4541,O[C@H]([C@H](O)[C@@H](CN(C(C)C)CCCNC(NC4=CC=C(C(C)(C)C)C=C4)=O)O3)[C@@H]3N1C2=C(C(N)=NC=N2)C(Br)=C1,SGC 0946,56962337,"1-[3-[[[(2R,3S,4R,5R)-5-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl](isopropyl)amino]propyl]-3-[4-(2,2-dimethylethyl)phenyl]urea",C28H40BrN7O4,[1561178-17-3],632.08,Enzymes,Other Lysine Methyltransferases,Inhibitor,Highly potent and selective DOT1L inhibitor; cell permeable,2,CC(C)N(CCCNC(=O)Nc1ccc(C(C)(C)C)cc1)C[C@H]1O[C@@H](n2cc(Br)c3c(N)ncnc32)[C@H](O)[C@@H]1O,840,1
4544,NC1=CC=CC(CNC(C2=CN=C(OC3=CC=C(OCC4=CC=CC(F)=C4)C=C3)C=C2)=O)=C1.Cl.Cl,YM 244769,90488952,N-[(3-Aminophenyl)methyl]-6-[4-[(3-fluorophenyl)methoxy]phenoxy]-3-pyridinecarboxamide dihydrochloride,C26H22FN3O3.2HCl,[1780390-65-9],516.39,Transporters,Na+/Ca2+ Exchanger,Inhibitor,Na+/Ca2+ exchange inhibitor (reverse mode); neuroprotective,1,Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1,442,1
4551,C1(OC4=CC=CC5=C4C=CC=C5)=NC(NC3=CC=C(N6CCOCC6)C=C3)=C2C(N(C7CCCCC7)C=N2)=N1,Purmorphamine,5284329,9-Cyclohexyl-N-[4-(4-morpholinyl)phenyl]-2-(1-naphthalenyloxy)-9H-purin-6-amine,C31H32N6O2,[483367-10-8],525.12,7-TM Receptors,Smoothened Receptors,Agonist,Smo receptor agonist,4,c1ccc2c(Oc3nc(Nc4ccc(N5CCOCC5)cc4)c4ncn(C5CCCCC5)c4n3)cccc2c1,312,1
4552,O=C(CN2CCC(C3=CC=CC=N3)CC2)NC1=CC=CC(C)=C1.Cl.Cl,A 412997 dihydrochloride,90488953,N-(3-Methylphenyl)-4-(2-pyridinyl)-1-piperidineacetamide,C19H23N3O.2HCl,[1347744-96-0],400.35,7-TM Receptors,D4 Receptors,Agonist,Selective D4 agonist,1,Cc1cccc(NC(=O)CN2CCC(c3ccccn3)CC2)c1,251,0
4554,CC1=CC(OCC(O)=O)=CC(C)=C1CC2=CC(C(C)C)=C(O)C=C2,GC 1,9862248,"2-[4-[[4-Hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]acetic acid",C20H24O4,[211110-63-3],328.4,Nuclear Receptors,Other Nuclear Receptors,Agonist,High affinity thyroid receptor ? (TR?) and TR? agonist; thyromimetic,6,Cc1cc(OCC(=O)O)cc(C)c1Cc1ccc(O)c(C(C)C)c1,427,1
4556,C[C@H]1[C@@H](N(C2=NC=NC3=C2C=CN3)C)CN(C(CC#N)=O)CC1.OC(CC(O)=O)(C(O)=O)CC(O)=O,CP 690550 citrate,10174505,"(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-?-oxo-1-piperidinepropanenitrile citrate",C16H20N6O.C6H8O7,[540737-29-9],504.49,Enzymes,JAK Kinase,Inhibitor,Potent JAK inhibitor,1,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,658,1
4559,O=C2NC1=CC(NC4=C(C)C=CC(NC(NC5=C(F)C=CC(C(F)(F)F)=C5)=O)=C4)=CC=C1/C2=C/C3=CC=CN3,GNF 5837,59397065,"N-[3-[[2,3-Dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-6-yl]amino]-4-methylphenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea",C28H21F4N5O2,[1033769-28-6],535.49,Enzyme-Linked Receptors,Trk Receptors,Inhibitor,"Potent Trk inhibitor; inhibits TrkA, TrkB and TrkC",2,Cc1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1Nc1ccc2c(c1)NC(=O)/C2=C\c1ccc[nH]1,486,1
4565,C1(C2=NC(NCC4=CC=C(C5=CC=CC=C5)C=C4)=C(C3=CC=CC=C3)N=N2)=NC=CC=C1,ML 228,46742353,"N-([1,1'Biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine",C27H21N5,[1357171-62-0],415.49,Cell biology,Hypoxia Inducible Factors,Activator,HIF pathway activator,1,c1ccc(-c2ccc(CNc3nc(-c4ccccn4)nnc3-c3ccccc3)cc2)cc1,739,1
4588,OCCN(CCO)C2=NC1=C(N3CCCCCCC3)N=C(N(CCO)CCO)N=C1C(N4CCCCCCC4)=N2,8MDP,16756415,"2,2',2'',2'''-[[4,8-Bis(hexahydro-1(2H)-azocinyl)pyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilo]tetrakisethanol",C28H48N8O4,[29491-75-6],565.23,Transporters,Nucleoside Transporters,Inhibitor,Potent equilibrative nucleoside transporter (ENT) inhibitor,1,OCCN(CCO)c1nc(N2CCCCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCCCC3)c2n1,40,0
4593,O=C(CCNC1=NC(C2=CC=CC=N2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)O,GSK J1,56963315,"N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-?-alanine",C22H23N5O2,[1373422-53-7],443.5,Enzymes,Histone Demethylases,Inhibitor,Potent JMJD3/UTX inhibitor,1,O=C(O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2ccccn2)n1,738,1
4594,O=C(CCNC1=NC(C2=CC=CC=N2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)OCC,GSK J4,71729975,"N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-?-alanine ethyl ester",C24H27N5O2,[1373423-53-0],417.5,Enzymes,Histone Demethylases,Inhibitor,Histone KDM inhibitor; cell permeable,2,CCOC(=O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2ccccn2)n1,738,0
4597,C12=CC=CC=C1N=C(N[C@H]3C(C=CC=C4)=C4CCC3)N2.Cl,NS 8593 hydrochloride,71311765,"N-[(1R)-1,2,3,4-Tetrahydro-1-naphthalenyl]-1H-benzimidazol-2-amine hydrochloride",C17H17N3.HCl,[875755-24-1],299.8,Ion Channels,Ca2+-Activated Potassium Channels,Modulator,Selective KCa2 (SK) channel negative modulator; inhibits SK currents,1,c1ccc2c(c1)CCC[C@H]2Nc1nc2ccccc2[nH]1,142,0
4601,FC1=CC(COC2=CC=C(CCC(O)=O)C=C2)=C(C3=CC=C(C)C=C3)C=C1,TUG 891,57522038,"4-[(4-Fluoro-4'-methyl[1,1'-biphenyl]-2-yl)methoxy]-benzenepropanoic acid",C23H21FO3,[1374516-07-0],364.41,7-TM Receptors,Free Fatty Acid Receptors,Agonist,Potent and selective FFA4 (GPR120) agonist,2,Cc1ccc(-c2ccc(F)cc2COc2ccc(CCC(=O)O)cc2)cc1,441,1
4602,O=C(NN)CSC(N1C2=CC=CC=C2)=NC3=C(C(C4=CC=CC=C4)=CS3)C1=O,LDN 27219,1150683,"2-[(3,4-Dihydro-4-oxo-3,5-diphenylthieno[2,3-d]pyrimidin-2-yl)thio]acetic acid hydrazide",C20H16N4O2S2,[312946-37-5],408.5,Enzymes,Other Transferases,Inhibitor,Transglutaminase 2 (TG2) inhibitor; reversible,1,NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1,231,1
4603,NC1=NC(SCC3=NC=CN3)=C(C#N)C(C2=CC=C(O)C=C2)=C1C#N,LUF 5834,1150683,"2-Amino-4-(4-hydroxyphenyl)-6-[(1H-imidazol-2-ylmethyl)thio]-3,5-pyridinecarbonitrile",C17H12N6OS.0.2C2H5OH,[333962-91-7],362.09,7-TM Receptors,Adenosine A2A Receptors,Agonist,Potent adenosine A2A and A2B receptor partial agonist,1,N#Cc1c(N)nc(SCc2ncc[nH]2)c(C#N)c1-c1ccc(O)cc1,73,0
4607,O=C(NCCO)C1=CC(C(NCCO)=O)=CC(C(NCCO)=O)=C1,LM 22A4,2054170,"N,N',N''Tris(2-hydroxyethyl)-1,3,5-benzenetricarboxamide",C15H21N3O6,[37988-18-4],339.34,Enzyme-Linked Receptors,Trk Receptors,Agonist,Potent TrkB agonist,2,O=C(NCCO)c1cc(C(=O)NCCO)cc(C(=O)NCCO)c1,341,1
4608,ClC1=C2C(N(CC3=NC=C(C)C(OC)=C3C)C=N2)=NC(N)=N1,BIIB 021,16736529,"6-Chloro-9-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-9H-purin-2-amine",C14H15ClN6O,[848695-25-0],327.77,Cell biology,Hsp90,Inhibitor,Selective Hsp90 inhibitor,1,COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc32)c1C,828,1
4612,NC(C1=CC(C2=CC=CC(OC(NC3CCCCC3)=O)=C2)=CC=C1)=O,URB 597,1383884,"Cyclohexylcarbamic acid 3'-(Aminocarbonyl)-[1,1'-biphenyl]-3-yl ester",C20H22N2O3,[546141-08-6],342.9,Enzymes,Fatty Acid Amide Hydrolase (FAAH),Inhibitor,Potent and selective FAAH inhibitor,1,NC(=O)c1cccc(-c2cccc(OC(=O)NC3CCCCC3)c2)c1,50,1
4613,O=C(/C=C\C(O)=O)O.CCCCCNC(N/N=C/C1=CNC2=C1C=C(OC)C=C2)=N,Tegaserod maleate,135413539,2-[(5-Methoxy-1H-indol-3-yl)methylene]-N-pentyl-hydrazinecarboximidamide maleate,C16H23N5O.C4H4O4,[189188-57-6],417.46,7-TM Receptors,5-HT4 Receptors,Agonist,5-HT4 partial agonist,1,CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,416,1
4616,CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2,Olmesartan,158781,"4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid",C24H26N6O3,[144689-24-7],464.52,7-TM Receptors,Angiotensin AT1 Receptors,Antagonist,Potent AT1 antagonist,1,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,664,1
4618,CC2=C(N=C(C4=CC=CC=C4)O2)CCOC(C=C1)=CC=C1C[C@@H](CNC(CC)=O)N/C(C)=C\C(C3=CC=C(C(F)(F)F)C=C3)=O,GW 6471,446738,"N-((2S)-2-(((1Z)-1-Methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)prop-1-enyl)amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)propyl)propanamide",C35H36F3N3O4,[880635-03-0],619.67,Nuclear Receptors,PPARalpha Receptors,Antagonist,PPAR? antagonist,6,CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cc1)N/C(C)=C\C(=O)c1ccc(C(F)(F)F)cc1,438,1
4622,[H][C@@]12CC3=C(NN=C3C(O)=O)[C@@]([H])1C2,MK 1903,49763030,"(4aR,5aR)-4,4a,5,5a-Tetrahydro-1H-cyclopropa[4,5]cyclopenta[1,2]pyrazole-3-carboxylic acid",C8H8N2O2,[1268882-43-4],164.16,7-TM Receptors,Hydroxycarboxylic Acid Receptors,Agonist,Potent and selective GPR109A (HCA2) agonist,2,O=C(O)c1n[nH]c2c1C[C@H]1C[C@@H]21,3,1
4624,CC(C)C1=C(NC(NC3=CC=C(Cl)C=C3)=O)C(N(C2=CC=CC=C2)N1C)=O,TC-FPR 43,24776341,"N-(4-Chlorophenyl)-N-[2,3-dihydro-1-methyl-5-(1-methylethyl)-3-oxo-2-phenyl-1H-pyrazol-4-yl]-urea",C20H21ClN4O2,[903895-98-7],384.86,7-TM Receptors,Formyl Peptide Receptors,Agonist,Potent FPR2 agonist,1,CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C,597,0
4625,O=C(N5[C@H]([C@](N6CCN(C)CCC6)=S)CCC5)NCC(C(C)=C2)=CC=C2C(N1C(C=CC=C3)=C3NC(N(C)N=C4)=C4C1)=O,TC OT 39,135413563,"(2S)-N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-2-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)thioxomethyl]-1-pyrrolidinecarboxamide",C32H40N8O2S,[479232-57-0],618.8,7-TM Receptors,Oxytocin Receptors,Agonist,Potent non-peptide oxytocin receptor partial agonist; also V1a receptor antagonist,1,Cc1cc(C(=O)N2Cc3cnn(C)c3Nc3ccccc32)ccc1CNC(=O)N1CCC[C@H]1C(=S)N1CCCN(C)CC1,496,1
4629,FC1=NC=CC(C2=CC=C(OCC3=CC=CC=C3)C(C(NC4=CC=CN=C4)=O)=C2)=C1,GSK2578215A,68107965,5-(2-Fluoro-4-pyridinyl)-2-(phenylmethoxy)-N-3-pyridinylbenzamide,C24H18FN3O2,[1285515-21-0],399.42,Enzymes,LRRK2,Inhibitor,"Potent, selective LRRK2 inhibitor; brain penetrant",1,O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1,474,1
4630,NC1=NON=C1C3=NC2=CN=CC(CNC4CCNCC4)=C2N3CC.Cl.Cl,SB 747651A dihydrochloride,90488958,"2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-4-piperidinyl-1H-imidazo[4,5-c]pyridine-7-methanamine dihydrochloride",C16H22N8O.2HCl,[1781882-72-1],419.82,Enzymes,Other Kinases,Inhibitor,Potent MSK1 inhibitor; also inhibits other AGC group kinases,3,CCn1c(-c2nonc2N)nc2cncc(CNC3CCNCC3)c21,818,1
4632,O=C(NC3=CC=C(F)C=C3)N2C(C4=CC=C(C(F)(F)F)C=C4)C1=CC=CC=C1CC2,TC-I 2000,57326210,"N-(4-Fluorophenyl)-3,4-dihydro-1-[4-(trifluoromethyl)phenyl]-2(1H)-isoquinolinecarboxamide",C23H18F4N2O,[1159996-20-9],418.9,Ion Channels,TRPM,Blocker,TRPM8 blocker,1,O=C(Nc1ccc(F)cc1)N1CCc2ccccc2C1c1ccc(C(F)(F)F)cc1,513,1
4641,CC2=NC1=CC=CC=C1N2S(C3=C(C)C=CC([N+]([O-])=O)=C3)(=O)=O,BI 6015,3269393,2-Methyl-1-[(2-methyl-5-nitrophenyl)sulfonyl]-1H-benzimidazole,C15H13N3O4S,[93987-29-2],331.35,Cell biology,Other Transcription Factors,Antagonist,Hepatocyte nuclear factor 4? (HNF4?) antagonist,1,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)n1c(C)nc2ccccc21,88,0
4642,ClC1=CC=C(C(C(C)C)C(NC2=NC=CS2)=O)C=C1,4-CMTB,4307629,4-chloro-?-(1-methylethyl)-N-2-thiazolylbenzeneacetamide,C14H15ClN2OS,[300851-67-6],299.3,7-TM Receptors,Free Fatty Acid Receptors,Agonist,FFA2 agonist; also exhibits positive allosteric modulatory activity,1,CC(C)C(C(=O)Nc1nccs1)c1ccc(Cl)cc1,604,0
4647,COC1=CC=C(N4N=NN=C4)C=C1CN[C@@H]2[C@H]([C@]3=CC=CC=C3)NCCC2.Cl.Cl,GR 203040,127944,"(2S,3S)-N-[[2-Methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl]-2-phenyl-3-piperidinamine dihydrochloride",C20H24N6O.2HCl,[168398-02-5],446.38,7-TM Receptors,NK1 Receptor,Antagonist,Potent and selective NK1 antagonist,1,COc1ccc(-n2cnnn2)cc1CN[C@H]1CCCN[C@H]1c1ccccc1,357,0
4650,O=C(N3[C@H](C)C4=NC=CC=C4)NC2=C3C1=CC(OC)=C(C5=C(C)ON=C5C)C=C1N=C2.Cl.Cl,I-BET 151 dihydrochloride,170320,"7-(3,5-Dimethyl-4-isoxazolyl)-1,3-dihydroxy-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-2H-imidazo[4,5-c]quinolin-2-one dihydrochloride",C23H21N5O3.2HCl,[1883545-47-8],506.39,Cell biology,Bromodomains,Inhibitor,BET bromodomain inhibitor; also promotes differentiation of hiPSCs into megakaryocytes,5,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12,379,1
4652,O=C(CCCCCCC(NO)=O)NC1=CC=CC=C1,SAHA,5311,N-Hydroxy-N'-phenyloctanediamide,C14H20N2O3,[149647-78-9],264.32,Enzymes,Non-selective HDACs,Inhibitor,Class I and II HDAC inhibitor,2,O=C(CCCCCCC(=O)Nc1ccccc1)NO,211,1
4655,CC1=CC=C(S(OCC(NC2=CC=C(C(O)=O)C(O)=C2)=O)(=O)=O)C=C1,NSC 74859,252682,2-Hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]benzoic acid,C16H15NO7S,[501919-59-1],365.36,Cell biology,STAT,Inhibitor,Selective STAT3 inhibitor,1,Cc1ccc(S(=O)(=O)OCC(=O)Nc2ccc(C(=O)O)c(O)c2)cc1,105,1
4657,CN(C)CCC2=CNC1=CC=C(C[C@H](N3)COC3=O)C=C12,Zolmitriptan,60857,(4S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone,C16H21N3O2,[139264-17-8],287.36,7-TM Receptors,5-HT1D Receptors,Agonist,Potent 5-HT1B/1D/1F agonist,1,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,797,0
4660,NC1=C2C(N(C4=CC=CC(C5=CN=NN5CC6=CC(C7=CC=CC=C7)=CC=C6)=C4)N=C2C3=CC=C(Cl)C=C3)=NC=N1,KB SRC 4,73349077,"1-[3-[1-([1,1'-Biphenyl]-3-ylmethyl)-1H-1,2,3-triazol-5-yl]phenyl]-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",C32H23ClN8,[1380088-03-8],555.03,Enzymes,Src Kinases,Inhibitor,Potent and selective c-Src inhibitor,1,Nc1ncnc2c1c(-c1ccc(Cl)cc1)nn2-c1cccc(-c2cnnn2Cc2cccc(-c3ccccc3)c2)c1,834,0
4663,CC(C1=CC(OC)=C(O)C=C1)=O,Apocynin,2214,4'-Hydroxy-3'-methoxyacetophenone,C9H10O3,[498-02-2],166.17,Enzymes,NADPH Oxidase,Inhibitor,NADPH-oxidase inhibitor,1,COc1cc(C(C)=O)ccc1O,365,0
4668,O=C(NS(C5=CC=CC=C5)(=O)=O)CC(C=C4)=CC=C4N3CC2=C(OCC)C1=CC=CC=C1C(OCC)=C2C3=O,GW 627368,5312130,"4-(4-,9-Diethoxy-1,3-dihydro-1-oxo-2H-benz[f]isoindol-2-yl)-N-(phenylsulfonyl)benzeneacetamide",C30H28N2O6S,[439288-66-1],549.12,7-TM Receptors,Prostanoid Receptors,Antagonist,Selective EP4 receptor competitive antagonist,1,CCOc1c2c(c(OCC)c3ccccc13)C(=O)N(c1ccc(CC(=O)NS(=O)(=O)c3ccccc3)cc1)C2,190,1
4677,ClC1=CC(Cl)=C(OCCOC2=CC=C(CF)N=C2Cl)C=C1,CYM 50260,44620894,"2-Chloro-3-[2-(2,4-dichlorophenoxy)ethoxy]-6-(fluoromethyl)pyridine",C14H11Cl3FNO2,[1355026-60-6],350.6,7-TM Receptors,Sphingosine-1-phosphate Receptors,Agonist,Potent and selective S1P4 agonist,1,FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1,569,1
4686,OC1=C(C(/C=C/C2=CC=C(O)C=C2)=O)C(OC)=CC(O)=C1C/C=C(C)/C,Xanthohumol,639665,"(2E)-1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one",C21H22O5,[6754-58-1],358.9,Enzymes,p97 ATPase,Inhibitor,p97 ATPase (VCP) inhibitor,2,COc1cc(O)c(CC=C(C)C)c(O)c1C(=O)/C=C/c1ccc(O)cc1,889,1
4691,O=C2C1=CC=CC=C1C(C(NCC4=CC=C(OC(F)(F)F)C=C4)=O)N2C3CCOCC3,NAV 26,44540282,"2,3-Dihydro-3-oxo-2-(tetrahydro-2H-pyran-4-yl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-1H-isoindole-1-carboxamide",C22H21F3N2O4,[1198160-14-3],434.41,Ion Channels,Voltage-gated Sodium Channels,Blocker,Selective Nav1.7 channel blocker,1,O=C(NCc1ccc(OC(F)(F)F)cc1)C1c2ccccc2C(=O)N1C1CCOCC1,702,1
4694,O=C1CN=C(C3=CC=CN3)C2=C(C=CC(Cl)=C2)N1,Ro 5-3335,64983,"7-Chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-2H-1,4-benzodiazepin-2-one",C13H10ClN3O,[30195-30-3],259.69,Cell biology,Other Transcription Factors,Inhibitor,Core binding factor inhibitor; attenuates hematopoiesis,2,O=C1CN=C(c2ccc[nH]2)c2cc(Cl)ccc2N1,766,0
4708,ClC(C=C(C3=CC(C(O)=O)=NN3C4=CC=CC(OC)=C4)C=C2)=C2C1CCCCC1,TC LPA5 4,66552906,5-(3-Chloro-4-cyclohexylphenyl)-1-(3-methoxyphenyl)-1H-pyrazole-3-carboxylic acid,C23H23ClN2O3,[1393814-38-4],410.89,7-TM Receptors,Lysophosphatidic Acid Receptors,Antagonist,LPA5 receptor antagonist,1,COc1cccc(-n2nc(C(=O)O)cc2-c2ccc(C3CCCCC3)c(Cl)c2)c1,52,1
4712,OC(C2=CC(CO)=C(O)C=C2)CNCCCCCCOCCCCC1=CC=CC=C1.OC4=C(C(O)=O)C=CC3=CC=CC=C34,Salmeterol xinafoate,56801,"4-Hydroxy-?1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylic acid salt",C25H37NO4.C11H8O3,[94749-08-3],603.75,7-TM Receptors,Adrenergic Beta-2 Receptors,Agonist,Long-acting ?2 agonist; bronchodilator,1,OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,431,0
4715,O=C(OC4=CC=C([N+]([O-])=O)C=C4)N(CC3)CCN3CC1=CC(OC2=CC=CC=C2)=CC=C1,JZL 195,46232606,4-[(3-Phenoxyphenyl)methyl]-1-piperazinecarboxylic acid 4-nitrophenyl ester,C24H23N3O5,[1210004-12-8],433.46,Enzymes,Fatty Acid Amide Hydrolase (FAAH),Inhibitor,Dual FAAH and MAGL inhibitor,1,O=C(Oc1ccc([N+](=O)[O-])cc1)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1,451,1
4716,FC1=CC=C(/C=C(C)/C(CC)=N/O)C=C1,A 967079,42641861,"(1E,3E)-1-(4-Fluorophenyl)-2-methyl-1-pentene-3-one oxime",C12H14FNO,[1170613-55-4],207.24,Ion Channels,TRPA1,Blocker,Selective TRPA1 channel blocker,1,CCC(=N\O)/C(C)=C/c1ccc(F)cc1,884,0
4724,FC1=CC=C(N2N=CC(S(N(C3=CC=C(NC(NC4=CC=CC=C4)=O)C=C3)C)(=O)=O)=C2)C=C1,BTT 3033,49841251,1-(4-Fluorophenyl)-N-methyl-N-[4[[(phenylamino)carbonyl]amino]phenyl]-1H-pyrazole-4-sulfonamide,C23H20FN5O3S,[1259028-99-3],465.5,Enzyme-Linked Receptors,Integrins,Inhibitor,Selective inhibitor of integrin ?2?1,1,CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(-c2ccc(F)cc2)c1,510,0
4731,O=C(CCC3=CC=C(OC)C(OC)=C3)NC2=NC1=CC=C(Cl)C=C1S2,KY 02111,8582409,"N-(6-Chloro-2-benzothiazolyl)-3,4-dimethoxybenzenepropanamide",C18H17ClN2O3S,[1118807-13-8],376.86,Cell biology,Cardiomyocyte Stem Cells,Other,Inhibits canonical Wnt signaling. Promotes differentiation of human ESCs and iPSCs into cardiomyocytes,1,COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC,157,1
4732,CC2=CC(N3CCCCC3)=NC1=CC=CC=C12,ML 204,230710,4-Methyl-2-(1-piperidinyl)quinoline,C15H18N2,[5465-86-1],226.32,Ion Channels,TRPC,Blocker,Selective TRPC4 blocker,1,Cc1cc(N2CCCCC2)nc2ccccc12,155,1
4735,OCCOCCN(CC4)CCN4C2=NC1=CC=CC=C1SC3=C2C=CC=C3.O=C(/C=C/C(O)=O)O.OCCOCCN(CC8)CCN8C6=NC5=CC=CC=C5SC7=C6C=CC=C7,Quetiapine hemifumarate,5281025,"2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol hemifumarate",C21H25N3O2S.0.5C4H4O4,[111974-72-2],441.54,7-TM Receptors,Non-selective 5-HT2,Antagonist,5-HT2 antagonist; also D2 antagonist; atypical antipsychotic,1,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,270,0
4737,O=C1C(C#N)=C[C@@]2(C)[C@](CC[C@]([C@@]4(C)[C@]([H])3[C@@]5([H])[C@@](CCC(C)(C)C5)([C@](N6C=NC=C6)=O)CC4)(C)C2=CC3=O)([H])C(C)1C,CDDO Im,9958995,"1-(2-Cyano-3,12,28-trioxooleana-1,9(11)-dien-28-yl)-1H-imidazole",C34H43N3O3,[443104-02-7],541.72,Cell biology,Nrf2,Activator,Nrf2 signaling activator,2,CC1(C)CC[C@]2(C(=O)n3ccnc3)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1,11,1
4745,FC(F)C1=NN(C2=C(Cl)C=CC=C2Cl)C(C3=CN=C(NC(C(C)C)=O)S3)=C1,LIMKi 3,56965901,"N-[5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methylpropanamide",C17H14Cl2F2N4OS,[1338247-35-0],431.29,Enzymes,LIMK,Inhibitor,Potent LIM kinase inhibitor; antitumor,3,CC(C)C(=O)Nc1ncc(-c2cc(C(F)F)nn2-c2c(Cl)cccc2Cl)s1,491,1
4746,CC2CC(C)(C)N(C(CN3C(C(C=CC=C4)=C4C3=O)=O)=O)C1=CC=CC=C12,ML SA1,2880983,"2-[2-(3,4-Dihydro-2,2,4-trimethyl-1(2H)-quinolinyl)-2-oxoethyl]-1H-isoindole-1,3(2H)-dione",C22H22N2O3,[332382-54-4],362.42,Ion Channels,TRPML,Activator,Activator of TRPML channels,1,CC1CC(C)(C)N(C(=O)CN2C(=O)c3ccccc3C2=O)c2ccccc21,143,1
4754,O=C(NC2=CC(Br)=CC=C2)C1=CC(S(N3CCCCCC3)(=O)=O)=CC=C1,AK 7,1328033,N-(3-Bromophenyl)-3-[(hexahydro-1H-azepin-1-yl)sulfonyl]benzamide,C19H21BrN2O3S,[420831-40-9],437.35,Enzymes,Class III HDACs (Sirtuins),Inhibitor,Selective SIRT2 inhibitor; brain penetrant,1,O=C(Nc1cccc(Br)c1)c1cccc(S(=O)(=O)N2CCCCCC2)c1,483,0
4758,CC1=C(NS(=O)(C)=O)C=C(C3=NN2C(C(NC(OCC)=O)=C3)=NN=C2C)C=C1,Bromosporine,72943187,"N-[(6-3-Methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate",C17H20N6O4S,[1619994-69-2],408.94,Cell biology,Bromodomains,Inhibitor,Broad spectrum bromodomain inhibitor,1,CCOC(=O)Nc1cc(-c2ccc(C)c(NS(C)(=O)=O)c2)nn2c(C)nnc12,497,1
4767,O=S(C1=CC=C(C(F)(F)F)C(S(NC3CCNCC3)(=O)=O)=C1)(C2=CC=CC=C2)=O.Cl,WAY 316606 hydrochloride,25186563,5-(Phenylsulfonyl)-N-4-piperidinyl-2-(trifluoromethyl)benzene sulfonamide hydrochloride,C18H19F3N2O4S2.HCl,[1781835-02-6],484.94,Cell biology,Beta-catenin,Other,Secreted Frizzled-related protein-1 (sFRP-1) inhibitor; increases Wnt signaling,1,O=S(=O)(NC1CCNCC1)c1cc(S(=O)(=O)c2ccccc2)ccc1C(F)(F)F,98,1
4773,CC(C)(C)C1=CC(C(/C(C#N)=N/NC2=CC=CC(Cl)=C2)=O)=NO1,ESI 09,6077765,"?-[(2-(3-Chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-?-oxo-3-isoxazolepropanenitrile",C16H15ClN4O2,[263707-16-0],330.77,Enzymes,EPAC,Inhibitor,Epac inhibitor,2,CC(C)(C)c1cc(C(=O)/C(C#N)=N/Nc2cccc(Cl)c2)no1,603,1
4774,O=C1NC=CC(NC[C@H](C5=CC=CC(Cl)=C5)O)=C1C3=NC2=CC(N4CCOCC4)=CC(C)=C2N3,BMS 536924,135440466,4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone,C25H26ClN5O3,[468740-43-4],479.96,Enzyme-Linked Receptors,Insulin and insulin-like Receptors,Inhibitor,Dual IR/IGF1R inhibitor,1,Cc1cc(N2CCOCC2)cc2nc(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c12,618,1
4775,O=S(C1(C(NO)=O)CCN(CCOC)CC1)(C2=CC=C(OC3=CC=C(OC(F)(F)F)C=C3)C=C2)=O.Cl,SD 2590 hydrochloride,9893894,N-Hydroxy-1-(2-methoxyethyl)-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide hydrochloride,C22H25F3N2O7S.HCl,[226395-93-3],554.96,Enzymes,Matrix Metalloprotease,Inhibitor,Potent MMP inhibitor,1,COCCN1CCC(C(=O)NO)(S(=O)(=O)c2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)CC1,703,1
4776,CN([C@@](CC3=CC=C(Br)C=C3)(C)C(N1C2=CC(Cl)=CC(Cl)=C2)=O)C1=O,BIRT 377,9803375,"(5R)-5-[(4-Bromophenyl)methyl]-3-(3,5-dichlorophenyl)-1,5-dimethyl-2,4-imidazolidinedione",C18H15BrCl2N2O2,[213211-10-0],442.13,Enzyme-Linked Receptors,Integrins,Modulator,Potent negative allosteric modulator of LFA-1,1,CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@@]1(C)Cc1ccc(Br)cc1,586,1
4777,O=[C@@]([C@H]3CCCCN3S(C4=CC=C(C)C=C4)(=O)=O)NC1=NC(C2=CC=C(OC)C=C2)=CS1,ML 277,53347902,(2R)-N-[4-(4-Methoxyphenyl)-2-thiazolyl]-1-[(4-methylphenyl)sulfonyl]-2-piperidinecarboxamide,C23H25N3O4S2,[1401242-74-7],476.09,Ion Channels,Voltage-Gated Potassium Channels,Activator,Selective KV7.1 (KCNQ1) potassium channel activator; augments IKs current,1,COc1ccc(-c2csc(NC(=O)[C@H]3CCCCN3S(=O)(=O)c3ccc(C)cc3)n2)cc1,108,0
4778,CCS(C1=NC(C2=CC=CC(OCC3=CC=CC=C3)=C2)=CC(C(F)(F)F)=N1)=O,BETP,49868481,2-(Ethylsulfinyl)-4-[3-(phenylmethoxy)phenyl]-6-(trifluoromethyl)pyrimidine,C20H17F3N2O2S,[1371569-69-5],406.42,7-TM Receptors,Glucagon-Like Peptide 1 Receptors,Modulator,Positive allosteric modulator of GLP-1 receptors,1,CCS(=O)c1nc(-c2cccc(OCc3ccccc3)c2)cc(C(F)(F)F)n1,206,1
4780,C\C(CN(CCC2N(C)CCC2)C(C3=CC(OC)=C(OC)C(OC)=C3)=O)=C/C1=C(F)C=CC=C1.OC(/C=C/C(O)=O)=O,VUF 11207 fumarate,90488970,"N-[(2E)-3-(2-Fluorophenyl)-2-methyl-2-propen-1-yl]-3,4,5-trimethoxy-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]benzamide fumarate",C27H35FN2O4.C4H4O4,[1785665-61-3],604.67,7-TM Receptors,Chemokine CXC Receptors,Agonist,Potent ACKR3 (CXCR7) agonist,1,COc1cc(C(=O)N(CCC2CCCN2C)C/C(C)=C/c2ccccc2F)cc(OC)c1OC,333,1
4781,O=C(NC4C(NCCCC4)=O)C1=C(NC(C2=CC3=C(C=CC=C3)S2)=O)C=CC=C1,ANA 12,2799722,N-[2-[[(Hexahydro-2-oxo-1H-azepin-3-yl)amino]carbonyl]phenyl]benzo[b]thiophene-2-carboxamide,C22H21N3O3S,[219766-25-3],416.5,Enzyme-Linked Receptors,Trk Receptors,Antagonist,TrkB receptor antagonist,2,O=C(Nc1ccccc1C(=O)NC1CCCCNC1=O)c1cc2ccccc2s1,532,1
4782,O=C(NCC2(N(C)C)CCCC2)C1=CC(OC)=C(OCC3=CC=CC=C3)C(OC)=C1.Cl,Org 25543 hydrochloride,10095215,"N-[[1-(Dimethylamino)cyclopentyl]methyl]-3,5-dimethoxy-4-(phenylmethoxy)benzamide hydrochloride",C24H32lN2O4.HCl,[495076-64-7],453.48,Transporters,Glycine Transporters,Inhibitor,Potent and selective GlyT2 inhibitor,1,COc1cc(C(=O)NCC2(N(C)C)CCCC2)cc(OC)c1OCc1ccccc1,203,1
4784,CC(OC(C5=CC=CC=C5)=N4)=C4CCOC(C3=C2SC=C3)=CC=C2CC1C(NC(S1)=O)=O,Edaglitazone,9825701,"5-[[4-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy]benzo[b]thien-7-yl]methyl]-2,4-thiazolidinedione",C24H20N2O4S2,[213411-83-7],464.56,Nuclear Receptors,PPARgamma Receptors,Agonist,Potent and selective PPAR? agonist; antidiabetic,1,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2SC(=O)NC2=O)c2sccc12,438,0
4788,BrC1=CC(C2=NN=NN2)=C(NC(NC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)=S)C=C1,NS 11021,24825677,"N'-[3,5-Bis(trifluoromethyl)phenyl]-N-[4-bromo-2-(2H-tetrazol-5-yl-phenyl]thiourea",C16H9BrF6N6S,[956014-19-0],511.24,Ion Channels,Ca2+-Activated Potassium Channels,Activator,Activator of BKCa (KCa1.1) channels,1,FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nnn[nH]2)cc(C(F)(F)F)c1,550,1
4791,CCOC1=NC(C=CC=C5C(O)=O)=C5N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2,Candesartan,2541,"2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid",C24H20N6O3,[139481-59-7],444.95,7-TM Receptors,Angiotensin AT1 Receptors,Antagonist,AT1 antagonist,1,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,664,0
4793,BrC1=C(F)C(Br)=C(CCC(C)N2C=O)C2=C1,CE3F4,21781066,"5,7-Dibromo-6-fluoro-3,4-dihydro-2-methyl-1(2H)-quinolinecarboxaldehyde",C11H10Br2FNO,[143703-25-7],351.01,Enzymes,EPAC,Inhibitor,Noncompetitive Epac1 inhibitor,1,CC1CCc2c(cc(Br)c(F)c2Br)N1C=O,33,1
4796,FC(C=C3)=CC=C3[C@]1(CCCN(C)C)OCC2=C1C=CC(C#N)=C2.OC(C(O)=O)=O,Escitalopram oxalate,146571,"(+)-(S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalate",C20H21FN2O.C2H2O4,[219861-08-2],414.43,Transporters,5-HT Transporters,Inhibitor,Selective serotonin reuptake inhibitor (SSRI),2,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,75,1
4798,CNCC[C@@H](C3=CC=CS3)OC2=CC=CC1=CC=CC=C12.Cl,(S)-Duloxetine hydrochloride,60834,(+)-(S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine hydrochloride,C18H19NOS.HCl,[136434-34-9],333.88,Transporters,5-HT Transporters,Inhibitor,Potent 5-HT and NA reuptake inhibitor (SNRI); also blocks dopamine reuptake,1,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,774,1
4806,NCCNC1=NC3=C(C=C(C)C=C3)N2C1=NC=C2C.Cl,BMS 345541,9926054,"N1-(1,8-Dimethylimidazo[1,2-a]quinoxalin-4-yl)-1,2-ethanediamine hydrochloride",C14H17N5.HCl,[547757-23-3],309.8,Enzymes,IkB Kinase,Inhibitor,Selective allosteric inhibitor of IKK; anti-inflammatory,1,Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1,831,1
4809,O=C2N(CC3=CC=C(OCCN(C)C)N=C3)C1=NC(NCCCC)=NC(N)=C1N2,DSR 6434,25071151,"6-Amino-2-(butylamino)-9-[[6-[2-(dimethylamino)ethoxy]-3-pyridinyl]methyl]-7,9-dihydro-8H-purin-8-one",C19H28N8O2,[1059070-10-8],413.99,Enzyme-Linked Receptors,Toll-like Receptors,Agonist,Potent TLR7 agonist,1,CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1,666,1
4818,FC(C=C4)=CC=C4C(N(C3)CC3(C(O)=O)COC2=CC1=CC=C(OC)C=C1C=C2)=O,PF 04418948,25114442,1-(4-Fluorobenzoyl)-3-[[(6-methoxy-2-naphthalenyl)oxy]methyl]-3-azetidinecarboxylic acid,C23H20FNO5,[1078166-57-0],409.41,7-TM Receptors,Prostanoid Receptors,Antagonist,Potent and selective EP2 receptor antagonist,1,COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1,278,1
4825,O=C(C4=CC=C(C(C)(C)C)C=C4)NC1=CN2C(C=CC(N3C=NC=C3)=C2)=N1.Cl.Cl,TC ASK 10,68661090,"4-(1,1-Dimethylethyl)-N-[6-(1H-imidazol-1-yl)imidazo[1,2-a]pyridin-2-yl]benzamide dihydrochloride",C21H21N5O.2HCl,[1005775-56-3],441.36,Enzymes,ASK1,Inhibitor,Potent and selective ASK1 inhibitor; orally bioavailable,2,CC(C)(C)c1ccc(C(=O)Nc2cn3cc(-n4ccnc4)ccc3n2)cc1,477,0
4826,NC1=C(C)C(C)=C(NCC(N(C)C2CCN(CC3=CC=C(C(N)=O)C=C3)CC2)=O)C(C)=C1C,SUN 11602,22245705,"4-[[4-[[2-[(4-Amino-2,3,5,6-tetramethylphenyl)amino]acetyl]methylamino]-1-piperidinyl]methyl]benzamide",C26H37N5O2,[704869-38-5],451.61,Enzyme-Linked Receptors,FGFR,Other,Basic fibroblast growth factor (bFGF) mimetic; neuroprotective,2,Cc1c(C)c(NCC(=O)N(C)C2CCN(Cc3ccc(C(N)=O)cc3)CC2)c(C)c(C)c1N,303,1
4836,CC(C)(C#N)C1=CC=CC(C(NC2=CC(NC3=CC(C(N(C)C=N4)=O)=C4C=C3)=C(C)C=C2)=O)=C1,AZ 628,11676786,"3-(1-Cyano-1-methylethyl)-N-[3-[(3,4-dihydro-3-methyl-4-oxo-6-quinazolinyl)amino]-4-methylphenyl]benzamide",C27H25N5O2,[878739-06-1],451.52,Enzymes,Raf Kinase,Inhibitor,Potent Raf kinase inhibitor,1,Cc1ccc(NC(=O)c2cccc(C(C)(C)C#N)c2)cc1Nc1ccc2ncn(C)c(=O)c2c1,485,1
4837,O=C(NC3=CC=[C@@]([C@H]4CC[C@H](CC(O)=O)CC4)C=C3)C1=NN=C(NC2=CC(F)=C(F)C=C2)O1,AZD 3988,23648867,"trans-4-[-[[[5-[(3,4-Difluorophenyl)amino]-1,3,4-oxadiazol-2-yl]carbonyl]amino]phenyl]cyclohexaneacetic acid",C23H22F2N4O4,[892489-52-0],456.44,Enzymes,Diacylglycerol O-Acyltransferase,Inhibitor,Potent and selective DGAT-1 inhibitor,1,O=C(O)C[C@H]1CC[C@H](c2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cc2)CC1,521,1
4839,OC(C1=C(N[C@@H](C2=CC(C)=CN3C2=NC(N4CCOCC4)=CC3=O)C)C=CC=C1)=O,AZD 6482,44137675,"(-)-2-[[(1R)-1-[7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid",C22H24N4O4,[1173900-33-8],430.97,Enzymes,PI 3-Kinase,Inhibitor,Potent and selective PI 3-K? inhibitor,1,Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,311,1
4842,O=C2NC1=CC(C(N(C)C)=O)=CC=C1/C2=C(C4=CC=CC=C4)/NC3=CC(CN(C)C)=CC=C3,BIX 02189,46931012,"(3Z)-3-[[[3-[(Dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-N,N-dimethyl-2-oxo-1H-indole-6-carboxamide",C27H28N4O2,[1265916-41-3],467.56,Enzymes,MEK,Inhibitor,Selective MEK5 and ERK5 inhibitor,2,CN(C)Cc1cccc(N/C(=C2\C(=O)Nc3cc(C(=O)N(C)C)ccc32)c2ccccc2)c1,247,0
4844,CC1=CC(C)=C(S(N2C(C)=CC(C)=C2)(=O)=O)C(C)=C1,HJC 0350,22200891,"2,4-Dimethyl-1-[(2,4,6-trimethylphenyl)sulfonyl]-1H-pyrrole",C15H19NO2S,[885434-70-8],277.38,Enzymes,EPAC,Inhibitor,Selective Epac2 inhibitor,1,Cc1cc(C)c(S(=O)(=O)n2cc(C)cc2C)c(C)c1,77,1
4845,O=C(NC3=CC(C(NC)=O)=CC=C3)N1CCC(OC2=C(Cl)C=CC=C2)CC1,A 939572,24905400,4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-piperidinecarboxamide,C20H22ClN3O3,[1032229-33-6],387.86,Enzymes,Stearoyl-CoA 9-desaturase,Inhibitor,Potent SCD-1 inhibitor,1,CNC(=O)c1cccc(NC(=O)N2CCC(Oc3ccccc3Cl)CC2)c1,484,1
4854,BrC1=CC(CCC2=C(F)C=CC=C2C3=NCCN3)=C(OC)C=C1.Cl,ML 00253764 hydrochloride,90488979,"2-[2-[2-(5-Bromo-2-methoxyphenyl)ethyl]-3-fluorophenyl]-4,5-dihydro-2-1H-imidazole hydrochloride",C18H18BrFN2O.HCl,[1706524-94-8],413.71,7-TM Receptors,Melanocortin Receptors,Antagonist,Melanocortin MC4 receptor antagonist; brain penetrant,2,COc1ccc(Br)cc1CCc1c(F)cccc1C1=NCCN1,359,1
4857,CC(C)C1=CC=C2C(C(C(C=C(C(O)=O)C(N)=N3)=C3O2)=O)=C1,Amlexanox,2161,"2-Amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-carboxylic acid",C16H14N2O4,[68302-57-8],298.29,Enzymes,TANK binding kinase (TBK),Inhibitor,Selective inhibitor of TBK,1,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1,803,1
4862,FC(F)(F)C(C=C4)=CC=C4C1=CC=C(C(C3=CC=C(C5CCNCC5)C=C3)=CC(C(O)=O)=C2)C2=C1.Cl,PPTN hydrochloride,121513852,4-[4-(4-Piperidinyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthalenecarboxylic acid hydrochloride,C29H24F3NO2.HCl,,516.46,7-TM Receptors,Purinergic P2Y Receptors,Antagonist,High affinity and selective P2Y14 antagonist,1,O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1,555,1
4865,C1(NC2=CC(NC=N3)=C3C=C2)=NC=CC(NC4=CC(C5CC5)=NN4)=N1,APY 29,42627755,"N2-1H-Benzimidazol-6-yl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine",C17H16N8,[1216665-49-4],350.38,Enzymes,IRE1,Other,Inhibits IRE1? autophosphorylation; activates IRE1? endoribonuclease activity,2,c1cc(Nc2cc(C3CC3)n[nH]2)nc(Nc2ccc3nc[nH]c3c2)n1,621,1
4868,CC1=C(S(NC2=CC=C(C(O)(C(F)(F)F)C(F)(F)F)C=C2)(=O)=O)SC(NC(C)=O)=N1,SR 1001,44241473,"N-[4-Methyl-5-[[[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]amino]sulfonyl]-2-thiazolylacetamide",C15H13F6N3O4S2,[1335106-03-0],477.4,Nuclear Receptors,Retinoic Acid-related Orphan Receptors,Inverse Agonist,ROR?/? inverse agonist,1,CC(=O)Nc1nc(C)c(S(=O)(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)s1,519,0
4869,FC(C=C(C(O)(C(F)(F)F)C(F)(F)F)C=C4)=C4C(C=C3)=CC=C3CN(CC2)CCN2CC1=CC=NC=C1,SR 2211,51035449,"2-Fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-a,a-bis(trifluoromethyl)-[1,1'-biphenyl]-4-methanol",C26H24F7N3O,[1359164-11-6],527.48,Nuclear Receptors,Retinoic Acid-related Orphan Receptors,Inverse Agonist,Selective ROR? inverse agonist,2,OC(c1ccc(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)c(F)c1)(C(F)(F)F)C(F)(F)F,556,1
4870,O=C2N(C3=CC=CC(OC4=CC=C([N+]([O-])=O)C=C4)=C3)C(C1=CC(C(O)=O)=CC=C12)=O,H2L 5765834,1365686,"2,3-Dihydro-2-[3-(4-nitrophenoxy)phenyl]-1,3-dioxo-1H-isoindole-5-carboxylic acid",C21H12N2O7,[420841-84-5],408.83,7-TM Receptors,Lysophosphatidic Acid Receptors,Antagonist,"LPA1,3,5 antagonist",1,O=C(O)c1ccc2c(c1)C(=O)N(c1cccc(Oc3ccc([N+](=O)[O-])cc3)c1)C2=O,451,0
4872,O=C(OC(C(F)(F)F)C(F)(F)F)N(CC5)CCC5C(C2=CC=C(OCO3)C3=C2)(O)C1=CC(OCO4)=C4C=C1,KML 29,71656212,"4-[Bis(1,3-benzodioxol-5-yl)hydroxymethyl]-1-piperidinecarboxylic acid 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ester",C24H21F6NO7,[1380424-42-9],549.42,Enzymes,MAGL,Inhibitor,Highly potent and selective MAGL inhibitor,2,O=C(OC(C(F)(F)F)C(F)(F)F)N1CCC(C(O)(c2ccc3c(c2)OCO3)c2ccc3c(c2)OCO3)CC1,750,1
4874,OC(C(F)(F)F)(C(F)(F)F)C(C=C1)=CC=C1NC(C2=CC=C(C(F)(F)F)C=C2)=O,SR 1078,17980288,"N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide",C17H10F9NO2,[1246525-60-9],431.25,Nuclear Receptors,Retinoic Acid-related Orphan Receptors,Agonist,ROR?/? agonist,1,O=C(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccc(C(F)(F)F)cc1,519,0
4876,O=C(C3=CC(OC)=C(OC)C(OC)=C3)N(CCOC)C1=NC(C2=CC=CC=C2)=CS1,Eact,3173542,"3,4,5-Trimethoxy-N-(2-methoxyethyl)-N-(4-phenyl-2-thiazolyl)benzamide",C22H24N2O5S,[461000-66-8],428.5,Ion Channels,Ca2+-Activated Chloride Channels,Activator,Activator of Ca2+-activated Cl- channel transmembrane protein 16A (TMEM16A),1,COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(-c2ccccc2)cs1,333,0
4880,CC(C)C1=CC(C2=NC(C=CC=C3)=C3NC2=O)=C(NC(C4=CC=CS4)=O)C=C1,ML 281,53377448,"N-[2-(3,4-Dihydro-3-oxo-2-quinoxalinyl)-4-(1-methylethyl)phenyl]-2-thiophenecarboxamide",C22H19N3O2S,[1404437-62-2],389.47,Enzymes,Other Kinases,Inhibitor,STK33 inhibitor,1,CC(C)c1ccc(NC(=O)c2cccs2)c(-c2nc3ccccc3[nH]c2=O)c1,162,1
4883,O=C(N[C@H](CC3=CC=CC=C3)[C@@](O)=O)C2=C(Cl)C1=CC=C(F)C=C1S2,CU CPT 4a,53242268,N-[(3-Chloro-6-fluorobenzo[b]thien-2-yl)carbonyl]-D-phenylalanine,C18H13ClFNO3S,[1279713-77-7],377.82,Enzyme-Linked Receptors,Toll-like Receptors,Inhibitor,Selective TLR3 inhibitor,2,O=C(N[C@H](Cc1ccccc1)C(=O)O)c1sc2cc(F)ccc2c1Cl,195,1
4888,CC(C)CNC1=NC(NCC2=CSC(C3=CC=CC=C3)=N2)=NC=C1.Cl,KHS 101 hydrochloride,90488983,"N4-(2-Methylpropyl)-N2-[(2-phenyl-4-thiazolyl)methyl]-2,4-pyrimidinediamine hydrochloride",C18H21N5S.HCl,,384.93,Cell biology,Neural Stem Cells,Other,Selective inducer of neuronal differentiation in hippocampal neural progenitors,1,CC(C)CNc1ccnc(NCc2csc(-c3ccccc3)n2)n1,174,1
4891,COC(C(OC)=C1)=CC=C1C2=CC(OC[C@H]3CCCN(C)C3)=C(OCCN(C(CC)=O)C4)C4=C2,I-CBP 112,90488984,"1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one",C27H36N2O5,[1640282-31-0],486.61,Cell biology,Bromodomains,Inhibitor,Selective CBP/p300 BRD inhibitor,1,CCC(=O)N1CCOc2c(cc(-c3ccc(OC)c(OC)c3)cc2OC[C@H]2CCCN(C)C2)C1,377,1
4897,O=C(N(C3CCCCC3)C2CCCCC2)C1=NOC(C4CC4)=C1,CYM 5541,17253208,"N,N-Dicyclohexyl-5-cyclopropyl-3-isoxazolecarboxamide",C19H28N2O2,[945128-26-7],316.44,7-TM Receptors,Sphingosine-1-phosphate Receptors,Agonist,Selective S1P3 receptor allosteric agonist,1,O=C(c1cc(C2CC2)on1)N(C1CCCCC1)C1CCCCC1,54,1
4899,ClC1=C(OC)C(NC(C4=CC=CN=C4C)=O)=C2C(C(C=CN=C3)=C3N2)=C1.Cl.Cl,ML 120B dihydrochloride,90488985,"N-(6-Chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl-3-pyridinecarboxamide dihydrochloride",C19H15ClN4O2.2HCl,[1782573-78-7],453.23,Enzymes,IkB Kinase,Inhibitor,Novel IKK2-selective inhibitor,1,COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C,380,1
4902,ClC1=CC=C(C(NC(C)CCC)=O)C=C1Cl,NSC 405020,346721,"3,4-Dichloro-N-(1-methylbutyl)benzamide",C12H15Cl2NO,[7497-07-6],260.16,Enzymes,Class I HDACs,Inhibitor,Histone deacetylase inhibitor,1,CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1,623,0
4904,CC(C)N1CCN(C2=NC=C(C3=CC(N(C(C)C)N=C4)=C4C(C(NCC5=C(CCC)C=C(C)NC5=O)=O)=C3)C=C2)CC1,UNC 1999,72551585,"N-[(1,2-Dihydro-6-methyl-2-oxo-4-propyl-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-[4-(1-methylethyl)-1-piperazinyl]-3-pyridinyl]-1H-indazole-4-carboxamide",C33H43N7O2,[1431612-23-5],578.75,Enzymes,EZH2,Inhibitor,Potent and selective EZH2/EZH1 inhibitor,1,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccc(N3CCN(C(C)C)CC3)nc2)cc2c1cnn2C(C)C,660,1
4905,CC(C)N1CCN(C2=NC=C(C3=CC(N(C(C)C)N=C4)=C4C(C(N(C)CC5=C(CCC)C=C(C)N(C)C5=O)=O)=C3)C=C2)CC1,UNC 2400,91691116,"N-[(1,2-Dihydro-1,6-dimethyl-2-oxo-4-propyl-3-pyridinyl)methyl]-N-methyl-1-(1-methylethyl)-6-[6-[4-(1-methylethyl)-1-piperazinyl]-3-pyridinyl]-1H-indazole-4-carboxamide",C35H47N7O2,[1433200-49-7],602.29,Enzymes,EZH2,Control,Negative control of UNC 1999 (Cat. No. 4904),1,CCCc1cc(C)n(C)c(=O)c1CN(C)C(=O)c1cc(-c2ccc(N3CCN(C(C)C)CC3)nc2)cc2c1cnn2C(C)C,660,0
4907,CC1=CC(C)=CC(C)=C1C2=NOC3C2C4CCC3C4,SN 2,11834987,"3a,4,5,6,7,7a-Hexahydro-3-(2,4,6-trimethylphenyl)-4,7-methano-1,2-benzisoxazole",C17H21NO,[823218-99-1],255.35,Ion Channels,TRPML,Activator,Selective TRPML3 channel activator,1,Cc1cc(C)c(C2=NOC3C4CCC(C4)C23)c(C)c1,81,1
4916,CC(C)(N)C1=NC(C2=CC=C(OC(F)(F)F)C=C2)=CN1,PF 04885614,65459349,1-Methyl-[1-[4-(4-trifluoromethoxy)phenyl]-imidazol-2-yl]-ethanamine,C13H14F3N3O,,289.76,Ion Channels,Voltage-gated Sodium Channels,Blocker,Potent and selective NaV1.8 channel blocker; active in vivo,1,CC(C)(N)c1nc(-c2ccc(OC(F)(F)F)cc2)c[nH]1,705,1
4942,[Ca++].O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=CC=CC=C2N=C1C1CC1)CC([O-])=O.O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=CC=CC=C2N=C1C1CC1)CC([O-])=O,Pitavastatin calcium,5282451,"(3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid hemicalcium salt",C25H23FNO4.0.5Ca,[147526-32-7],476.53,Enzymes,HMG-CoA Reductase,Inhibitor,HMG-CoA reductase inhibitor,1,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,62,1
4946,C1(C(C4=CC=CC=C4)=C(C5=CC=CC=C5)O3)=C3N=CN=C1NC[C@H]2OCCC2,AIM 100,11501591,"5,6-Diphenyl-N-[[(2S)-tetrahydro-2-furanyl]methyl]furo[2,3-d]pyrimidin-4-amine",C23H21N3O2,[873305-35-2],375.93,Enzymes,Ack1,Inhibitor,Potent and selective Ack1 (TNK2) inhibitor,2,c1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1,230,1
4949,O=C2[C@]([C@]3=CC(Cl)=CC=C3OC)(F)C1=CC=C(C(F)(F)F)C=C1N2,MaxiPost,214350,"(3S)-3-(5-Chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl)-2H-Indol-2-one",C16H10ClF4NO2,[187523-35-9],359.7,Ion Channels,Voltage-Gated Potassium Channels,Modulator,Potassium channel modulator; exerts subtype-specific effects,2,COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(C(F)(F)F)ccc21,553,1
4951,COC1=C(OC)C=CC(CCN2CCN(CCCC3=CC=CC=C3)CC2)=C1.Cl.Cl,SA 4503 dihydrochloride,9954941,"1-[2-(3,4-Dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)-piperazine dihydrochloride",C23H32N2O2.2HCl,[165377-44-6],445.93,Other Pharmacology,Sigma1 Receptors,Agonist,Selective ?1 receptor agonist,2,COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC,289,0
4959,O=C1N(C5=CC=C(C(O)=O)C=C5)C(C4=CC=CC(O)=C4)C2=C1NN=C2C3=CC=C(C)C=C3,CID 16020046,16020046,"4-[4,6-Dihydro-4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxopyrrolo[3,4-c]pyrazol-5(1H)-yl]benzoic acid",C25H19N3O4,[834903-43-4],429.94,7-TM Receptors,GPR55,Antagonist,Selective GPR55 antagonist,2,Cc1ccc(-c2n[nH]c3c2C(c2cccc(O)c2)N(c2ccc(C(=O)O)cc2)C3=O)cc1,125,1
4962,ClC(C=C(Cl)C=C2)=C2CCCCCC[C@@H](OC1=O)C[C@]1(O)CC(O)=O,SB 204990,10340264,"(3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid",C18H22Cl2O5,[154566-12-8],389.27,Enzymes,ATP Citrate Lyase,Inhibitor,ATP citrate lyase (ACLY) inhibitor,2,O=C(O)C[C@@]1(O)C[C@@H](CCCCCCc2ccc(Cl)cc2Cl)OC1=O,589,1
4963,O=C(C4=CN=CC=N4)NNC1=NC(C=C(F)C=C3)=C3N2C1=CC=C2.Cl,SC 144 hydrochloride,66921431,"2-(7-Fluoropyrrolo[1,2-a]quinoxalin-4-yl) 2-pyrazinecarboxylic acid hydrazide hydrochloride",C16H11FN6O.HCl,[917497-70-2],358.76,Cell biology,Cytokines,Other,gp130 inhibitor; blocks cytokine-triggered gp130 signaling,3,O=C(NNc1nc2cc(F)ccc2n2cccc12)c1cnccn1,542,1
4968,FC1=CC(C3=NC2=CC(OC)=C(OC)C=C2C(N[C@H]4[C@H]([C@](C)(O)C)CNC4)=N3)=C(O)C=C1.Cl.Cl,CCT 241533 dihydrochloride,49867844,"(3R,4S)-4-[[2-(5-Fluoro-2-hydroxyphenyl)-6,7-dimethoxy-4-quinazolinyl]amino]-?,?-dimethyl-3-pyrrolidinemethanol dihydrochloride",C23H27FN4O4.2HCl,[1962925-28-5],524.42,Enzymes,Checkpoint Kinases,Inhibitor,Potent Chk2 inhibitor,1,COc1cc2nc(-c3cc(F)ccc3O)nc(N[C@@H]3CNC[C@H]3C(C)(C)O)c2cc1OC,396,1
4970,CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1C1=CC=C(C=C1)C#N)C1=NC=C(C=C1)C(O)=O)C1=CC(Cl)=CC(Cl)=C1,BMS 688521,11699447,"6-[(5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4,4]non-7-yl]-3-pyridinecarboxylic acid",C26H19Cl2N5O4,[893397-44-9],554.39,Enzyme-Linked Receptors,Integrins,Inhibitor,Potent inhibitor of the LFA-1/ICAM interaction,1,CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@]12CN(c1ccc(C(=O)O)cn1)C[C@H]2c1ccc(C#N)cc1,587,1
4972,ClC(C=C3)=CN=C3N/N=C(C2=CC=CC=C2)/C1=CC=CC=N1,JIB 04,6519698,5-Chloro-2-[(E)-2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-yl]pyridine,C17H13ClN4,[199596-05-9],308.76,Enzymes,Histone Demethylases,Inhibitor,Pan Jumonji inhibitor; active in vivo,2,Clc1ccc(N/N=C(\c2ccccc2)c2ccccn2)nc1,737,1
4977,O=C(N4CCN(C)CC4)CN[C@@H]1C[C@H]1[C@]2=CC=C(OCC3=CC=CC=C3)C=C2.Cl.Cl,RN 1 dihydrochloride,90488995,"1-(4-methyl-1-piperazinyl)-2-[[(1R*,2S*)-2-[4-phenylmethoxy)phenyl]cyclopropyl]amino]ethanone dihydrochloride",C23H29N3O2.2HCl,[1781835-13-9],470.44,Enzymes,Histone Demethylases,Inhibitor,LSD1 inhibitor,2,CN1CCN(C(=O)CN[C@@H]2C[C@H]2c2ccc(OCc3ccccc3)cc2)CC1,204,1
4978,OC(C=C3)=CC2=C3N(CCC2)C1=NC(NC4=CC=C(S(NCC5CC5)(=O)=O)C=C4)=NC=C1,Pyrintegrin,46223724,"N-(Cyclopropylmethyl)-4-[[4-(3,4-dihydro-6-hydroxy-1(2H)-quinolinyl)-2-pyrimidinyl]amino]benzenesulfonamide",C23H25N5O3S,[1228445-38-2],451.54,Cell biology,Stem Cell Proliferation,Other,Enhances survival of human ESCs following enzymatic dissociation,2,O=S(=O)(NCC1CC1)c1ccc(Nc2nccc(N3CCCc4cc(O)ccc43)n2)cc1,407,1
4982,O=C(N1CCC[C@@H](O)C1)C(C(F)=C2)=CC=C2C#CC3=CC=C(OC)C=C3,ML 337,60204017,[2-Fluoro-4-[2-(4-methoxyphenyl)ethynyl]phenyl][(3R)-3-hydroxy-1-piperidinyl]methanone,C21H20FNO3,[1443118-44-2],353.39,7-TM Receptors,Glutamate (Metabotropic) Group II Receptors,Modulator,Selective negative allosteric modulator of mGlu3 receptors,1,COc1ccc(C#Cc2ccc(C(=O)N3CCC[C@@H](O)C3)c(F)c2)cc1,332,1
4986,NC1=NC=C(C3=CC=CC(O)=C3)C=C1C2=CC(OC)=C(OC)C(OC)=C2,K 02288,46173038,"3-[(6-Amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenol",C20H20N2O4,[1431985-92-0],356.88,Enzyme-Linked Receptors,BMP and Other Activin Receptors,Inhibitor,Type 1 BMP receptor inhibitor,1,COc1cc(-c2cc(-c3cccc(O)c3)cnc2N)cc(OC)c1OC,814,1
4997,O=C(C)/C=C1SC2=CC=C(O)C=C2N\1CC,INDY,69538603,(1Z)-1-(3-Ethyl-5-hydroxy-2(3H)-benzothiazolylidene)-2-propanone,C12H13NO2S,[1169755-45-6],235.3,Enzymes,DYRK,Inhibitor,DYRK1A/B inhibitor,2,CCN1/C(=C/C(C)=O)Sc2ccc(O)cc21,19,0
5009,COC1=CC(C)=C(SC3=CN=C(NC(C4=CC=C(CNC(C)C(C)(C)C)C=C4)=O)S3)C=C1C(N2CCN(C(C)=O)CC2)=O,BMS 509744,11467730,"N-[5-[[5-[(4-Acetyl-1-piperazinyl)carbonyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[[(1,2,2-trimethylpropyl)amino]methyl]benzamide",C32H41N5O4S2,[439575-02-7],623.83,Enzymes,ITK,Inhibitor,Potent and selective ITK inhibitor,2,COc1cc(C)c(Sc2cnc(NC(=O)c3ccc(CNC(C)C(C)(C)C)cc3)s2)cc1C(=O)N1CCN(C(C)=O)CC1,492,1
5011,CC2(C)[C@H](O)[C@@H](N(S(C)(=O)=O)C)C1=CC(OCCCC(F)(F)F)=CC=C1O2,HMR 1556,9887834,"N-[(3R,4S)-3,4-Dihydro-3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy)-2H-1-benzopyran-4-yl]-N-methylmetanesulfonamide",C17H24F3NO5S,[223749-46-0],411.44,Ion Channels,Voltage-Gated Potassium Channels,Blocker,Potent and selective Iks channel blocker,3,CN([C@H]1c2cc(OCCCC(F)(F)F)ccc2OC(C)(C)[C@@H]1O)S(C)(=O)=O,74,0
5012,NC1=C2C(N(C4CCCC4)N=C2C3=CC=C(OC5=CC=CC=C5)C=C3)=NC=N1,PCI 29732,22347110,"1-Cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",C22H21N5O,[330786-25-9],371.44,Enzymes,Brutons Tyrosine Kinase (BTK),Inhibitor,Potent BTK inhibitor,1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCC1,832,1
5013,CC(C2)(C)N(CC)C(C)(C)CC2OC1=CC=C(C(NC3=CC=C(NC(NC4=NOC(C(C)(C)C)=C4)=O)C=C3)=O)N=C1,AC 710,54760053,"N-[4-[[[[5-(1,1-Dimethethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]-5-[(1-ethyl-2,2,6,6-tetramethyl-4-piperidinyl)oxy]-2-pyridinecarboxamide",C31H42N6O4,[1351522-04-7],562.7,Enzyme-Linked Receptors,PDGFR,Inhibitor,Potent and selective PDGFR family inhibitor,1,CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C,322,1
5029,OC1=CC=C(/C=C(C#N)/C(O)=O)C=C1,CHC,5328791,2-Cyano-3-(4-hydroxyphenyl)-2-propenoic acid,C10H7NO3,[28166-41-8],189.17,Transporters,Monocarboxylate Transporters,Inhibitor,MCT inhibitor; decreases glycoloysis,2,N#C/C(=C\c1ccc(O)cc1)C(=O)O,888,1
5032,NC(C=C4)=CC=C4C1=NN(C(C)=O)[C@H](C)CC2=C1C=C(OCO3)C3=C2,Talampanel,164509,"(8R)-7-Acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine",C19H19N3O3,[161832-65-1],350.88,Ion Channels,AMPA Receptors,Antagonist,Non-competitive non-NMDA iGluR antagonist,1,CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3,753,0
5041,O=C1[C@H](N[C@]([C@H]2NCCC2)=O)CCN1CC(N)=O,PAOPA,44281634,(3R)-2-Oxo-3-[[(2S)-2-Pyrrolidinylcarbonyl]amino]-1-pyrrolidineacetamide,C11H18N4O3,[114200-31-6],254.29,7-TM Receptors,D2 Receptors,Modulator,Allosteric modulator of D2 receptors,1,NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O,43,1
5047,O=C(C2=CC=CC=C2C3=O)/C3=C\C1=CC=CN=C1,PRT 4165,207893,"2-(3-Pyridinylmethylene)-1H-Indene-1,3(2H)-dione",C15H9NO2,[31083-55-3],237.04,Enzymes,Ubiquitin E3 Ligases,Inhibitor,Inhibitor of Bmi1/Ring1A; blocks histone H2A ubiquitination,1,O=C1C(=Cc2cccnc2)C(=O)c2ccccc21,763,1
5050,OCCNC1C2=C(C(C=C(C4=CC=CC=C4)C=C3)=C3N2)CCC1,CASIN,2882155,"2-[(2,3,4,9-Tetrahydro-6-phenyl-1H-carbazol-1-yl)amino]ethanol",C20H22N2O,[425399-05-9],310.9,Enzymes,Rho,Inhibitor,Cdc42 inhibitor,2,OCCNC1CCCc2c1[nH]c1ccc(-c3ccccc3)cc21,228,1
5051,O=C(NC2=CC=C(CC(N(C)[C@@H](CC(C)C)C(NCC[C@@H]([C@@](O)=O)N[C@]([C@H]3N(S(C4=CC(Cl)=CC(Cl)=C4)(=O)=O)CCC3)=O)=O)=O)C=C2)NC1=CC=CC=C1C,BIO 5192,10350459,"(2S)-2-[[[(2S)-1-[(3,5-Dichlorophenyl)sulfonyl]-2-pyrrolidinyl]carbonyl]amino]-4-[[(2S)-4-methyl-2-[methyl[2-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]-1-oxopentyl]amino]butanoic acid",C38H46Cl2N6O8S,[327613-57-0],835.8,Enzyme-Linked Receptors,Integrins,Inhibitor,Highly potent and selective inhibitor of integrin ?4?1 (VLA-4),1,Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N(C)[C@@H](CC(C)C)C(=O)NCC[C@H](NC(=O)[C@@H]2CCCN2S(=O)(=O)c2cc(Cl)cc(Cl)c2)C(=O)O)cc1,202,0
5053,FC1(F)CCC(C2=C(F)C=CC=C2)(C3=CC=C(O)C=C3)CC1,AC 186,71245042,"4-[4,4-Difluoro-1-(2-fluorophenyl)cyclohexyl]phenol",C18H17F3O,[1421854-16-1],306.32,Nuclear Receptors,Estrogen and Related Receptors,Agonist,Potent and selective ER? agonist; neuroprotective,1,Oc1ccc(C2(c3ccccc3F)CCC(F)(F)CC2)cc1,886,1
5061,O=C(NCC3=CC=CC(O)=C3)NC1=NC(C2=CC=NC=C2)=CS1.Cl.Cl,RKI 1447 dihydrochloride,90489001,N-[(3-Hydroxyphenyl)methyl]-N'-[4-(4-pyridinyl)-2-thiazolyl]urea dihydrochloride,C16H14N4O2S.2HCl,0,435.32,Enzymes,Rho-kinases,Inhibitor,Potent and selective ROCK inhibitor; antitumor,1,O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1,465,1
5065,C/C(C1=NC=CC=C1)=N\NC(N2CCC2)=S,NSC 319726,5351307,1-Azetidinecarbothioic acid [1-(2-pyridinyl)ethylidene]hydrazide,C11H14N4S,[71555-25-4],234.32,Cell biology,p53,Activator,Reactivator of mutant p53,1,C/C(=N\NC(=S)N1CCC1)c1ccccn1,737,0
5066,O=S(C1=CC=C(NC(C(C4=CC=CC=C4)C3=CC=CC=C3)=O)C=C1)(NC2=NC=CS2)=O,ICA 121431,998021,?-Phenyl-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]benzeneacetamide,C23H19N3O3S2,[313254-51-2],458.56,Ion Channels,Voltage-gated Sodium Channels,Blocker,Potent and selective NaV1.3 and NaV1.1 channel blocker,1,O=C(Nc1ccc(S(=O)(=O)Nc2nccs2)cc1)C(c1ccccc1)c1ccccc1,605,1
5068,CC(C3)(C)CC(C1=C3NC(C)=C(C(OCC)=O)C1C2=CC=C(C4=CC=CC=C4)C=C2)=O,ITD 1,44135961,"4-[1,1'-Biphenyl]-4-yl-1,4,5,6,7,8-hexahydro-2,7,7-trimethyl-5-oxo-3-quinolinecarboxylic acid ethyl ester",C27H29NO3,[1099644-42-4],415.52,Enzyme-Linked Receptors,TGF-beta Receptors,Other,Selective inhibitor of TGF-? signaling; induces cardiomyocyte differentiation in ESCs,1,CCOC(=O)C1=C(C)NC2=C(C(=O)CC(C)(C)C2)C1c1ccc(-c2ccccc2)cc1,129,1
5069,O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1,Teriflunomide,54684141,2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide,C12H9F3N2O2,[108605-62-5],270.21,Enzymes,Dihyroorotate Dehydrogenase,Inhibitor,Inhibitor of DHODH; active metabolite of Leflunomide,1,C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,516,0
5071,NC(N=C2)=NC1=C2C(CC(C3=CC=CO3)C1)=O,NKY 80,2772368,"2-Amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone",C12H11N3O2,[299442-43-6],229.23,Enzymes,Adenylyl Cyclase,Inhibitor,Adenylyl cyclase inhibitor,1,Nc1ncc2c(n1)CC(c1ccco1)CC2=O,547,1
5072,O=C(C3=C(O)C=CC=C3)/C=C/N1[C@H](C4)CN(C2=NC=CC=C2)[C@H]4C1,PFI 3,78243717,"(2E)-1-(2-Hydroxyphenyl)-3-[(1R,4R)-5-(pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]prop-2-en-1-one",C19H19N3O2,[1819363-80-8],321.37,Cell biology,Bromodomains,Inhibitor,Potent and selective SMARCA2/4 and polybromo 1 inhibitor,3,O=C(/C=C/N1C[C@H]2C[C@@H]1CN2c1ccccn1)c1ccccc1O,732,1
5077,CC1=C(OC4=CC(CC(N5)=O)=C5C=C4)C=C(NC(C2=CC=C(CN3CCN(CC)CC3)C(C(F)(F)F)=C2)=O)C=C1.Cl.Cl,DDR1-IN-1 dihydrochloride,90489006,"N-[3-[(2,3-Dihydro-2-oxo-1H-indol-5-yl)oxy]-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)benzamide dihydrochloride",C30H31F3N4O3.2HCl,[1780303-76-5],625.51,Enzyme-Linked Receptors,Other RTKs,Inhibitor,Selective DDR1 inhibitor,1,CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(Oc4ccc5c(c4)CC(=O)N5)c3)cc2C(F)(F)F)CC1,409,1
5080,CC1=CC(C3=C(OCCCN)C2=CC(C4=CC=CC(O)=C4)=C(Cl)C=C2N=C3)=CC(C)=C1,TC-G 1003,52936725,"3-[4-(3-Aminopropoxy)-7-chloro-3-(3,5-dimethylphenyl)-6-quinolinyl]phenol",C26H25ClN2O2,[1021912-42-4],437.44,7-TM Receptors,Somatostatin Receptors,Agonist,High affinity somatostatin sst2 agonist,1,Cc1cc(C)cc(-c2cnc3cc(Cl)c(-c4cccc(O)c4)cc3c2OCCCN)c1,813,1
5081,O=C(C(F)(F)F)N(C2=C(C)C=C(C)C=C2)/N=C/C1=CC=CC(OC)=C1,J 147,25229652,"2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide",C18H17F3N2O2,[1146963-51-0],350.33,Cell biology,Amyloid Beta Peptides,Other,Neuroprotective and neurotrophic compound; reduces A?40 and A?42 levels,1,COc1cccc(/C=N/N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1,424,1
5083,O=C1C=C(C4=CC(F)=C(Cl)N=C4Cl)NC2=C(C3=CC=CC=C3)C(C(F)(F)F)=NN12,QO 58,51351551,"5-(2,6-Dichloro-5-fluoro-3-pyridinyl)-3-phenyl-2-(trifluoromethyl)-pyrazolo[1,5-a]pyrimidin-7(4H)-one",C18H8Cl2F4N4O,[1259536-62-3],443.18,Ion Channels,Voltage-Gated Potassium Channels,Activator,Kv7 channel opener,1,O=c1cc(-c2cc(F)c(Cl)nc2Cl)[nH]c2c(-c3ccccc3)c(C(F)(F)F)nn12,255,1
5086,CC1(C)C2=C(C=C(N(C3=NC=C(C(O)=O)C=N3)C)C(OCCCCCC)=C2)C(C)(C)CC1,PA 452,9803242,"2-[[3-(Hexyloxy)-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]methylamino]-5-pyrimidinecarboxylic acid",C26H37N3O3,[457657-34-0],444.09,Nuclear Receptors,Retinoid X Receptor,Antagonist,RXR antagonist,1,CCCCCCOc1cc2c(cc1N(C)c1ncc(C(=O)O)cn1)C(C)(C)CCC2(C)C,457,1
5087,O=C(N[C@@H](CC(C)C)C(O)=O)C2=NN(C(C3=C(OC)C=CC=C3OC)=C2)C1=C(C=CC(Cl)=C4)C4=NC=C1,TC NTR1 17,44157038,"N-[[1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]-L-leucine",C27H27ClN4O5,[1146757-96-1],536.49,7-TM Receptors,Neurotensin Receptors,Partial Agonist,Selective NTS1 partial agonist,1,COc1cccc(OC)c1-c1cc(C(=O)N[C@@H](CC(C)C)C(=O)O)nn1-c1ccnc2cc(Cl)ccc12,353,0
5088,O=C(NC3=CC(C(NCC4=CC(Cl)=CC=C4)=O)=CC=C3Cl)C2=CC1=CN=C(OC)N=C1NC2=O,TC-S 7004,57523919,"N-[2-Chloro-5-[[[(3-chlorophenyl)methyl]amino]carbonyl]phenyl]-7,8-dihydro-2-methoxy-7-oxopyrido[2,3-d]pyrimidine-6-carboxamide",C23H17Cl2N5O4,[1386979-55-0],516.34,Enzymes,DYRK,Inhibitor,Potent and selective DYRK1A/B inhibitor,1,COc1ncc2cc(C(=O)Nc3cc(C(=O)NCc4cccc(Cl)c4)ccc3Cl)c(=O)[nH]c2n1,615,1
5089,O=C(N(CCC(O)=O)O)CCCCCCCCC1CC1,TC-E 5002,71735843,N-(9-Cyclopropyl-1-oxononyl)-N-hydroxy-?-alanine,C15H27NO4,[1453071-47-0],285.38,Enzymes,Histone Demethylases,Inhibitor,Selective KDM2/7 inhibitor,1,O=C(O)CCN(O)C(=O)CCCCCCCCC1CC1,25,1
5096,O=C(C2=CC=C(OCC(NC3CCN(CC4=CC=CC=C4)CC3)=O)C=C2)C1=CC=CC=C1.Cl,AdipoRon hydrochloride,78243714,2-(4-Benzyoylphenoxy)-N-[1-(phenylmethyl)-4-piperidinyl]acetamide hydrochloride,C27H28N2O3.HCl,[1781835-20-8],473.99,7-TM Receptors,Other Peptide Receptors,Other,Orally active AdipoR1 and AdipoR2 agonist; antidiabetic,1,O=C(COc1ccc(C(=O)c2ccccc2)cc1)NC1CCN(Cc2ccccc2)CC1,304,1
5106,O=C(NC6(CC6)C5=CC=CC=C5)C2=C(CN4CCC(N7CCCCC7)CC4)C(C3=CC(C(F)(F)F)=CC=C3)=NC1=CC(Br)=CC=C12,GSK 2193874,53464483,"3-([1,4'-Bipiperidin]-1'-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide",C37H38BrF3N4O,[1336960-13-4],691.62,Ion Channels,TRPV,Antagonist,Potent and selective TRPV4 antagonist; orally active,2,O=C(NC1(c2ccccc2)CC1)c1c(CN2CCC(N3CCCCC3)CC2)c(-c2cccc(C(F)(F)F)c2)nc2cc(Br)ccc12,691,1
5107,NC1=NC=NC2=C1C(C3=CC(CCN4C(CC5=CC=CC(C(F)(F)F)=C5)=O)=C4C=C3)=CN2C,GSK 2606414,53469448,"1-[5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydro-1H-indol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone",C24H20F3N5O,[1337531-36-8],460.45,Enzymes,PERK,Inhibitor,Potent and selective PERK inhibitor; orally bioavailable,2,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21,835,1
5111,O=C(CN(C)C)N4CCC(C4=C5)=CC(OC)=C5NC1=NC(NC3=C(C(NC)=O)C(F)=CC=C3)=C2C(NC=C2)=N1,GSK 1838705,25182616,"2-[[2-[[1-[(Dimethylamino)ethanoyl]-5-(methyloxy)-2,3-dihydro-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide",C27H29FN8O3,[1116235-97-2],559.59,Enzyme-Linked Receptors,Insulin and insulin-like Receptors,Inhibitor,Potent IR and IGF1R inhibitor; also inhibits anaplastic lymphoma kinase (ALK),1,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12,402,1
5112,N#CC1=CC(C2=NC(C3=CN=CC=C3)=NO2)=CC=C1,NS 9283,11998180,"3-[3-(3-Pyridinyl)-1,2,4-oxadiazol-5-yl]benzonitrile",C14H8N4O,[913830-15-6],248.24,Ion Channels,Nicotinic (a4b2) Receptors,Modulator,Positive allosteric modulator of ?4?2 nAChRs,1,N#Cc1cccc(-c2nc(-c3cccnc3)no2)c1,718,1
5116,O=C(C#C)N(C(C2=CC=CS2)C(NCC(OCC)=O)=O)C1=CC=C(OC)C=C1OC,PACMA 31,66555902,"N-(2,4-Dimethoxyphenyl)-N-(1-oxo-2-propyn-1-yl)-2-(2-thienyl)glycylglycine ethyl ester",C21H22N2O6S,[1401089-31-3],430.47,Enzymes,Protein Disulfide Isomerase,Inhibitor,Irreversible protein disulfide isomerase (PDI) inhibitor,1,C#CC(=O)N(c1ccc(OC)cc1OC)C(C(=O)NCC(=O)OCC)c1cccs1,418,1
5129,CC1=CC(OC2=CC=NC=C2C(N3C(C=CC=C4)=C4N(C5CC5)CC3)=O)=C(C)C=C1,TC-G 1005,71450251,"(4-Cyclopropyl-3,4-dihydro-1(2H)-quinoxalinyl)[4-(2,5-dimethylphenoxy)-3-pyridinyl]methanone",C25H25N3O2,[1415407-60-1],399.48,7-TM Receptors,GPBA Receptors,Agonist,Potent and selective GPBA receptor (TGR5) agonist,2,Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc32)c1,495,1
5132,CC(C)N(CC4)CCC4NC1=C2C(C=C(OCCCN3CCCC3)C(OC)=C2)=NC(N5CCC(F)(F)CC5)=N1,UNC 0642,53315878,"2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine",C29H44F2N6O2,[1481677-78-4],555.71,Enzymes,G9a/GLP,Inhibitor,Potent and selective G9a and GLP inhibitor,2,COc1cc2c(NC3CCN(C(C)C)CC3)nc(N3CCC(F)(F)CC3)nc2cc1OCCCN1CCCC1,393,1
5133,O=C(NC3=NC=C(C(O)=O)C=C3)C1=CC(O[C@@H](C)COC)=CC(O[C@@H](C)CC2=CC=CC=C2)=C1,GKA 50,11340230,6-[[3-[(1S)-2-Methoxy-1-methylethoxy]-5-[(1S)-1-methyl-2-phenylethoxy]benzoyl]amino-3-pyridinecarboxylic acid,C26H28N2O6,[851884-87-2],469.01,Enzymes,Hexokinases,Activator,Glucokinase activator,1,COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(C(=O)Nc2ccc(C(=O)O)cn2)c1,213,1
5140,ClC1=CC(NCC2=CC=C(C(N[C@H]([C@@](NC4CC4)=O)CC3CCCC3)=O)S2)=C(C)N=C1,GSK 2830371,70983932,5-[[(5-Chloro-2-methyl-3-pyridinyl)amino]methyl]-N-[(1S)-1-(cyclopentylmethyl)-2-(cycloprpylamino)-2-oxoethyl]-2-thiophenecarboxamide,C23H29ClN4O2S,[1404456-53-6],465.52,Enzymes,Protein Ser/Thr Phosphatases,Inhibitor,Potent and selective allosteric inhibitor of Wip1 phosphatase,1,Cc1ncc(Cl)cc1NCc1ccc(C(=O)N[C@@H](CC2CCCC2)C(=O)NC2CC2)s1,330,1
5148,O=C(CC3=CC=C(C4=CC=NC(C)=C4)C=C3)NC1=CC=C(C2=CC=CN=C2)C=C1,Wnt-C59,57519544,4-(2-Methyl-4-pyridinyl)-N-[4-(3-pyridinyl)phenyl]benzeneacetamide,C25H21N3O,[1243243-89-1],383.95,Enzymes,PORCN,Inhibitor,Highly potent PORCN inhibitor,3,Cc1cc(-c2ccc(CC(=O)Nc3ccc(-c4cccnc4)cc3)cc2)ccn1,473,1
5149,O=C2N4C(CCC4)OC1=CC3=C(OCCO3)C=C12,CX 614,6451148,"2,3,6a,7,8,9-Hexahydro-11H-1,4-dioxino[2,3-g]pyrrolo[2,1-b][1,3]benzoxazin-11-one",C13H13NO4,[191744-13-5],247.25,Ion Channels,AMPA Receptors,Modulator,Positive allosteric modulator of AMPA receptors,2,O=C1c2cc3c(cc2OC2CCCN12)OCCO3,34,1
5153,NC1=NC4=C(C=CC=C4)N1C3=NC2=C(OC)C=CC=C2C(NCC5=CC=CC=C5)=N3,ML 240,49830258,2-(2-Amino-1H-benzimidazole-1-yl)-8-methoxy-N-(phenylmethyl)-4-quinazolinamine,C23H20N6O,[1346527-98-7],396.44,Enzymes,p97 ATPase,Inhibitor,ATP-competitive inhibitor of p97 ATPase,1,COc1cccc2c(NCc3ccccc3)nc(-n3c(N)nc4ccccc43)nc12,170,0
5160,CC(C2=CN=CN2)C1=C(C)C(C)=CC=C1.Cl,Medetomidine hydrochloride,68601,"4-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole hydrochloride",C13H16N2.HCl,[86347-15-1],241.24,7-TM Receptors,Adrenergic Alpha-2 Receptors,Agonist,Potent and highly selective ?2 agonist,1,Cc1cccc(C(C)c2cnc[nH]2)c1C,758,0
5163,COC1=C(OCCCN4CCCC4)C=C(N=C(N)C32CCC3)C2=C1,A 366,76285486,"5'-Methoxy-6'-[3-(1-pyrrolidinyl)propoxy]spiro[cyclobutane-1,3'-[3H]indol]-2'-amine",C19H27N3O2,[1527503-11-2],329.44,Enzymes,G9a/GLP,Inhibitor,Potent and selective G9a/GLP inhibitor,2,COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1,394,1
5164,O=C2C1=CC=C(OCC4=CC(C(O)=O)=CC=C4)C=C1OC=C2C3=CC=C(NS(=O)(C)=O)C=C3,CVT 10216,23661666,3-[[[3-[4-[(Methylsulfonyl)amino]phenyl]-4-oxo-4H-1-benzopyran-7-yl]oxy]methyl]benzoic acid,C24H19NO7S,[1005334-57-5],465.48,Enzymes,Aldehyde Dehydrogenase,Inhibitor,Potent and selective ALDH2 inhibitor,1,CS(=O)(=O)Nc1ccc(-c2coc3cc(OCc4cccc(C(=O)O)c4)ccc3c2=O)cc1,801,1
5166,OC(\C=C/C(O)=O)=O.C1(CC(C3CCCCC3)C2CCCCC2)NCCCC1,Perhexiline maleate,5284439,"2-(2,2-Dicyclohexylethyl)piperidine maleate",C19H35N.C4H4O4,[6724-53-4],393.56,Enzymes,Other Transferases,Inhibitor,Carnitine palmitoyltransferase 1 and 2 (CPT1/2) inhibitor,2,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,56,1
5180,O=C(OCC)C1=CC(N)=C(NC2CCCCC2)C=C1,Ferrostatin 1,4068248,Ethyl 3-amino-4-(cyclohexylamino)benzoate,C15H22N2O2,[347174-05-4],262.35,Cell biology,Ferroptosis,Inhibitor,Selective inhibitor of erastin induced ferroptosis,1,CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1,51,1
5181,OC1C2=C(C=CC(Cl)=C2)N(C(C3=C(C)C=C(NC(C4=CC=CC=C4C)=O)C=C3)=O)CCC1,Tolvaptan,216237,"N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide",C26H25ClN2O3,[150683-30-0],448.94,7-TM Receptors,Vasopressin Receptors,Antagonist,Potent and selective vasopressin V2 receptor antagonist; renoprotective and orally active,1,Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1,494,1
5185,ClC1=C(OCCN2CCN(C)CC2)C(Cl)=CC(C(N[C@@H](CC3=CC=CC=C3)C(OCC)=O)=O)=C1O.Cl.Cl,JTE 607 dihydrochloride,9938544,"N-[3,5-Dichloro-2-hydroxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]benzoyl]-L-phenylalanine ethyl ester dihydrochloride",C25H31Cl2N3O5.2HCl,[188791-09-5],615.38,Cell biology,Cytokines,Other,Cytokine release inhibitor; anti-inflammatory,1,CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O,196,1
5189,O=S(C2=C(NC3=CC(OC5=CC(F)=CC(F)=C5)=CC(C(O)=O)=C3)C1=CC=C(C6=CN=C(OC)N=C6OC)C=C1N=C2)(NC4CC4)=O,GSK 2837808A,71533725,"3-[[3-[(Cyclopropylamino)sulfonyl]-7-(2,4-dimethoxy-5-pyrimidinyl)-4-quinolinyl]amino]-5-(3,5-difluorophenoxy)benzoic acid",C31H25F2N5O7S,[1445879-21-9],654.12,Enzymes,Lactate Dehydrogenase A,Inhibitor,"Potent, selective LDHA inhibitor",4,COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(C(=O)O)c4)c(S(=O)(=O)NC4CC4)cnc3c2)c(OC)n1,96,1
5190,FC1=CC(NC3=NC(N(CC)C(C(C5=CC=C(Cl)C=C5Cl)=C4)=O)=C4C=N3)=CC=C1N2CCNCC2,FRAX 486,68060125,"6-(2,4-Dichlorophenyl)-8-ethyl-2-[[3-fluoro-4-(1-piperazinyl)phenyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one",C25H23Cl2FN6O,[1232030-35-1],522.4,Enzymes,P21-activated Kinases,Inhibitor,Potent PAK inhibitor; brain penetrant and orally bioavailable,1,CCn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2cnc(Nc3ccc(N4CCNCC4)c(F)c3)nc21,404,0
5197,FC1=CC=C(N=CN=C2NCC3=CC=C(F)C=C3)C2=C1,Spautin 1,51037431,6-Fluoro-N-[(4-Fluorophenyl)methyl]-4-quinazolinamine,C15H11F2N3,[1262888-28-7],271.26,Enzymes,Deubiquitinating Enzymes,Inhibitor,USP10 and USP13 inhibitor; inhibits autophagy,1,Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1,388,0
5198,CS(C4(CC4)C1=CC(N5[C@H](C)COCC5)=NC(C2=CC=CC3=C2C=CN3)=N1)(=O)=O,AZ 20,46244454,4-[4-[(3R)-3-Methyl-4-morpholinyl]-6-[1-(methylsulfonyl)cyclopropyl]-2-pyrimidinyl]-1H-indole,C21H24N4O3S,[1233339-22-4],417.01,Enzymes,ATM & ATR Kinase,Inhibitor,Potent and selective ATR kinase inhibitor; antitumor,1,C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1,323,1
5199,FC1=CC=CC(C2=CC(NC(N)=O)=C(C(N[C@@H]3CNCCC3)=O)S2)=C1.Cl,AZD 7762 hydrochloride,56972142,3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-thiophenecarboxamide hydrochloride,C17H19FN4O2S.HCl,[1246094-78-9],430.4,Enzymes,Checkpoint Kinases,Inhibitor,Potent and selective ATP-competitive inhibitor of Chk1 and Chk2; also enhances CRISPR-Cpf1-mediated genome editing,1,NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1,531,0
5202,NC(C(C=C3)=CC=C3C1=CC=C(C2=CC=C(C(N)=N)C=C2)O1)=N.Cl.Cl,Furamidine dihydrochloride,462428,"4,4'-(2,5-Furandiyl)bis-benzenecarboximidamide dihydrochloride",C18H16N4O.2HCl,[55368-40-6],390.78,Enzymes,Protein Arginine Methyltransferases,Inhibitor,Selective PRMT1 inhibitor,1,N=C(N)c1ccc(-c2ccc(-c3ccc(C(=N)N)cc3)o2)cc1,874,1
5206,O=C(N6C=NC=N6)N(CC5)CCC5C(C2=CC=C(OCO3)C3=C2)C1=CC(OCO4)=C4C=C1,JJKK 048,76313567,"4-[Bis(1,3-benzodioxol-5-yl)methyl]-1-piperidinyl]-1H-1,2,4-triazol-1-yl-methanone",C23H22N4O5,[1515855-97-6],434.44,Enzymes,MAGL,Inhibitor,Potent and selective MAGL inhibitor,1,O=C(N1CCC(C(c2ccc3c(c2)OCO3)c2ccc3c(c2)OCO3)CC1)n1cncn1,750,0
5232,CN2C=C(C3=CC=NC(NC4=C(OC)C=C(N5CCN(C)CC5)C=C4)=N3)C1=CC=NC=C12,AZ 191,72716071,"N-[2-Methoxy-4-(4-methyl-1-piperazinyl)phenyl]-4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-pyrimidinamine",C24H27N7O,[1594092-37-1],452.04,Enzymes,DYRK,Inhibitor,Potent DYRK1B inhibitor,1,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2cn(C)c3cnccc23)n1,400,1
5240,FC(C(Cl)=C4)=CC=C4NC1=C2C(C=NC(NCC3=CN=CC=C3)=C2)=NC=C1C#N,TC-S 7006,9549300,"4-[(3-Chloro-4-fluorophenyl)amino]-6-[(3-pyridinylmethyl)amino]-1,7-naphthyridine-3-carbonitrile",C21H14ClFN6,[871307-18-5],422.85,Enzymes,Other Kinases,Inhibitor,Potent and selective Tpl2 (Cot; MAP3K8) inhibitor,1,N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1,390,0
5256,CC(C=C4)=CC=C4S(NC2C3=C(C=CC=C3)OC1=CC=CC=C12)(=O)=O,AH 7614,233085,4-Methyl-N-9H-xanthen-9-yl-benzenesulfonamide,C20H17NO3S,[6326-06-3],351.42,7-TM Receptors,Free Fatty Acid Receptors,Antagonist,Selective FFA4 (GPR120) antagonist,1,Cc1ccc(S(=O)(=O)NC2c3ccccc3Oc3ccccc32)cc1,106,0
5257,CC1=CC(C)=CC(C)=C1NS(C2=CC=C(OC)C=C2)(=O)=O,GSK 137647,743974,"4-Methoxy-N-(2,4,6-trimethylphenyl)benzenesulfonamide",C16H19NO3S,[349085-82-1],305.39,7-TM Receptors,Free Fatty Acid Receptors,Agonist,Potent and selective FFA4 (GPR120) agonist,1,COc1ccc(S(=O)(=O)Nc2c(C)cc(C)cc2C)cc1,100,1
5258,CCC1=C(C4=CC=CC=C4)C(C5=CC=CC=C5)=NN1C2=CC=CC=C2C3=CC=CC(OCC(O)=O)=C3,BMS 309403,16122583,"2-[[2'-(5-Ethyl-3,4-diphenyl-1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]oxy]-acetic acid",C31H26N2O3,[300657-03-8],474.55,Cell biology,Other Lipid Metabolism,Inhibitor,Potent and selective FABP4 inhibitor,1,CCc1c(-c2ccccc2)c(-c2ccccc2)nn1-c1ccccc1-c1cccc(OCC(=O)O)c1,239,1
5260,NC1=NC(SC)=NC(OC(C=C4)=CC=C4C3=NN=C(N3)NC2=CC(C(F)(F)F)=CC=C2)=C1,KG 5,53328059,"2-(Methylthio)-6-[4-[5-[[3-(trifluoromethyl)phenyl]amino]-1H-1,2,4-triazol-3-yl]phenoxy]-4-pyrimidinamine",C20H16F3N7OS,[877874-85-6],477.47,Enzymes,Raf Kinase,Inhibitor,"PDGFR?, B-Raf, c-Raf, FLT3 and KIT inhibitor",1,CSc1nc(N)cc(Oc2ccc(-c3nnc(Nc4cccc(C(F)(F)F)c4)[nH]3)cc2)n1,688,1
5262,CC1=CN=C(C2=CC(N3CCN(C(CCS(C)(=O)=O)=O)CC3)=NC=C2Cl)C(C)=C1.Cl,PF 5274857 hydrochloride,90489027,"1-[4-(5'-Chloro-3,5-dimethyl[2,4'-bipyridin]-2'-yl-1-piperazinyl]-3-(methylsulfonyl)-1-propanone hydrochloride",C20H25ClN4O3S.HCl,[1613439-62-5],482.43,7-TM Receptors,Smoothened Receptors,Antagonist,High affinity and selective Smoothened (Smo) receptor antagonist,1,Cc1cnc(-c2cc(N3CCN(C(=O)CCS(C)(=O)=O)CC3)ncc2Cl)c(C)c1,662,1
5263,CC2=C(C3=CC=C(O)C=C3)N(CC4=CC=C(OCCN5CCCCCC5)C=C4)C1=CC=C(O)C=C12.OC(C)=O,Bazedoxifene acetate,154256,1-[[4-[2-(Hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol acetate,C30H34N2O3.C2H4O2,[198481-33-3],530.65,Nuclear Receptors,Estrogen and Related Receptors,Modulator,Potent and selective estrogen receptor modulator (SERM),1,Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,643,1
5266,CN(N=C4)C=C4CCN1C=NC(C3=CN(C)N=C3)=C1C2=CC=C(C#N)C=C2,BAZ2-ICR,91654625,4-[4-(1-Methyl-1H-pyrazole-4-yl)-1-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]-1H-imidazol-5-yl]benzonitrile,C20H19N7,[1665195-94-7],361.91,Cell biology,Bromodomains,Inhibitor,Selective BAZ2 inhibitor,1,Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(C#N)cc2)cn1,70,1
5269,O=C(C2=CC=CC(NC(C3=CC(C)=NO3)=O)=C2)NC1=CC(C(F)(F)F)=CC=C1,T 5601640,9438169,3-Methyl-N-[3-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-5-isoxazolecarboxamide,C19H14F3N3O3,[924473-59-6],389.33,Enzymes,LIMK,Inhibitor,Selective LIMK2 inhibitor; antitumor,1,Cc1cc(C(=O)Nc2cccc(C(=O)Nc3cccc(C(F)(F)F)c3)c2)on1,483,0
5270,NC1=C2C(N([C@@H]3O[C@H](CO)[C@H](O)[C@@H]3O)C=C2C#N)=NC=N1,Toyocamycin,12444444,"4-Amino-7-?-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile",C12H13N5O4,[606-58-6],309.28,Other Pharmacology,Antibiotics,Other,Adenosine analog; antifungal antibiotic,1,N#Cc1cn([C@@H]2O[C@H](CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,841,0
5271,O=C(N)C1=C(NC(C2CCCCC2)=O)SC(NC3=CC=CC=C3)=N1,UNC 3230,46355372,5-[(Cyclohexylcarbonyl)amino]-2-(phenylamino)-thiazolecarboxamide,C17H20N4O2S,[1031602-63-7],344.43,Enzymes,Other Kinases,Inhibitor,Potent and selective PIP5K1C inhibitor; antinociceptive,1,NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1,186,1
5272,O=S(N2C1=CC=CC=C1C3(CCN(C([C@H](NC(C(C)(N)C)=O)COCC4=CC=CC=C4)=O)CC3)C2)(C)=O.CS(O)(=O)=O,MK 0677,6450830,"2-Amino-N-[(1R)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methylpropanamide methanesulfonate",C27H36N4O5S.CH3SO3H,[159752-10-0],638.28,7-TM Receptors,Ghrelin Receptors,Agonist,High affinity ghrelin receptor agonist,1,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12,194,1
5276,NC1=NC=C(CC2=CC=C(Br)C=C2)S1,NS 19504,727750,5-[(4-Bromophenyl)methyl]-2-thiazolamine,C10H9BrN2S,[327062-46-4],269.16,Ion Channels,Ca2+-Activated Potassium Channels,Activator,Activator of BKCa (KCa1.1) channels,1,Nc1ncc(Cc2ccc(Br)cc2)s1,879,1
5277,O=C(N2CCCC(C(NC3=CC=C(Cl)C=C3)=O)C2)C1=CC=CC(C4=CC=CO4)=C1,CCG 203971,71681561,N-(4-Chlorophenyl)-1-[3-(2-furanyl)benzoyl]-3-piperidinecarboxamide,C23H21ClN2O3,[1443437-74-8],408.88,Cell biology,Other Transcription Factors,Other,Inhibits the MRTF/SRF gene transcription pathway; antifibrotic agent,1,O=C(Nc1ccc(Cl)cc1)C1CCCN(C(=O)c2cccc(-c3ccco3)c2)C1,599,1
5281,O=C(N1C)N(CC(N(CC)CC2=CC=CC=C2)=O)C3=C1C=NC(C4=CC=CC=C4)=N3,AC 5216,6433109,"N-Ethyl-7,8-dihydro-7-methyl-8-oxo-2-phenyl-N-(phenylmethyl)-9H-purine-9-acetamide",C23H23N5O2,[226954-04-7],401.46,Other Pharmacology,Translocator Protein,Ligand,Selective TSPO ligand,1,CCN(Cc1ccccc1)C(=O)Cn1c(=O)n(C)c2cnc(-c3ccccc3)nc21,218,1
5282,COC1=C(CN([C@@H]2CC[C@@H](NC)CC2)C(C3=C(Cl)C4=C(C(F)=CC=C4F)S3)=O)C=C(C5=CC=NC=C5)C=C1,SAG 21k,16678532,"3-Chloro-4,7-difluoro-N-[[2-methoxy-5-(4-pyridinyl)phenyl]methyl]-N-trans-4-(methylamino)cyclohexyl]benzo[b]thiophene-2-carboxamide",C29H28ClF2N3O2S,[946002-48-8],560.57,Cell biology,Hedgehog Signaling,Activator,Hedgehog signaling activator; brain penetrant and orally bioavailable,2,CN[C@H]1CC[C@H](N(Cc2cc(-c3ccncc3)ccc2OC)C(=O)c2sc3c(F)ccc(F)c3c2Cl)CC1,327,1
5288,OCCN1N=CC(C2=C(F)C=CC(C3=CNN=C3C4=CC=CC(C)=N4)=C2)=C1,R 268712,11703284,4-[2-Fluoro-5-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]phenyl]-1H-pyrazole-1-ethanol,C20H18FN5O,[879487-87-3],363.39,Enzyme-Linked Receptors,TGF-beta Receptors,Inhibitor,Potent and selective inhibitor of TGF-?RI,1,Cc1cccc(-c2n[nH]cc2-c2ccc(F)c(-c3cnn(CCO)c3)c2)n1,741,0
5291,O=C(N4CCC(C=C(OC)C(OC)=C5)=C5C4)/C=C/C2=C(C3=CC=CC=C3)N(C)C1=NC=CC=C12.Cl,SIS3,16079005,"1,2,3,4-Tetrahydro-6,7-dimethoxy-2-[(2E)-3-(1-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1-oxo-2-propenyl]-isoquinoline hydrochloride",C28H27N3O3.HCl,[521984-48-5],499,Enzyme-Linked Receptors,TGF-beta Receptors,Other,Selective Smad3 inhibitor; inhibits TGF-?R1 signaling,2,COc1cc2c(cc1OC)CN(C(=O)/C=C/c1c(-c3ccccc3)n(C)c3ncccc13)CC2,372,0
5293,O=C(NC2=NN=C(C3=CC=CO3)O2)NCC1=CC=CC=N1,NK 252,71618700,"N-[5-(2-Furanyl)-1,3,4-oxadiazol-2-yl]-N'-(2-pyridinylmethyl)urea",C13H11N5O3,[1414963-82-8],285.26,Cell biology,Nrf2,Activator,Nrf2 activator,1,O=C(NCc1ccccn1)Nc1nnc(-c2ccco2)o1,735,1
5297,N#CC1=CC=C(C2=CC=C(C(C)CNS(C(C)C)(=O)=O)C=C2)C=C1,LY 404187,9928016,"N-[2-(4'-Cyano[1,1'-biphenyl]-4-yl)propyl]-2-propanesulfonamide",C19H22N2O2S,[211311-95-4],342.46,Ion Channels,AMPA Receptors,Modulator,Selective positive allosteric modulator of AMPA receptors,1,CC(CNS(=O)(=O)C(C)C)c1ccc(-c2ccc(C#N)cc2)cc1,67,0
5299,O=C(NCC4(CCOCC4)N3CCN(C5=CC=CC=C5)CC3)C1=CC=CN=C1SC2=CC=CC=C2,JNJ 47965567,66553218,2-(Phenylthio)-N-[[tetrahydro-4-(4-phenyl-1-piperazinyl)-2H-pyran-4-yl]methyl-3-pyridinecarboxamide,C28H32N4O2S,[1428327-31-4],488.64,Ion Channels,P2X Receptors,Antagonist,Potent and selective P2X7 antagonist; brain penetrant,5,O=C(NCC1(N2CCN(c3ccccc3)CC2)CCOCC1)c1cccnc1Sc1ccccc1,472,1
5300,CS(C(CC3)CCN3C1=CC(C(CC)(F)F)=C(C(N)=C(C(N)=O)S2)C2=N1)(=O)=O,BI 605906,23652660,"3-Amino-4-(1,1-difluoropropyl)-6-[4-(methylsulfonyl)-1-piperidinyl]thieno[2,3-b]pyridine-2-carboxamide",C17H22F2N4O3S2,[960293-88-3],432.51,Enzymes,IkB Kinase,Inhibitor,Selective IKK? inhibitor,1,CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12,329,1
5303,O=C1NN=C(C[C@@H]2CCN(C(C3CC3)=O)C2)N1C4=CC=C(C5=CC=C(OC=C6)C6=C5)C=C4,GSK 2194069,67376285,"4-[4-(5-Benzofuranyl)phenyl]-5-[[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one",C25H24N4O3,[1332331-08-4],428.48,Enzymes,Fatty Acid Synthase,Inhibitor,Potent human fatty acid synthase (hFASN) inhibitor,1,O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(-c3ccc4occc4c3)cc2)C1,66,1
5307,O=C(NC(C2=CC=C(F)C=C2)C1=CC=C(F)C=C1)C3(CCCC3)NC([C@@H](NC(C(CC)(CC)NC(C(C)C)=O)=O)CCCNC(N)=N)=O.OC(C(F)(F)F)=O,MM 102,71520620,1-[[(2S)-5-[(Aminoiminomethyl)amino]-2-[[2-ethyl-2-[(2-methyl-1-oxopropyl)amino]-1-oxobutyl]amino]-1-oxopentyl]amino]-N-[bis(4-fluorophenyl)methyl]-cyclopentanecarboxamide trifluoroacetate,C35H49F2N7O4.CF3CO2H,[1883545-52-5],783.83,Enzymes,WDR5,Other,Potent WDR5/MLL interaction inhibitor,3,CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC1(C(=O)NC(c2ccc(F)cc2)c2ccc(F)cc2)CCCC1,116,0
5309,O=C(NC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)C1=C(C(F)(F)F)N=C(Cl)N=C1,SP 100030,9910975,"N-[3,5-Bis(trifluoromethyl)phenyl]-2-chloro-4-(trifluoromethyl)-5-pyrimidinecarboxamide",C14H5ClF9N3O,[154563-54-9],437.65,Cell biology,NF-kB/IkB,Inhibitor,NF-?B and AP-1 dual inhibitor,1,O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cnc(Cl)nc1C(F)(F)F,518,0
5316,O=C(NS(C4=CC=C(Cl)S4)(=O)=O)NC(C=C3)=CC=C3N2C(C1=CC(F)=C(NC)C=C1NC2=O)=O,Elinogrel,16066663,"5-Chloro-N-[[[4-[6-Fluoro-1,4-dihydro-7-(methylamino)-2,4-dioxo-3(2H)-quinazolinyl]phenyl]amino]carbonyl]-2-thiophenesulfonamide",C20H15ClFN5O5S2,[936500-94-6],523.95,7-TM Receptors,Purinergic P2Y Receptors,Antagonist,P2Y12 antagonist,1,CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,512,1
5317,NC(C1=CC=C(C2=CC=C(OC(N(C)CC3=CC(C4=CC=CC=C4)=CC=C3)=O)C=C2)C=C1)=O,WWL 123,90209976,"N-[[1,1'-Biphenyl]-3-ylmethyl)-N-methylcarbamic acid 4'-(aminocarbonyl)[1,1'-biphenyl]-4-yl ester",C28H24N2O3,[1338574-83-6],436.5,Enzymes,Other Hydrolases,Inhibitor,?/?-hydrolase domain 6 (ABHD6) inhibitor; antiepileptic,1,CN(Cc1cccc(-c2ccccc2)c1)C(=O)Oc1ccc(-c2ccc(C(N)=O)cc2)cc1,208,1
5321,ClC1=CC=C(NC(NC2=CC(C3=CC=CC(N4CCCC4)=N3)=CC=C2)=O)C=C1,PSNCBAM-1,11560249,N-(4-Chlorophenyl)-N'-[3-[6-(1-pyrrolidinyl)-2-pyridinyl]phenyl]urea,C22H21ClN4O,[877202-74-9],392.88,7-TM Receptors,CB1 Receptors,Modulator,Negative allosteric modulator of CB1 receptors,1,O=C(Nc1ccc(Cl)cc1)Nc1cccc(-c2cccc(N3CCCC3)n2)c1,597,1
5322,FC1=CC(OC2=CN=CN=C2)=CC(C(NC3=NC(C)=CS3)=O)=C1,VU 0409106,50990953,3-Fluoro-N-(4-methyl-2-thiazolyl)-5-(5-pyrimidinyloxy)benzamide,C15H11FN4O2S,[1276617-62-9],330.34,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Modulator,Potent and selective negative allosteric modulator of mGlu5 receptors,1,Cc1csc(NC(=O)c2cc(F)cc(Oc3cncnc3)c2)n1,505,1
5323,O=C(OC)C1=CC(NC(C3=CC=CC(OC)=C3)=O)=C(N2CCN(C)CC2)C=C1,WDR5 0103,6457069,3-[(3-Methoxybenzoyl)amino]-4-(4-methyl-1-piperazinyl)benzoic acid methyl ester,C21H25N3O4,[890190-22-4],383.44,Enzymes,WDR5,Other,WDR5 antagonist,1,COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1,482,1
5324,COC1=C(OCC2=CC=CC=C2)C=CC(CN(CCN)C(C3=CC=CS3)=O)=C1.Cl,M8 B hydrochloride,69316632,N-(2-Aminoethyl)-N-[[3-methoxy-4-(phenylmethoxy)phenyl]methyl]-2-thiophenecarboxamide hydrochloride,C22H24N2O3S.HCl,[883976-12-3],441.97,Ion Channels,TRPM,Blocker,Potent and selective TRPM8 channel blocker,1,COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1,203,0
5325,CN(CCOC1=CC=C(CC2SC(NC2=O)=O)C=C1)C3=CC=CC=N3,Rosiglitazone,77999,"5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione",C18H19N3O3S,[122320-73-4],357.43,Nuclear Receptors,PPARgamma Receptors,Agonist,Potent and selective PPAR? agonist; antidiabetic agent,1,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,439,0
5327,CC(OC(C(NS(C4=CC=CC=C4C)(=O)=O)=O)=C3)=C3COC(C=C2)=CC=C2C1=NC=C(OC)C=C1.Cl,BGC 20-1531 hydrochloride,121513858,4-[[4-(5-Methoxy-2-pyridinyl)phenoxy]methyl]-5-methyl-N-[(2-methylphenyl)sulfonyl]-2-furancarboxamide hydrochloride,C26H24N2O6S.HCl,[1962928-26-2],556.02,7-TM Receptors,Prostanoid Receptors,Antagonist,High affinity and selective EP4 antagonist,1,COc1ccc(-c2ccc(OCc3cc(C(=O)NS(=O)(=O)c4ccccc4C)oc3C)cc2)nc1,539,1
5328,ClC1=CC=C(/N=C(NNC2=CC=C(Cl)C=C2)/C(C(C)(C)C)=O)C=C1,TY 52156,16046248,"N-(4-Chlorophenyl)-3,3-dimethyl-2-oxobutanimidic 2-(4-chlorophenyl) hydrazide",C18H19Cl2N3O,[934369-14-9],364.27,7-TM Receptors,Sphingosine-1-phosphate Receptors,Antagonist,S1P3 receptor antagonist,2,CC(C)(C)C(=O)/C(=N/c1ccc(Cl)cc1)NNc1ccc(Cl)cc1,601,1
5329,ClC2=CC=C(S(NCCN)(=O)=O)C1=CN=CC=C12.Cl.Cl,CKI 7 dihydrochloride,16078955,N-(2-Aminoethyl)-5-chloro-8-isoquinolinesulfonamide dihydrochloride,C11H12ClN3O2S.2HCl,[1177141-67-1],358.67,Enzymes,Casein Kinase 1,Inhibitor,CK1 inhibitor,1,NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12,851,1
5331,NC(C[C@@H]1N=C(C4=CC=C(Cl)C=C4)C3=C(SC(C)=C3C)N2C1=NN=C2C)=O,CPI 203,71291068,"(6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide",C19H18ClN5OS,[1446144-04-2],417.92,Cell biology,Bromodomains,Inhibitor,BET bromodomain inhibitor; arrests cell cycle at G1 phase,1,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(N)=O)c1nnc(C)n1-2,578,0
5332,COC1=CC=C(NC2=C3C=CN=C2C4=CC=CC5=C4C=CC=C5)C3=C1,SP 141,59620153,"6-Methoxy-1-(1-naphthalenyl)-9H-pyrido[3,4-b]indole",C22H16N2O,[1253491-42-7],324.38,Enzymes,Ubiquitin E3 Ligases,Inhibitor,High affinity MDM2 inhibitor,1,COc1ccc2[nH]c3c(-c4cccc5ccccc45)nccc3c2c1,776,1
5337,CC1=CC=CC(C(NC2=CC(NC(C3=CC=CC=C3OC)=O)=CC=C2)=O)=C1,ML 365,46785920,2-Methoxy-N-[3-[(3-methylbenzoyl)amino]phenyl]benzamide,C22H20N2O3,[947914-18-3],364.91,Ion Channels,Two-P Potassium Channels,Blocker,Potent and selective K2P3.1 (TASK-1) channel blocker,1,COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1,483,1
5338,O=C(C1=CC=C(C2=CC=CC=C2)C=C1)N(C3)CCC4=C3C(N5CCC(C(CCC)=O)CC5)=NC=N4,PK-THPP,53464059,"1-[1-[6-[[1,1'-Biphenyl]-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]-4-piperidinyl]-1-butanone",C29H32N4O2,[1332454-07-5],468.59,Ion Channels,Two-P Potassium Channels,Blocker,Potent K2P9.1 (TASK-3) channel blocker,1,CCCC(=O)C1CCN(c2ncnc3c2CN(C(=O)c2ccc(-c4ccccc4)cc2)CC3)CC1,279,1
5344,COC1=CC=C(N2CCN(C(C3=CC4=C(C(C=CC=C5)=C5S(C4)(=O)=O)S3)=O)CC2)C=C1,ML 349,16193817,"(5,5-Dioxido-4H-thieno[3,2-c][1]benzothiopyran-2-yl)[4-(4-methoxyphenyl)-1-piperazinyl]methanone",C23H22N2O4S2,[890819-86-0],459.06,Enzymes,Other Hydrolases,Inhibitor,Selective and reversible lysophospholipase 2 (LYPLA2) inhibitor,1,COc1ccc(N2CCN(C(=O)c3cc4c(s3)-c3ccccc3S(=O)(=O)C4)CC2)cc1,268,1
5345,ClC1=C(NC(CN2CCN(C(C3=CC=CO3)=O)CC2)=O)C=C(C(F)(F)F)C=C1,ML 348,3238952,N-[2-Chloro-5-(trifluoromethyl)phenyl]-4-(2-furanylcarbonyl)-1-piperazineacetamide,C18H17ClF3N3O3,[899713-86-1],415.79,Enzymes,Other Hydrolases,Inhibitor,Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor,1,O=C(CN1CCN(C(=O)c2ccco2)CC1)Nc1cc(C(F)(F)F)ccc1Cl,551,0
5355,CNC1=NC(NCC2=C(Cl)C=C(NS(C)(=O)=O)C=C2)=CC(C3=NC=CC=C3)=N1,TC-G 1008,91826086,N-[3-Chloro-4-[[[2-(methylamino)-6-(2-pyridinyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide,C18H19ClN6O2S,[1621175-65-2],418.9,7-TM Receptors,Orphan 7-TM Receptors,Agonist,Potent and selective GPR39 agonist,3,CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(-c2ccccn2)n1,740,1
5356,CN1N=CC(C(C=C2)=NN3C2=NN=C3SC4=CC5=CC=CN=C5C=C4)=C1,SGX 523,24779724,"6-[[6-(1-Methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]thio]quinoline",C18H13N7S,[1022150-57-7],359.41,Enzyme-Linked Receptors,MET Receptors,Inhibitor,Selective and potent c-MET kinase inhibitor,1,Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,725,1
5357,CCCCC(C=C2)=CC=C2NS(C1=CC=C(F)C=C1)(=O)=O,DC 260126,2843133,N-(4-Butylphenyl)-4-fluorobenzenesulfonamide,C16H18FNO2S,[346692-04-4],307.38,7-TM Receptors,Free Fatty Acid Receptors,Antagonist,FFA1 (GPR40) antagonist,1,CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1,101,1
5358,CC(C)C1=C(S(C)(=O)=O)C=C(C(NC(N)=N)=O)C=C1,Cariporide,151172,N-(Aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide,C12H17N3O3S,[159138-80-4],301.37,Transporters,Na+/H+ Exchanger,Inhibitor,Selective NHE1 inhibitor; cardioprotective and antitumor,1,CC(C)c1ccc(C(=O)NC(=N)N)cc1S(C)(=O)=O,873,1
5361,C1(N[C@@H]2C[C@H]2[C@]3=CC=CC=C3)CCNCC1.Cl.Cl,GSK LSD 1 dihydrochloride,91663353,"rel-N-[(1S,2R)-2-Phenylcyclopropyl]-4-piperidinamine dihydrochloride",C14H20N2.2HCl,,289.24,Enzymes,Histone Demethylases,Inhibitor,Potent and selective LSD1 inhibitor,2,c1ccc([C@@H]2C[C@H]2NC2CCNCC2)cc1,134,0
5362,CC(C)(C)C1=CC=C(OC[C@@H]2CN3C(O2)=NC(C(N)=O)=C3C)C=C1,TASP 0433864,124201847,"(2S)-2-[[4-(1,1-Dimethylethyl)phenoxy]methyl]-2,3-dihydro-5-methylimidazo[2,1-b]oxazole-6-carboxamide",C18H23N3O3,[1431980-60-7],329.39,7-TM Receptors,Glutamate (Metabotropic) Group II Receptors,Modulator,Selective positive allosteric modulator of mGlu2 receptors,1,Cc1c(C(N)=O)nc2n1C[C@@H](COc1ccc(C(C)(C)C)cc1)O2,864,1
5363,ON2C1=CC(C3=CC=CC=C3)=CC(C(F)(F)F)=C1C=C2C(OC)=O,NHI 2,51355147,Methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indole-2-carboxylate,C17H12F3NO3,[1269802-97-2],335.28,Enzymes,Lactate Dehydrogenase A,Inhibitor,LDHA inhibitor,1,COC(=O)c1cc2c(C(F)(F)F)cc(-c3ccccc3)cc2n1O,236,1
5373,CC(OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](NC(C)=O)[C@@H](OC(C)C)O1)=O,C34,91691128,"1-Methylethyl 2-(acetylamino)-2-deoxy-?-D-glucopyranoside 3,4,6-triacetate",C17H27NO9,[40592-88-9],389.4,Enzyme-Linked Receptors,Toll-like Receptors,Inhibitor,TLR4 inhibitor,2,CC(=O)N[C@H]1[C@@H](OC(C)C)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O,31,1
5380,O=C(NC2=CC(C)=NN2C3=CC=CC=C3)NC1=CC(F)=C(F)C=C1,ML 297,56642816,"N-(3,4-Difluorophenyl)-N'-(3-methyl-1-phenyl-1H-pyrazol-5-yl)urea",C17H14F2N4O,[1443246-62-5],328.32,Ion Channels,Inward rectifier Potassium Channels,Activator,Selective Kir3.1/3.2 (GIRK1/2) channel activator,1,Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(-c2ccccc2)n1,248,0
5388,ClC1=C(N(S(C3=CC=C(C(O)=O)C=C3)(=O)=O)CC2=CC=C(OC(F)(F)F)C=C2)N=CC(C(F)(F)F)=C1,RQ 00203078,49783953,4-[[[3-Chloro-5-(trifluoromethyl)-2-pyridinyl][[4-(trifluoromethoxy)phenyl]methyl]amino]sulfonyl]benzoic acid,C21H13ClF6N2O5S,[1254205-52-1],554.85,Ion Channels,TRPM,Antagonist,Potent and selective TRPM8 antagonist; orally active,1,O=C(O)c1ccc(S(=O)(=O)N(Cc2ccc(OC(F)(F)F)cc2)c2ncc(C(F)(F)F)cc2Cl)cc1,461,0
5389,FC1=C(C(C2=CC=C(Br)C=C2)=O)C=CC(OCCCCCCN(C)CC=C)=C1.OC(/C=C/C(O)=O)=O,Ro 48-8071 fumarate,9959583,(4-Bromophenyl)[2-fluoro-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]phenyl]methanone,C23H27BrFNO2.C4H4O4,[189197-69-1],564.44,Cell biology,Other Lipid Metabolism,Inhibitor,"2,3-Oxidosqualene cyclase (OSC) inhibitor; blocks cholesterol synthesis",1,C=CCN(C)CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1,437,1
5391,CC(C)N1N=C(C#CC3=CC=CC=C3)C2=C1N=CN=C2N,SPP 86,66549796,"1-(1-Methylethyl)-3-(2-phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",C16H15N5,[1357349-91-7],281.82,Enzyme-Linked Receptors,Other RTKs,Inhibitor,Potent RET inhibitor,1,CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc21,833,0
5393,O=C2N(C)C3=C(N=C(NC5=CC=C(C(N6CCC(N7CCN(C)CC7)CC6)=O)C=C5OCC)N=C3)N(C4CCCC4)C1=CC=CC=C12,ERK5-IN-1,71604307,"11-Cyclopentyl-2-[[2-ethoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dihydro-5-methyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one",C36H46N8O3,[1435488-37-1],656.82,Enzymes,ERK,Inhibitor,Potent and selective ERK5 inhibitor,1,CCOc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C1CCCC1)c1ccccc1C(=O)N2C,398,1
5406,CC(C)CN(S(C3=NC(C)=CS3)(=O)=O)C1=C(OCC4=CC=C(C(O)=O)C=C4)C=C(CCC2)C2=C1,ONO 8130,9827317,"4-[[[2,3-Dihydro-6-[(2-methylpropyl)[(4-methyl-2-thiazolyl)sulfonyl]amino]-1H-indene-5yl]oxy]methyl]benzoic acid",C25H28N2O5S2,[459841-96-4],500.63,7-TM Receptors,Prostanoid Receptors,Antagonist,EP1 receptor antagonist,1,Cc1csc(S(=O)(=O)N(CC(C)C)c2cc3c(cc2OCc2ccc(C(=O)O)cc2)CCC3)n1,462,1
5408,O=C2N(CC3=CC=CC=C3)C([C@@H]([C@@H](C)C)N(CCCN)C(C4=CC=C(C)C=C4)=O)=NC1=CC(Cl)=CC=C12,Ispinesib,6851740,"N-(3-Aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methylbenzamide",C30H33ClN4O2,[336113-53-2],517.06,Enzymes,Kinesin,Inhibitor,High affinity and selective allosteric KSP inhibitor,1,Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,220,1
5410,FC(C(C=CC=C3)=C3C1=CC(C(F)(F)F)=C(NC(C4=NOC5(CCCCC5)C4)=N2)C2=C1)(F)F,TC-I 2014,45274257,3-[7-(Trifluoromethyl)-5-[2-(trifluoromethyl)phenyl]-1H-benzimidazol-2-yl]-1-oxa-2-azaspiro[4.5]dec-2-ene,C23H19F6N3O,[1221349-53-6],467.41,Ion Channels,TRPM,Antagonist,Potent TRPM8 antagonist,1,FC(F)(F)c1ccccc1-c1cc(C(F)(F)F)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,689,1
5413,O=C(OC5=C(C)C=CC=C5C)N(C4=CC=C(OC)C=C4OC)C1=NC(NC(C=C3)=CC=C3N2CCN(C)CC2)=NC=C1,WH-4-023,11844351,"2,6-Dimethylphenyl-N-(2,4-dimethoxyphenyl)-N-[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]carbamate",C32H36N6O4,[837422-57-8],568.67,Enzymes,Src Kinases,Inhibitor,Potent and selective Lck and Src inhibitor; also inhibits SIK,1,COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)c(OC)c1,403,0
5414,CNC1=CC=C([N+]([O-])=O)C=C1N2C=C(C3=CC=C(C(F)(F)F)C=C3)N=C2,CU-T12-9,91826088,N-Methyl-4-nitro-2-(4-(4-trifluoromethyl)phenyl)-1H-imidazol-1-yl)aniline,C17H13F3N4O2,,362.31,Enzyme-Linked Receptors,Toll-like Receptors,Agonist,Potent TLR1/2 agonist,1,CNc1ccc([N+](=O)[O-])cc1-n1cnc(-c2ccc(C(F)(F)F)cc2)c1,90,1
5424,C12=CC=CC=C1N=C(C4=CC=C(OC[C@H]([C@H]8CCNCC8)N5C(C7=CC=CC=C7)=NC6=C5C=CC=C6)C=C4)N2CC3=CC=CC=C3.Cl.Cl.Cl,Deltarasin,91826089,2-[4-[(2S)-2-(2-Phenyl-1H-benzimidazol-1-yl)-2-(4-piperidinyl)ethoxy]phenyl]-1-(phenylmethyl)-1H-benzimidazole trihydrochloride,C40H37N5O.3HCl,[1440898-82-7],785.2,Enzymes,Ras GTPases,Other,High affinity PDE?-KRas interaction inhibitor; binds to PDE?,1,c1ccc(Cn2c(-c3ccc(OC[C@H](C4CCNCC4)n4c(-c5ccccc5)nc5ccccc54)cc3)nc3ccccc32)cc1,165,1
5425,O=C(NC1=NN=CS1)C2=CN=CC=C2,TGN 020,4173511,"N-1,3,4-Thiadiazol-2-yl-3-pyridinecarboxamide",C8H6N4OS,[51987-99-6],206.22,Ion Channels,Aquaporins,Blocker,Aquaporin 4 (AQP4) channel blocker,2,O=C(Nc1nncs1)c1cccnc1,476,1
5430,O=C(N)C2=NN(C=C2NC(C3=COC(C4=CC=NC(C)=C4)=N3)=O)C1CCOCC1.Cl,AS 2444697,118719434,N-[3-Aminocarbonyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-2-(2-methyl-4-pyridinyl)-4-oxazolecarboxamide hydrochloride,C19H20N6O4.HCl,[1287665-60-4],459.88,Enzymes,IRAK,Inhibitor,Potent and selective IRAK4 inhibitor,1,Cc1cc(-c2nc(C(=O)Nc3cn(C4CCOCC4)nc3C(N)=O)co2)ccn1,543,1
5433,CC(C1=CC=C(NC(/C=C/C2=CC=C(CC)O2)=O)C=C1)=O,Heclin,7464118,N-(4-Acetylphenyl)-3-(5-ethyl-2-furanyl)-2-propenamide,C17H17NO3,[890605-54-6],283.32,Enzymes,Ubiquitin E3 Ligases,Inhibitor,HECT E3 ubiquitin ligase inhibitor,1,CCc1ccc(/C=C/C(=O)Nc2ccc(C(C)=O)cc2)o1,609,1
5438,O=C(C(F)(F)F)C2=CN(CC(N[C@@H](CC(C)C)C(O)=O)=O)C1=CC=C(NS(C3=CC=C(C)C=C3)(=O)=O)C=C12,NTRC 824,101873359,"N-[2-[5-[[(4-Methylphenyl)sulfonyl]amino]-3-(2,2,2-trifluoroacetyl)-1H-indol-1-yl]acetyl]-L-leucine",C25H26F3N3O6S,[1623002-61-8],571.57,7-TM Receptors,Neurotensin Receptors,Antagonist,Potent and selective non-peptide NTS2 antagonist,1,Cc1ccc(S(=O)(=O)Nc2ccc3c(c2)c(C(=O)C(F)(F)F)cn3CC(=O)N[C@@H](CC(C)C)C(=O)O)cc1,104,1
5443,O=C(NN3CCS(CC3)(=O)=O)C1=NN(C2=CC=C(Cl)C=C2Cl)C(C4=CC=C(C#CCCC#N)C=C4)=C1C,AM 6545,46912919,"5-[4-(4-Cyano-1-butyn-1-yl)phenyl]-1-(2,4-dichlorophenyl)-N-(1,1-dioxido-4-thiomorpholinyl)-4-methyl-1H-pyrazole-3-carboxamide",C26H23Cl2N5O3S,[1245626-05-4],556.46,7-TM Receptors,CB1 Receptors,Antagonist,High affinity and selective CB1 antagonist,2,Cc1c(C(=O)NN2CCS(=O)(=O)CC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(C#CCCC#N)cc1,580,1
5445,NC1=NC(OCCCC)=NC(N2CC3=CC=CC(CC(OC)=O)=C3)=C1NC2=O,SM 324405,23079483,"Methyl 3-[(6-amino-2-butoxy-7,8-dihydro-8-oxo-9H-purin-9-yl)methyl]benzeneacetate",C19H23N5O4,[677773-91-0],385.42,Enzyme-Linked Receptors,Toll-like Receptors,Agonist,Potent TLR7 agonist,1,CCCCOc1nc(N)c2[nH]c(=O)n(Cc3cccc(CC(=O)OC)c3)c2n1,666,0
5449,O=C2C1=CC=CC=C1N=C(C(N4CCN(C(COC5=CC=C(Cl)C=C5)=O)CC4)C)N2C3=C(OCC)C=CC=C3,Erastin,11214940,2-[1-[4-[2-(4-Chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-quinazolinone,C30H31ClN4O4,[571203-78-6],547.04,Ion Channels,Other Channel Modulators,Other,Mitochondrial VDAC modulator; also Ferroptosis activator,2,CCOc1ccccc1-n1c(C(C)N2CCN(C(=O)COc3ccc(Cl)cc3)CC2)nc2ccccc2c1=O,699,1
5455,CC(C)C1=CC=C(N(CC2=CC=C(N(C)C)C=C2)C(C3C(C=C(OC)C=C4)=C4CCC3)=O)C=C1.Cl,W 54011,5311121,"N-[[4-(Dimethylamino)phenyl]methyl]-1,2,3,4-tetrahydro-7-methoxy-N-[4-(1-methylethyl)phenyl]-1-naphthalenecarboxamide hydrochloride",C30H36N2O2.HCl,[405098-33-1],502.09,Cell biology,Complement,Antagonist,High affinity C5a receptor antagonist,1,COc1ccc2c(c1)C(C(=O)N(Cc1ccc(N(C)C)cc1)c1ccc(C(C)C)cc1)CCC2,223,0
5456,F[C@@]2(F)[C@H]1C3=C(C=CC=C3)[C@H](N5CCN(C[C@H](COC6=CC=CC7=C6C=CC=N7)O)CC5)C4=C(C=CC=C4)[C@H]12.Cl.Cl.Cl,Zosuquidar trihydrochloride,153997,"(?R)-4-[(1a?,6?,10b?)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-?-[(5-quinolinyloxy)methyl]-1-piperazineethanol trihydrochloride",C32H31F2N3O2.3HCl,[167465-36-3],718.06,Transporters,Multidrug Transporters,Inhibitor,High affinity P-gp inhibitor,1,O[C@@H](COc1cccc2ncccc12)CN1CCN([C@@H]2c3ccccc3[C@@H]3[C@H](c4ccccc42)C3(F)F)CC1,349,1
5495,O=C(C1=CC=C(F)C=C1)NC2=NNC3=NC(C4=C5N(C=CC(OC)=C5)N=C4)=C(F)C=C32,CW 008,59528098,"4-Fluoro-N-[5-fluoro-6-(5-methoxypyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl]benzamide",C21H14F2N6O2,[1134613-19-6],433.88,Enzymes,Protein Kinase A,Activator,PKA signaling activator; promotes osteogenesis from hMSCs,1,COc1ccn2ncc(-c3nc4[nH]nc(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1,509,1
5496,CC(C(C=CC(N1[C@@H]([C@H](CCC1=O)NS(=O)(CC(C)C)=O)C2=CC=C(C=C2)Cl)=C3)=C3N4C)=CC4=O,LP 99,91827372,"N-[(2R,3S)-2-(4-Chlorophenyl)-1-(1,2-dihydro-1,4-dimethyl-2-oxo-7-quinolinyl)-6-oxo-3-piperidinyl]-2-methyl-1-propanesulfonamide",C26H30ClN3O4S,[1808951-93-0],516.05,Cell biology,Bromodomains,Inhibitor,Selective BRD7 and BRD9 inhibitor,1,Cc1cc(=O)n(C)c2cc(N3C(=O)CC[C@H](NS(=O)(=O)CC(C)C)[C@H]3c3ccc(Cl)cc3)ccc12,584,1
5497,CC(C(C=C1)=C(N2C)C=C1N3[C@@H](C4=CC=C(Cl)C=C4)[C@H](NS(=O)(CC(C)C)=O)CCC3=O)=CC2=O,ent-LP 99,,"N-[(2S,3R)-2-(4-Chlorophenyl)-1-(1,2-dihydro-1,4-dimethyl-2-oxo-7-quinolinyl)-6-oxo-3-piperidinyl]-2-methyl-1-propanesulfonamide",C26H30ClN3O4S,[1808948-28-8],520.55,Cell biology,Bromodomains,Control,Negative Control for LP 99,1,Cc1cc(=O)n(C)c2cc(N3C(=O)CC[C@@H](NS(=O)(=O)CC(C)C)[C@@H]3c3ccc(Cl)cc3)ccc12,584,0
5517,CC2=NC1=CC=C(C3=C(N)C(C(C4=C(C5=CC=CC=C5)N(C)N(C6=CC=CC=C6)C4=O)=O)=CC=C3C)C=C1C=C2.Cl,AMG PERK 44,121513867,"4-[2-Amino-4-methyl-3-(2-methyl-6-quinolinyl)benzoyl]-1,2-dihydro-1-methyl-2,5-diphenyl-3H-pyrazol-3-one hydrochloride",C34H28N4O2.HCl,0,588.09,Enzymes,PERK,Inhibitor,Potent and selective PERK inhibitor; orally bioavailable,1,Cc1ccc2cc(-c3c(C)ccc(C(=O)c4c(-c5ccccc5)n(C)n(-c5ccccc5)c4=O)c3N)ccc2n1,242,1
5521,O=C(NC1=NOC(C)=C1)C(C2=CC=CC=C2)N(CCC3)C4=C3C=CC=C4,CIM 0216,42887770,"3,4-Dihydro-N-(5-methyl-3-isoxazolyl)-?-phenyl-1(2H)-quinolineacetamide",C21H21N3O2,[1031496-06-6],347.41,Ion Channels,TRPM,Agonist,Selective TRPM3 agonist,1,Cc1cc(NC(=O)C(c2ccccc2)N2CCCc3ccccc32)no1,147,1
5522,O=C(C1=C2C=C(C(C)=O)O1)C3=CC=CC=C3C2=O,Napabucasin,10331844,"2-Acetylnaphtho[2,3-b]furan-4,9-dione",C14H8O4,[83280-65-3],240.21,Cell biology,STAT,Inhibitor,STAT3 inhibitor; also blocks cancer stem cell self-renewal,1,CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O,761,1
5550,COC1=C(N2C=C(C)N=C2)C=CC(/C=C3CCCN([C@@H](C)C4=CC=C(F)C=C4)C\3=O)=C1,E 2012,11560787,(3E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-2-piperidone,C25H26FN3O2,[870843-42-8],419.49,Enzymes,Gamma-Secretase,Modulator,?-secretase modulator; Notch-sparing,1,COc1cc(/C=C2\CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1,343,1
5553,ClC1=C(/C=N/NC(N)=N)C=CC=C1.OC(O)=O,Sephin 1,121513868,(2E)-2-[(2-Chlorophenyl)methylene]-hydrazinecarboximidamide carbonic acid salt,C8H9ClN4.CH2O3,[1883549-35-6],258.66,Enzymes,Protein Ser/Thr Phosphatases,Inhibitor,Inhibitor of the regulatory subunit PPP1R15A of protein phosphatase 1,1,N=C(N)N/N=C/c1ccccc1Cl,869,1
5565,O=C(C(O)=O)C2=CN(CC3=CC=CC=C3)C1=CC=C(C4=CC=C(OC(F)(F)F)C=C4)C=C12,Tiplaxtinin,6450819,?-Oxo-1-(phenylmethyl)-5-[4-(trifluoromethoxy)phenyl]-1H-indole-3-acetic acid,C24H16F3NO4,[393105-53-8],439.38,Enzymes,Plasminogen Activator Inhibitor 1,Inhibitor,Plasminogen activator inhibitor-1 (PAI-1) inhibitor,2,O=C(O)C(=O)c1cn(Cc2ccccc2)c2ccc(-c3ccc(OC(F)(F)F)cc3)cc12,168,1
5567,NC1=C2C(N([C@H]3[C@H](O)[C@H](O)[C@@H](CN(CCCNC(NC4=CC=C(C(C)(C)C)C=C4)=O)C(C)C)O3)C=C2)=NC=N1,EPZ 004777,56962336,"7-[5-Deoxy-5-[[3-[[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]propyl](1-methylethyl)amino]-?-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine",C28H41N7O4,[1338466-77-5],557.69,Enzymes,Other Lysine Methyltransferases,Inhibitor,Highly potent DOT1L inhibitor,1,CC(C)N(CCCNC(=O)Nc1ccc(C(C)(C)C)cc1)C[C@H]1O[C@@H](n2ccc3c(N)ncnc32)[C@H](O)[C@@H]1O,840,0
5577,NS(OC1=CC=C(NC(NC2=CC(C)=CC(C)=C2)=O)C=C1)(=O)=O,S4,53342705,"4-[[[(3,5-Dimethylphenyl)amino]carbonyl]amino]phenyl sulfamate",C15H17N3O4S,[1330061-67-0],339.88,Enzymes,Carbonic anhydrases,Inhibitor,High affinity and selective CA IX and CA XII inhibitor,1,Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1,510,0
5584,O=C2CCC1=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C1N2,Aripiprazole,60795,"7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone",C23H27Cl2N3O2,[129722-12-9],448.39,7-TM Receptors,D2 Receptors,Agonist,High affinity D2 and 5-HT1A receptor partial agonist; also 5-HT2A antagonist,1,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,275,0
5585,O=C(NC1(CCCCC1)C(NCC#N)=O)C(C=C2)=CC=C2N3CCN(CCC)CC3,Balicatib,10201696,N-[1-(Cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide,C23H33N5O2,[354813-19-7],411.54,Enzymes,Cathepsin,Inhibitor,Potent and selective cathepsin K inhibitor,1,CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1,274,0
5586,ClC1=C(CSC2=NN=C(C3=NC=CN=C3)S2)C(Cl)=CC=C1,Yoda 1,2746822,"2-[5-[[(2,6-Dichlorophenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]pyrazine",C13H8Cl2N4S2,[448947-81-7],355.27,Ion Channels,Piezo Channels,Activator,Piezo1 channel activator,2,Clc1cccc(Cl)c1CSc1nnc(-c2cnccn2)s1,846,1
5589,NCCC2=CN(S(C3=C(Cl)N=C4N3C=CS4)(=O)=O)C1=CC=CC=C12.O=C(O)C(O)=O,WAY 181187 oxalate,121513871,"1-[(6-Chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-1H-indole-3-ethanamine oxalate",C15H13ClN4O2S2.C2H2O4,[1883548-85-3],488.93,7-TM Receptors,5-HT6 Receptors,Agonist,High affinity and selective 5-HT6 agonist,2,NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12,634,1
5590,O=C(N(C)C=C1C2=CC(OC)=C(CN(C)C)C=C2OC)C3=C1C=CN=C3,BI 9564,117072549,"4-[4-[(Dimethylamino)methyl]-2,5-dimethoxyphenyl]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one",C20H23N3O3,[1883429-22-8],357.91,Cell biology,Bromodomains,Inhibitor,Potent and selective BRD9 and BRD7 inhibitor; orally active,1,COc1cc(-c2cn(C)c(=O)c3cnccc23)c(OC)cc1CN(C)C,378,1
5592,OC1=CC=CC(NC2=CC=NC3=C2SC(C4=CC=CC(CN5CCOCC5)=C4)=C3)=C1.Cl.Cl,LCB 03-0110 dihydrochloride,121513872,"3-[[2-[3-(4-Morpholinylmethyl)phenyl]thieno[3,2-b]pyridin-7-yl]amino]phenol dihydrochloride",C24H23N3O2S.2HCl,0,526.48,Enzymes,Src Kinases,Inhibitor,"Potent c-SRC kinase inhibitor; also inhibits DDR2, BTK and Syk",1,Oc1cccc(Nc2ccnc3cc(-c4cccc(CN5CCOCC5)c4)sc23)c1,307,1
5601,O=C1C2=CC=CC(CC(O)=O)=C2OC3=C1C=CC(C)=C3C,DMXAA,123964,"5,6-Dimethyl-9-oxo-9H-xanthene-4-acetic acid",C17H14O4,[117570-53-3],282.29,Cell biology,STING-Dependent Signaling,Agonist,mSTING agonist; induces antitumor immunological responses,1,Cc1ccc2c(=O)c3cccc(CC(=O)O)c3oc2c1C,783,1
5603,O=C(OC(C)(C)C)C[C@H]1N=C(C4=CC=C(Cl)C=C4)C3=C(SC(C)=C3C)N2C1=NN=C2C,(-)-JQ1,49871818,"(6R)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester",C23H25ClN4O2S,[1268524-71-5],466,Cell biology,Bromodomains,Control,Inactive control for (+)-JQ1,1,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,578,0
5605,O=C(CN(CC)CC)N1C2=C(C=CC=C2)CCC3=C1C=C(NC(OCC)=O)C=C3,CINPA 1,969470,"Ethyl [5-[(diethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]carbamate",C23H29N3O3,[102636-74-8],395.49,Nuclear Receptors,Constitutive Androstane Receptor,Antagonist,Potent CAR antagonist,1,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CN(CC)CC)c1ccccc1CC2,148,1
5614,CN1C(C2=CC=NC=C2)=NN=C1O[C@H](C)C3=NOC(C4=CC=CC(Cl)=C4)=C3,AZD 2066,16041426,"4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine",C19H16ClN5O2,[934282-55-0],386.32,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Antagonist,mGlu5 antagonist; orally bioavailable and brain penetrant,1,C[C@@H](Oc1nnc(-c2ccncc2)n1C)c1cc(-c2cccc(Cl)c2)on1,710,1
5615,OCCNC(NC(C=C1)=CC=C1C2=NC(C3(CC3)S(C4CC4)(=O)=O)=CC(N5[C@@H](C)COCC5)=N2)=S,AZD 3147,25168990,N-[4-[4-[1-(Cyclopropylsulfonyl)cyclopropyl]-6-[(3S)-3-methyl-4-morpholinyl]-2-pyrimidinyl]phenyl]-N'-(2-hydroxyethyl)thiourea,C24H31N5O4S2,[1101810-02-9],517.66,Enzymes,mTOR,Inhibitor,Potent and selective dual mTORC1 and 2 inhibitor; orally bioavailable,1,C[C@H]1COCCN1c1cc(C2(S(=O)(=O)C3CC3)CC2)nc(-c2ccc(NC(=S)NCCO)cc2)n1,323,0
5617,C[C@@H](C1=NC=C(F)C=N1)NC2=NC=C(Cl)C(NC3=NNC(C)=C3)=N2,AZD 1480,16659841,"5-Chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidine-2,4-diamine",C14H14ClFN8,[935666-88-9],348.77,Enzymes,JAK Kinase,Inhibitor,Potent and selective JAK2 inhibitor; antiangiogenic,1,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)n[nH]1,95,1
5621,O=C(N1[C@](C(N(CC2=CC(Cl)=CC=C2)CCCC(O)=O)=O)(C)CC1)C3=CSC4=C3C=CC=C4,GLPG 0974,57520598,4-[[[(2R)-1-(Benzo[b]thien-3-ylcarbonyl)-2-methyl-2-azetidinyl]carbonyl][(3-chlorophenyl)methyl]amino]butanoic acid,C25H25ClN2O4S,[1391076-61-1],485,7-TM Receptors,Free Fatty Acid Receptors,Antagonist,Potent FFA2 antagonist,2,C[C@]1(C(=O)N(CCCC(=O)O)Cc2cccc(Cl)c2)CCN1C(=O)c1csc2ccccc12,616,1
5622,O=C1N(C)C2=C(N=C(NC3=CN(C4CCNCC4)N=C3)N=C2C)N(C)C5=CC6=CC=CC=C6C=C51,HTH 01-015,78357766,"5,13-Dihydro-4,5,13-trimethyl-2-[[1-(4-piperidinyl)-1H-pyrazol-4-yl]amino]-6H-naphtho[2,3-e]pyrimido[5,4-b][1,4]diazepin-6-one",C26H28N8O,[1613724-42-7],495.57,Enzymes,NUAK,Inhibitor,Potent and selective NUAK1 inhibitor,1,Cc1nc(Nc2cnn(C3CCNCC3)c2)nc2c1N(C)C(=O)c1cc3ccccc3cc1N2C,856,1
5625,O=C([C@@H]1CCCC[C@@H]1C(O)=O)N2CCC3=CC=CC=C3[C@H]2CN4C(C(C=CC=C5)=C5C4=O)=O,ML 334,56840728,"(1S,2R)-2-[[(1S)-1-[(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]carbonyl]cyclohexanecarboxylic acid",C26H26N2O5,[1432500-66-7],451,Cell biology,Nrf2,Activator,Inhibitor of Keap1- Nrf2 interaction,1,O=C(O)[C@H]1CCCC[C@H]1C(=O)N1CCc2ccccc2[C@H]1CN1C(=O)c2ccccc2C1=O,143,0
5626,O=C(N(CCO)C4=CC=CC=C4)NC(C=C3)=CC=C3C1=C2C(NC=C2C)=NC=N1,SR 7826,45381385,"N-(2-Hydroxyethyl)-N'-[4,5-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-yl)phenyl]-N-phenylurea",C22H21N5O2,[1219728-20-7],387.43,Enzymes,LIMK,Inhibitor,Potent and selective LIMK inhibitor; antitumor,1,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccccc4)cc3)c12,234,1
5632,CC1=NC=CC(C2=CN(CC3=CC=CC=C3)C4=CN=CC=C42)=N1,AZ Dyrk1B 33,118735338,"3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine",C19H16N4,[1679330-37-0],300.36,Enzymes,DYRK,Inhibitor,Potent and selective Dyrk1B kinase inhibitor,1,Cc1nccc(-c2cn(Cc3ccccc3)c3cnccc23)n1,169,1
5641,O=C(C1=CC=CN=C1)NC2=NN3C(C=C(C(F)(F)F)C=C3NC4CC4)=N2,MSC 2032964A,25214468,"N-[5-(Cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-3-pyridinecarboxamide",C16H13F3N6O,[1124381-43-6],366.81,Enzymes,ASK1,Inhibitor,Potent and selective ASK1 inhibitor; orally bioavailable,2,O=C(Nc1nc2cc(C(F)(F)F)cc(NC3CC3)n2n1)c1cccnc1,476,0
5642,CN1C(CNC2=CC(C(NCC3=CC=CC=C3C(F)(F)F)=O)=CC=C2)=NN=C1C4=CC=NC=C4,CMPD101,11677079,"3-[[[4-Methyl-5-(4-pyridinyl)-4H-1,2,4-triazol-3-yl]methyl]amino]-N-[[2-(trifluoromethyl)phenyl]methyl]benzamide",C24H21F3N6O,[865608-11-3],470.96,Enzymes,Heterotrimeric G-protein GTPases,Inhibitor,Potent and selective GRK2/3 inhibitor,1,Cn1c(CNc2cccc(C(=O)NCc3ccccc3C(F)(F)F)c2)nnc1-c1ccncc1,709,1
5651,O=C(NC(C(C)C)C(C1=NN=C(C(C)(C)C)O1)=O)CN(C(C2=CC=CC=C2)=NC=C3N)C3=O,ONO 6818,216294,"5-Amino-N-[1-[[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]carbonyl]-2-methylpropyl]-6-oxo-2-phenyl-1(6H)-pyrimidineacetamide",C23H28N6O4,[208848-19-5],457.01,Enzymes,Elastase,Inhibitor,High affinity and selective human neutrophil elastase 1 (HNE1) inhibitor; orally active,1,CC(C)C(NC(=O)Cn1c(-c2ccccc2)ncc(N)c1=O)C(=O)c1nnc(C(C)(C)C)o1,237,1
5653,COC1=CC=C(N2C(SCC3=NC(C4=CC=C(C)C=C4)=NO3)=NN=C2C5=CC=NC=C5)C=C1,JW 74,16013152,"4-[4-(4-Methoxyphenyl)-5-[[[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]thio]-4H-1,2,4-triazol-3-yl]-pyridine",C24H20N6O2S,[863405-60-1],456.52,Cell biology,Other Wnt Signaling,Inhibitor,Wnt pathway inhibitor,1,COc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1,711,1
5654,CCCCOC1=C2C=NNC2=NC=C1C(C3=C(C=C(C=C3F)C)F)=O,BMS 265246,5329775,"(4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl) (2,6-difluoro-4-methylphenyl)methanone",C18H17F2N3O2,[582315-72-8],345.34,Enzymes,Cyclin-dependent Kinase,Inhibitor,Cdk inhibitor; potently inhibits cdk1 and cdk2,1,CCCCOc1c(C(=O)c2c(F)cc(C)cc2F)cnc2[nH]ncc12,501,1
5655,C12=CC=CC=C1C3=C(C(NC4=CC(OCCO5)=C5C=C4)=NN3)C2,GN 44028,71625259,"N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1,4-dihydroindeno[1,2-c]pyrazol-3-amine",C18N15N3O2,[1421448-26-1],305.33,Cell biology,Hypoxia Inducible Factors,Inhibitor,Potent HIF-1? inhibitor,1,c1ccc2c(c1)Cc1c(Nc3ccc4c(c3)OCCO4)n[nH]c1-2,755,1
5661,NCCCOC1=CC2=CC=CC=C2C=C1C(NCCOC3=C(C(NC4=CC=C(Cl)C=C4O)=O)C=C(C=CC=C5)C5=C3)=O.Cl,666-15,71566396,3-(3-Aminopropoxy)-N-[2-[[3-[[(4-chloro-2-hydroxyphenyl)amino]carbonyl]-2-naphthalenyl]oxy]ethyl]-2-naphthalenecarboxamide hydrochloride,C33H30ClN3O5.HCl,[1433286-70-4],620.52,Cell biology,Other Transcription Factors,Inhibitor,Potent and selective CREB inhibitor,2,NCCCOc1cc2ccccc2cc1C(=O)NCCOc1cc2ccccc2cc1C(=O)Nc1ccc(Cl)cc1O,594,1
5666,O=C(CNC(C1=CC=CC(Cl)=C1)=O)N[C@@H](C)C2=CC=CC=C2,JNJ 63533054,2548547,3-Chloro-N-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]benzamide,C17H17ClN2O2,[1802326-66-4],316.78,7-TM Receptors,Orphan 7-TM Receptors,Agonist,Potent and selective GPR139 agonist,1,C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1,602,0
5671,ClC1=C(S(=O)(N)=O)C(O)=C(NC(NC2=C(Cl)C(Cl)=CC=C2)=O)C=C1,SB 332235,9887803,"6-Chloro-3-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-2-hydroxybenzenesulfonamide",C13H10Cl3N3O4S,[276702-15-9],410.66,7-TM Receptors,Chemokine CXC Receptors,Antagonist,Potent CXCR2 antagonist,1,NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O,549,1
5672,CS(C1=CC=CC=C1COC2=C(C#N)SC(N3C4=CC(OC)=C(OC)C=C4N=C3)=C2)(=O)=O,GSK 319347A,11626927,"5-(5,6-Dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(methylsulfonyl)phenyl]methoxy]-2-thiophenecarbonitrile",C22H19N3O5S2,[862812-98-4],474.03,Enzymes,IkB Kinase,Inhibitor,Potent and selective IKK? inhibitor,1,COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC,538,0
5675,N#CC1=CN(CC(C)C)C2=C1C=C(OC3=CC=C(NC([C@H]4NCCC4)=O)C=C3)C=C2,AZ PFKFB3 26,118735769,(2S)-N-[4-[[3-Cyano-1-(2-methylpropyl)-1H-indol-5-yl]oxy]phenyl]-2-pyrrolidinecarboxamide,C24H26N4O2,[1704740-52-2],402.49,Enzymes,PFKFB3,Inhibitor,Potent and selective PFKFB3 inhibitor,1,CC(C)Cn1cc(C#N)c2cc(Oc3ccc(NC(=O)[C@@H]4CCCN4)cc3)ccc21,448,1
5678,O=C(NC2=CC=C(S(N3CCN(C(C)C)CC3)(=O)=O)C=C2)C1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O.Cl,RN 9893 hydrochloride,121513879,N-[4-[[4-(1-Methylethyl)-1-piperazinyl]sulfonyl]phenyl]-2-nitro-4-(trifluoromethyl)benzamide hydrochloride,C21H23F3N4O5S.HCl,[1803003-68-0],536.95,Ion Channels,TRPV,Antagonist,Potent and selective TRPV4 antagonist,1,CC(C)N1CCN(S(=O)(=O)c2ccc(NC(=O)c3ccc(C(F)(F)F)cc3[N+](=O)[O-])cc2)CC1,91,1
5679,O[C@@H]1[C@H](NC([C@@H](NC(C)=O)CC4=CC=C(OC)C=C4)=O)[C@@H](CO)O[C@H]1N3C2=NC=NC(N(C)C)=C2N=C3,N-Acetylpuromycin,46173769,"3'-[[(2S)-2-(Acetylamino)-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyladenosine",C24H31N7O6,[22852-13-7],518.05,Enzyme-Linked Receptors,TGF-beta Receptors,Other,Downregulates SnoN and Ski protein expression; promotes TGF-? signaling,2,COc1ccc(C[C@H](NC(C)=O)C(=O)N[C@@H]2[C@@H](CO)O[C@@H](n3cnc4c(N(C)C)ncnc43)[C@@H]2O)cc1,843,0
5681,COC1=C(N=C(NC2=NN=C(C3=CC=C(OC)C=C3)O2)S4)C4=CC=C1,N106,3236395,"4-Methoxy-N-[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl-2-benzothiazolamine",C17H14N4O3S,[862974-25-2],354.38,Enzymes,Other Ligases,Activator,"Activator of SUMO-activating enzyme, E1 ligase",1,COc1ccc(-c2nnc(Nc3nc4c(OC)cccc4s3)o2)cc1,463,1
5682,O=C(CN)NC(C=C1)=CC=C1N2C(C(C=C3)=CC4=C3C5=CC=CC=C5C=C4)=CC(C(F)(F)F)=N2,OSU 03012,10027278,2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]acetamide,C26H19F3N4O,[742112-33-0],460.45,Enzymes,Phosphoinositide-dependent Kinase 1,Inhibitor,PDPK1 (PDK1) inhibitor; inhibits Akt signaling,1,NCC(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc3c(ccc4ccccc43)c2)cc1,682,0
5692,O=C1NC2=CC=C(Cl)C=C2C(C3=C(C(C)C)C=CC=C3)SC1,ITH 12575,124201848,"7-Chloro-1,5-dihydro-5-[2-(1-methylethyl)phenyl]-4,1-benzothiazepin-2(3H)-one",C18H18ClNOS,[1802013-08-6],336.36,Transporters,Na+/Ca2+ Exchanger,Inhibitor,Mitochondrial Na+/Ca2+ exchange (mNCX) inhibitor,1,CC(C)c1ccccc1C1SCC(=O)Nc2ccc(Cl)cc21,767,0
5693,O=C(C1=CC=C(F)C=C1)N(C2)CCC3=C2OC(COC4=CC=CC=C4)=N3,VU 0409551,56846694,"[6,7-Dihydro-2-(phenoxymethyl)oxazolo[5,4-c]pyridin-5(4H)-yl](fluorophenyl)methanone",C20H17FN2O3,[1363281-27-9],352.36,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Modulator,Selective positive allosteric modulator of mGlu5 receptors; brain penetrant and orally bioavailable,1,O=C(c1ccc(F)cc1)N1CCc2nc(COc3ccccc3)oc2C1,278,0
5694,CC1=CC(C)=CC(C)=C1S(N(CC2=CC=C(C(F)(F)F)O2)CC(C=C3)=CC=C3C4=CC(S(C)(=O)=O)=CC=C4)(=O)=O,GSK 2033,46203250,"2,4,6-Trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide",C29H28F3NO5S,[1221277-90-2],591.66,Nuclear Receptors,LXR-like Receptors,Antagonist,Potent LXR antagonist,1,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2ccc(C(F)(F)F)o2)c(C)c1,76,1
5699,CN1C(C2=CC=C(COCCOC)C=C2)=CC3=C(C(C4=CC=CC=C4)=NO3)C1=O,IP7e,9908426,"6-[4-[(2-Methoxyethoxy)methyl]phenyl]-5-methyl-3-phenyl-isoxazolo[4,5-c]pyridin-4(5H)-one",C23H22N2O4,[500164-74-9],390.43,Nuclear Receptors,Nerve Growth Factor IB-like Receptors,Activator,Potent Nurr1 activator,1,COCCOCc1ccc(-c2cc3onc(-c4ccccc4)c3c(=O)n2C)cc1,245,1
5705,NC1=CC=CC=C1OC2=CC=C3C(SN=C3N)=C2.Cl.Cl,M62812,44224214,"6-(2-Aminophenoxy)-1,2-benzisothiazol-3-amine dihydrochloride",C13H11N3OS.2HCl,[613263-00-6],330.23,Enzyme-Linked Receptors,Toll-like Receptors,Inhibitor,TLR-4 inhibitor,1,Nc1ccccc1Oc1ccc2c(N)nsc2c1,811,1
5707,CC1=C(C)C=C(C)C(C)=C1S(=O)(NC2=C(C=CC=C3)C3=C(N4C[C@@H](C(O)=O)CC4)C=C2)=O,RA 839,91971266,"(3S)-1-[4-[[(2,3,5,6-Tetramethylphenyl)sulfonyl]amino]-1-naphthalenyl]-3-pyrrolidinecarboxylic acid",C25H28N2O4S,[1832713-02-6],452.57,Cell biology,Nrf2,Activator,Nrf2 activator; inhibits Nrf2/Keap1 interaction,1,Cc1cc(C)c(C)c(S(=O)(=O)Nc2ccc(N3CC[C@H](C(=O)O)C3)c3ccccc23)c1C,188,1
5713,CC(C)OC1=CC=C(C2=CNC=C2CN(CCN)C)C=C1.Cl.Cl,MS 023 dihydrochloride,121513886,"N1-Methyl-N1-[[4-[4-(1-methylethoxy)phenyl]-1H-pyrrol-3-yl]methyl]-1,2-ethanediamine dihydrochloride",C17H25N3O.2HCl,[1992047-64-9],369.33,Enzymes,Protein Arginine Methyltransferases,Inhibitor,Potent and selective type I PRMT inhibitor,1,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCN)cc1,744,1
5715,CC(C=C1C)=CC=C1C(CC2=C3N=C(CC)O2)CC3=O,(+/-)-ADX 71743,53391766,"6-(2,4-Dimethylphenyl)-2-ethyl-6,7-dihydro-4(5H)-benzoxazolone",C17H19NO2,0,269.34,7-TM Receptors,Glutamate (Metabotropic) Group III Receptors,Modulator,Negative allosteric modulator of mGlu7 receptors; brain penetrant,2,CCc1nc2c(o1)CC(c1ccc(C)cc1C)CC2=O,80,1
5722,NC1=NC(NCC2=CC=CC=C2)=NC(C3=CC=CC=C3CO)=N1,Ogerin,56707820,"2-[4-Amino-6-[(phenylmethyl)amino]-1,3,5-triazin-2-yl]benzenemethanol",C17H17N5O,[1309198-71-7],307.35,7-TM Receptors,Orphan 7-TM Receptors,Modulator,Selective positive allosteric modulator at GPR68,2,Nc1nc(NCc2ccccc2)nc(-c2ccccc2CO)n1,170,0
5729,O=C(NC(C)C)CN1C(C2=CC(OCCCN3CCOCC3)=CN=C2N=C1C4=CC=C(F)C(Cl)=C4)=O.Cl,TASP 0390325,86765292,"2-(3-Chloro-4-fluorophenyl)-N-(1-methylethyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo-pyrido[2,3-d]pyrimidine-3(4H)-acetamide hydrochloride",C25H29ClFN5O4.HCl,[1642187-96-9],585.96,7-TM Receptors,Vasopressin Receptors,Antagonist,Potent and selective V1B receptor antagonist; orally bioavailable,1,CC(C)NC(=O)Cn1c(-c2ccc(F)c(Cl)c2)nc2ncc(OCCCN3CCOCC3)cc2c1=O,317,1
5730,O=C(O)[C@@H]1[C@@H](C2=CC=C(OC)C=C2)N(CC(N(CCCC)CCCC)=O)C[C@H]1C3=CC4=C(OCO4)C=C3,A 127722,159594,"rel-(2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid",C29H38N2O6,[195704-72-4],510.62,7-TM Receptors,Endothelin ETA Receptors,Antagonist,"Highly potent, selective ETA antagonist; orally bioavailable",1,CCCCN(CCCC)C(=O)CN1C[C@@H](c2ccc3c(c2)OCO3)[C@H](C(=O)O)[C@H]1c1ccc(OC)cc1,751,1
5737,FC1=C(C=CC=C1)NC2=NC3=NON=C3N=C2NC4=C(C=CC=C4)F,BAM 15,565708,"N5,N6-bis(2-Fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine",C16H10F2N6O,[210302-17-3],344.79,Cell biology,Oxidative Phosphorylation,Other,Mitochondrial protonophore uncoupler,2,Fc1ccccc1Nc1nc2nonc2nc1Nc1ccccc1F,760,0
5742,N#CC1=CN(CC2=C(C)ON=C2C)C3=C1C=C(OC4=CC=C(NC([C@H]5NCCC5)=O)C=C4)C=C3,AZ PFKFB3 67,91668554,"(2S)-N-[4-[[3-Cyano-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-1H-indol-5-yl]oxy]phenyl]-2-pyrrolidinecarboxamide",C26H25N5O3,[1704741-11-6],460.01,Enzymes,PFKFB3,Inhibitor,Potent and selective PFKFB3 inhibitor,1,Cc1noc(C)c1Cn1cc(C#N)c2cc(Oc3ccc(NC(=O)[C@@H]4CCCN4)cc3)ccc21,448,0
5744,CC(C1)(C)NC(C)(C)CC1N2C=CC3=C2C=CC(C4=NC(S(=O)(CCC)=O)=NC(NC5CC5)=C4)=C3,NVS-CECR2-1,117072550,"N-Cyclopropyl-2-(propylsulfonyl)-6-(1-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-indol-5-yl)pyrimidin-4-amine",C27H37N5O2S,[1992047-61-6],513.7,Cell biology,Bromodomains,Inhibitor,"Potent and selective inhibitor of cat eye syndrome chromosome region, candidate 2 (CECR2)",1,CCCS(=O)(=O)c1nc(NC2CC2)cc(-c2ccc3c(ccn3C3CC(C)(C)NC(C)(C)C3)c2)n1,652,1
5752,NC1=NC=C(C3=CN=C(N)C=C3)C=C1C2=CC=C(Cl)C=C2.Cl.Cl,PF 06260933 dihydrochloride,118701007,"5-(4-Chlorophenyl)-[3,3'-bipyridine]-6,6'-diamine dihydrochloride",C16H13ClN4.2HCl,,369.68,Enzymes,Other MAPK,Inhibitor,MAP4K4 (HGK) inhibitor; also inhibits MINK and TNIK,1,Nc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cn1,814,0
5754,CC1=CC(OCC2=CC=C(CN3CCC[C@@H]3CO)C=C2)=CC(CS(C4=CC=CC=C4)(=O)=O)=C1.Cl,PF 543 hydrochloride,121230770,(2R)-1-[[(4-[[3-Methyl-5-[(phenylsulfonyl)methyl]phenoxy]methyl]phenyl]methyl]-2-pyrrolidinemethanol hydrochloride,C27H31NO4S.HCl,[1706522-79-3],502.07,Enzymes,Sphingosine Kinase,Inhibitor,Potent and selective SphK1 inhibitor,1,Cc1cc(CS(=O)(=O)c2ccccc2)cc(OCc2ccc(CN3CCC[C@@H]3CO)cc2)c1,200,1
5756,CC1(CC1)OC2=CC=C3C(C(C4=NC=NC(N5C[C@@H](C)O[C@@H](C)C5)=C4)=NN3)=C2,MLi-2,78319901,"rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidyl]-5-[(1-methylcyclopropyl)oxy]-1H-indazole",C21H25N5O2,[1627091-47-7],383.96,Enzymes,LRRK2,Inhibitor,Potent and selective LRRK2 inhibitor,1,C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1,653,1
5757,O=C(C1=CC(OC)=C(OC)C=C1NC(C2=CN=C(C=CC=C3)C3=C2)=O)NC(C=C4)=CC=C4CCN5CC6=CC(OC)=C(OC)C=C6CC5.Cl.Cl,Tariquidar dihydrochloride,121513890,"N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]-3-quinolinecarbxamide dihydrochloride",C38H38N4O6.2HCl,[1992047-62-7],755.69,Transporters,Multidrug Transporters,Inhibitor,Potent P-glycoprotein (P-gp) inhibitor,1,COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2,373,1
5759,NC1=C(S(CCCC)=O)SC2=NC(C3=CC=CS3)=CC(C4=CC=CC=C4)=C21,SW 033291,3337839,"2-(Butylsulfinyl)-4-phenyl-6-(2-thienyl)-thieno[2,3-b]pyridin-3-amine",C21H20N2OS3,[459147-39-8],412.59,Enzymes,Other Dehydrogenases,Inhibitor,High affinity 15-PGDH inhibitor; promotes hematopoiesis and hepatocyte proliferation,1,CCCCS(=O)c1sc2nc(-c3cccs3)cc(-c3ccccc3)c2c1N,152,1
5769,[Na+].O=C(COCC(NC4=C(C([O-])=O)C=C(Cl)C=C4)=O)N1CCN(C(C3=CC=CC=C3)C2=CC=CC=C2)CC1,TM 5275 sodium salt,53240409,5-Chloro-2-[[2-[2-[4-(Diphenylmethyl)-1-piperazinyl]-2-oxoethoxy]acetyl]amino]benzoic acid sodium salt,C28H27ClN3NaO5,[1103926-82-4],543.97,Enzymes,Plasminogen Activator Inhibitor 1,Inhibitor,Plasminogen activator inhibitor-1 (PAI-1) inhibitor; orally bioavailable,1,O=C(COCC(=O)N1CCN(C(c2ccccc2)c2ccccc2)CC1)Nc1ccc(Cl)cc1C(=O)[O-],596,0
5772,[Ca++].C[C@@H](C(OCC)=O)C[C@H](NC(CCC([O-])=O)=O)CC1=CC=C(C2=CC=CC=C2)C=C1.C[C@@H](C(OCC)=O)C[C@H](NC(CCC([O-])=O)=O)CC1=CC=C(C2=CC=CC=C2)C=C1,Sacubitril calcium,91827885,"Ethyl (?R,?S)-?-[(3-carboxy-1-oxopropyl)amino]-?-methyl-[1,1'-biphenyl]-4-pentanoate hemicalcium salt",C24H28NO5.�Ca,[1369773-39-6],435.02,Enzymes,Other Proteases,Inhibitor,Membrane metallo-endopeptidase (neprilysin) inhibitor prodrug; orally bioavailable,1,CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)[O-],197,1
5775,CC1=CC(N2C[C@H](C)N[C@H](C)C2)=NC=C1C3=CC=C(C(N4)=NC5=C(C=CN5C)C4=O)C=C3,AZ 6102,91663328,"rel-2-[4-[6-[(3R,5S)-3,5-Dimethyl-1-piperazinyl]-4-methyl-3-pyridinyl]phenyl]-3,7-dihydro-7-methyl-4H-pyrrolo[2,3-d]pyrimidin-4-one",C25H28N6O,[1645286-75-4],428.53,Enzymes,Tankyrase,Inhibitor,Potent TNKS1/2 inhibitor,1,Cc1cc(N2C[C@H](C)N[C@H](C)C2)ncc1-c1ccc(-c2nc3c(ccn3C)c(=O)[nH]2)cc1,673,1
5777,O[C@@H](CNC(C1=CC=NC(NC2CCC2)=C1)=O)CN3CC4=CC=CC=C4CC3.Cl.Cl,GSK 591 dihydrochloride,124201849,"2-(Cyclobutylamino)-N-[(2S)-3-(3,4-dihydro-2(1H)-isoquinolinyl)-2-hydropropyl]-4-pyridinecarboxamide dihydrochloride",C22H28N4O2.2HCl,[1616391-87-7],471.43,Enzymes,Protein Arginine Methyltransferases,Inhibitor,Potent and selective PRMT5 inhibitor,1,O=C(NC[C@H](O)CN1CCc2ccccc2C1)c1ccnc(NC2CCC2)c1,146,1
5781,O=C(NCC1=CC=C(C(F)(F)F)C=C1)NC2=CC=CC3=CN=CC=C32,A 425619,8068410,N-5-Isoquinolinyl-N'-[[(4-(trifluoromethyl)phenyl]methyl]urea,C18H14F3N3O,[581809-67-8],345.32,Ion Channels,TRPV,Antagonist,Potent TRPV1 antagonist,1,O=C(NCc1ccc(C(F)(F)F)cc1)Nc1cccc2cnccc12,465,0
5791,CN1C2=CC=C(C=C2C(C3=CC=C(C=C3)O)=NC(C1=O)CC4=CC5=CC=CC=C5C=C4)Cl,Bz 423,5497206,"7-Chloro-1,3-dihydro-5-(4-hydroxyphenyl)-1-methyl-3-(2-naphthalenylmethyl)-2H-1,4-benzodiazepin-2-one",C27H21ClN2O2,[216691-95-1],449.93,Enzymes,Other Synthases/Synthetases,Inhibitor,ATP synthase inhibitor; proapoptotic,1,CN1C(=O)C(Cc2ccc3ccccc3c2)N=C(c2ccc(O)cc2)c2cc(Cl)ccc21,579,1
5802,O=C1N(CCCN2CCCC2)C(SCC(OCC)=O)=NC3=C1SC4=C3C=CC=C4,A37,5049161,"Ethyl 2-[[3,4-dihydro-4-oxo-3-[3-(1-pyrrolidinyl)propyl][1]benzothieno[3,2-d]pyrimidin-2-yl]thio]acetate",C21H25N3O3S2,[896795-60-1],431.57,Enzymes,Aldehyde Dehydrogenase,Inhibitor,ALDH1A1 inhibitor,1,CCOC(=O)CSc1nc2c(sc3ccccc32)c(=O)n1CCCN1CCCC1,781,1
5813,CC([C@@H](C(O)=O)OC([C@@H](NC([C@H](C(C)C)OC([C@@H](NC(OC(C)(C)C)=O)C)=O)=O)C)=O)C,NSC 668036,71312060,"N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-(2S)-2-hydroxy-3-methylbutanoyl-L-alanine-(1S)-1-carboxy-2-methylpropyl ester",C21H36N2O9,[144678-63-7],460.52,Cell biology,Other Wnt Signaling,Inhibitor,Wnt signaling inhibitor; binds the PDZ domain of the Dishevelled (Dvl) protein,1,CC(C)[C@H](OC(=O)[C@H](C)NC(=O)[C@@H](OC(=O)[C@H](C)NC(=O)OC(C)(C)C)C(C)C)C(=O)O,29,1
5815,CS(N[C@@H](C)C1=CC=C(S(C2=C(S(=O)(C3=CC=C(OC)C=C3)=O)C=C(OC)C=C2)(=O)=O)C=C1)(=O)=O,SCH 336,10324989,N-[(1S)-1-[4-[[4-Methoxy-2-[(4-methoxyphenyl)sulfonyl]phenyl]sulfonyl]phenyl]ethyl]methanesulfonamide,C23H25NO8S3,[447459-51-0],539.64,7-TM Receptors,CB2 Receptors,Inverse Agonist,Highly potent and selective CB2 inverse agonist,1,COc1ccc(S(=O)(=O)c2cc(OC)ccc2S(=O)(=O)c2ccc([C@H](C)NS(C)(=O)=O)cc2)cc1,100,0
5826,FC1=CC=C(C2=CC=C(C=C2)CN3CC(N(C3=O)C4CC4)=O)N=C1CN5CCS(=O)(CC5)=O.Cl,LEI 101 hydrochloride,127021038,"3-Cyclopropyl-1-[[4-[6-[(1,1-dioxido-4-thiomorpholinyl)methyl]-5-fluoro-2-pyridinyl]phenyl]methyl]-2,4-imidazolidinedione hydrochloride",C23H25FN4O4S.HCl,0,508.99,7-TM Receptors,CB2 Receptors,Agonist,Potent and selective CB2 partial agonist; orally biovailable,1,O=C1CN(Cc2ccc(-c3ccc(F)c(CN4CCS(=O)(=O)CC4)n3)cc2)C(=O)N1C1CC1,65,1
5828,CC1=CC(C)=NC(O[C@H](C(O)=O)C(C2=CC=CC=C2)(OC)C3=CC=CC=C3)=N1,Ambrisentan,6918493,"(?S)-?-[(4,6-Dimethyl-2-pyrimidinyl)oxy]-?-methoxy-?-phenylbenzenepropanoic acid",C22H22N2O4,[177036-94-1],378.42,7-TM Receptors,Endothelin ETA Receptors,Antagonist,Selective ETA antagonist,1,COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,235,1
5832,CC(C1=CC(C)=CN2C(C=C(N3CCOCC3)N=C12)=O)NC4=CC=CC=C4,TGX 221,9907093,"7-Methyl-2-(4-morpholinyl)-9-[1-(phenylamino)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one",C21H24N4O2,[663619-89-4],364.44,Enzymes,PI 3-Kinase,Inhibitor,Potent and selective PI 3-kinase ? inhibitor,1,Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,311,0
5833,CC(C1=CC(C)=C(C=C1)Cl)NC2=CC=C(C(C3=CC(C)=C(C(C)=C3)C(NC4(C(O)=O)CC4)=O)=C2)F,Ex 26,59393740,"1-[[[5'-[[1-(4-Chloro-3-methylphenyl)ethyl]amino]-2'-fluoro-3,5-dimethyl[1,1'-biphenyl]-4-yl]carbonyl]amino]-cyclopropanecarboxylic acid",C28H28ClFN2O3,[1233332-37-0],494.98,7-TM Receptors,Sphingosine-1-phosphate Receptors,Antagonist,Potent and selective S1P1 receptor antagonist,1,Cc1cc(C(C)Nc2ccc(F)c(-c3cc(C)c(C(=O)NC4(C(=O)O)CC4)c(C)c3)c2)ccc1Cl,561,1
5843,CCOC1=C(NC2=NC=C3N(C)C(=O)C4=C(C=CC=C4)N(C3=N2)S(C)(=O)=O)C=CC(=C1)C(=O)N1CCC(CC1)N1CCN(C)CC1,AX 15836,122705989,"5,11-Dihydro-2-[[2-ethoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5-methyl,11-(methylsulfonyl)-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one",C32H40N8O5S,[2035509-96-5],684.81,Enzymes,ERK,Inhibitor,Potent and selective ERK5 inhibitor,1,CCOc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(S(C)(=O)=O)c1ccccc1C(=O)N2C,398,0
5844,O=C(N(C)C1CCCCCCC1)OC2=NSN=C2N3CCOCC3,JZP 430,121513897,"4-(4-Morpholinyl)-1,2,5-thiadiazol-3-yl N-cyclooctyl-N-methylcarbamate",C16H26N4O3S,[1672691-74-5],354.47,Enzymes,Other Hydrolases,Inhibitor,Potent and irreversible ?/?-hydrolase domain 6 (ABHD6) inhibitor,1,CN(C(=O)Oc1nsnc1N1CCOCC1)C1CCCCCCC1,39,0
5854,CCOC(C1=CC=C(O1)CN(S(=O)(C2=C(C=C(C=C2C)C)C)=O)CC3=CC=C(C4=CC(S(C)(=O)=O)=CC=C4)C=C3)=O,SR 9238,71478195,"Ethyl 5-[[[[3'-(Methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl][(2,4,6-trimethylphenyl)sulfonyl]amino]methyl]-2-furancarboxylate",C31H33NO7S2,[1416153-62-2],595.73,Nuclear Receptors,LXR-like Receptors,Inverse Agonist,Potent and selective LXR inverse agonist,1,CCOC(=O)c1ccc(CN(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)S(=O)(=O)c2c(C)cc(C)cc2C)o1,76,0
5855,ClC(C=C1)=CC=C1CN(CC2CCN(C(OCC)=O)C2)CC3=CC=C([N+]([O-])=O)S3,SR 9009,57394020,Ethyl 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-1-pyrrolidinecarboxylate,C20H24ClN3O4S,[1379686-30-2],437.94,Nuclear Receptors,Rev-Erb Receptors,Agonist,Rev-Erb?/? agonist,1,CCOC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,574,0
5866,FC1=CC=C(COC2=C(Br)C(N(C3=CC(C(NC)=O)=CC=C3C)C(C)=C2)=O)C(F)=C1,PH 797804,22049997,"(-)-3-[3-Bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxo-1(2H)-pyridinyl]-N,4-dimethylbenzamide",C22H19BrF2N2O3,[1358027-80-1],477.3,Enzymes,p38,Inhibitor,Potent and selective p38?/? inhibitor,1,CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,527,1
5868,OC(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(C2=C(C=CC=C2)Cl)=O,SR 0987,2323435,"2-Chloro-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]benzamide",C16H10ClF6NO2,[303126-97-8],397.7,Nuclear Receptors,Retinoic Acid-related Orphan Receptors,Agonist,T cell-specific ROR? (ROR?t) agonist,1,O=C(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1Cl,519,1
5869,CC1=NC2=C(NC(C3=CC=C(OC(C)C)C=C3)=O)C=CC=C2C=C1,CDN 1163,16016585,4-(1-Methylethoxy)-N-(2-methyl-8-quinolinyl)benzamide,C20H20N2O2,[892711-75-0],320.38,Enzymes,Ca2+-ATPase,Activator,SERCA2 allosteric activator,2,Cc1ccc2cccc(NC(=O)c3ccc(OC(C)C)cc3)c2n1,479,1
5871,O=C(C(CC1=CC=C(C=C1)Cl)N)OC.Cl,pCPA methyl ester hydrochloride,26531,4-Chloro-DL-Phenylalanine methyl ester hydrochloride,C10H12ClNO2.HCl,[14173-40-1],250.12,Enzymes,Hydroxylases,Inhibitor,Tryptophan hydroxylase inhibitor,1,COC(=O)C(N)Cc1ccc(Cl)cc1,600,0
5872,C[C@@H](NC1=C2SC(NC2=NC(SCC3=C(C(Cl)=CC=C3)F)=N1)=O)CO,AZ 10397767,11858154,"5-[[(3-Chloro-2-fluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one",C15H14ClFN4O2S2,[333742-63-5],400.88,7-TM Receptors,Chemokine CXC Receptors,Antagonist,Potent CXCR2 antagonist,1,C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2[nH]c(=O)sc12,847,1
5902,C[N+]1(C)[C@]2([H])[C@H]3[C@H](O3)[C@@]1([H])C[C@@H](OC(C(C4=CC=CS4)(O)C5=CC=CS5)=O)C2.[Br-],Tiotropium bromide,5487426,"(1?,2?,4?,5?,7?)-7-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide",C19H22BrNO4S2,[136310-93-5],481.43,7-TM Receptors,Non-selective Muscarinics,Antagonist,Potent muscarinic receptor antagonist,2,C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,153,1
5904,[Na+].CC(O)(C1=C(C=CC=C1)CC[C@H](C2=CC(/C=C/C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)SCC5(CC5)CC(O)=O)C,Montelukast sodium,23663996,1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid sodium salt,C35H35ClNNaO3S,[151767-02-1],626.19,7-TM Receptors,Leukotriene and Related Receptors,Antagonist,CysLT1 and GPR17 antagonist,1,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,590,1
5906,CS(O)(=O)=O.CN1CCN(CC1)CC2=CC=C(C(NC3=CC=C(C(NC4=NC=CC(C5=CN=CC=C5)=N4)=C3)C)=O)C=C2,Imatinib mesylate,123596,4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate,C29H31N7O.CH4O3S,[220127-57-1],594.21,Enzymes,Abl Kinase,Inhibitor,Potent and selective v-Abl tyrosine kinase inhibitor; also inhibits PDGFR and c-kit,2,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,473,0
5913,CC1=C(NC(O[C@H](C)C2=CC=CC=C2)=O)N(C3=CC=C(C4=CC=C(C5(CC5)C(O)=O)C=C4)C=C3)N=N1,Ro 6842262,71265339,"1-[4'-[4-Methyl-5-[[[(1R)-1-phenylethoxy]carbonylamino]-1H-1,2,3-triazol-1-yl][1,1'-biphenyl]-4-yl]cyclopropanecarboxylic acid",C28H26N4O4,[1396006-71-5],487.03,7-TM Receptors,Lysophosphatidic Acid Receptors,Antagonist,Potent LPA1 antagonist,1,Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1,175,1
5914,CN1C=NC2=C1C(N(C=N2)CC3=NC(CCC4=CC=C(C=C4)Cl)=NO3)=O,AM 0902,73297271,"1-[[3-[2-(4-Chlorophenyl)ethyl]-1,2,4-oxadiazol-5-yl]methyl]-1,7-dihydro-7-methyl-6H-purin-6-one",C17H15ClN6O2,[1883711-97-4],370.79,Ion Channels,TRPA1,Blocker,Potent and selective TRPA1 antagonist,1,Cn1cnc2ncn(Cc3nc(CCc4ccc(Cl)cc4)no3)c(=O)c21,577,1
5915,C[C@H](C1=NC(C2=C(N(C3CCOCC3)N=C2)N1)=O)N4CC(OC5=CC=CC=C5)C4,PF 04449613,46851937,"1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-4H-pyrazolo[3,4-d]pyrimidin-4-one",C21H25N5O3,[1236858-52-8],395.45,Enzymes,Phosphodiesterases,Inhibitor,Potent PDE9 inhibitor; brain penetrant,2,C[C@H](c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1)N1CC(Oc2ccccc2)C1,267,1
5920,CC1=C(C2(C3=CC=C(C(O)=O)C=N3)CC2)C=C4C(C(C)(CCC4(C)C)C)=C1,LG 100268,3922,"6-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl]-3-pyridinecarboxylic acid",C24H29NO2,[153559-76-3],363.49,Nuclear Receptors,Retinoid X Receptor,Agonist,Potent and selective RXR agonist; also activates RXR/PPAR? heterodimers,1,Cc1cc2c(cc1C1(c3ccc(C(=O)O)cn3)CC1)C(C)(C)CCC2(C)C,454,0
5922,N[C@@H](CC1=CC=CC=C1)CNC2=C3C4=C(SC3=NC(C5=CC=NC=C5)=N2)CCCC4.Cl.Cl,CRT 0066854 hydrochloride,131954580,"(2S)-3-Phenyl-N1-[5,6,7,8-tetrahydro-2-(4-pyridinyl)[1]benzothieno[2,3-d]pyrimidin-4-yl]-1,2-propanediamine dihydrochloride",C24H25N5S.2HCl,0,497.49,Enzymes,Protein Kinase C,Inhibitor,PKC? and PKC? inhibitor,1,N[C@H](CNc1nc(-c2ccncc2)nc2sc3c(c12)CCCC3)Cc1ccccc1,173,0
5931,ClC1=C(OC2=CC=C(Cl)C=C2C3=CNN=C3N)C=C(F)C(S(NC4=CSC=N4)(=O)=O)=C1.CC5=CC=C(S(=O)(O)=O)C=C5,PF 05089771,71554187,4-[2-(3-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-4-thiazolylbenzenesulfonamide tosylate,C18H12Cl2FN5O3S2.C7H8O3S,[1430806-04-4],672.56,Ion Channels,Voltage-gated Sodium Channels,Blocker,Potent and selective Nav1.7 channel blocker,1,Nc1n[nH]cc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,568,1
5934,CC(CCN1C(CN2CCN(C(C3CC3)=O)CC2)=NC4=C1C(N(C(N4C)=O)C)=O)C.Cl,NCT 501 hydrochloride,124201852,"8-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]methyl]-3,7-dihydro-1,3-dimethyl-7-(3-methylbutyl)-1H-purine-2,6-dione hydrochloride",C21H32N6O3.HCl,0,457.48,Enzymes,Aldehyde Dehydrogenase,Inhibitor,Potent and selective ALDH1A1 inhibitor,1,CC(C)CCn1c(CN2CCN(C(=O)C3CC3)CC2)nc2c1c(=O)n(C)c(=O)n2C,675,1
5943,O=C(NC1=C(Cl)C=CC=C1)CN2[C@H]3CCC[C@@H]2C[C@](NC(C4=CC(OC)=C(OC)C(OC)=C4)=O)([H])C3,ML 339,60202254,"N-[(1R,3S,5S)-9-(2-((2-Chlorophenyl)amino)-2-exoethyl)-9-azabicyclo[3.3.1]nonan-3-yl)-3,4,5-trimethoxybenzamide",C26H32ClN3O5,,502,7-TM Receptors,Chemokine CXC Receptors,Antagonist,Potent and selective hCXCR6 antagonist,1,COc1cc(C(=O)N[C@H]2C[C@@H]3CCC[C@H](C2)N3CC(=O)Nc2ccccc2Cl)cc(OC)c1OC,334,1
5944,FC1=CC=CC(Cl)=C1CN2C(CSC3=CC=C(C(NCC4=CC=CO4)=O)C=C23)=O,G10,5077622,"4-[(2-Chloro-6-fluorophenyl)methyl]-N-(2-furanylmethyl)-3,4-dihydro-3-oxo-2H-1,4-benzothiazine-6-carboxamide",C21H16ClFN2O3S,[702662-50-8],430.88,Cell biology,STING-Dependent Signaling,Other,Activator of STING-dependent signaling,1,O=C(NCc1ccco1)c1ccc2c(c1)N(Cc1c(F)cccc1Cl)C(=O)CS2,544,1
5951,ClC1=CC(F)=CC=C1CN2N=C3C(C(F)(F)F)=CC=CC3=C2C4=CC=C(F)C=C4,WAY 252623,16734800,2-[(2-Chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole,C21H12ClF5N2,[875787-07-8],422.78,Nuclear Receptors,LXR-like Receptors,Agonist,Potent LXR agonist,1,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,681,1
5952,O=C(C1=CC(S(NC2(CC2)C)(=O)=O)=CC=C1N3CC4=CC(C)=NN4C)N(CC5=CN=C(C)S5)C3=O,PDD 00017273,121398766,"1-[(1,3-Dimethyl-1H-pyrazol-5-yl)methyl]-1,2,3,4-tetrahydro-N-(1-methylcyclopropyl)-3-[(2-methyl-5-thiazolyl)methyl]-2,4-dioxo-6-quinazolinesulfonamide",C23H26N6O4S2,[1945950-21-9],514.62,Enzymes,Other Hydrolases,Inhibitor,Potent and selective poly (ADP ribose) glycohydrolase (PARG) inhibitor; cell permeable,2,Cc1cc(Cn2c(=O)n(Cc3cnc(C)s3)c(=O)c3cc(S(=O)(=O)NC4(C)CC4)ccc32)n(C)n1,654,1
5960,CC1(C)SCCN(S(C2=CC=C(OCC#CC)C=C2)(=O)=O)[C@H]1C(NO)=O,TMI 1,5288615,"(3S)-4-[[4-(2-Butyn-1-yloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide",C17H22N2O5S2,[287403-39-8],398.49,Enzymes,ADAMs,Inhibitor,Adam 17 (TACE) and MMP inhibitor; orally bioavailable,1,CC#CCOc1ccc(S(=O)(=O)N2CCSC(C)(C)[C@@H]2C(=O)NO)cc1,109,1
5970,OCCCC1=CC=C(C(N2C3=C(C)C=C(N(C)C(N4C)=O)C4=C3)=O)C5=C1C=CC=C5C2=O,BAY 299,122705990,"6-(3-Hydroxypropyl)-2-(1,3,6-trimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)-1H-benzo[de]isoquinoline-1,3(2H)-dione",C25H23N3O4,[2080306-23-4],429.47,Cell biology,Bromodomains,Inhibitor,Potent and selective BRD1 and TAF1 inhibitor,1,Cc1cc2c(cc1N1C(=O)c3cccc4c(CCCO)ccc(c34)C1=O)n(C)c(=O)n2C,345,1
5983,CC(C=CC=C1)=C1COC2=CC=C(C=C2)C3C4=C(CC(C)(C)CC4=O)OC5=C3C(CC(C)(C)C5)=O,BMS 986187,17379334,"3,4,5,6,7,9-Hexahydro-3,3,6,6-tetramethyl-9-[4-[(2-methylphenyl)methoxy]phenyl]-1H-xanthene-1,8(2H)-dione",C31H34O4,[684238-37-7],475.11,7-TM Receptors,Delta Opioid Receptors,Modulator,Potent positive allosteric modulator of ? receptor,1,Cc1ccccc1COc1ccc(C2C3=C(CC(C)(C)CC3=O)OC3=C2C(=O)CC(C)(C)C3)cc1,129,0
5984,CN1CCN(C(C2=CC=C(N3N=C(C4=CC=C(C(O)=O)C=C4)C=C3C5=CC(C(C)(C)C)=CC(C(C)(C)C)=C5)C=C2)=O)CC1,LY 2955303,71552369,"4-[5-[3,5-Bis(1,1-dimethylethyl)phenyl]-1-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-1H-pyrazol-3-yl]benzoic acid",C36H42N4O3,[1433497-19-8],605.76,Nuclear Receptors,Retinoic Acid Receptors,Antagonist,High affinity and selective RAR? antagonist,1,CN1CCN(C(=O)c2ccc(-n3nc(-c4ccc(C(=O)O)cc4)cc3-c3cc(C(C)(C)C)cc(C(C)(C)C)c3)cc2)CC1,459,1
5986,ClC1=CC=C(C2=C3NC(C4=CC=C([N+]([O-])=O)C=C4)=CC(N3N=C2CC5=CC=CC=C5)=O)C=C1,NAV 2729,2257249,"3-(4-Chlorophenyl)-5-(4-nitrophenyl)-2-(phenylmethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one",C25H17ClN4O3,[419547-11-8],456.88,Enzymes,Arf,Inhibitor,Selective ARF6 inhibitor,2,O=c1cc(-c2ccc([N+](=O)[O-])cc2)[nH]c2c(-c3ccc(Cl)cc3)c(Cc3ccccc3)nn12,255,0
5989,CC1=CC=C(N2N=C(C(C)(C)C)C=C2NC(NC3=CC=C(C4=C3C=CC=C4)OCCN5CCOCC5)=O)C=C1,BIRB 796,156422,"N-[3-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]urea",C31H37N5O3,[285983-48-4],527.66,Enzymes,p38,Inhibitor,High affinity and selective p38 kinase inhibitor,1,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,321,1
5995,O=C(NC(S1)=NC(C1=CC=C2)=C2OC3=NC=NC(C4=CC=C(C(F)(F)F)C=C4)=C3)C,AMG 517,16007367,N-[4-[[6-[4-(Trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]acetamide,C20H13F3N4O2S,[659730-32-2],457.43,Ion Channels,TRPV,Antagonist,Potent TRPV1 antagonist,1,CC(=O)Nc1nc2c(Oc3cc(-c4ccc(C(F)(F)F)cc4)ncn3)cccc2s1,464,1
5999,O=C(C)C1=CC(C2=CC=CC=C2OCC3CC3)=C4N=CC=CN41,TP 472N,124201853,"1-(8-(2-(Cyclopropylmethoxy)phenyl)pyrrolo[1,2-a]pyrimidin-6-yl)ethanone",C19H18N2O2,,306.36,Cell biology,Bromodomains,Control,Negative control for TP 472,1,CC(=O)c1cc(-c2ccccc2OCC2CC2)c2ncccn12,729,1
6000,O=C(C)C1=CC(C2=CC(C(NC3CC3)=O)=CC=C2C)=C4N=CC=CN41,TP 472,123773279,"3-(6-Acetylpyrrolo[1,2-a]pyrimidin-8-yl)-N-cyclopropyl-4-methylbenzamide",C20H19N3O2,,333.38,Cell biology,Bromodomains,Inhibitor,Potent BRD9/7 inhibitor,1,CC(=O)c1cc(-c2cc(C(=O)NC3CC3)ccc2C)c2ncccn12,729,0
6005,CN(C[C@H](C1=CC=CC=C1)NC(N2CC3=C(C2(C)C)NN=C3NC4=C5SC=CC5=NC(C)=N4)=O)C.Cl.Cl,PF 3758309 dihydrochloride,91885498,"N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide dihydrochloride",C25H30N8OS.2HCl,0,631.11,Enzymes,P21-activated Kinases,Inhibitor,Potent PAK4 inhibitor; orally available,2,Cc1nc(Nc2n[nH]c3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1,177,1
6007,O/N=C(NC1=CC(Cl)=C(F)C=C1)/C2=NON=C2N,INCB 024360-analog,11978742,"4-Amino-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide",C9H7ClFN5O2,[914471-09-3],271.64,Enzymes,"Indoleamine 2,3 dioxygenase",Inhibitor,"Potent indoleamine 2,3-dioxygenase (IDO) inhibitor",1,Nc1nonc1/C(=N/O)Nc1ccc(F)c(Cl)c1,559,1
6008,O=C(N(C)CC1=CC(C2CCN(CCNC)CC2)=NC=C1)C3=CC=CC(OC4=CC=CC=C4)=C3,TP 064,122707126,N-Methyl-N-((2-(1-(2-(methylamino)ethyl)piperidin-4-yl)pyridin-4-yl)methyl)-3-phenoxybenzamide,C28H34N4O2,[2080306-20-1],467.61,Enzymes,Protein Arginine Methyltransferases,Inhibitor,Potent and selective PRMT 4 inhibitor,1,CNCCN1CCC(c2cc(CN(C)C(=O)c3cccc(Oc4ccccc4)c3)ccn2)CC1,452,1
6009,OC1=CC=C2C3=C(C(OC2=C1C4OCCCO4)=O)CNCC3,B I09,86290458,"7-(1,3-Dioxan-2-yl)-1,2,3,4-tetrahydro-8-hydroxy-5H-[1]benzopyrano[3,4-c]pyridin-5-one",C16H17NO5,[1607803-67-7],303.31,Enzymes,IRE1,Inhibitor,IRE1 endonuclease inhibitor; cell permeable,1,O=c1oc2c(C3OCCCO3)c(O)ccc2c2c1CNCC2,2,1
6024,CC1=NC(N)=C2N=NN(C2=N1)C[C@H]3CN(CCO3)CC4=NC=CS4.Cl,PF 04671536 hydrochloride,131954582,"5-Methyl-3-[[(2R)-4-(2-thiazolylmethyl)-2-morpholinyl]methyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-7-amine hydrochloride",C14H18N8OS.HCl,[1305116-67-9],409.89,Enzymes,Phosphodiesterases,Inhibitor,Potent and selective PDE8B/8A inhibitor,1,Cc1nc(N)c2nnn(C[C@H]3CN(Cc4nccs4)CCO3)c2n1,820,1
6025,C[C@@H](C1=C(C(F)=CC=C1Cl)Cl)OC2=CC(C3=CN(C4CCNCC4)N=C3)=CN=C2N,(S)-Crizotinib,56671814,"3-[(1S)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine",C21H22Cl2FN5O,[1374356-45-2],454.84,Enzymes,MutT homolog-1 (MTH1),Inhibitor,MTH1 inhibitor,1,C[C@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,855,1
6029,CN(CC1)CCN1C2=CC=C(NC3=NC(N(CC)C(C(C4=CC=C(C5=CN=CS5)C=C4Cl)=C6)=O)=C6C=N3)C=C2,FRAX 597,70934541,"6-[2-Chloro-4-(5-thiazolyl)phenyl]-8-ethyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]pyrido[2,3-d]pyrimidin-7-(8H)-one",C29H28ClN7OS,[1286739-19-2],562.6,Enzymes,P21-activated Kinases,Inhibitor,Potent group I PAK inhibitor,1,CCn1c(=O)c(-c2ccc(-c3cncs3)cc2Cl)cc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21,404,1
6037,ClC1=CC=C(C(C2=CC=C(N(CCO)CCO)C=C2)C3=CC=C(N(CCO)CCO)C=C3)C=C1,LM22B 10,542158,"2,2',2',2'''-[[(4-Chlorophenyl)methylene]bis(4,1-phenylenenitrilo)]tetrakisethanol",C27H33ClN2O4,[342777-54-2],489.52,Enzyme-Linked Receptors,Trk Receptors,Agonist,TrkB and TrkC agonist; brain penetrant,2,OCCN(CCO)c1ccc(C(c2ccc(Cl)cc2)c2ccc(N(CCO)CCO)cc2)cc1,885,1
6047,O=C([C@@H](NC([C@@H]1CCCN1S(=O)(C2=CC=CC=C2)=O)=O)CC3=CC=C(C=C3)OC(N4CCCC4)=O)O.[Na+],BOP,10301396,N-(Benzenesulfonyl)-L-prolyl-L-O-(1-pyrrolidinylcarbonyl)tyrosine sodium salt,C25H28N3O7SNa,[1947348-42-6],555.58,Enzyme-Linked Receptors,Integrins,Inhibitor,Dual ?9?1/?4?1 integrin inhibitor; preferentially mobilizes HSCs,1,O=C(O)[C@H](Cc1ccc(OC(=O)N2CCCC2)cc1)NC(=O)[C@@H]1CCCN1S(=O)(=O)c1ccccc1,199,1
6053,N1(C2=CC=C(C3=CN4N=CC(C5=CC=NC6=C5C=CC=C6)=C4N=C3)C=C2)CCNCC1.Cl.Cl,LDN 193189 dihydrochloride,91900717,"4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride",C25H22N6.2HCl,[1435934-00-1],510.92,Enzyme-Linked Receptors,BMP and Other Activin Receptors,Inhibitor,Potent and selective ALK2 and ALK3 inhibitor; promotes neural induction of hPSCs,4,c1ccc2c(-c3cnn4cc(-c5ccc(N6CCNCC6)cc5)cnc34)ccnc2c1,743,0
6068,CN(C1=CC=CC(C2=NN3C(C)=NN=C3C=C2)=C1)C(C)=O,Lin28 1632,2737312,"N-Methyl-N-[3-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]acetamide",C15H15N5O,[108825-65-6],299.33,Cell biology,"DNA, RNA and Protein Synthesis",Inhibitor,RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor,2,CC(=O)N(C)c1cccc(-c2ccc3nnc(C)n3n2)c1,724,1
6071,FC1=C(NC2=CC=CC=C2NS(C)(=O)=O)N=C(NC3=C(OC)C=C(N4CCOCC4)C=C3)N=C1,CZC 25146,44252884,N-[2-[[5-Fluoro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]methanesulfonamide,C22H25FN6O4S,[1191911-26-8],488.54,Enzymes,LRRK2,Inhibitor,Potent LRRK2 inhibitor,1,COc1cc(N2CCOCC2)ccc1Nc1ncc(F)c(Nc2ccccc2NS(C)(=O)=O)n1,400,0
6075,ClC1=CC=C([C@H]2[C@H](N(C(N3CC(NCC3)=O)=O)C(C4=CC=C(OC)C=C4OC(C)C)=N2)C5=CC=C(Cl)C=C5)C=C1,Nutlin 3a,11433190,"4-[[(4S,5R)-4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone",C30H30Cl2N4O4,[675576-98-4],590.5,Enzymes,Ubiquitin E3 Ligases,Inhibitor,MDM2 antagonist; active enantiomer of Nutlin-3 (Cat. No. 3984),1,COc1ccc(C2=N[C@@H](c3ccc(Cl)cc3)[C@@H](c3ccc(Cl)cc3)N2C(=O)N2CCNC(=O)C2)c(OC(C)C)c1,583,0
6082,CC#C[C@H](C1=CC=C(C=C1)OCC2=CC=CC(C3=CC=C(C(F)(F)F)C=C3)=C2)CC([O-])=O.CC#C[C@H](C4=CC=C(C=C4)OCC5=CC=CC(C6=CC=C(C(F)(F)F)C=C6)=C5)CC([O-])=O.[Ca+2],AMG 837 hemicalcium salt,46854655,"(?S)-?-1-Propyn-1-yl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]benzenepropanoic acid hemicalcium salt",C26H20F3O3.�Ca,[1291087-14-3],479.99,7-TM Receptors,Free Fatty Acid Receptors,Agonist,Potent free fatty acid receptor 1 (FFA1/GPR40) partial agonist,1,CC#C[C@@H](CC(=O)[O-])c1ccc(OCc2cccc(-c3ccc(C(F)(F)F)cc3)c2)cc1,207,0
6085,CCOC(C1=CC(C#N)=C(N2CCC(C(NS(=O)(CC3=CC=CC=C3)=O)=O)CC2)N=C1C)=O,AZD 1283,23649325,Ethyl 5-cyano-2-methyl-6-[4-[[[(phenylmethyl)sulfonyl]amino]carbonyl]-1-piperidinyl]-3-pyridinecarboxylate,C23H26N4O5S,[919351-41-0],475.04,7-TM Receptors,Purinergic P2Y Receptors,Antagonist,High affinity P2Y12 antagonist,1,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC2)nc1C,189,1
6089,CC(C)(C(/C(N1C=NC=N1)=C/C2=CC([N+]([O-])=O)=CC=C2)=O)C,Nexinhib20,5715188,"4,4-Dimethyl-1-(3-nitrophenyl)-2-(1H-1,2,4-triazol-1-yl)-1-penten-3-one",C15H16N4O3,[331949-35-0],300.31,Enzymes,Other Small Monomeric GTPases,Inhibitor,Rab27 inhibitor; inhibits neutrophil exocytosis; active in vivo,1,CC(C)(C)C(=O)/C(=C/c1cccc([N+](=O)[O-])c1)n1cncn1,867,1
6098,O=C(OC1=NSN=C1N2CCCCC2)N3CCOCC3,Lalistat 1,648404,"4-(Piperidin-1-yl)-1,2,5-thiadiazol-3-yl morpholine-4-carboxylate",C12H18N4O3S,[501104-16-1],298.36,Enzymes,Lysosomal Acid Lipase (LAL),Inhibitor,Potent and selective LAL inhibitor,1,O=C(Oc1nsnc1N1CCCCC1)N1CCOCC1,39,1
6099,O=C(N1CCCCC1)OC2=NSN=C2N3CCCCC3,Lalistat 2,46867138,"4-(Piperidin-1-yl)-1,2,5-thiadiazol-3-yl piperidine-1-carboxylate",C13H20N4O2S,[1234569-09-5],296.39,Enzymes,Lysosomal Acid Lipase (LAL),Inhibitor,Selective LAL inhibitor,1,O=C(Oc1nsnc1N1CCCCC1)N1CCCCC1,39,0
6106,CC(NCCSC1=NC2=CSC=C2C(N1C3=CC=C(C=C3)OCC(F)(F)F)=O)=O,T 3364366,86685411,"N-[2-[[3,4-Dihydro-4-oxo-3-[4-(2,2,2-trifluoroethoxy)phenyl]thieno[3,4-d]pyrimidin-2-yl]thio]ethyl]acetamide",C18H16F3N3O3S2,[1356354-09-0],443.46,Enzymes,Other Oxygenases/Oxidases,Inhibitor,Potent and reversible fatty acid desaturase 1 inhibitor; orally bioavailable,1,CC(=O)NCCSc1nc2cscc2c(=O)n1-c1ccc(OCC(F)(F)F)cc1,701,1
6113,C1CNCCC12C(=NC3=CC=CC=C3N2)NCC4=CC(=CC=C4)Cl.Cl,Liproxstatin-1 hydrochloride,134160236,"N-[(3-Chlorophenyl)methyl]spiro[piperidine-4,2'(1'H)-quinoxalin]-3'-amine hydrochloride",C19H21ClN4.HCl,0,386.32,Cell biology,Ferroptosis,Inhibitor,Potent ferroptosis inhibitor,1,Clc1cccc(CNC2=Nc3ccccc3NC23CCNCC3)c1,613,1
6114,O=C(O)C1=CNC2=CC(Cl)=C(C3=CC=C(C4(CCC4)O)C=C3)C=C21,PF 06409577,71748255,6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic acid,C19H16ClNO3,[1467057-23-3],341.79,Enzymes,AMPK,Activator,Potent and selective allosteric activator of AMPK,1,O=C(O)c1c[nH]c2cc(Cl)c(-c3ccc(C4(O)CCC4)cc3)cc12,799,1
6115,NC1=NC=C2C(N(C(C)(C)CO)C=C2C(C3=CN=CC(NC(CC4=CC=C(Cl)C=N4)=O)=C3)=O)=N1,PF 06273340,66571548,"N-[5-[[2-Amino-7-(2-hydroxy-1,1-dimethylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl]-3-pyridinyl]-5-chloro-2-pyridineacetamide",C23H22ClN7O3,[1402438-74-7],479.93,Enzyme-Linked Receptors,Trk Receptors,Inhibitor,Potent and selective pan-Trk inhibitor; peripherally restricted,1,CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc21,591,1
6116,CC1=CC=CC2=C1NC(C2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O)=O,BHPI,3860640,"1,3-Dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl-2H-indol-2-one",C21H17NO3,[56632-39-4],335.86,7-TM Receptors,Estrogen (GPER) Receptors,Antagonist,ER? antagonist; also activates unfolded protein response; active in vivo,1,Cc1cccc2c1NC(=O)C2(c1ccc(O)cc1)c1ccc(O)cc1,887,1
6119,BrC1=CC=C(C=C1)CCC2(OCCO2)CN3C=CN=C3.Cl,OB 24 hydrochloride,45265865,"1-[[2-[2-(4-Bromophenyl)ethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazole hydrochloride",C15H17BrN2O2.HCl,[939825-12-4],373.67,Enzymes,Heme Oxygenase,Inhibitor,Potent and selective heme oxygenase 1 (HO-1) inhibitor,1,Brc1ccc(CCC2(Cn3ccnc3)OCCO2)cc1,880,1
6125,F[C@@H]1C[C@@H]1C(NC2=CC(NC(C3=C(C=C(C#N)C=C3F)Cl)=O)=CC=N2)=O,TC JL 37,56934550,"2-Chloro-4-cyano-6-fluoro-N-[2-[[[(1R,2R)-2-fluorocyclopropyl]carbonyl]amino]-4-pyridinyl]benzamide",C17H11ClF2N4O2,[1258294-34-6],376.74,Enzymes,JAK Kinase,Inhibitor,Potent TYK2 inhibitor,1,N#Cc1cc(F)c(C(=O)Nc2ccnc(NC(=O)[C@H]3C[C@H]3F)c2)c(Cl)c1,560,1
6137,CN1C2=C(C(N(C1=O)C)=O)N=C(C3CCCC3)N2,"8-Cyclopentyl-1,3-dimethylxanthine",1917,8-Cyclopentyltheophylline,C12H16N4O2,[35873-49-5],257.29,7-TM Receptors,Adenosine A1 Receptors,Antagonist,High affinity adenosine A1 receptor antagonist,1,Cn1c(=O)c2nc(C3CCCC3)[nH]c2n(C)c1=O,671,1
6143,OC1=CC=CC(C(OC2=C(C(F)=CC=C2)OC(C3=CC(O)=CC=C3)=O)=O)=C1,WZB 117,46830365,"3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate)",C20H13FO6,[1223397-11-2],368.31,Transporters,Glucose Transporters,Inhibitor,GLUT inhibitor,1,O=C(Oc1cccc(F)c1OC(=O)c1cccc(O)c1)c1cccc(O)c1,126,1
6156,O=C(N[C@@H](C(C)(C)C)C(N1C[C@@H](C[C@H]1C(NCC2=CC=C(C3=C(N=CS3)C)C=C2)=O)O)=O)C4(C#N)CC4,VH 298,122199236,"(2S,4R)-1-((S)-2-(1-cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide",C27H33N5O4S,[2097381-85-4],528.15,Enzymes,Ubiquitin E3 Ligases,Inhibitor,High-affinity inhibitor of VHL,1,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(C#N)CC2)C(C)(C)C)cc1,115,1
6157,O=C(N[C@@H](C(C)(C)C)C(N1C[C@H](C[C@H]1C(NCC2=CC=C(C3=C(N=CS3)C)C=C2)=O)O)=O)C4(C#N)CC4,cis VH 298,127021044,"(2S,4S)-1-((S)-2-(1-cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide",C27H33N5O4S,[2097381-86-5],541.67,Enzymes,Ubiquitin E3 Ligases,Control,Negative control for VH 298,1,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@H](O)CN2C(=O)[C@@H](NC(=O)C2(C#N)CC2)C(C)(C)C)cc1,115,0
6163,CC1=C(C(NC2=C(C=CC(Cl)=C2)Cl)=O)C(C3=C(N1)CCCC3=O)C4=CC=CO4,AR 420626,11509934,"N-(2,5-Dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide",C21H18Cl2N2O3,[1798310-55-0],417.29,7-TM Receptors,Free Fatty Acid Receptors,Agonist,FFA3 agonist,1,CC1=C(C(=O)Nc2cc(Cl)ccc2Cl)C(c2ccco2)C2=C(CCCC2=O)N1,546,1
6164,CCOC1=CC(N)=C(C=C1)OC2=CC=C(C=C2)OCC3=C(C=CC(F)=C3)F,SEA 0400,644100,"2-[4-[(2,5-Difluorophenyl)methoxy]phenoxy]-5-ethoxybenzenamine",C21H19F2NO3,[223104-29-8],371.38,Transporters,Na+/Ca2+ Exchanger,Inhibitor,Potent Na+/Ca2+ exchanger (NCX) inhibitor,1,CCOc1ccc(Oc2ccc(OCc3cc(F)ccc3F)cc2)c(N)c1,441,0
6165,CC1=CC(C)=C(C(O)(C2=NC3=CC=CC=C3S2)C)C=C1,AC 265347,52943938,"?-(2,4-Dimethylphenyl)-?-methyl-2-benzothiazolemethanol",C17H17NOS,[1253901-26-6],283.39,7-TM Receptors,Calcium-Sensing Receptor,Modulator,Biased allosteric modulator of calcium-sensing receptor (CaSR),1,Cc1ccc(C(C)(O)c2nc3ccccc3s2)c(C)c1,79,1
6170,C[C@H](C1=CC=CC2=C1C=CC=C2)NCCCC3=CC(C(F)(F)F)=CC=C3.Cl,Cinacalcet hydrochloride,156418,N-[(1R)-1-(1-Naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine hydrochloride,C22H22F3N.HCl,[364782-34-3],393.87,7-TM Receptors,Calcium-Sensing Receptor,Agonist,Allosteric Calcium-sensing receptor (CaSR) agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailable,1,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,772,0
6171,OC1=C(C=C(C2=C1N=CC=C2)Cl)CN3CCN(C4=CC=CC=N4)CC3,MLS 1547,1093278,5-Chloro-7-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-8-quinolinol,C19H19ClN4O,[315698-36-3],354.83,7-TM Receptors,D2 Receptors,Agonist,G protein-biased D2 partial agonist,1,Oc1c(CN2CCN(c3ccccn3)CC2)cc(Cl)c2cccnc12,730,1
6174,COC1=CC=C(C=C1)CNC2=NC(N(CCO)CCO)=NC3=C2N=CN3C(C)C,CVT 313,6918386,"2,2'-[[6-[[(4-Methoxyphenyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]imino]bis[ethanol]",C20H28N6O3,[199986-75-9],404.97,Enzymes,Cyclin-dependent Kinase,Inhibitor,Cdk2 and cdk5 inhibitor,1,COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1,825,0
6176,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,FTY 720,107969,"2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride",C19H33NO2.HCl,[162359-56-0],343.93,7-TM Receptors,Sphingosine-1-phosphate Receptors,Agonist,Potent S1P receptor agonist; also immunosuppressant,1,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,21,1
6180,CC1=C(C2=CC=C(S(C)(=O)=O)C=C2)C=CC(OCC3=NN=C(N3C4=CN=CC=C4)SC5CCCC5)=C1,NMS 873,71521142,"3-[3-(Cyclopentylthio)-5-[[[2-methyl-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-4H-1,2,4-triazol-4-yl]pyridine",C27H28N4O3S2,[1418013-75-8],520.67,Enzymes,p97 ATPase,Inhibitor,Potent and selective p97 ATPase (VCP) allosteric inhibitor,1,Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(S(C)(=O)=O)cc1,713,1
6181,CC1=C(C2=C(N3C(C)=NN=C3[C@@H](N=C2C4=CC=C(C=C4)Cl)CC(NC5=CC=C(C=C5)O)=O)S1)C,OTX 015,9936746,"(6S)-4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide",C25H22ClN5O2S,[202590-98-5],510.01,Cell biology,Bromodomains,Inhibitor,BET bromodomain inhibitor; orally bioavailable,1,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2,578,0
6193,CC1=C(C2=CC=C(C=C2)Cl)N(C3=C(C=C(C=C3)Cl)Cl)N=C1C(N)=O,AM 4113,66844170,"5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide",C17H12Cl3N3O,[614726-85-1],380.66,7-TM Receptors,CB1 Receptors,Antagonist,High affinity and selective CB1 antagonist,1,Cc1c(C(N)=O)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,580,0
6194,O=C(C1=C(C=CC(Cl)=C1)NC(COCC(NC2=CC=CC(C3=COC=C3)=C2)=O)=O)O.[Na+],TM 5441,44250349,5-Chloro-2-[[2-[2-[[3-(3-furanyl)phenyl]amino]-2-oxoethoxy]acetyl]amino]benzoic acid sodium salt,C21H16ClN2NaO6,,455.3,Enzymes,Plasminogen Activator Inhibitor 1,Inhibitor,Plasminogen activator inhibitor-1 (PAI-1) inhibitor,1,O=C(COCC(=O)Nc1ccc(Cl)cc1C(=O)O)Nc1cccc(-c2ccoc2)c1,596,1
6195,COC1=CC(OC)=C(S(=O)(N2C([C@@](C3=CC(Cl)=CC=C23)(C4=C(C=CC=C4)OC)N5C[C@@H](C[C@H]5C(N(C)C)=O)O)=O)=O)C=C1,SSR 149415,9895468,"(2S,4R)-1-[(3R)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide",C30H32ClN3O8S,[439687-69-1],630.11,7-TM Receptors,Vasopressin Receptors,Antagonist,Potent and selective vasopressin V1B antagonist,1,COc1ccc(S(=O)(=O)N2C(=O)[C@@](c3ccccc3OC)(N3C[C@H](O)C[C@H]3C(=O)N(C)C)c3cc(Cl)ccc32)c(OC)c1,355,1
6196,[Na+].CC1=C(C2=CC(F)=CC=C2N=C1C3=CC=C(C4=C(C=CC=C4)F)C=C3)C(O)=O,Brequinar sodium,23663964,"6-Fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium",C23H14F2NO2Na,[96201-88-6],433.38,Enzymes,Dihyroorotate Dehydrogenase,Inhibitor,Potent and selective DHODH inhibitor,3,Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O,241,0
6198,COC1=C(C(NC2=C(N3CCNC[C@H]3C)C=C4N(C(N(C4=C2)C)=O)C)=O)C=CC=C1,GSK 6853,121232405,"N-[2,3-dihydro-1,3-dimethyl-6-[(2R)-2-methyl-1-piperazinyl]-2-oxo-1H-benzimidazol-5-yl]-2-methoxybenzamide",C22H27N5O3,[1910124-24-1],413.98,Cell biology,Bromodomains,Inhibitor,Potent and selective BRPF1 inhibitor,1,COc1ccccc1C(=O)Nc1cc2c(cc1N1CCNC[C@H]1C)n(C)c(=O)n2C,344,1
6201,CC1=CC=C(S(=O)(N[C@H](C(N[C@H](C(N)=O)CC2=CC=CC=C2)=O)CCN)=O)C3=C1C=CC=C3.OC(C(F)(F)F)=O,J 2156,11442741,"(1'S,2S)-4-Amino-N-(1'-carbamoyl-2'-phenylethyl)-2-(4""-methyl-1""-naphthalenesulfonylamino)butanamide trifluoroacetate",C24H28N4O4S.C2HF3O2,0,591.61,7-TM Receptors,Somatostatin Receptors,Agonist,Selective high affinity human sst4 agonist,1,Cc1ccc(S(=O)(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)c2ccccc12,198,1
6202,NC(C1=CC2=C(C=CC(N3CCN(CC3)CCCCC4=CNC5=C4C=C(C#N)C=C5)=C2)O1)=O.Cl,Vilazodone hydrochloride,6918313,5-[4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide hydrochloride,C26H27N5O2.HCl,[163521-08-2],487,7-TM Receptors,5-HT1A Receptors,Agonist,Potent 5-HT1A partial agonist and SSRI; antidepressant,1,N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,798,1
6203,COC1=C(C(N(CC)C2=C(N3CCNC[C@H]3C)C=C4N(C(N(C4=C2)C)=O)C)=O)C=CC=C1.Cl,GSK 9311 hydrochloride,121232406,"N-[2,3-Dihydro-1,3-dimethyl-6-[(2R)-2-methyl-1-piperazinyl]-2-oxo-1H-benzimidazol-5-yl]-N-ethyl-2-methoxybenzamide hydrochloride",C24H31N5O3.HCl,0,487.51,Cell biology,Bromodomains,Control,Negative control for GSK 6853,1,CCN(C(=O)c1ccccc1OC)c1cc2c(cc1N1CCNC[C@H]1C)n(C)c(=O)n2C,344,0
6208,O=C(C1=CC=C(C=C1)CNC(OCC2=CN=CC=C2)=O)NC3=CC=CC=C3N,MS 275,4261,(Pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,[209783-80-2],376.41,Enzymes,Class I HDACs,Inhibitor,HDAC (Class I) inhibitor,1,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,478,0
6219,O[C@@H](C(O)=O)[C@H](C(O)=O)O.COC1=CC=C(C=C1)C[C@H](NC[C@@H](C2=CC(NC=O)=C(C=C2)O)O)C,Arformoterol tartrate,9827062,N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide L-tartrate,C19H24N2O4.C4H6O6,[200815-49-2],494.49,7-TM Receptors,Adrenergic Beta-2 Receptors,Agonist,Long-acting ?2 agonist (LABA),1,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,430,0
6223,OC(C(F)(F)F)(C(F)(F)F)C1=CC(F)=C(C2=CC=C(C=C2)NC(CC3=C([N+]([O-])=O)C=CC=C3)=O)C=C1,XY 018,130248006,"N-[2'-Fluoro-4'-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl][1,1'biphenyl]-4-yl]-2-nitrobenzeneacetamide",C23H15F7N2O4,[1873358-87-2],516.36,Nuclear Receptors,Retinoic Acid-related Orphan Receptors,Antagonist,ROR? antagonist; inhibits AR expression,1,O=C(Cc1ccccc1[N+](=O)[O-])Nc1ccc(-c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2F)cc1,556,0
6230,CNCC1=CC=C(C2=C3CCNC(C4=C3C(N2)=CC(F)=C4)=O)C=C1.O=S(C[C@@]5(C6(C)C)CC[C@@H]6CC5=O)(O)=O,Rucaparib camsylate,53356947,"8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2,ef][2]benzazepin-6-one (1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonic acid",C19H18FN3O.C10H16O4S,[1327258-57-0],555.66,Enzymes,Poly(ADP-ribose) Polymerase,Inhibitor,PARP inhibitor,1,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,60,1
6231,O=C(/C=C/CN1CCCCC1)NC2=C(OC)C=C(N=CN=C3NC4=CC=C(F)C(Cl)=C4)C3=C2,Dacomitinib,11511120,(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide,C24H25ClFN5O2,[1110813-31-4],487.96,Enzyme-Linked Receptors,EGFR,Inhibitor,Potent irreversible pan ErbB inhibitor,1,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,390,0
6232,COC1=C(C=CC=C1)OC2=C(N=C(C3=NC=CC=N3)N=C2NS(=O)(C4=CC=C(C(C)(C)C)C=C4)=O)OCCO,Bosentan,104865,"4-(1,1-Dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide",C27H29N5O6S,[147536-97-8],569.63,7-TM Receptors,Non-selective Endothelin,Antagonist,High affinity dual ETA and ETB receptor antagonist;orally bioavailable,1,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,114,1
6236,NNC(=O)C1=C(Cl)C2=C(Cl)C=CC=C2S1,O8 OGG1 Inhibitor,874733,"3,4-Dichlorobenzo[b]thiophene-2-carbohydrazide",C9H6Cl2N2OS,[350997-39-6],261.13,Enzymes,Glycosylases,Inhibitor,Potent and selective 8-oxoguanine DNA glycosylase 1 (OGG1) inhibitor,1,NNC(=O)c1sc2cccc(Cl)c2c1Cl,870,1
6237,ClC1=CC=C(C(N(C2CCCCC2)CC3=CC=CC=C3)=O)C=C1,FPS ZM1,24752728,4-Chloro-N-cyclohexyl-N-(phenylmethyl)benzamide,C20H22ClNO,[945714-67-0],327.85,Cell biology,RAGE,Antagonist,High affinity antagonist of RAGE,1,O=C(c1ccc(Cl)cc1)N(Cc1ccccc1)C1CCCCC1,217,1
6239,O=C(C1=C(C2(N3C=CC=C(C3=NC2=O)C)CC1=O)N4CCCCC4)OCC,SAK 3,71655974,"Ethyl 8'-methyl-2',4-dioxo-2-(piperidin-1-yl)-2'H-spiro[cyclopent[2]ene-1,3'-imidazo[1,2-a]pyridine]-3-carboxylate",C20H23N3O4,[1256269-87-0],373.91,Ion Channels,Cav3.x Channels,Activator,Potent CaV3.1 and 3.3 activator; orally bioavailable,1,CCOC(=O)C1=C(N2CCCCC2)C2(CC1=O)C(=O)N=C1C(C)=CC=CN12,41,1
6243,CC1=C(C2=CC=C3N(C(C4=C(C=CC=C4)C)=O)CCC3=C2)N=C(S1)NC(CC5=CC=C6OCOC6=C5)=O,ML 385,1383822,"N-[4-[2,3-Dihydro-1-(2-methylbenzoyl)-1H-indol-5-yl]-5-methyl-2-thiazolyl]-1,3-benzodioxole-5-acetamide",C29H25N3O4S,[846557-71-9],511.59,Cell biology,Nrf2,Inhibitor,Nrf2 inhibitor; phenotypically lethal,1,Cc1ccccc1C(=O)N1CCc2cc(-c3nc(NC(=O)Cc4ccc5c(c4)OCO5)sc3C)ccc21,748,0
6245,CC1=NC(C2=C(C3=CC=C4OCOC4=C3)NC(C56CCC(CC6)(C(N)=O)CC5)=N2)=CC=C1,SM 16,10387982,"4-[4-(1,3-Benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-2-yl]bicyclo[2.2.2]octane-1-carboxamide",C25H26N4O3,[614749-78-9],435,Enzyme-Linked Receptors,TGF-beta Receptors,Inhibitor,Potent TGF-?RI inhibitor; orally bioavailable,1,Cc1cccc(-c2nc(C34CCC(C(N)=O)(CC3)CC4)[nH]c2-c2ccc3c(c2)OCO3)n1,746,0
6248,CCN1C2=CC=C(NC3=NC(NCCCN4CCOCC4)=NC=C3)C=C2C5=CC=CC=C51,EHop 016,51031035,"N4-(9-Ethyl-9H-carbazol-3-yl)-N2-[3-(4-morpholinyl)propyl]-2,4-pyrimidinediamine",C25H30N6O,[1380432-32-5],430.55,Enzymes,Rho,Inhibitor,Rac inhibitor,1,CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc21,779,0
6249,CCN(CC1=CC2=C(C=C(C=C2)COC(NC3=CC=C(C(NO)=O)C=C3)=O)C=C1)CC.Cl,Givinostat hydrochloride,10095659,[6-[(Diethylamino)methyl]-2-naphthalenyl]methyl-N-[4-[(hydroxyamino)carbonyl]phenyl]carbamate hydrochloride,C24H27N3O4.HCl,[199657-29-9],475.97,Enzymes,Non-selective HDACs,Inhibitor,Histone deacetylase inhibitor,1,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(=O)NO)cc3)ccc2c1,480,1
6251,C[C@@H]([C@H](C1=CC=CC=C1)N(C)C)NC2=NN3C(C)=NN=C3C4=CC=CC=C24,L Moses dihydrochloride,131698638,"(1S, 2S)-N1,N1-Dimethyl-N2-(3-methyl-1,2,4-triazolo[3,4-a]phthalazin-6-yl)-1-phenylpropane-1,2-diamine dihydrochloride",C21H24N6.2HCl,0,455.9,Cell biology,Bromodomains,Inhibitor,High affinity and selective PCAF bromodomain inhibitor,1,Cc1nnc2c3ccccc3c(N[C@@H](C)[C@H](c3ccccc3)N(C)C)nn12,178,1
6258,N1(CCCCC1)CCOC2=CC=CC(C3=NNC4=CC=C(C5=NN=CN5)C=C34)=C2.Cl.Cl,CC 401 dihydrochloride,66576998,"3-[3-[2-(1-Piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole dihydrochloride",C22H24N6O.2HCl,0,474.9,Enzymes,JNK/c-jun,Inhibitor,High affinity JNK inhibitor; also inhibits HCMV replication,1,c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1,644,1
6273,ClC1=C(C2=CN=CC=C2C3=CN=C(NC4=CC=C(O)C=C4)S3)C=CC(C)=C1,CRT 0105950,117918970,4-[[5-[3-(2-Chloro-4-methylphenyl)-4-pyridinyl]-2-thiazolyl]amino]phenol,C21H16ClN3OS,[1661845-86-8],398.39,Enzymes,LIMK,Inhibitor,Potent LIMK1/2 inhibitor,1,Cc1ccc(-c2cnccc2-c2cnc(Nc3ccc(O)cc3)s2)c(Cl)c1,562,1
6278,ClC1=CC=CC(OC(F)(F)F)=C1C2=CC=C3NC(NC3=C2)=O,JNJ 55511118,122656423,"5-[2-Chloro-6-(trifluoromethoxy)phenyl]-1,3-dihydro-2H-benzimidazol-2-one",C14H8ClF3N2O2,[2036081-86-2],328.67,Ion Channels,AMPA Receptors,Modulator,High affinity and selective negative modulator of AMPA receptors containing TARP-?8,1,O=c1[nH]c2ccc(-c3c(Cl)cccc3OC(F)(F)F)cc2[nH]1,707,1
6279,CC(C1=CC(N2CC[C@H](C2)N)=NC(N)=N1)C.Cl.Cl,JNJ 39758979 dihydrochloride,129628806,4-[(3R)-3-Amino-1-pyrrolidinyl]-6-(1-methylethyl)-2-pyridinamine dihydrochloride,C11H19N5.2HCl,0,298.72,7-TM Receptors,Histamine H4 Receptors,Antagonist,High affinity and selective histamine H4 antagonist; orally bioavailable,1,CC(C)c1cc(N2CC[C@@H](N)C2)nc(N)n1,816,0
6280,ON=C1C2=CC(=CC=C2C2=CC=C(C=C12)S(=O)(=O)NC1CCCCC1)S(=O)(=O)NC1CCCCC1,FIN 56,118986699,"N2,N7-Dicyclohexyl-9-(hydroxyimino)-9H-fluorene-2,7-disulfonamide",C25H31N3O5S2,[1083162-61-1],517.66,Cell biology,Ferroptosis,Activator,Ferroptosis activator,1,O=S(=O)(NC1CCCCC1)c1ccc2c(c1)C(=NO)c1cc(S(=O)(=O)NC3CCCCC3)ccc1-2,99,1
6281,CCCCCCCCOC1=C(C(F)(F)F)C=C(C2=NOC([C@@H]3CCCN3C(N)=N)=N2)C=C1.Cl,SLM 6031434 hydrochloride,134812833,"(2S)-2-[3-[4-(Octyloxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-1-pyrrolidinecarboximidamide hydrochloride",C22H30F3N5O2.HCl,[1897379-34-8],494.46,Enzymes,Sphingosine Kinase,Inhibitor,Selective sphingosine kinase 2 (Sphk2) inhibitor,1,CCCCCCCCOc1ccc(-c2noc([C@@H]3CCCN3C(=N)N)n2)cc1C(F)(F)F,695,1
6284,ONC(C1=CC=CC(C(NCCC2=CC=CC=C2)=O)=C1)=O,BRD 73954,71680913,"N1-Hydroxy-N3-(2-phenylethyl)-1,3-benzenedicarboxamide",C16H16N2O3,[1440209-96-0],284.31,Enzymes,Class II HDACs,Inhibitor,Dual histone deacetylase (HDAC) 6/8 inhibitor,1,O=C(NO)c1cccc(C(=O)NCCc2ccccc2)c1,210,0
6285,[H][C@@]12CC[C@](C(C)=O)([C@]1(CC[C@]3([C@]2(C=C(C4=CC(CC[C@]34C)=O)C)[H])[H])C)OC(C)=O,Megestrol Acetate,11683,"17-(Acetyloxy)-6-methylpregna-4,6-diene-3,20-dione",C24H32O4,[595-33-5],384.51,Nuclear Receptors,Progesterone Receptor,Agonist,Synthetic progesterone analog,1,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,9,1
6289,O=C(N1CCOCC1)C2=CC(OC)=C(NC3=NC(NC)=C(C(Cl)=CN4)C4=N3)C=C2,JH-II-127,112499966,"[4-[[5-Chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxyphenyl]-4-morpholinyl-methanone",C19H21ClN6O3,[1700693-08-8],416.87,Enzymes,LRRK2,Inhibitor,Potent and selective LRRK2 inhibitor,1,CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]cc(Cl)c12,399,1
6298,CNC1=NN=C(S1)SCC2=CC=CC=C2,MS 21570,805117,"N-Methyl-5-[(phenylmethyl)thio]-1,3,4-thiazadiazol-2-amine",C10H11N3S2,[65373-29-7],237.34,7-TM Receptors,GPR171,Antagonist,GPR171 antagonist,1,CNc1nnc(SCc2ccccc2)s1,214,1
6299,CC(C(NC1=CC(C(O)=O)=CC(C(O)=O)=C1)=O)=C,MS 15203,773544,"5-[(2-Methyl-1-oxo-2-propen-1-yl)amino]-1,3-benzenedicarboxylic acid",C12H11NO5,[73912-52-4],249.22,7-TM Receptors,GPR171,Agonist,Potent and selective GPR171 partial agonist,1,C=C(C)C(=O)Nc1cc(C(=O)O)cc(C(=O)O)c1,517,1
6305,NC1=C2CN(C(C2=CC=C1)=O)C3CCC(NC3=O)=O,Lenalidomide,216326,"3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione",C13H13N3O3,[191732-72-6],263.76,Enzymes,Ubiquitin E3 Ligases,Other,Cereblon binder; induces ubiquitination and degradation of CK1? by E3 ubiquitin ligase,2,Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,36,1
6311,[H][C@]12CC3=C([C@@H](C4=CC5=C(C=C4)OCO5)N1C(CN(C2=O)C)=O)NC6=CC=CC=C36,Tadalafil,110635,"(6R,12aR)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione",C22H19N3O4,[171596-29-5],389.4,Enzymes,Phosphodiesterases,Inhibitor,Potent and highly selective PDE5 inhibitor; orally bioavailable,1,CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,752,1
6319,CC(NC(C1=NOC(C(C(F)(F)F)(C(F)(F)F)O)C1)=O)CC(OC(C)(C)C)=O,CBM 301940,10387489,"tert-Butyl 3-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-4,5-dihydroisoxazole-3-carboxamido)butanoate",C15H20F6N2O5,[902146-11-6],422.32,Enzymes,Decarboxylases,Inhibitor,Potent malonyl-CoA decarboxylase inhibitor; orally bioavailable,1,CC(CC(=O)OC(C)(C)C)NC(=O)C1=NOC(C(O)(C(F)(F)F)C(F)(F)F)C1,30,1
6320,CC1=CC=C(S(=O)(C2=C(C=C(C=C2C)C)C)=O)C=C1,ESI 05,272513,"1,3,5-Trimethyl-2-[(4-methylphenyl)sulfonyl]benzene",C16H18O2S,[5184-64-5],274.38,Enzymes,EPAC,Inhibitor,Epac2 inhibitor,1,Cc1ccc(S(=O)(=O)c2c(C)cc(C)cc2C)cc1,77,0
6324,CC1=CC(NC2=NC(OC3=CC=C([N+]([O-])=O)C=C3)=NC(Cl)=C2)=NN1,Autophinib,129626605,6-Chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-nitrophenoxy)-pyrimidinamine,C14H11ClN6O3,[1644443-47-9],346.73,Enzymes,PI 3-Kinase,Inhibitor,Potent VPS34 inhibitor,1,Cc1cc(Nc2cc(Cl)nc(Oc3ccc([N+](=O)[O-])cc3)n2)n[nH]1,94,1
6330,COCC1=NC=C(C2=CC3=C(N=CC(C(N)=O)=C3N[C@H](C4=NN(C=C4)C)C)C=C2F)C=C1,AZ 5704,130470684,7-Fluoro-6-[6-(methoxymethyl)-3-pyridinyl]-4-[[(1S)-1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino]-3-quinolinecarboxamide,C23H23FN6O2,[1941214-06-7],438.97,Enzymes,ATM & ATR Kinase,Inhibitor,Potent and selective ATM kinase inhibitor; orally bioavailable,1,COCc1ccc(-c2cc3c(N[C@@H](C)c4ccn(C)n4)c(C(N)=O)cnc3cc2F)cn1,528,1
6336,ClC1=CC=CC(N2CCN(CC2)CCCN3N=C4C=CC=CN4C3=O)=C1.Cl,Trazodone hydrochloride,62935,"2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one hydrochloride",C19H22ClN5O.HCl,[25332-39-2],417.33,7-TM Receptors,5-HT2A Receptors,Antagonist,5-HT2A and ?1 adrenoceptor antagonist; also enhances neural differentiation; antidepressant and neuroprotectant,1,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,272,1
6340,NC1=NC2=NC(N)=C(C3=CC(Cl)=CC=C3)N=C2C(N)=N1,Epiblastin A,118987042,"6-(3-Chlorophenyl)-2,4,7-pteridinetriamine",C12H10ClN7,[16470-02-3],287.71,Enzymes,Casein Kinase 1,Inhibitor,CK1 inhibitor; converts epiblast stem cells to ESCs and promotes ESC self-renewal,1,Nc1nc(N)c2nc(-c3cccc(Cl)c3)c(N)nc2n1,815,1
6342,CN(C)CCOC1=CC=C(C=C1)/C(C2=CC=CC=C2)=C(CC)\C3=CC=CC=C3,Tamoxifen,2733526,"2-[4-[(1Z)-1,2-Diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethylethanamine",C26H29NO,[10540-29-1],371.51,Nuclear Receptors,Estrogen and Related Receptors,Modulator,Estrogen receptor partial agonist/antagonist,1,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,435,0
6343,[Ca++].CC(C1=C(C(C2=CC=C(F)C=C2)=NC(N(S(C)(=O)=O)C)=N1)/C=C/[C@@H](O)C[C@@H](O)CC(OOC(C[C@H](O)C[C@H](O)/C=C/C(C(C3=CC=C(F)C=C3)=NC(N(S(C)(=O)=O)C)=N4)=C4C(C)C)=O)=O)C,Rosuvastatin calcium,5282455,"(3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl])-3,5-dihydroxyhept-6-enoic acid hemicalcium salt",C22H27FN3O6S.�Ca,[147098-20-2],518.59,Enzymes,HMG-CoA Reductase,Inhibitor,Potent HMG-CoA reductase inhibitor,1,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)OOC(=O)C[C@H](O)C[C@H](O)/C=C/c1c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)nc1C(C)C,62,0
6344,NC(C1=CC=C(C=C1)OC2=CC=C(C(N)=O)C=C2)=O,OUL 35,236501,"4,4'-Oxybis[benzamide]",C14H12N2O3,[6336-34-1],256.26,Enzymes,Poly(ADP-ribose) Polymerase,Inhibitor,Selective PARP-10 inhibitor,1,NC(=O)c1ccc(Oc2ccc(C(N)=O)cc2)cc1,445,1
6346,NC1=NC(C2=C(C3=CC=C(F)C=C3)N=CN2C4CCN(CC5=NOC=C5)CC4)=CC=N1,PF 5006739,51353555,4-[4-(4-Fluorophenyl)-1-[1-(3-isoxazolylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]-2-pyrimidinamine,C22H22FN7O,[1293395-67-1],419.46,Enzymes,Casein Kinase 1,Inhibitor,Potent CK1?/? inhibitor,2,Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCN(Cc3ccon3)CC2)n1,64,0
6347,ClC1=C(CN2CC3(CCN(C(CC4=CN(C=C(C)S5)C5=N4)=O)CC3)C2)C=CC(N6N=CC=N6)=C1,PF 04628935,70682037,"1-[2-[[2-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl]methyl]-2,7-diazaspiro[3.5]non-7-yl]-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone",C24H26ClN7OS,[1383719-97-8],496.03,7-TM Receptors,Ghrelin Receptors,Inverse Agonist,Potent ghrelin receptor inverse agonist,1,Cc1cn2cc(CC(=O)N3CCC4(CC3)CN(Cc3ccc(-n5nccn5)cc3Cl)C4)nc2s1,632,1
6349,O=C(/C=C/CN(C)C)NC1=C(OCC)C=C(N=CC(C#N)=C2NC3=CC=C(F)C(Cl)=C3)C2=C1,Pelitinib,6445562,(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide,C24H23ClFN5O2,[257933-82-7],476.93,Enzyme-Linked Receptors,EGFR,Inhibitor,Potent and irreversible EGFR inhibitor; orally bioavailable,1,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,390,0
6351,CN([C@H]1CN(C2=CC(C3=CC=CC=C3)=NC4=CC=NN24)CC1)C,(R)-ZINC 3573,95882507,"(3R)-N,N-Dimethyl-1-(5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-3-pyrrolidinamine",C18H21N5,[2089389-15-9],307.4,7-TM Receptors,Mas-related G Protein-Coupled Receptors,Agonist,MRGPRX2 agonist,1,CN(C)[C@@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1,246,1
6353,CC(S(=O)(N[C@H]1CC2=CC=C(C3=CN=C(C=C3)F)C=C2C1)=O)C,UoS 12258,46398805,"N-[(2S)-5-(6-Fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",C17H19FN2O2S,[875927-64-3],334.41,Ion Channels,AMPA Receptors,Modulator,Positive allosteric modulator of AMPA receptors,1,CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)nc3)cc2C1,97,1
6359,COC1=C2C(N([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O)C=N2)=NC(N)=N1,Nelarabine,3011155,9-?-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine,C11H15N5O5,[121032-29-9],297.27,Cell biology,"DNA, RNA and Protein Synthesis",Inhibitor,Purine nuceloside analog; inhibits DNA synthesis,1,COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,841,0
6363,NC([C@H](N(S(=O)(C1=CC=C(C=C1)Cl)=O)CC2=C(C=C(C3=NOC=N3)C=C2)F)CCC(F)(F)F)=O,Avagacestat,46883536,"(2R)-2-[[(4-Chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide",C20H17ClF4N4O4S,[1146699-66-2],520.89,Enzymes,Gamma-Secretase,Inhibitor,Highly potent ?-secretase inhibitor; orally bioavailable,1,NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(-c2ncon2)cc1F)S(=O)(=O)c1ccc(Cl)cc1,571,1
6364,CCOC(N1CCC(NC2=C(C(C2=O)=O)NCCN3CCN(C4=CC(C(F)(F)F)=CC=C4)CC3)CC1)=O.Cl,Squarunkin A hydrochloride,,"Ethyl 4-((3,4-dioxo-2-((2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)amino)cyclobut-1-en-1-yl)amino)piperidine-1-carboxylate hydrochloride",C25H32F3N5O4.HCl,0,569.02,Enzymes,Src Kinases,Other,UNC119 chaperone-cargo interaction inhibitor; disrupts Src activation,1,CCOC(=O)N1CCC(Nc2c(NCCN3CCN(c4cccc(C(F)(F)F)c4)CC3)c(=O)c2=O)CC1,271,1
6367,CC(C)(NC(CN1CCC(CC1)CNC(C2=CC(Cl)=CC(F)=C2)=O)=O)C,Z 944,44540045,"4-[[(3-Chloro-5-fluorobenzoyl)amino)methyl]-N-(1,1-dimethylethyl)-1-piperidineacetamide",C19H27ClFN3O2,[1199236-64-0],383.89,Ion Channels,Cav3.x Channels,Blocker,CaV3.x blocker,1,CC(C)(C)NC(=O)CN1CCC(CNC(=O)c2cc(F)cc(Cl)c2)CC1,340,0
6369,OC(N1C2=NC(CCC)=N1)=C(C(C)=N2)NS(=O)(C3=CC=C(C4CCCCC4)C=C3)=O,GNE 9278,22432385,"4-Cyclohexyl-N-(7-hydroxy-5-methyl-2-propyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)benzenesulfonamide",C21H27N5O3S,[901230-11-3],429.54,Ion Channels,NMDA Receptors,Modulator,Positive allosteric modulator of NMDA receptors; acts in transmembrane domain,1,CCCc1nc2nc(C)c(NS(=O)(=O)c3ccc(C4CCCCC4)cc3)c(O)n2n1,103,1
6374,FC(F)(C1=CC=C(N=C1)OC2=CC=CC(/C=C3CCN(C(NC4=CC=CN=N4)=O)CC\3)=C2)F,PF 04457845,24771824,N-3-Pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-1-piperidinecarboxamide,C23H20F3N5O2,[1020315-31-4],455.43,Enzymes,Fatty Acid Amide Hydrolase (FAAH),Inhibitor,Potent and selective irreversible FAAH inhibitor,1,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,471,1
6383,COC1=CC2=C(N=CC=C2NC(C3=CC([N+]([O-])=O)=CC=C3Cl)=O)C=C1,SR 16832,134160241,2-Chloro-N-(6-methoxy-4-quinolinyl)-5-nitrobenzamide,C17H12ClN3O4,[2088135-12-8],357.75,Nuclear Receptors,PPARgamma Receptors,Antagonist,Dual site PPAR? inhibitor,1,COc1ccc2nccc(NC(=O)c3cc([N+](=O)[O-])ccc3Cl)c2c1,93,0
6384,CC1=CC(N(C(C2CCCCC2)=C1)O)=O,Ciclopirox,2749,6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone,C12H17NO2,[29342-05-0],207.27,Enzymes,Histone Demethylases,Inhibitor,Pan-histone demethylase inhibitor,1,Cc1cc(C2CCCCC2)n(O)c(=O)c1,53,1
6387,CNC(NC1=CC=C2C(CC[C@@]23OC(N(C3=O)CC(N([C@H](C(F)(F)F)C)CC4=CC=C(C=C4)F)=O)=O)=C1)=O,A 485,118958122,"(1R)-N-[(4-Fluorophenyl)methyl]-2,3-dihydro-5-[[(methylamino)carbonyl]amino]-2',4'-dioxo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]spiro[1H-indene-1,5'-oxazolidine]-3'-acetamide",C25H24F4N4O5,[1889279-16-6],545.49,Enzymes,Histone Acetyltransferases,Inhibitor,Potent and selective p300/CBP inhibitor; orally bioavailable,1,CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O,515,1
6405,CC1=NC(C2=C(C3=NC=C(C(F)(F)F)C=C3)N(C)N=C2)=C4N1N=CN=C4N5CCC5,PF 05180999,60143346,"4-(1-Azetidinyl)-7-methyl-5-[1-methyl-5-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]-imidazo[5,1-f][1,2,4]triazine",C19H17F3N8,[1394033-54-5],414.39,Enzymes,Phosphodiesterases,Inhibitor,Potent and selective PDE2A inhibitor,1,Cc1nc(-c2cnn(C)c2-c2ccc(C(F)(F)F)cn2)c2c(N3CCC3)ncnn12,698,1
6407,CC(NCCC(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3.Cl,Fendiline Hydrochloride,5702162,"N-(3,3-Diphenylpropyl)-?-methylbenzylamine hydrochloride",C23H25N.HCl,[13636-18-5],351.91,Enzymes,Ras GTPases,Inhibitor,Inhibits KRas localization to the plasma membrane; also L-type calcium channel blocker,1,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,179,0
6411,CC(C)(C1=CC=C(C=C1)OC2CCCCC2O)C,tBPC,16033,"2-[4-(1,1-Dimethylethyl)phenoxy]cyclohexanol",C16H24O2,[1942-71-8],248.36,7-TM Receptors,NPY Receptors,Modulator,Positive allosteric modulator of NPY Y4 receptor,1,CC(C)(C)c1ccc(OC2CCCCC2O)cc1,864,0
6429,CC1=C([N+]([O-])=O)C(C(N2CCN(C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)CC2)=O)=NO1,ML 210,49766530,[4-[Bis(4-chlorophenyl)methyl]-1-piperazinyl](5-methyl-4-nitro-3-isoxazolyl)methanone,C22H20Cl2N4O4,[1360705-96-9],475.32,Enzymes,Ras GTPases,Inhibitor,Selectively kills mutant HRAS-expressing cells; glutathione peroxidase inhibitor; induces ferroptosis,1,Cc1onc(C(=O)N2CCN(C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)CC2)c1[N+](=O)[O-],576,1
6431,CS(O)(=O)=O.CC1=CC=C(N(C2=CC(O)=CC=C2)CC3=NCCN3)C=C1,Phentolamine Mesylate,91430,"3-[[(4,5-Dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol methanesulfonate",C17H19N3O.CH4O3S,[65-28-1],377.46,7-TM Receptors,Non-selective Adrenergic Alpha Receptors,Antagonist,Adrenergic ? receptor antagonist; antihypertensive,1,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,123,1
6435,CC(C)C1=C(C=CC=C1)C1=NC=C(C)C(NCC2=CC=C(C=C2)N2C=CN=N2)=N1,ML 323,60167849,"5-Methyl-2-[2-(1-methylethyl)phenyl]-N-[[4-(1H-1,2,3-triazol-1-yl)phenyl]methyl]-4-pyrimidinamine",C23H24N6,[1572414-83-5],384.48,Enzymes,Deubiquitinating Enzymes,Inhibitor,Potent and selective USP1-UAF1 allosteric inhibitor,1,Cc1cnc(-c2ccccc2C(C)C)nc1NCc1ccc(-n2ccnn2)cc1,172,1
6438,CC1CCC2=NC(N)=C(C(C3=CN=CC=C3)=C2C1)C#N,BRD 6989,3835861,"2-Amino-5,6,7,8-tetrahydro-6-methyl-4-(3-pyridinyl)-3-quinolinecarbonitrile",C16H16N4,[642008-81-9],264.33,Enzymes,Cyclin-dependent Kinase,Inhibitor,Cdk8 inhibitor; enhances IL-10 production,1,CC1CCc2nc(N)c(C#N)c(-c3cccnc3)c2C1,719,1
6439,COC1=C(C=CC=C1)NC2=NC(C3=C(N=C(S3)NC(C)=O)C)=CS2,JNJ 0966,1117189,"N-[2-[(2-Methoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]acetamide",C16H16N4O2S2,[315705-75-0],360.45,Enzymes,Matrix Metalloprotease,Inhibitor,Pro-MMP9 activation inhibitor,1,COc1ccccc1Nc1nc(-c2sc(NC(C)=O)nc2C)cs1,352,1
6448,CNC1=C(C#N)N=C(C2=CC=CC3=C2C=CC=C3)O1,ML 351,664510,5-(Methylamino)-2-(1-naphthalenyl)-4-oxazolecarbonitrile,C15H11N3O,[847163-28-4],249.27,Enzymes,Lipoxygenase,Inhibitor,Selective 12/15 LOX inhibitor; active in vivo,1,CNc1oc(-c2cccc3ccccc23)nc1C#N,776,0
6454,CC1=CN=C(C=N1)NC(NC2=C(C=C(C(Br)=C2)C)OC[C@@H]3CNCCO3)=O,LY 2603618,11955855,N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea,C18H22BrN5O3,[911222-45-2],440.8,Enzymes,Checkpoint Kinases,Inhibitor,Potent and selective Chk1 inhibitor,1,Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,386,1
6470,CN[C@H](C(N[C@H](C(N1CCC[C@H]1C(N[C@@H]2CCCC3=CC=CC=C23)=O)=O)C4CCCCC4)=O)C.Cl,A 410099.1,131858992,"N-Methyl-L-alanyl-(2S)-2-cyclohexylglycyl-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-L-prolinamide hydrochloride",C27H40N4O3.HCl,[762274-58-8],514.1,Cell biology,Inhibitor of Apoptosis (IAP),Inhibitor,High affinity XIAP antagonist; active in vivo,1,CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]1CCCc2ccccc21)C1CCCCC1,142,0
6479,COC1=CC2=C(C(C3=CC(C)=C(C=C3)O)=CC=N2)C=C1,CU CPT 9a,135567383,2-Methyl-4-(7-methoxy-4-quinolinyl)phenol,C17H15NO2,[2165340-32-7],269.81,Enzyme-Linked Receptors,Toll-like Receptors,Inhibitor,Highly potent TLR8 inhibitor,1,COc1ccc2c(-c3ccc(O)c(C)c3)ccnc2c1,383,0
6482,CN1C2=C(C(N(C3=CN=C(N=C13)NC4=CC=C(S(N)(=O)=O)C=C4)C)=O)SC=C2,XMU MP 1,121499143,"4-[(6,10-Dihydro-5,10-dimethyl-6-oxo-5H-pyrimido[5,4-b]thieno[3,2-e][1,4]diazepin-2-yl)amino]benzenesulfonamide",C17H16N6O3S2,[2061980-01-4],429.99,Enzymes,Other Kinases,Inhibitor,Potent and selective MST1/2 inhibitor; orally bioavailable,1,CN1C(=O)c2sccc2N(C)c2nc(Nc3ccc(S(N)(=O)=O)cc3)ncc21,405,1
6486,C[C@H](C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)O[C@H]2OCCN([C@H]2C3=CC=C(C=C3)F)CC4=NNC(N4)=O,Aprepitant,6918365,"5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one",C23H21F7N4O3,[170729-80-3],534.43,7-TM Receptors,NK1 Receptor,Antagonist,Potent long-acting hNK1 antagonist,1,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,693,0
6491,COCCN1C(C)=[N+](C2=C1C(C3=CC=CC=C3C2=O)=O)CC4=NC=CN=C4.[Br-],YM 155,46931000,"4,9-Dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(2-pyrazinylmethyl)-1H-naphth[2,3-d]imidazolium bromide",C20H19BrN4O3,[781661-94-7],443.29,Cell biology,Inhibitor of Apoptosis (IAP),Inhibitor,Survivin suppressor,1,COCCn1c2c([n+](Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O,764,1
6492,CC(S(=O)(C1=CC2=C(N=CC=C2NC3=CC=C4SC=NC4=C3)C=C1)=O)C,GSK'872,54674134,N-5-Benzothiazolyl-6-[(1-methylethyl)sulfonyl]-4-quinolinamine,C19H17N3O2S2,[1346546-69-7],401.51,Enzymes,RIP Kinases,Inhibitor,Potent and selective RIP3 kinase inhibitor,1,CC(C)S(=O)(=O)c1ccc2nccc(Nc3ccc4scnc4c3)c2c1,381,1
6505,CC(C1=CC(C(C)C)=C(C(C(C)C)=C1)CC(NS(=O)(OC2=C(C(C)C)C=CC=C2C(C)C)=O)=O)C,Avasimibe,166558,"2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)acetyl)sulfamate",C29H43NO4S,[166518-60-1],501.72,Enzymes,Acyl-CoA:Cholesterol Acyltransferase,Inhibitor,ACAT inhibitor,1,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(C(C)C)cccc2C(C)C)c(C(C)C)c1,428,1
6506,C[C@H]1CC[C@@H](NC2=C3C=CNC3=NC=N2)CN1C(C=C)=O.OC(CC(O)=O)=O,PF 06551600 malonate,124203830,"1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malate",C15H19N5O.C3H4O4,[2140301-97-7],389.41,Enzymes,JAK Kinase,Inhibitor,Potent and selective JAK3 inhibitor,1,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C,658,0
6507,N[C@@H](C12CC3CC(C2)CC(C3)(C1)O)C(N4[C@H]5C[C@H]5C[C@H]4C#N)=O.Cl,Saxagliptin hydrochloride,56841574,"(1S,3S,5S)-2-[(2S)-Amino(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile hydrochloride",C18H25N3O2.HCl,[709031-78-7],365.38,Enzymes,Dipeptidyl Peptidase IV (DPP-IV),Inhibitor,High affinity DPP-IV inhibitor; active in vivo,1,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,5,1
6508,O=C(C1=CC2=C(S1)CCCCC2)N3CCC(N4C(NC5=CC=CC=C45)=O)CC3,GSK 1702934A,16376051,"1,3-Dihydro-1-[1-[(5,6,7,8-tetrahydro-4H-cyclohepta[b]thien-2-yl)carbonyl]-4-piperidinyl]-2H-benzimidazol-2-one",C22H25N3O2S,[924377-85-5],395.52,Ion Channels,TRPC,Activator,Potent and selective TRPC3/6 activator,1,O=C(c1cc2c(s1)CCCCC2)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,262,0
6516,O[C@H](CN1CCC2=CC=CC=C2C1)CNC(C3=NC=NC(NC4COC4)=C3)=O,EPZ 015666,90241673,"N-[(2S)-3-(3,4-Dihydro-2(1H)-isoquinolinyl)-2-hydroxypropyl]-6-(3-oxetanylamino)-4-pyrimidinecarboxamide",C20H25N5O3,[1616391-65-1],392.45,Enzymes,Protein Arginine Methyltransferases,Inhibitor,Potent and selective PRMT5 inhibitor,1,O=C(NC[C@H](O)CN1CCc2ccccc2C1)c1cc(NC2COC2)ncn1,146,0
6518,FC1=CC=C(C=C1)CNC(C2CCN(S(=O)(C3=CC(Cl)=CC(Cl)=C3)=O)CC2)=O,BI 01383298,134604213,"1-[(3,5-Dichlorophenyl)sulfonyl]-N-[(4-fluorophenyl)methyl]-4-piperidinecarboxamide",C19H19Cl2FN2O3S,[2227549-00-8],445.34,Transporters,Other Ion Pumps/Transporters,Inhibitor, Potent and selective SLC13A5 (Na+/citrate cotransporter) inhibitor,1,O=C(NCc1ccc(F)cc1)C1CCN(S(=O)(=O)c2cc(Cl)cc(Cl)c2)CC1,285,0
6520,[H][C@@]12CC=C([C@]1(CC[C@]3([C@]2(CC=C4C[C@@H](OC(C)=O)CC[C@]34C)[H])[H])C)C5=CN=CC=C5,Abiraterone acetate,9821849,"(3?)-17-(3-Pyridinyl)androsta-5,16-dien-3-yl acetate",C26H33NO2,[154229-18-2],391.55,Enzymes,Cytochrome P450,Inhibitor,Potent CYP17A1 inhibitor,1,CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,720,1
6528,O=C(NC1=NNC2=C1C=CC(C3=CC=CC(NS(=O)(N(CC)CC)=O)=C3)=C2)C4CC4,SGC AAK1 1,134812845,"N-(6-(3-((N,N-diethylsulfamoyl)amino)phenyl)-1H-indazol-3-yl)cyclopropanecarboxamide",C21H25N5O3S,[2247894-32-0],432.02,Enzymes,Other Kinases,Inhibitor,AAK1 and BMP2K inhibitor; activates Wnt signaling,1,CCN(CC)S(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,48,1
6534,O=C1N(C)C(C(N(CC2=NN=C(C3=CC(Cl)=C(Cl)C=C3)O2)C(N4CCNCC4)=N5)=C5N1C)=O.Cl,TH 5427 hydrochloride,137919865,"7-[[5-(3,4-Dichlorophenyl)-1,3,4-oxadiazol-2-yl]methyl]-1,3-dimethyl-8-(piperazine-1-yl)-1H-purine-2,6-dione hydrochloride",C20H20Cl2N8O3.HCl,,550.31,Enzymes,Other Hydrolases,Inhibitor,Potent NUDT5 inhibitor,1,Cn1c(=O)c2c(nc(N3CCNCC3)n2Cc2nnc(-c3ccc(Cl)c(Cl)c3)o2)n(C)c1=O,674,1
6537,CCCCNC1=NC=C(C(N[C@H]2CC[C@@H](CC2)O)=N1)C(NCC3=CC=C(N4C=CN=C4)C=C3)=O,UNC 2881,71721525,2-(Butylamino)-4-[(trans-4-hydroxycyclohexyl)amino]-N-[[4-(1H-imidazol-1-yl)phenyl]methyl]-5-pyrimidinecarboxamide,C25H33N7O2,[1493764-08-1],463.58,Enzyme-Linked Receptors,Other RTKs,Inhibitor,Potent Mer kinase inhibitor,1,CCCCNc1ncc(C(=O)NCc2ccc(-n3ccnc3)cc2)c(N[C@H]2CC[C@H](O)CC2)n1,823,1
6538,OC(/C=C\C(O)=O)=O.CN1CC[C@@H](NC(NC2=CC=C(C#N)C=C2)=O)C[C@@H]1C3=NC4=CC=CC=C4N3,PF 04449913 maleate,122640033,"1-((2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate salt",C21H22N6O.C4H4O4,[2030410-25-2],495.01,7-TM Receptors,Smoothened Receptors,Antagonist,Potent Smo antagonist,1,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,161,1
6539,CS(O)(=O)=O.COC1=CC(C2=CC3=CC=CC=C3N2)=N/C1=C/C4=C(C=C(N4)C)C,Obatoclax mesylate,16681698,"2-[2-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene)-3-methoxy-2H-pyrrol-5-yl]-1H-indole methanesulfonate",C20H19N3O.CH3SO3H,[803712-79-0],417.99,Cell biology,Bcl-2 Family,Inhibitor,Inhibitor of Bcl-2 family members; antiapoptotic,1,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C/c1[nH]c(C)cc1C,771,1
6541,COC1=NC=CN=C1NS(=O)(C2=C(Cl)C(Cl)=CC=C2)=O,AZD 2098,10308720,"2,3-Dichloro-N-(3-methoxy-2-pyrazinyl)benzenesulfonamide",C11H9Cl2N3O3S,[566203-88-1],343.19,7-TM Receptors,Chemokine CC Receptors,Antagonist,Potent and selective CCR4 antagonist,1,COc1nccnc1NS(=O)(=O)c1cccc(Cl)c1Cl,849,1
6542,COC1=C(C=C2[C@H](CC2=C1)CN(CCCN3CCC4=CC(OC)=C(C=C4CC3=O)OC)C)OC.Cl,Ivabradine hydrochloride,3045381,"3-[3-[[[(7S)-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one hydrochloride",C27H36N2O5.HCl,[148849-67-6],518.56,Ion Channels,HCN Channels,Blocker,HCN channel blocker; inhibits If pacemaker current,1,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2,374,0
6544,ClC1=CC(Cl)=C(C(NC2=CC=C(C(NC3=CC=CC=C3)=O)C=C2)=O)C=C1,CID 1375606,1375606,"2,4-Dichloro-N-(phenylcarbamoyl)phenylbenzamide",C20H14Cl2N2O2,[313493-80-0],385.24,7-TM Receptors,Orphan 7-TM Receptors,Agonist,GPR27 agonist,1,O=C(Nc1ccccc1)c1ccc(NC(=O)c2ccc(Cl)cc2Cl)cc1,519,0
6545,CCOC(C1=C(C2=CC=CC=C2)OC3=CC=C(C=C13)OC4=C([N+]([O-])=O)N=CN4C)=O,OB-1,1113704,Ethyl 5-(1-methyl-4-nitro-1H-imidazol-5-yloxy)-2-phenylbenzofuran-3-carboxylate,C21H17N3O6,[300803-69-4],407.38,Ion Channels,Piezo Channels,Other,Stomatin-like protein-3 (STOML3) oligomerization inhibitor,1,CCOC(=O)c1c(-c2ccccc2)oc2ccc(Oc3c([N+](=O)[O-])ncn3C)cc12,238,1
6558,O=C(NC1CCCC2=CC=CC=C12)CNC(C3=CC=C(C4=CC=CC=C4)C=C3)=O,CP 43,46673962,"N-(2-Oxo-2-((1,2,3,4-tetrahydronaphthalen-1-yl)amino)ethyl)-[1,1'-biphenyl]-4-carboxamide",C25H24N2O2,[850467-66-2],393.48,Enzymes,Other Kinases,Inhibitor,Potent TAOK inhibitor,1,O=C(CNC(=O)c1ccc(-c2ccccc2)cc1)NC1CCCc2ccccc21,142,0
6559,CC([C@@H](C(N[C@H](C(N[C@H]1C2=CC=CC=C2CCN(C1=O)C)=O)C)=O)O)C,LY 450139,9843750,"(2S)-2-Hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]butanamide",C19H27N3O4,[425386-60-3],365.94,Enzymes,Gamma-Secretase,Inhibitor,?-secretase pseudo-inhibitor,1,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21,184,1
6564,BrC1=CC2=C(NC3=CC(OC)=C(OC)C(OC)=C3)C=CN=C2C=C1,SGC GAK 1,50877865,"6-Bromo-N-(3,4,5-trimethoxyphenyl)-4-quinolinamine",C18H17BrN2O3,[2226517-76-4],389.24,Enzymes,Other Kinases,Inhibitor,High affinity cyclin G associated kinase (GAK) inhibitor,1,COc1cc(Nc2ccnc3ccc(Br)cc23)cc(OC)c1OC,381,0
6568,ClC1=C(CSC2=NN=C(O2)C3=CC=CN3)C(Cl)=CC=C1,Dooku 1,137321150,"2-[(2,6-Dichlorobenzyl)thio)-5-(1H-pyrrol-2-yl)-1,3,4-oxadiazole",C13H9Cl2N3OS,,326.2,Ion Channels,Piezo Channels,Modulator,Reversibly blocks Yoda1 activity; does not affect constitutive Piezo1 activity,1,Clc1cccc(Cl)c1CSc1nnc(-c2ccc[nH]2)o1,846,0
6576,ClC1=NC=C(C=C1)OC[C@H]2CCN2.Cl,ABT 594 hydrochloride,72193963,(R)-5-(Azetidin-2-ylmethoxy)-2-chloropyridine hydrochloride,C9H11ClN2O.HCl,[203564-54-9],244.12,Ion Channels,Nicotinic (a4b2) Receptors,Agonist,Selective ?4?2 nAChR agonist,1,Clc1ccc(OC[C@H]2CCN2)cn1,853,1
6577,CC(C)(C1=NC2=C3C=CNC(C3=C4C=C(C=CC4=C2N1)F)=O)C,Pyridone 6,5494425,"2-(1,1-Dimethylethyl)-9-fluoro-1,6-dihydro-7H-benz[h]imidazo[4,5-f]isoquinolin-7-one",C18H16FN3O,[457081-03-7],331.86,Enzymes,JAK Kinase,Inhibitor,Potent pan-JAK inhibitor; induces intermediate mesoderm; cell-permeable,1,CC(C)(C)c1nc2c3cc[nH]c(=O)c3c3cc(F)ccc3c2[nH]1,861,1
6578,COC1=CC=C2NC(C(C(C3=NN=NN3CCC4=CC=CC=C4)N5CCN(C6CCCCC6)CC5)=CC2=C1)=O,GT 949,3195790,3-((4-Cyclohexylpiperazin-1-yl)(1-phenethyl-1H-tetrazol-5-yl)methyl)-6-methoxyquinolin-2(1H)-one,C30H37N7O2,[460330-27-2],527.66,Transporters,Glutamate Transporters,Modulator,Potent and selective positive allosteric modulator of EAAT2,1,COc1ccc2[nH]c(=O)c(C(c3nnnn3CCc3ccccc3)N3CCN(C4CCCCC4)CC3)cc2c1,265,1
6579,CC1=CC(C)=C(C=C1N2C=CN3N=C(C4=CN=CC=C4)C=C23)NC(C5=CC(S(F)(F)(F)(F)F)=CC(C#N)=C5)=O,BAY 826,71623052,"[3-Cyano-5-[[[2,4-dimethyl-5-[6-(3-pyridinyl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl]amino]carbonyl]phenyl]pentafluorosulfur",C26H19F5N6OS,[1448316-08-2],563.03,Enzyme-Linked Receptors,Other RTKs,Inhibitor,Potent Tie2 inhibitor,1,Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1,475,1
6583,FC1=CC=C(C=C1)NC2=NC(C3=CC=CC=C3)=CS2,UCLA GP130 2,1284592,N-(4-Fluorophenyl)-4-phenyl-2-thiazolamine,C15H11FN2S,[339303-87-6],270.32,Cell biology,Cytokines,Agonist,gp130 agonist; brain penetrant and neuroprotectant,1,Fc1ccc(Nc2nc(-c3ccccc3)cs2)cc1,504,0
6597,COCC(NCCC1=C(NC2=CC=C(C=C12)O)C)=O,SPRi 3,52911386,N-[2-(5-Hydroxy-2-methyl-1H-indol-3-yl)ethyl]-2-methoxyacetamide,C14H18N2O3,[1292285-54-1],262.3,Enzymes,Other Reductase,Inhibitor,Potent sepiapterin reductase (SPR) inhibitor; attenuates proliferation of CD4+ T cells,1,COCC(=O)NCCc1c(C)[nH]c2ccc(O)cc12,565,1
6598,ClC1=CC(C2=C3N=C(NCCOCCO4)C=CN3N=C2)=CC4=C1.Cl,OD 36 hydrochloride,,"6-Chloro-10,11,14,17-tetrahydro-13H-1,16-etheno-4,8-metheno-1H-pyrazolo[3,4-g][1,14,4,6]dioxadiazacyclohexadecine hydrochloride",C16H15ClN4O2.HCl,[1638644-62-8],371.73,Enzymes,RIP Kinases,Inhibitor,Potent RIP2 kinase inhibitor,1,Clc1cc2cc(c1)-c1cnn3ccc(nc13)NCCOCCO2,857,1
6614,CC1=C(C(O)=O)C=C(C2=CC=CS2)O1,Jedi2,2796026,2-Methyl-5-(2-thienyl)-3-furancarboxylic acid,C10H8O3S,[651005-90-2],208.23,Ion Channels,Piezo Channels,Activator,Piezo1 channel activator,1,Cc1oc(-c2cccs2)cc1C(=O)O,150,0
6618,CC(CC1=C(C2=CC=C(P(O)(O)=O)O2)N=C(S1)N)C,MB 05032,11289630,P-[5-[2-Amino-5-(2-methylpropyl)-4-thiazolyl]-2-furanyl]phosphonic acid,C11H15N2O4PS,[261365-11-1],302.29,Enzymes,Other Transferases,Inhibitor,Potent FBPase inhibitor; promotes HSC expansion,1,CC(C)Cc1sc(N)nc1-c1ccc(P(=O)(O)O)o1,875,1
6626,C#CCNC1=NC(C2=CC=C(N3C=CN=C3)C=C2)=CC=N1,AP C5,137919866,4-[4-(1H-Imidazol-1-yl)phenyl]-N-2-propyn-1-yl-2-pyrimidinamine,C16H13N5,[2234272-10-5],275.31,Enzymes,Protein Kinase G,Inhibitor,Potent and selective PKG2 inhibitor,1,C#CCNc1nccc(-c2ccc(-n3ccnc3)cc2)n1,823,0
6641,FC(F)OC(C=C1)=C(OCC2CC2)C=C1C(NC3=C(Cl)C=NC=C3Cl)=O,Roflumilast,449193,"3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide",C17H14Cl2F2N2O3,[162401-32-3],403.21,Enzymes,Phosphodiesterases,Inhibitor,Potent and selective PDE4 inhibitor,1,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,369,0
6652,CN(S(=O)(C1=CC(C(NC2=NC=C(S2)C)=O)=C(N3CCCC3)C=C1)=O)C,NGI 1,2519269,5-[(Dimethylamino)sulfonyl]-N-(5-methyl-2-thiazolyl)-2-(1-pyrrolidinyl)benzamide,C17H22N4O3S2,[790702-57-7],394.51,Enzymes,Other Transferases,Inhibitor,Oligosaccharyltransferase (OST) inhibitor; anti-flaviviral,1,Cc1cnc(NC(=O)c2cc(S(=O)(=O)N(C)C)ccc2N2CCCC2)s1,493,1
6653,CC1=CC=C(C(COC(C2=CC=CC(NC(C3=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C3)=O)=C2)=O)=O)C=C1,FM19G11,1730746,"2-Oxo-2-(p-tolyl)ethyl 3-(2,4-dinitrobenzamido)benzoate",C23H17N3O8,[329932-55-0],467.9,Cell biology,Hypoxia Inducible Factors,Inhibitor,HIF ?-subunit inhibitor,1,Cc1ccc(C(=O)COC(=O)c2cccc(NC(=O)c3ccc([N+](=O)[O-])cc3[N+](=O)[O-])c2)cc1,92,1
6654,N1(N=NC2=C(N=CN=C12)SC3=NC4=CC=CC=C4O3)CC5=CC=CC=C5,VAS 2870,4058452,"7-(2-Benzoxazolylthio)-3-(phenylmethyl)-3H-1,2,3-triazolo[4,5-d]pyrimidine",C18H12N6OS,[722456-31-7],360.39,Enzymes,NADPH Oxidase,Inhibitor,NADPH oxidase (Nox) inhibitor,1,c1ccc(Cn2nnc3c(Sc4nc5ccccc5o4)ncnc32)cc1,166,1
6657,COC1=C(C=CC(C2CC(NC3=C2C(N=C(N3)N)=O)=O)=C1)OCC=C,PA 8,6485327,"2-Amino-5,8-dihydro-5-[3-methoxy-4-(2-propen-1-yloxy)phenyl]pyrido[2,3-d]pyrimidine-4,7(3H,6H)-dione",C17H18N4O4,[878437-15-1],342.35,7-TM Receptors,PACAP Receptors,Antagonist,PAC1 receptor antagonist,1,C=CCOc1ccc(C2CC(=O)Nc3[nH]c(N)nc(=O)c32)cc1OC,368,1
6662,CCCCCCCCOC(CC(C(O)=O)=C)=O,4-Octyl itaconate,14239884,2-Methylenebutanedioic acid 4-octyl ester,C13H22O4,[3133-16-2],242.31,Cell biology,Nrf2,Activator,Nrf2 activator; cell permeable,1,C=C(CC(=O)OCCCCCCCC)C(=O)O,23,1
6663,C[C@@H](NCCOC1=C(C=CC=C1)OCC(F)(F)F)CC2=CC(C(N)=O)=C3N(CCC3=C2)CCCO,Silodosin,5312125,"2,3-Dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carboxamide",C25H32F3N3O4,[160970-54-7],495.53,7-TM Receptors,Adrenergic Alpha-1 Receptors,Antagonist,Selective ?1A antagonist,1,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,346,0
6668,CN(S(=O)(C1=CC(C(N2CCN(C3=C(C(C)=CC=C3)C)CC2)=O)=C(N4CCCC4)C=C1)=O)C,ML 184,2440433,"3-[[4-(2,3-Dimethylphenyl)-1-piperazinyl]carbonyl]-N,N-dimethyl-4-(1-pyrrolidinyl)benzenesulfonamide",C25H34N4O3S,[794572-10-4],470.63,7-TM Receptors,GPR55,Agonist,Selective GPR55 agonist; also promotes NSC proliferation and differentiation,1,Cc1cccc(N2CCN(C(=O)c3cc(S(=O)(=O)N(C)C)ccc3N3CCCC3)CC2)c1C,493,0
6675,CCC1=CC=C(C=C1)NC(NC2=CNC3=CC=CC=C23)=O,H 151,7616033,N-(4-Ethylphenyl)-N'-1H-indol-3-yl-urea,C17H17N3O,[941987-60-6],279.34,Cell biology,STING-Dependent Signaling,Antagonist,STING antagonist,1,CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1,794,0
6677,OC(CN1C2=CC=CC=C2C(C3=C1C=CC=C3)=O)=O,CMA,38072,9-Oxo-10(9H)-acridineacetic acid,C15H11NO3,[38609-97-1],257.75,Cell biology,STING-Dependent Signaling,Agonist,Murine-selective STING agonist,1,O=C(O)Cn1c2ccccc2c(=O)c2ccccc21,782,0
6689,NC1=CC=C(C=C1)OC2=CC=C(C(C(F)(F)F)(C(F)(F)F)C3=CC=C(C=C3)OC4=CC=C(C=C4)N)C=C2,GI 530159,94652,"4,4'-[[2,2,2-Trifluoro-1-(trifluoromethyl)ethylidene]bis(4,1-phenyleneoxy)]bis[benzenamine]",C27H20F6N2O2,[69563-88-8],518.45,Ion Channels,Two-P Potassium Channels,Activator,K2P2.1 (TREK-1) and K2P10.1 (TREK-2) channel activator,1,Nc1ccc(Oc2ccc(C(c3ccc(Oc4ccc(N)cc4)cc3)(C(F)(F)F)C(F)(F)F)cc2)cc1,445,0
6692,FC1=CC(C2=CC=CC=N2)=CC(C(NNS(=O)(C3=C(C=CC=C3)F)=O)=O)=C1,WM 1119,133080719,2-Fluoro-N'-(3-fluoro-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide,C18H13F2N3O3S,[2055397-28-7],389.38,Enzymes,Histone Acetyltransferases,Inhibitor,High affinity KAT6A (MOZ) competitive inhibitor,1,O=C(NNS(=O)(=O)c1ccccc1F)c1cc(F)cc(-c2ccccn2)c1,540,1
6701,CC1=CC(NC(NC2=C(C(F)(F)F)C=CC=C2)=N)=CC(C)=C1,1A-116,71543346,"N-(3,5-Dimethylphenyl)-N'-[2-(trifluoromethyl)phenyl]guanidine",C16H16F3N3,[1430208-73-3],307.31,Enzymes,Rho,Inhibitor,Rac1 inhibitor; blocks Rac1-P-Rex1 interaction,1,Cc1cc(C)cc(NC(=N)Nc2ccccc2C(F)(F)F)c1,78,0
6709,CC(OC1=NC=C(C2=NC(C3=C4C=CN(C4=CC=C3)CCCC(O)=O)=NO2)C=C1Cl)C,GSK 2018682,24988201,"4-[5-[5-Chloro-6-(1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-1H-indole-1-butanoic acid",C22H21ClN4O4,[1034688-30-6],440.88,7-TM Receptors,Sphingosine-1-phosphate Receptors,Agonist,S1P1 and S1P5 agonist,1,CC(C)Oc1ncc(-c2nc(-c3cccc4c3ccn4CCCC(=O)O)no2)cc1Cl,717,1
6710,[H][C@@]12CCO[C@@]1(OC[C@@H]2OC(N[C@H]([C@@H](CN(S(=O)(C3=CC=C(C=C3)N)=O)CC(C)C)O)CC4=CC=CC=C4)=O)[H],Darunavir,213039,"(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl N-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamate",C27H37N3O7S,[206361-99-1],552.16,Enzymes,Other Proteases,Inhibitor,Highly potent HIV protease inhibitor,1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,191,1
6712,CC1=NC(C2=NNC=C2C3=CC=NC4=C3C=CC=C4)=CC=C1,A 77-01,10469233,4-[3-(6-Methyl-2-pyridinyl)-1H-pyrazol-4-yl]quinoline,C18H14N4,[607737-87-1],286.33,Enzyme-Linked Receptors,TGF-beta Receptors,Inhibitor,Potent inhibitor of TGF-?RI,1,Cc1cccc(-c2n[nH]cc2-c2ccnc3ccccc23)n1,741,1
6724,OC(C1=C(C=C(C=C1)Cl)NC(COC2=C(C=CC=C2)Cl)=O)=O,CBA,2264067,4-Chloro-2-[[2-(2-chlorophenoxy)acetyl]amino]benzoic acid,C15H11Cl2NO4,[351424-20-9],340.16,Ion Channels,TRPM,Blocker,Selective TRPM4 blocker,1,O=C(COc1ccccc1Cl)Nc1cc(Cl)ccc1C(=O)O,596,0
6728,NC1=C(C=CC(F)=C1)NC(/C=C/C2=CN(N=C2)C/C=C/C3=CC=CC=C3)=O,RGFP 966,56650312,(2E)-N-(2-Amino-4-fluorophenyl)-3-[1-(3-phenyl-2-propen-1-yl)-1H-pyrazol-4-yl]-2-propenamide,C21H19FN4O,[1357389-11-7],371.41,Enzymes,Class I HDACs,Inhibitor,Potent and selective HDAC3 inhibitor,1,Nc1cc(F)ccc1NC(=O)/C=C/c1cnn(C/C=C/c2ccccc2)c1,607,1
6742,CC(NC1=NN=C(S(N)(=O)=O)S1)=O,Acetazolamide,1986,"N-[5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide",C4H6N4O3S2,[59-66-5],222.25,Enzymes,Carbonic anhydrases,Inhibitor,Carbonic anhydrase inhibitor,1,CC(=O)Nc1nnc(S(N)(=O)=O)s1,894,1
6753,ClC1=CC=C(C=C1)OCCCCCCN/C(NC#N)=N/C2=CC=NC=C2,CHS 828,148198,N-[6-(4-Chlorophenoxy)hexyl]-N'-cyano-N''-4-pyridinylguanidine,C19H22ClN5O,[200484-11-3],371.86,Enzymes,NAMPT,Inhibitor,NAMPT inhibitor; active in vivo and cytotoxic,1,N#CN/C(=N\c1ccncc1)NCCCCCCOc1ccc(Cl)cc1,72,1
6754,OC1=C(C=C(C2=CN=CC=C2C3=CC=C(N4CCOCC4)C=C3)C=C1F)F,LJI308,118704762,"2,6-Difluoro-4-[4-[4-(4-morpholinyl)phenyl]-3-pyridinyl]phenol",C21H18F2N2O2,[1627709-94-7],368.38,Enzymes,RSK,Inhibitor,Potent pan-RSK inhibitor,1,Oc1c(F)cc(-c2cnccc2-c2ccc(N3CCOCC3)cc2)cc1F,310,1
6755,CCN(CCN(C(CN1C2=C(C(N=C1SCC3=CC=C(C=C3)F)=O)CCC2)=O)CC4=CC=C(C5=CC=C(C(F)(F)F)C=C5)C=C4)CC,Darapladib,9939609,"N-[2-(Diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1H-cyclopentapyrimidine-1-acetamide",C36H38F4N4O2S,[356057-34-6],684.79,Enzymes,Phospholipases,Inhibitor,Potent lp-PLA2 inhibitor,1,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2,221,1
6759,CC1=CC(NC(CCC2=CC=CC=C2)=O)=C(C=C1)O,AA 147,882909,N-(2-Hydroxy-5-methylphenyl)benzenepropanamide,C16H17NO2,[393121-74-9],255.31,Cell biology,Other ER stress/UPR,Other,ER proteostasis regulator,1,Cc1ccc(O)c(NC(=O)CCc2ccccc2)c1,211,0
6760,NC(N/N=C/C1=C(C(Cl)=CC=C1)Cl)=N,Raphin 1,5356739,"(2E)-2-[(2,3-Dichlorophenyl)methylene]hydrazinecarboximidamide",C8H8Cl2N4,[2022961-17-5],231.08,Enzymes,Protein Ser/Thr Phosphatases,Inhibitor,Inhibitor of the regulatory subunit PPP1R15B of protein phosphatase 1; orally bioavailable and brain penetrant,1,N=C(N)N/N=C/c1cccc(Cl)c1Cl,869,0
6764,C[C@@H](C1=CN=CC(N2CCN(C3=CC=CC=N3)CC2)=N1)NC(CCC4=CC(F)=C(C=C4)F)=O,B 973B,137319851,"3,4-Difluoro-N-[(1S)-1-[6-[4-(2-pyridinyl)-1-piperazinyl]-2-pyrazinyl]ethyl]benzenepropanamide",C24H26F2N6O,[2244989-34-0],452.5,Ion Channels,Nicotinic (a7) Receptors,Modulator,Positive allosteric modulator of ?7 nAChRs; analgesic,1,C[C@H](NC(=O)CCc1ccc(F)c(F)c1)c1cncc(N2CCN(c3ccccn3)CC2)n1,661,1
6765,CC(C)(C1=CC(C(C)(C)C)=NC(N2CCN3C(C2)=NN=C3C4=CC=C(C=C4)OC(F)(F)F)=N1)C,JTP 103237,91884614,"7-[4,6-Bis(1,1-dimethylethyl)-2-pyrimidinyl]-5,6,7,8-tetrahydro-3-[4-(trifluoromethoxy)phenyl]-1,2,4-triazolo[4,3-a]pyrazine",C24H29F3N6O,[1883864-16-1],474.52,Enzymes,Other Transferases,Inhibitor,Potent and selective monoacyglycerol acyltransferase 2 (MOGAT2) inhibitor,1,CC(C)(C)c1cc(C(C)(C)C)nc(N2CCn3c(nnc3-c3ccc(OC(F)(F)F)cc3)C2)n1,705,0
6766,C1(NCC2=CC=CO2)=NC3=CC=CC=C3N1CC4=CC=CC=C4,AC 1903,667146,N-(2-Furanylmethyl)-1-(phenylmethyl)-1H-benzimidazol-2-amine,C19H17N3O,[831234-13-0],307.86,Ion Channels,TRPC,Blocker,Selective TRPC5 blocker,1,c1ccc(Cn2c(NCc3ccco3)nc3ccccc32)cc1,165,0
6770,[H][C@]12CCCN1CCN(C(C3=CC(S(=O)(NC4=C(C=CC=C4)F)=O)=C(C=C3Cl)F)=O)C2,ABT 639,46851313,"4-Chloro-2-fluoro-N-(2-fluorophenyl)-5-[[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]benzenesulfonamide",C20H20ClF2N3O3S,[1235560-28-7],455.91,Ion Channels,Cav3.x Channels,Blocker,CaV3.2 and CaV3.1 channel blocker; orally bioavailable,1,O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCC[C@@H]2C1,331,1
6774,COC1=C(C(NCCC2=CC=C(S(N)(=O)=O)C=C2)=O)C=C(C=C1)Cl,16673-34-0 NLRP3i,85542,N-[2-[4-(Aminosulfonyl)phenyl]ethyl]-5-chloro-2-methoxybenzamide,C16H17ClN2O4S,[16673-34-0],368.84,Cell biology,Inflammasomes,Inhibitor,NLRP3 inflammasome inhibitor,1,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(N)(=O)=O)cc1,335,0
6777,CCC(NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3)=O,TAK 375,208902,"N-[2-[(8S)-1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propanamide",C16H21NO2,[196597-26-9],259.34,7-TM Receptors,Melatonin (MT) Receptors,Agonist,Very high affinity and selective melatonin receptor agonist,1,CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3,326,1
6784,CC1=NC(CC2=CC(C(F)(F)F)=CC(F)=C2)=NN1C3=CC(C)=C(C(N)=O)C=C3,FTBMT,56649300,"4-[3-[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]-5-methyl-1H-1,2,4-triazol-1-yl]-2-methylbenzamide",C19H16F4N4O,[1358575-02-6],392.35,7-TM Receptors,Orphan 7-TM Receptors,Agonist,Potent and selective GPR52 agonist; orally bioavailable and BBB permeable,1,Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O,684,1
6787,O=C(C(C1=CN(C2=CC=CC=C12)CC3=CC=CC=C3)=O)NC4=CC=CC=C4,KI-7,73350966,?-Oxo-N-phenyl-1-(phenylmethyl)-1H-indole-3-acetamide,C23H18N2O2,[1489263-00-4],354.4,7-TM Receptors,Adenosine A2B Receptors,Modulator,Positive allosteric modulator of A2B receptors,1,O=C(Nc1ccccc1)C(=O)c1cn(Cc2ccccc2)c2ccccc12,168,0
6788,CC(C)(C1=CC(NC(NC2=CC=C(C3=CN4C(SC5=CC(OCCN6CCOCC6)=CC=C45)=N3)C=C2)=O)=NO1)C,Quizartinib,24889392,"N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea",C29H32N6O4S,[950769-58-1],565.17,Enzyme-Linked Receptors,FLT3,Inhibitor,Highly potent FLT3 inhibitor,1,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,322,0
6793,CC1=NC(NC2=NC=C(C(NC3=C(C=CC=C3Cl)C)=O)S2)=CC(N4CCN(CC4)CCO)=N1,Dasatinib,3062316,N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide,C22H26ClN7O2S,[302962-49-8],488.01,Enzymes,Src Kinases,Inhibitor,Highly potent pan-Src/Bcr-Abl inhibitor,1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,489,1
6803,CC1=CC(N2CCC3(CC2)CN(CCN3C)C4=NC(C5=CC(OC)=CC(OC)=C5)=NO4)=CC=N1,MRK 740,137331596,"3-(3,5-Dimethoxyphenyl)-5-(1-methyl-9-(2-methylpyridin-4-yl)-1,4,9-triazaspiro[5.5]undecan-4-yl)-1,2,4-oxadiazole",C25H32N6O3,,478.07,Enzymes,Other Lysine Methyltransferases,Inhibitor,Potent PRDM9 inhibitor,1,COc1cc(OC)cc(-c2noc(N3CCN(C)C4(CCN(c5ccnc(C)c5)CC4)C3)n2)c1,712,1
6812,CN(C/C=C/C(NC1=CC2=C(N=CN=C2NC3=CC(Cl)=C(C=C3)F)C=C1O[C@H]4CCOC4)=O)C.OC(/C=C\C(O)=O)=O.OC(/C=C\C(O)=O)=O,Afatinib dimaleate,15606394,(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide dimaleate,C24H25ClFN5O3.2C4H4O4,[850140-73-7],722.58,Enzyme-Linked Receptors,EGFR,Inhibitor,Potent dual specificity EGFR/HER2 inhibitor; active in vivo,1,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,390,1
6816,OP(O)(O)=O.N[C@H](CC1=C(C=C(C(F)=C1)F)F)CC(N2CCN3C(C2)=NN=C3C(F)(F)F)=O,Sitagliptin phosphate,6451150,"(3R)-3-Amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-1-butanone phosphate",C16H15F6N5O.H3O4P,[654671-78-0],523.33,Enzymes,Dipeptidyl Peptidase IV (DPP-IV),Inhibitor,Potent and selective DPP IV inhibitor,1,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,692,0
6819,[H][C@]1([C@H](C2=CC(C(F)(F)F)=NC3=C(C(F)(F)F)C=CC=C23)O)CCCCN1.Cl,Mefloquine hydrochloride,65329,"(?S)-rel-?-(2R)-2-Piperidinyl-2,3-bis(trifluoromethyl-4-quinolinemethanol hydrochloride",C17H16F6N2O.HCl,[51773-92-3],423.78,Cell biology,Gap Channels,Blocker,Cx36 and Cx50 gap channel blocker; also antimalarial and antischistosomal,1,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,680,1
6821,O=C(N(CC1=CC=C(Cl)C=C1)CC2=CC=CO2)C3=NC(S(=O)(CC)=O)=NC=C3Cl,ZAP 180013,2988718,5-Chloro-N-[(4-chlorophenyl)methyl]-2-(ethylsulfonyl)-N-(2-furanylmethyl)-4-pyrimidinecarboxamide,C19H17Cl2N3O4S,[873080-25-2],454.32,Enzyme-Linked Receptors,Other RTKs,Inhibitor,Zap70 inhibitor; inhibits interaction with ITAMs,1,CCS(=O)(=O)c1ncc(Cl)c(C(=O)N(Cc2ccc(Cl)cc2)Cc2ccco2)n1,575,1
6830,CC1=NC2=C(C3=CC=CC=C3N(C(C4=CC=C(C=C4)NC(C5=C(C6=CC=CC=C6)C=CC=C5)=O)=O)CC2)N1,Conivaptan hydrochloride,151171,"N-[4-[(4,5-Dihydro-2-methylimidazo[4,5-d][benzazepin-6(1H)-yl)carbonyl]phenyl-[1,1'-biphenyl]-2-carboxamide hydrochloride",C32H26N4O2.HCl,[168626-94-6],589.09,7-TM Receptors,Vasopressin Receptors,Antagonist,Very high affinity vasopressin V1A and V2 antagonist; orally bioavailable,1,Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2,249,0
6857,CNCC1=C(C=CC=C1)C1=CSC(=C1)[C@@H](C)NC1=NC(C)=NC2=C1C=C(OC)C(OC)=C2,BAY 293,,"(R)-6,7-Dimethoxy-2-methyl-N-[1-[4-[2-[(methylamino)methyl]phenyl]thiophene-2-yl]ethyl]quinazolin-4-amine",C25H28N4O2S,[2244904-70-7],457.6,Enzymes,Ras GTPases,Inhibitor,Potent KRas/SOS1 interaction inhibitor,1,CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1,397,1
6859,CC(C)NC1=CC(=NC=N1)C1=CSC(=N1)N(C)C(=O)C1=CC=C(F)C=C1,FITM,16660135,"4-Fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide",C18H18FN5OS,[932737-65-0],371.43,7-TM Receptors,Glutamate (Metabotropic) Group I Receptors,Modulator,Potent and selective negative allosteric modulator of mGlu1 receptors,1,CC(C)Nc1cc(-c2csc(N(C)C(=O)c3ccc(F)cc3)n2)ncn1,506,1
6874,OC(=O)C1=CC=C(N=C1)C(=O)N[C@@H](C1=CC(F)=C(OC(F)(F)F)C=C1)C1=C(F)C=CC=N1,AMG 333,71144018,6-[[[(S)-(3-Fluoro-2-pyridinyl)[3-fluoro-4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]-3-pyridinecarboxylic acid,C20H12F5N3O4,[1416799-28-4],453.33,Ion Channels,TRPM,Antagonist,Potent and selective TRPM8 antagonist; active in vivo,1,O=C(O)c1ccc(C(=O)N[C@@H](c2ccc(OC(F)(F)F)c(F)c2)c2ncccc2F)nc1,708,1
6877,CC(C)C1=CC(Br)=C(OCC(=O)NC2CC(C)(C)NC(C)(C)C2)C=C1,VU 0134992,1319582,"2-(2-Bromo-4-isopropylphenoxy)-N-(2,2,6,6-tetramethylpiperidin-4-yl)acetamide",C20H31BrN2O2,[755002-90-5],411.38,Ion Channels,Inward rectifier Potassium Channels,Blocker,Kir4.1 blocker,1,CC(C)c1ccc(OCC(=O)NC2CC(C)(C)NC(C)(C)C2)c(Br)c1,429,1
6884,COC1=CC=C(C=C1)C1=CN=C(NCC2=CC(OC)=CC=C2)N1C,TC SL C5,1096509,5-(4-Methoxyphenyl)-N-[(3-methoxyphenyl)methyl]-1-methyl-1H-Imidazol-2-amine,C19H21N3O2,[827327-28-6],332.41,Cell biology,"DNA, RNA and Protein Synthesis",Inhibitor,Metastasis-associated lung adenocarcinoma transcript 1 (Malat1) RNA inhibitor,1,COc1ccc(-c2cnc(NCc3cccc(OC)c3)n2C)cc1,422,1
6886,CC1(C2=CC(Cl)=CC=C2N(C3=CC=C(C=C13)Cl)CCC4=NN=NN4)C,ML 67-33,86272454,"2,7-Dichloro-9,10-dihydro-9,9-dimethyl-10-[2-(2H-tetrazol-5-yl)ethyl]acridine",C18H17Cl2N5,[1443290-89-8],374.27,Ion Channels,Two-P Potassium Channels,Activator,"K2P2.1 (TREK-1), K2P10.1 (TREK-2) and K2P4.1 (TRAAK) channel activator",1,CC1(C)c2cc(Cl)ccc2N(CCc2nnn[nH]2)c2ccc(Cl)cc21,588,1
6888,CC1=C(OCCNC(=O)C2=CC=CS2)C=CC(Cl)=C1,ML 402,592973,N-[2-(4-Chloro-2-methylphenoxy)ethyl]-2-thiophenecarboxamide,C14H14ClNO2S,[298684-44-3],295.78,Ion Channels,Two-P Potassium Channels,Activator,Selective TREK channel activator,1,Cc1cc(Cl)ccc1OCCNC(=O)c1cccs1,594,0
6889,CC(OC(NC1CCN(CC1)CC2=C(C3=C(C(Cl)=C2)C=CC=N3)O)=O)C,ML 418,91667465,Isopropyl (1-((5-chloro-8-hydroxyquinolin-7-yl)methyl)piperidin-4-yl)carbamate,C19H24ClN3O3,[1928763-08-9],377.87,Ion Channels,Inward rectifier Potassium Channels,Blocker,Kir 7.1 inhibitor; also inhibits Kir 6.2,1,CC(C)OC(=O)NC1CCN(Cc2cc(Cl)c3cccnc3c2O)CC1,730,0
6893,COC1=C(F)C(F)=C(C=C1)C1=C2N=C(C)C=C(N2N=C1C)C(F)(F)F,VU 6005649,131954513,"3-(2,3-Difluoro-4-methoxyphenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine",C16H12F5N3O,[2137047-43-7],357.28,7-TM Receptors,Glutamate (Metabotropic) Group III Receptors,Modulator,Positive allosteric modulators of mGlu7 and mGlu8 receptors; also NK1 antagonist; brain penetrant,1,COc1ccc(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)c(F)c1F,686,1
6899,CCCCN(CC1=CC=CC=C1)C(=O)C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=C1,TH 257,,N-Butyl-4-[(phenylamino)sulfonyl]-N-(phenylmethyl)benzamide,C24H26N2O3S,[2244678-29-1],422.54,Enzymes,LIMK,Inhibitor,Potent and selective allosteric LIMK 1/2 inhibitor,1,CCCCN(Cc1ccccc1)C(=O)c1ccc(S(=O)(=O)Nc2ccccc2)cc1,101,0
6904,COC1=C(C=CC(C(O)=O)=C1)NC([C@@H]2N[C@H]([C@@]([C@H]2C3=C(C(Cl)=CC=C3)F)(C4=C(C=C(C=C4)Cl)F)C#N)CC(C)(C)C)=O,Idasanutlin,53358942,"4-[[[(2R,3S,4R,5S)-3-(3-Chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxybenzoic acid",C31H29Cl2F2N3O4,[1229705-06-9],616.49,Enzymes,Ubiquitin E3 Ligases,Inhibitor,Potent MDM2 inhibitor; inhibits MDM2-p53 interaction,1,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,356,1
6908,COC1=CC=CC(OC)=C1C1=CC=C(C[C@H](NC(=O)C2=C(Cl)C=CC=C2Cl)C(O)=O)C=C1,TR 14035,9912743,"(?S)-?-[(2,6-Dichlorobenzoyl)amino]-2',6'-dimethoxy[1,1'-biphenyl]-4-propanoic acid",C24H21Cl2NO5,[232271-19-1],478.83,Enzyme-Linked Receptors,Integrins,Antagonist,Potent integrin ?4?7 and ?4?1 (VLA-4) antagonist; orally bioavailable,1,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,195,0
6960,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CN=C4NC=CC4=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC(=C(NCC3CCOCC3)C=C2)[N](=O)=O)=C(C1)C1=CC=C(Cl)C=C1,ABT 199,49846579,"4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",C45H50ClN7O7S,[1257044-40-8],868.45,Cell biology,Bcl-2 Family,Inhibitor,"Selective, high affinity Bcl-2 inhibitor; orally bioavailable",1,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,655,1
6972,COC1=CC=C(C=C1)CC(NCC2=C(C3=C(C(NCC4=C(C=C(C=C4)F)F)=O)C=CC=C3)C=CC=C2)=O,A 1899,9827303,"N-[(2,4-Difluorophenyl)methyl]-2'-[[[2-(4-methoxyphenyl)acetyl]amino]methyl][1,1'-biphenyl]-2-carboxamide",C30H26F2N2O3,[498577-46-1],500.55,Ion Channels,Two-P Potassium Channels,Blocker,Potent K2P3.1 (TASK-1) and K2P9.1 (TASK-3) blocker,1,COc1ccc(CC(=O)NCc2ccccc2-c2ccccc2C(=O)NCc2ccc(F)cc2F)cc1,526,1
6978,NC1(CCN(CC1)C1=C2C=CNC2=NC=N1)C(=O)N[C@@H](CCO)C1=CC=C(Cl)C=C1,AZD 5363,25227436,"4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide",C21H25ClN6O2,[1143532-39-1],433.42,Enzymes,Akt (Protein Kinase B),Inhibitor,Potent pan-AKT inhibitor,1,NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,657,1
6980,CC1=CC(=NN1CC1=CC=NC(=C1)N1CCN(CC1)C1CC1)C1=NC(=NO1)C1=CC=C(OC(F)(F)F)C=C1,BAY 87-2243,67377767,"1-Cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]piperazine",C26H26F3N7O2,[1227158-85-1],525.54,Cell biology,Oxidative Phosphorylation,Inhibitor,Mitochondrial complex I inhibitor,1,Cc1cc(-c2nc(-c3ccc(OC(F)(F)F)cc3)no2)nn1Cc1ccnc(N2CCN(C3CC3)CC2)c1,706,1
7027,NC1=C(C(NC2CC2)=O)SC3=NC(OC)=C(Cl)C(C)=C31,LY 2033298,11536903,"3-Amino-5-chloro-N-cyclopropyl-6-methoxy-4-methylthieno[2,3-b]pyridine-2-carboxamide",C13H14ClN3O2S,[886047-13-8],311.79,7-TM Receptors,M4 Receptors,Modulator,Selective positive allosteric modulator of M4 receptors; active in vivo; antipsychotic,1,COc1nc2sc(C(=O)NC3CC3)c(N)c2c(C)c1Cl,328,1
7064,COC1=CC=C2OC[C@@H](C(NC3=C(C=C(C4=CNN=C4)C=C3)OCCN(C)C)=O)CC2=C1.Cl.Cl,Ruxolitinib,25126798,"(3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile",C17H18N6,[941678-49-5],306.37,Enzymes,JAK,Inhibitor,Potent and selective JAK1/JAK2 inhibitor; orally bioavailable,1,COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)CO2,387,0
7158,CCC(COC([C@@H](N[P@](OC[C@H]1O[C@]([C@@H]([C@@H]1O)O)(C2=CC=C3N2N=CN=C3N)C#N)(OC4=CC=CC=C4)=O)C)=O)CC,FMF-04-159-2,,"N-[1-[[3-[[(2E)-4-(Dimethylamino)-1-oxo-2-buten-1-yl]amino]phenyl]sulfonyl]-4-piperidinyl]-4-[(2,4,6- trichlorobenzoyl)amino]-1H-pyrazole-3-carboxamide",C28H30Cl3N7O5S,[2364489-81-4],683.01,Enzymes,Cyclin-dependent Kinase,Inhibitor,Potent covalent CDK14 and CDK16 inhibitor; also inhibits other TAIRE kinase family members,1,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1,838,1
7163,N#CC[C@@H](N1C=C(C2=C3C=CNC3=NC=N2)C=N1)C4CCCC4,Chroman 1,,"(3S)-N-[2-[2-(Dimethylamino)ethoxy]-4-(1H-pyrazol-4-yl)phenyl]-3,4-dihydro-6-methoxy-2H-1-benzopyran-3-carboxamide dihydrochloride",C24H28N4O4.2HCl,,509.43,Cell biology,Rho-kinases,Inhibitor,Highly potent and selective ROCK 2 inhibitor; improves cell survival after cryogeneisis,1,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,659,1
7226,CN(C/C=C/C(NC1=CC=CC(S(=O)(N2CCC(NC(C3=NNC=C3NC(C4=C(C=C(C=C4Cl)Cl)Cl)=O)=O)CC2)=O)=C1)=O)C,Remdesivir,121304016,"2-Ethylbutyl (2S)-2-[[(S)-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy]phenoxyphosphoryl]amino]propanoate",C27H35N6O8P,[1809249-37-3],602.58,Enzymes,RNA Polymerase,Inhibitor,Viral RNA-dependent RNA polymerase (RdRP) inhibitor; broad spectrum antiviral nucelotide prodrug,1,CN(C)C/C=C/C(=O)Nc1cccc(S(=O)(=O)N2CCC(NC(=O)c3n[nH]cc3NC(=O)c3c(Cl)cc(Cl)cc3Cl)CC2)c1,611,1
7280,C[C@H](C1=CC=CC2=C1C=CC=C2)NC(C3=C(C=CC(N)=C3)C)=O,GRL 0617,24941262,5-Amino-2-methyl-N-[(1R)-1-(1-naphthalenyl)ethyl]benzamide,C20H20N2O,[1093070-16-6],304.39,Enzymes,Papain-like Proteases,Inhibitor,Coronavirus PLpro inhibitor,1,Cc1ccc(N)cc1C(=O)N[C@H](C)c1cccc2ccccc12,772,1